CA2579756C - Modulators of central nervous system neurotransmitters - Google Patents
Modulators of central nervous system neurotransmitters Download PDFInfo
- Publication number
- CA2579756C CA2579756C CA2579756A CA2579756A CA2579756C CA 2579756 C CA2579756 C CA 2579756C CA 2579756 A CA2579756 A CA 2579756A CA 2579756 A CA2579756 A CA 2579756A CA 2579756 C CA2579756 C CA 2579756C
- Authority
- CA
- Canada
- Prior art keywords
- methoxy
- tetrahydrofuran
- compound
- trans
- hexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 41
- 239000002858 neurotransmitter agent Substances 0.000 title abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 65
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 208000035475 disorder Diseases 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims description 237
- -1 3-cyclopentyloxy-4-methoxy-phenyl Chemical group 0.000 claims description 141
- 230000000694 effects Effects 0.000 claims description 75
- 230000005764 inhibitory process Effects 0.000 claims description 67
- 201000010099 disease Diseases 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 230000000697 serotonin reuptake Effects 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 230000000638 stimulation Effects 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 16
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 13
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 13
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 13
- 208000020925 Bipolar disease Diseases 0.000 claims description 11
- 208000015114 central nervous system disease Diseases 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 230000036506 anxiety Effects 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
- 206010013663 drug dependence Diseases 0.000 claims description 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 229940125436 dual inhibitor Drugs 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 6
- NGZFTPGHJJBJHZ-UHFFFAOYSA-N 4a,5,8,8a-tetrahydro-2h-phthalazin-1-one Chemical group C1C=CCC2C(=O)NN=CC21 NGZFTPGHJJBJHZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- QXJNTMSGRQZRFO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-2-[5-[[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]pentyl]-4a,5,8,8a-tetrahydrophthalazin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(C1CC=CCC1C1=O)=NN1CCCCCNCCC(C=1C=CC=CC=1)OC1=CC=C(C(F)(F)F)C=C1 QXJNTMSGRQZRFO-UHFFFAOYSA-N 0.000 claims 1
- GTTCSKCDKKCKIT-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[5-[[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]pentyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CCCCCNCCC(OC=3C=CC(=CC=3)C(F)(F)F)C=3C=CC=CC=3)C2)C=C1OC1CCCC1 GTTCSKCDKKCKIT-UHFFFAOYSA-N 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 84
- 238000000034 method Methods 0.000 abstract description 58
- 239000003795 chemical substances by application Substances 0.000 abstract description 33
- 230000000144 pharmacologic effect Effects 0.000 abstract description 13
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 230000037361 pathway Effects 0.000 abstract description 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 426
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 398
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 282
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 215
- 239000000047 product Substances 0.000 description 174
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 166
- 239000003921 oil Substances 0.000 description 164
- 235000019198 oils Nutrition 0.000 description 164
- 101150041968 CDC13 gene Proteins 0.000 description 144
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 144
- 239000000377 silicon dioxide Substances 0.000 description 136
- 238000005160 1H NMR spectroscopy Methods 0.000 description 133
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 132
- 238000004587 chromatography analysis Methods 0.000 description 125
- 230000027455 binding Effects 0.000 description 82
- 239000002904 solvent Substances 0.000 description 71
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 69
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 68
- 239000000243 solution Substances 0.000 description 67
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- 150000001412 amines Chemical class 0.000 description 62
- 125000003118 aryl group Chemical group 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 54
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 238000003818 flash chromatography Methods 0.000 description 49
- 239000012043 crude product Substances 0.000 description 46
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 44
- 230000015572 biosynthetic process Effects 0.000 description 44
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 44
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 42
- 125000000217 alkyl group Chemical group 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 40
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 39
- 102000055827 human SLC6A2 Human genes 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 39
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 38
- 230000009977 dual effect Effects 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 36
- 229910052938 sodium sulfate Inorganic materials 0.000 description 36
- 235000011152 sodium sulphate Nutrition 0.000 description 36
- 239000012267 brine Substances 0.000 description 32
- 238000000132 electrospray ionisation Methods 0.000 description 32
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 32
- 230000036515 potency Effects 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 239000003112 inhibitor Substances 0.000 description 29
- 230000003389 potentiating effect Effects 0.000 description 29
- 238000012360 testing method Methods 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 125000001072 heteroaryl group Chemical group 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 24
- 238000012048 forced swim test Methods 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- 238000004896 high resolution mass spectrometry Methods 0.000 description 23
- 229950005741 rolipram Drugs 0.000 description 23
- 239000003981 vehicle Substances 0.000 description 23
- 235000017557 sodium bicarbonate Nutrition 0.000 description 21
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 125000003710 aryl alkyl group Chemical group 0.000 description 20
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 19
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 19
- 125000000304 alkynyl group Chemical group 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 229960002464 fluoxetine Drugs 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 18
- 229960003920 cocaine Drugs 0.000 description 18
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 229940076279 serotonin Drugs 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 16
- 230000001154 acute effect Effects 0.000 description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 210000001853 liver microsome Anatomy 0.000 description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 125000004122 cyclic group Chemical group 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 125000003107 substituted aryl group Chemical group 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- 102100021738 Beta-adrenergic receptor kinase 1 Human genes 0.000 description 13
- 101000751445 Homo sapiens Beta-adrenergic receptor kinase 1 Proteins 0.000 description 13
- 125000002252 acyl group Chemical group 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 13
- 125000004093 cyano group Chemical group *C#N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 108010078791 Carrier Proteins Proteins 0.000 description 12
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000002503 metabolic effect Effects 0.000 description 12
- 239000002287 radioligand Substances 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 239000000935 antidepressant agent Substances 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 102220043690 rs1049562 Human genes 0.000 description 11
- 102100037281 Beta-adrenergic receptor kinase 2 Human genes 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 101000806653 Homo sapiens Beta-adrenergic receptor kinase 2 Proteins 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 10
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- 125000004103 aminoalkyl group Chemical group 0.000 description 9
- 229940005513 antidepressants Drugs 0.000 description 9
- 125000004966 cyanoalkyl group Chemical group 0.000 description 9
- 125000001188 haloalkyl group Chemical group 0.000 description 9
- 125000001145 hydrido group Chemical group *[H] 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 125000001624 naphthyl group Chemical group 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- SIIICDNNMDMWCI-YJNKXOJESA-N rti-55 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(I)C=C1 SIIICDNNMDMWCI-YJNKXOJESA-N 0.000 description 9
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 8
- GMSNWZQQHUPGEX-UHFFFAOYSA-N 4-(5-fluoro-2-methoxyphenyl)butanal Chemical compound COC1=CC=C(F)C=C1CCCC=O GMSNWZQQHUPGEX-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000994 depressogenic effect Effects 0.000 description 8
- 238000002224 dissection Methods 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 8
- 230000006742 locomotor activity Effects 0.000 description 8
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- CRLDWFVRQNUUSZ-UHFFFAOYSA-N 5-fluoro-2-methoxybenzaldehyde Chemical compound COC1=CC=C(F)C=C1C=O CRLDWFVRQNUUSZ-UHFFFAOYSA-N 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
- 125000003282 alkyl amino group Chemical group 0.000 description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 7
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 7
- 230000001430 anti-depressive effect Effects 0.000 description 7
- 125000005335 azido alkyl group Chemical group 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000004967 formylalkyl group Chemical group 0.000 description 7
- 125000004475 heteroaralkyl group Chemical group 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 7
- 150000003141 primary amines Chemical class 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 6
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 6
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 6
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 6
- OHEBDHWEKKBXTE-UHFFFAOYSA-M [Br-].CCC=C[Mg+] Chemical compound [Br-].CCC=C[Mg+] OHEBDHWEKKBXTE-UHFFFAOYSA-M 0.000 description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000011496 cAMP-mediated signaling Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000001561 neurotransmitter reuptake Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229950005184 piclamilast Drugs 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- VKCDGHXUHCILFI-UHFFFAOYSA-N 1-(5-fluoro-2-methoxyphenyl)pent-4-en-1-ol Chemical compound COC1=CC=C(F)C=C1C(O)CCC=C VKCDGHXUHCILFI-UHFFFAOYSA-N 0.000 description 5
- RRONQZXDHPPLJN-UHFFFAOYSA-N 3-(5-fluoro-2-methoxyphenyl)propanal Chemical compound COC1=CC=C(F)C=C1CCC=O RRONQZXDHPPLJN-UHFFFAOYSA-N 0.000 description 5
- XXFWDPHWYVNJQG-UHFFFAOYSA-N 4-[2-[5-(2-aminoethyl)oxolan-2-yl]ethyl]phenol Chemical compound O1C(CCN)CCC1CCC1=CC=C(O)C=C1 XXFWDPHWYVNJQG-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 101000631929 Homo sapiens Sodium-dependent serotonin transporter Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 5
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- LKTJWDXCFJJUGY-UHFFFAOYSA-N [5-(2-phenylethyl)oxolan-2-yl]methanamine Chemical compound O1C(CN)CCC1CCC1=CC=CC=C1 LKTJWDXCFJJUGY-UHFFFAOYSA-N 0.000 description 5
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
- 230000008503 anti depressant like effect Effects 0.000 description 5
- 125000001769 aryl amino group Chemical group 0.000 description 5
- 239000004305 biphenyl Substances 0.000 description 5
- 235000010290 biphenyl Nutrition 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 102000055801 human SLC6A4 Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000010807 negative regulation of binding Effects 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- JHGDKAVZPHNTRA-UHFFFAOYSA-N 1-methyl-2-(2-phenylethenyl)pyrrolidine Chemical compound CN1CCCC1C=CC1=CC=CC=C1 JHGDKAVZPHNTRA-UHFFFAOYSA-N 0.000 description 4
- RQGQABZKJKPSSY-UHFFFAOYSA-N 2-(2-phenylethenyl)pyrrolidine Chemical compound C1CCNC1C=CC1=CC=CC=C1 RQGQABZKJKPSSY-UHFFFAOYSA-N 0.000 description 4
- FZRYLYZNENTFJM-UHFFFAOYSA-N 2-(5-benzyloxolan-2-yl)ethanamine Chemical compound O1C(CCN)CCC1CC1=CC=CC=C1 FZRYLYZNENTFJM-UHFFFAOYSA-N 0.000 description 4
- DRGICVCSLCAAIX-UHFFFAOYSA-N 2-(5-fluoro-2-methoxyphenyl)acetaldehyde Chemical compound COC1=CC=C(F)C=C1CC=O DRGICVCSLCAAIX-UHFFFAOYSA-N 0.000 description 4
- ZJALSPSHBOOBKB-UHFFFAOYSA-N 2-(5-phenyloxolan-2-yl)ethanamine Chemical compound O1C(CCN)CCC1C1=CC=CC=C1 ZJALSPSHBOOBKB-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- LVTXUMILEHJXBF-UHFFFAOYSA-N 2-[5-[2-(3-fluoro-4-methylphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound C1=C(F)C(C)=CC=C1CCC1OC(CCN)CC1 LVTXUMILEHJXBF-UHFFFAOYSA-N 0.000 description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 4
- 230000000035 biogenic effect Effects 0.000 description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940126086 compound 21 Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- PPGQXIUFJSJUMP-UHFFFAOYSA-N methyl 2-[(4-methoxyphenyl)methyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NCC(C(=O)OC)CC1=CC=C(OC)C=C1 PPGQXIUFJSJUMP-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000004971 nitroalkyl group Chemical group 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- VQNJEBUSVIFNEJ-QWHCGFSZSA-N (2r,5s)-2-(bromomethyl)-5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolane Chemical compound COC1=CC=C(F)C=C1CC[C@@H]1O[C@@H](CBr)CC1 VQNJEBUSVIFNEJ-QWHCGFSZSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 3
- UBHUGMHEEPKCFE-UHFFFAOYSA-N (5-cyclohexyloxolan-2-yl)methanamine Chemical compound O1C(CN)CCC1C1CCCCC1 UBHUGMHEEPKCFE-UHFFFAOYSA-N 0.000 description 3
- IAIACGGIZWXQIK-UHFFFAOYSA-N (5-phenyloxolan-2-yl)methanamine Chemical compound O1C(CN)CCC1C1=CC=CC=C1 IAIACGGIZWXQIK-UHFFFAOYSA-N 0.000 description 3
- CZTCDDFRDBNKCZ-UHFFFAOYSA-N 1-(5-fluoro-2-methoxyphenyl)hept-6-en-3-ol Chemical compound COC1=CC=C(F)C=C1CCC(O)CCC=C CZTCDDFRDBNKCZ-UHFFFAOYSA-N 0.000 description 3
- MVDQFNDCXZEKKL-UHFFFAOYSA-N 2-(5-cyclohexyloxolan-2-yl)ethanamine Chemical compound O1C(CCN)CCC1C1CCCCC1 MVDQFNDCXZEKKL-UHFFFAOYSA-N 0.000 description 3
- PJDWTDSVCNJUGD-CHWSQXEVSA-N 2-[(2r,5r)-5-[(5-fluoro-2-methoxyphenyl)methyl]oxolan-2-yl]ethanamine Chemical compound COC1=CC=C(F)C=C1C[C@@H]1O[C@@H](CCN)CC1 PJDWTDSVCNJUGD-CHWSQXEVSA-N 0.000 description 3
- FOEJRTWJHDIANT-UONOGXRCSA-N 2-[(2r,5s)-5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound COC1=CC=C(F)C=C1CC[C@@H]1O[C@@H](CCN)CC1 FOEJRTWJHDIANT-UONOGXRCSA-N 0.000 description 3
- DWOBIDKCZRNQLS-UHFFFAOYSA-N 2-[5-(2-phenylethyl)oxolan-2-yl]ethanamine Chemical compound O1C(CCN)CCC1CCC1=CC=CC=C1 DWOBIDKCZRNQLS-UHFFFAOYSA-N 0.000 description 3
- AXZOXDOHTYZSEC-UHFFFAOYSA-N 2-[5-[2-(3,4-dimethoxyphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound C1=C(OC)C(OC)=CC=C1CCC1OC(CCN)CC1 AXZOXDOHTYZSEC-UHFFFAOYSA-N 0.000 description 3
- UNFMMIXTACHXBE-UHFFFAOYSA-N 2-[5-[2-(4-phenylphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound O1C(CCN)CCC1CCC1=CC=C(C=2C=CC=CC=2)C=C1 UNFMMIXTACHXBE-UHFFFAOYSA-N 0.000 description 3
- FJMPWLFGGHGIRS-UHFFFAOYSA-N 5-(5-fluoro-2-methoxyphenyl)pentanal Chemical compound COC1=CC=C(F)C=C1CCCCC=O FJMPWLFGGHGIRS-UHFFFAOYSA-N 0.000 description 3
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 3
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 3
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- AZMKBJHIXZCVNL-BXKDBHETSA-N [(2r,5r)-5-(5-fluoro-2-methoxyphenyl)oxolan-2-yl]methanamine Chemical compound COC1=CC=C(F)C=C1[C@@H]1O[C@@H](CN)CC1 AZMKBJHIXZCVNL-BXKDBHETSA-N 0.000 description 3
- XSHCWAXNAAOPES-UHFFFAOYSA-N [5-[1-(4-methoxynaphthalen-1-yl)ethyl]oxolan-2-yl]methanamine Chemical compound NCC1OC(CC1)C(C)C1=CC=C(C2=CC=CC=C12)OC XSHCWAXNAAOPES-UHFFFAOYSA-N 0.000 description 3
- JPFLICWOZSVVHL-UHFFFAOYSA-N [5-[2-(4-fluorophenyl)ethyl]oxolan-2-yl]methanamine Chemical compound O1C(CN)CCC1CCC1=CC=C(F)C=C1 JPFLICWOZSVVHL-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000005236 alkanoylamino group Chemical group 0.000 description 3
- 125000003302 alkenyloxy group Chemical group 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000003435 aroyl group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 125000001207 fluorophenyl group Chemical group 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000004795 grignard reagents Chemical class 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229960000299 mazindol Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- HKAWJATWXZIMNG-DLBZAZTESA-N n-ethyl-n-[[(2r,5s)-5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolan-2-yl]methyl]ethanamine Chemical compound O1[C@@H](CN(CC)CC)CC[C@@H]1CCC1=CC(F)=CC=C1OC HKAWJATWXZIMNG-DLBZAZTESA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 239000011591 potassium Chemical class 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- WJGRLWUHRJWBBV-UHFFFAOYSA-N (5-benzyloxolan-2-yl)methanamine Chemical compound O1C(CN)CCC1CC1=CC=CC=C1 WJGRLWUHRJWBBV-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 2
- JBTOJTDQIQAKMD-UHFFFAOYSA-N 1-(5-fluoro-2-methoxyphenyl)hept-5-en-3-ol Chemical compound COC1=CC=C(F)C=C1CCC(O)CC=CC JBTOJTDQIQAKMD-UHFFFAOYSA-N 0.000 description 2
- QIAUOHNLMACAES-UHFFFAOYSA-N 1-(5-fluoro-2-methoxyphenyl)hex-5-en-2-ol Chemical compound COC1=CC=C(F)C=C1CC(O)CCC=C QIAUOHNLMACAES-UHFFFAOYSA-N 0.000 description 2
- FFBBRGORNUZOIW-UHFFFAOYSA-N 1-(5-fluoro-2-methoxyphenyl)oct-7-en-4-ol Chemical compound COC1=CC=C(F)C=C1CCCC(O)CCC=C FFBBRGORNUZOIW-UHFFFAOYSA-N 0.000 description 2
- GUVOJEHXAIDBEA-UHFFFAOYSA-N 1-phenylhept-6-en-3-ol Chemical compound C=CCCC(O)CCC1=CC=CC=C1 GUVOJEHXAIDBEA-UHFFFAOYSA-N 0.000 description 2
- UPRVHILNDBBHRP-UHFFFAOYSA-N 1-phenylhex-5-en-2-ol Chemical compound C=CCCC(O)CC1=CC=CC=C1 UPRVHILNDBBHRP-UHFFFAOYSA-N 0.000 description 2
- HAQYIWOAJSLKHP-UHFFFAOYSA-N 1-phenylpent-4-en-1-ol Chemical compound C=CCCC(O)C1=CC=CC=C1 HAQYIWOAJSLKHP-UHFFFAOYSA-N 0.000 description 2
- COZIXZLDDAZRGK-UHFFFAOYSA-N 2-(2-phenylethyl)pyrrolidine Chemical compound C1CCNC1CCC1=CC=CC=C1 COZIXZLDDAZRGK-UHFFFAOYSA-N 0.000 description 2
- CQRLAEVYQKCECQ-UONOGXRCSA-N 2-[(2r,5s)-5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolan-2-yl]acetonitrile Chemical compound COC1=CC=C(F)C=C1CC[C@@H]1O[C@@H](CC#N)CC1 CQRLAEVYQKCECQ-UONOGXRCSA-N 0.000 description 2
- WHJDYUIQVMXSJM-UHFFFAOYSA-N 2-[5-(2-naphthalen-1-ylethyl)oxolan-2-yl]ethanamine Chemical compound O1C(CCN)CCC1CCC1=CC=CC2=CC=CC=C12 WHJDYUIQVMXSJM-UHFFFAOYSA-N 0.000 description 2
- DHHWCJQBNSUIRL-UHFFFAOYSA-N 2-[5-(4-bromophenyl)oxolan-2-yl]ethanamine Chemical compound O1C(CCN)CCC1C1=CC=C(Br)C=C1 DHHWCJQBNSUIRL-UHFFFAOYSA-N 0.000 description 2
- DKVLIYJBQDXUQZ-UHFFFAOYSA-N 2-[5-(4-tert-butylphenyl)oxolan-2-yl]ethanamine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1OC(CCN)CC1 DKVLIYJBQDXUQZ-UHFFFAOYSA-N 0.000 description 2
- IVYKSYUIYXEARJ-UHFFFAOYSA-N 2-[5-[1-(4-methoxynaphthalen-1-yl)ethyl]oxolan-2-yl]ethanamine Chemical compound NCCC1OC(CC1)C(C)C1=CC=C(C2=CC=CC=C12)OC IVYKSYUIYXEARJ-UHFFFAOYSA-N 0.000 description 2
- TUZLHPUVXHTPCQ-UHFFFAOYSA-N 2-[5-[2-(4-fluoro-3-methylphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound C1=C(F)C(C)=CC(CCC2OC(CCN)CC2)=C1 TUZLHPUVXHTPCQ-UHFFFAOYSA-N 0.000 description 2
- UHEZBYFOYQNDFX-UHFFFAOYSA-N 2-[5-[2-(4-hydroxyphenyl)ethyl]oxolan-2-yl]acetonitrile Chemical compound C1=CC(O)=CC=C1CCC1OC(CC#N)CC1 UHEZBYFOYQNDFX-UHFFFAOYSA-N 0.000 description 2
- ROOBJMDGPLUFAI-UHFFFAOYSA-N 2-[5-[2-(4-methoxyphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound C1=CC(OC)=CC=C1CCC1OC(CCN)CC1 ROOBJMDGPLUFAI-UHFFFAOYSA-N 0.000 description 2
- MUTFBMULHREIFF-UHFFFAOYSA-N 2-[5-[2-(4-methylphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound C1=CC(C)=CC=C1CCC1OC(CCN)CC1 MUTFBMULHREIFF-UHFFFAOYSA-N 0.000 description 2
- FOEJRTWJHDIANT-UHFFFAOYSA-N 2-[5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound COC1=CC=C(F)C=C1CCC1OC(CCN)CC1 FOEJRTWJHDIANT-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- GSDIOOSPCUFPSE-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-2h-phthalazin-1-one Chemical compound C1C=CC=C2C(=O)NNCC21 GSDIOOSPCUFPSE-UHFFFAOYSA-N 0.000 description 2
- MRBFFQVXMIGKST-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydro-2h-phthalazin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NNC(=O)C2C1CC=CC2 MRBFFQVXMIGKST-UHFFFAOYSA-N 0.000 description 2
- SPBLYQRLIHRIDE-DLBZAZTESA-N 4-[[(2r,5s)-5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolan-2-yl]methyl]morpholine Chemical compound COC1=CC=C(F)C=C1CC[C@@H]1O[C@@H](CN2CCOCC2)CC1 SPBLYQRLIHRIDE-DLBZAZTESA-N 0.000 description 2
- KBTMGSMZIKLAHN-UHFFFAOYSA-N 4-bromo-1,2-dimethoxybenzene Chemical compound COC1=CC=C(Br)C=C1OC KBTMGSMZIKLAHN-UHFFFAOYSA-N 0.000 description 2
- UCTMLZBVNPSJHC-UHFFFAOYSA-N 5-(2-aminoethyl)cyclohexa-2,4-diene-1,2-diol Chemical compound NCCC1=CC=C(O)C(O)C1 UCTMLZBVNPSJHC-UHFFFAOYSA-N 0.000 description 2
- KPRGOTLNGIBVFL-GINZOMEDSA-N 7-ketodehydroepiandrosterone Chemical group C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C(=O)C=C21 KPRGOTLNGIBVFL-GINZOMEDSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XZQDFXDUSGXENQ-UHFFFAOYSA-N 9-(5-fluoro-2-methoxyphenyl)non-1-en-5-ol Chemical compound COC1=CC=C(F)C=C1CCCCC(O)CCC=C XZQDFXDUSGXENQ-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- CLSUYIGLXGEXLU-QWHCGFSZSA-N [(2r,5s)-5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolan-2-yl]methanamine Chemical compound COC1=CC=C(F)C=C1CC[C@@H]1O[C@@H](CN)CC1 CLSUYIGLXGEXLU-QWHCGFSZSA-N 0.000 description 2
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 2
- RIYMOCBNKGQNQK-UHFFFAOYSA-N [5-(3-fluoro-4-methylphenyl)oxolan-2-yl]methanamine Chemical compound C1=C(F)C(C)=CC=C1C1OC(CN)CC1 RIYMOCBNKGQNQK-UHFFFAOYSA-N 0.000 description 2
- NZCDMSTWUUULEH-UHFFFAOYSA-N [5-(4-bromophenyl)oxolan-2-yl]methanamine Chemical compound O1C(CN)CCC1C1=CC=C(Br)C=C1 NZCDMSTWUUULEH-UHFFFAOYSA-N 0.000 description 2
- KHKLNHSDQIKVSU-UHFFFAOYSA-N [5-(4-chlorophenyl)oxolan-2-yl]methanamine Chemical compound O1C(CN)CCC1C1=CC=C(Cl)C=C1 KHKLNHSDQIKVSU-UHFFFAOYSA-N 0.000 description 2
- SUAFTJAVJHXARK-UHFFFAOYSA-N [5-(4-methoxyphenyl)oxolan-2-yl]methanamine Chemical compound C1=CC(OC)=CC=C1C1OC(CN)CC1 SUAFTJAVJHXARK-UHFFFAOYSA-N 0.000 description 2
- AZMKBJHIXZCVNL-UHFFFAOYSA-N [5-(5-fluoro-2-methoxyphenyl)oxolan-2-yl]methanamine Chemical compound COC1=CC=C(F)C=C1C1OC(CN)CC1 AZMKBJHIXZCVNL-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000005354 acylalkyl group Chemical group 0.000 description 2
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 2
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 description 2
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 2
- 125000005154 alkyl sulfonyl amino alkyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000006196 aroyl alkyl group Chemical group 0.000 description 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- USFRYJRPHFMVBZ-UHFFFAOYSA-M benzyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1=CC=CC=C1 USFRYJRPHFMVBZ-UHFFFAOYSA-M 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000005102 carbonylalkoxy group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 125000005159 cyanoalkoxy group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- VBZWLZWCHZBRPA-PKNBQFBNSA-N ethyl (e)-3-(4-methoxynaphthalen-1-yl)prop-2-enoate Chemical compound C1=CC=C2C(/C=C/C(=O)OCC)=CC=C(OC)C2=C1 VBZWLZWCHZBRPA-PKNBQFBNSA-N 0.000 description 2
- WWJDZWOSNXKWHH-UHFFFAOYSA-N ethyl 3-naphthalen-1-ylprop-2-enoate Chemical compound C1=CC=C2C(C=CC(=O)OCC)=CC=CC2=C1 WWJDZWOSNXKWHH-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 230000005873 inhibition of neurotransmitter uptake Effects 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000011777 magnesium Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 230000006883 memory enhancing effect Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WIQRCHMSJFFONW-UHFFFAOYSA-N norfluoxetine Chemical compound C=1C=CC=CC=1C(CCN)OC1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229960001779 pargyline Drugs 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000013275 serotonin uptake Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- DAAXYQZSKBPJOX-FQEVSTJZSA-N (2S)-2-amino-3-[4-[5-[3-(4-hydroxyphenyl)-4-methoxyphenyl]-1,2,4-oxadiazol-3-yl]phenyl]propanoic acid Chemical compound COC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=C(C=C3)C[C@@H](C(=O)O)N)C4=CC=C(C=C4)O DAAXYQZSKBPJOX-FQEVSTJZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- WIQRCHMSJFFONW-HNNXBMFYSA-N (3s)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound O([C@@H](CCN)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-HNNXBMFYSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- OYWRDHBGMCXGFY-UHFFFAOYSA-N 1,2,3-triazinane Chemical compound C1CNNNC1 OYWRDHBGMCXGFY-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- LORRLQMLLQLPSJ-UHFFFAOYSA-N 1,3,5-Trithiane, Natural products C1SCSCS1 LORRLQMLLQLPSJ-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- PQNPKQVPJAHPSB-UHFFFAOYSA-N 1,4,7-trithionane Chemical compound C1CSCCSCCS1 PQNPKQVPJAHPSB-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- AWNZMWZMSDWFCV-UHFFFAOYSA-N 1-(1-phenylpropan-2-yl)pyrrolidine Chemical compound C1CCCN1C(C)CC1=CC=CC=C1 AWNZMWZMSDWFCV-UHFFFAOYSA-N 0.000 description 1
- IVTZRJKKXSKXKO-UHFFFAOYSA-N 1-(2-fluorophenyl)piperazine Chemical compound FC1=CC=CC=C1N1CCNCC1 IVTZRJKKXSKXKO-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 description 1
- QCZYZCPNBMWKTK-UHFFFAOYSA-N 2-(2-phenylethyl)oxolane Chemical compound C1CCOC1CCC1=CC=CC=C1 QCZYZCPNBMWKTK-UHFFFAOYSA-N 0.000 description 1
- RKHMIFQEOGCPKG-UHFFFAOYSA-N 2-(bromomethyl)-5-(5-fluoro-2-methoxyphenyl)oxolane Chemical compound COC1=CC=C(F)C=C1C1OC(CBr)CC1 RKHMIFQEOGCPKG-UHFFFAOYSA-N 0.000 description 1
- KFZYBXRDAAEQRM-UHFFFAOYSA-N 2-(bromomethyl)-5-[(5-fluoro-2-methoxyphenyl)methyl]oxolane Chemical compound COC1=CC=C(F)C=C1CC1OC(CBr)CC1 KFZYBXRDAAEQRM-UHFFFAOYSA-N 0.000 description 1
- VQNJEBUSVIFNEJ-UHFFFAOYSA-N 2-(bromomethyl)-5-[2-(5-fluoro-2-methoxyphenyl)ethyl]oxolane Chemical compound COC1=CC=C(F)C=C1CCC1OC(CBr)CC1 VQNJEBUSVIFNEJ-UHFFFAOYSA-N 0.000 description 1
- UFMYOUPQYMYCGX-WIYYLYMNSA-N 2-[(2R,5R)-5-(5-fluoro-2-methoxyphenyl)oxolan-2-yl]-N-(2-phenylethyl)ethanamine Chemical compound COC1=CC=C(F)C=C1[C@@H]1O[C@@H](CCNCCC=2C=CC=CC=2)CC1 UFMYOUPQYMYCGX-WIYYLYMNSA-N 0.000 description 1
- POBGJRBZLFMWFX-ZWNOBZJWSA-N 2-[(2R,5R)-5-(5-fluoro-2-methoxyphenyl)oxolan-2-yl]acetonitrile Chemical compound COC1=CC=C(F)C=C1[C@@H]1O[C@@H](CC#N)CC1 POBGJRBZLFMWFX-ZWNOBZJWSA-N 0.000 description 1
- WFCMRRKVDOAHNR-ZWNOBZJWSA-N 2-[(2r,5r)-5-(5-fluoro-2-methoxyphenyl)oxolan-2-yl]ethanamine Chemical compound COC1=CC=C(F)C=C1[C@@H]1O[C@@H](CCN)CC1 WFCMRRKVDOAHNR-ZWNOBZJWSA-N 0.000 description 1
- QMGSXEQQPVJULR-CHWSQXEVSA-N 2-[(2r,5r)-5-[(5-fluoro-2-methoxyphenyl)methyl]oxolan-2-yl]acetonitrile Chemical compound COC1=CC=C(F)C=C1C[C@@H]1O[C@@H](CC#N)CC1 QMGSXEQQPVJULR-CHWSQXEVSA-N 0.000 description 1
- REVDCXMRAHHQBM-UHFFFAOYSA-N 2-[5-(1-naphthalen-1-ylethyl)oxolan-2-yl]ethanamine Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)C1CCC(CCN)O1 REVDCXMRAHHQBM-UHFFFAOYSA-N 0.000 description 1
- PAGJHDWYQWSJGO-UHFFFAOYSA-N 2-[5-(2-methoxy-1-naphthalen-1-ylethyl)oxolan-2-yl]ethanamine Chemical compound C=1C=CC2=CC=CC=C2C=1C(COC)C1CCC(CCN)O1 PAGJHDWYQWSJGO-UHFFFAOYSA-N 0.000 description 1
- XRSLIOZBPSRXHE-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)oxolan-2-yl]ethanamine Chemical compound O1C(CCN)CCC1C1=CC=C(F)C=C1 XRSLIOZBPSRXHE-UHFFFAOYSA-N 0.000 description 1
- HSTGLADRQKCBLZ-UHFFFAOYSA-N 2-[5-[2-(4-fluorophenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound O1C(CCN)CCC1CCC1=CC=C(F)C=C1 HSTGLADRQKCBLZ-UHFFFAOYSA-N 0.000 description 1
- GFGYKFVPZZLBGM-UHFFFAOYSA-N 2-[5-[2-(4-tert-butylphenyl)ethyl]oxolan-2-yl]ethanamine Chemical compound C1=CC(C(C)(C)C)=CC=C1CCC1OC(CCN)CC1 GFGYKFVPZZLBGM-UHFFFAOYSA-N 0.000 description 1
- LBHBYZMERVVPBK-UHFFFAOYSA-N 2-benzyloxolane Chemical compound C=1C=CC=CC=1CC1CCCO1 LBHBYZMERVVPBK-UHFFFAOYSA-N 0.000 description 1
- CMJBUEMLDSCLEF-UHFFFAOYSA-N 2-cyclohexyloxolane Chemical compound C1CCOC1C1CCCCC1 CMJBUEMLDSCLEF-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- TZYYJCQVZHDEMI-UHFFFAOYSA-N 2-phenyloxolane Chemical compound C1CCOC1C1=CC=CC=C1 TZYYJCQVZHDEMI-UHFFFAOYSA-N 0.000 description 1
- XPAHGXXAYUSFKN-UHFFFAOYSA-N 2-pyridin-3-ylcyclopropan-1-amine Chemical compound NC1CC1C1=CC=CN=C1 XPAHGXXAYUSFKN-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- ITJNARMNRKSWTA-RLXJOQACSA-N 3-(2-methoxyphenoxy)-3-phenyl-n-(tritritiomethyl)propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC([3H])([3H])[3H])OC1=CC=CC=C1OC ITJNARMNRKSWTA-RLXJOQACSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- FHQRDEDZJIFJAL-UHFFFAOYSA-N 4-phenylmorpholine Chemical compound C1COCCN1C1=CC=CC=C1 FHQRDEDZJIFJAL-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101100165918 Caenorhabditis elegans cam-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000639972 Homo sapiens Sodium-dependent dopamine transporter Proteins 0.000 description 1
- 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 1
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
- 101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ZJTJUVIJVLLGSP-UHFFFAOYSA-N Lumichrome Natural products N1C(=O)NC(=O)C2=C1N=C1C=C(C)C(C)=CC1=N2 ZJTJUVIJVLLGSP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229910017917 NH4 Cl Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108091065684 PDE4 family Proteins 0.000 description 1
- 102000039036 PDE4 family Human genes 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 1
- UNRUJFXXAULDMY-VXGBXAGGSA-N [(2r,5r)-5-[(5-fluoro-2-methoxyphenyl)methyl]oxolan-2-yl]methanamine Chemical compound COC1=CC=C(F)C=C1C[C@@H]1O[C@@H](CN)CC1 UNRUJFXXAULDMY-VXGBXAGGSA-N 0.000 description 1
- BWBCTVUBHWYIEP-UONOGXRCSA-N [(2r,5s)-5-[3-(5-fluoro-2-methoxyphenyl)propyl]oxolan-2-yl]methanamine Chemical compound COC1=CC=C(F)C=C1CCC[C@@H]1O[C@@H](CN)CC1 BWBCTVUBHWYIEP-UONOGXRCSA-N 0.000 description 1
- DONSYMUZEVFMFQ-UHFFFAOYSA-N [5-(1-naphthalen-1-ylethyl)oxolan-2-yl]methanamine Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)C1CCC(CN)O1 DONSYMUZEVFMFQ-UHFFFAOYSA-N 0.000 description 1
- OOZOQFAQHUVOAM-UHFFFAOYSA-N [5-(4-tert-butylphenyl)oxolan-2-yl]methanamine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1OC(CN)CC1 OOZOQFAQHUVOAM-UHFFFAOYSA-N 0.000 description 1
- IBMMANZZPBFJNC-UHFFFAOYSA-N [5-[2-(2,3,4,5,6-pentafluorophenyl)ethyl]oxolan-2-yl]methanamine Chemical compound O1C(CN)CCC1CCC1=C(F)C(F)=C(F)C(F)=C1F IBMMANZZPBFJNC-UHFFFAOYSA-N 0.000 description 1
- RKDGFPVZHOGFIL-UHFFFAOYSA-N [5-[2-[2-chloro-5-(trifluoromethyl)phenyl]ethyl]oxolan-2-yl]methanamine Chemical compound O1C(CN)CCC1CCC1=CC(C(F)(F)F)=CC=C1Cl RKDGFPVZHOGFIL-UHFFFAOYSA-N 0.000 description 1
- PYJCJGSGOLOIEF-UHFFFAOYSA-N [N].C1=CC=C2C(=O)NN=CC2=C1 Chemical group [N].C1=CC=C2C(=O)NN=CC2=C1 PYJCJGSGOLOIEF-UHFFFAOYSA-N 0.000 description 1
- MEAHOCBUVFCKNA-UHFFFAOYSA-N [O].C=1C=COC=1 Chemical group [O].C=1C=COC=1 MEAHOCBUVFCKNA-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002905 alkanoylamido group Chemical group 0.000 description 1
- 150000005304 alkyl bromide derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000007860 aryl ester derivatives Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical class [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000037185 brain physiology Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 1
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
- 102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 description 1
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
- 239000011575 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000005488 carboaryl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- ABSOMGPQFXJESQ-UHFFFAOYSA-M cesium;hydroxide;hydrate Chemical compound O.[OH-].[Cs+] ABSOMGPQFXJESQ-UHFFFAOYSA-M 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- ICLWWPUQPWTEEL-UHFFFAOYSA-N ethoxycarbonyl(triphenyl)phosphanium Chemical compound C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C(=O)OCC)C1=CC=CC=C1 ICLWWPUQPWTEEL-UHFFFAOYSA-N 0.000 description 1
- IRDMDOBNRAOICM-UHFFFAOYSA-N ethyl 3-(5-fluoro-2-methoxyphenyl)prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC(F)=CC=C1OC IRDMDOBNRAOICM-UHFFFAOYSA-N 0.000 description 1
- RQMJBEHLUOUKNK-UHFFFAOYSA-N ethyl 3-(5-fluoro-2-methoxyphenyl)propanoate Chemical compound CCOC(=O)CCC1=CC(F)=CC=C1OC RQMJBEHLUOUKNK-UHFFFAOYSA-N 0.000 description 1
- DBVHZKJBGPVFIC-UHFFFAOYSA-N ethyl 4-(5-fluoro-2-methoxyphenyl)butanoate Chemical compound CCOC(=O)CCCC1=CC(F)=CC=C1OC DBVHZKJBGPVFIC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 229940083609 fluoxetine 20 mg Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 102000048135 human PDE4D Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 208000009932 paget disease of bone 4 Diseases 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108010000947 protamine zinc Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- GUFUWKKDHIABBW-UHFFFAOYSA-N pyrrolidin-1-ylmethanol Chemical compound OCN1CCCC1 GUFUWKKDHIABBW-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000005864 sulfonamidyl group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Disclosed are agents having pharmacological activity against cellular receptors and intracellular singaling, particularly receptors and sigaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents.
Description
Modulators of Central Nervous System Neurotransmitters CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims benefit of US Provisional Application No.
60/581,210, filed June 19, 2004.
FIELD OF THE INVENTION
[0001] This application claims benefit of US Provisional Application No.
60/581,210, filed June 19, 2004.
FIELD OF THE INVENTION
[0002] The present invention pertains generally to the field of pharmacological modulation of cellular receptors and signaling.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[0003] Human central nervous system (CNS) disorders are heterogeneous diseases that affect a growing number of the population. Over 9.5% of the population in the Unitid States suffers from depressive disorders. Pharmacological studies have shown that alteration of the storage and/or metabolism of neurotransmitters such as serotonin and norepinephrine in the vesicles of presynaptic nerve endings could improve CNS disorders and diseases such as depression, memory or cognitive impairment, anxiety, and other diseases. For example, upon stimulation, nerve cells release serotonin and other neurotransmitters into the synaptic cleft to propagate nerve impulses. Thus, a potential treatment for depression may involve the inhibition of the natural reuptake of serotonin or other neurotransnaitters back into the cells.
For example, serotonin reuptake inhibition by selective serotonin reuptake inhibitors (SSR1s) result in a progressive increase in extracellular serotonin neurotransmitter concentrations and stimulation of postsynaptic receptors. However, SSRIs have a number of shortcomings including the slow onset of therapeutic action and tolerance and/or recalcitrance of efficacy.
For example, serotonin reuptake inhibition by selective serotonin reuptake inhibitors (SSR1s) result in a progressive increase in extracellular serotonin neurotransmitter concentrations and stimulation of postsynaptic receptors. However, SSRIs have a number of shortcomings including the slow onset of therapeutic action and tolerance and/or recalcitrance of efficacy.
[0004] Another target of antidepressant administration is the cAM1' signal transduction system, because chronic SSRI antidepressant treatment up-regulates this intracellular cascade at several levels. It has been noted that in animals treated repeatedly with SSRls, cyclic AMP
phosphodiesterase (form 4) (PDE4) is upregulated. Inhibitors of PDE4, such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models.
Consistent with this, it has been shown that drugs from this class possess clinical antidepressant efficacy, including reversal of cognitive deficits that occur in depression, as well as memory improvement and cognition enhancement for Alzheimer's Disease.
phosphodiesterase (form 4) (PDE4) is upregulated. Inhibitors of PDE4, such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models.
Consistent with this, it has been shown that drugs from this class possess clinical antidepressant efficacy, including reversal of cognitive deficits that occur in depression, as well as memory improvement and cognition enhancement for Alzheimer's Disease.
[0005] Current drug development theory suggests that compounds with molecular weight exceeding 500 daltons do not enter the CNS. In addition, the synergistic effects of combining SSRI functional activity and PDE4 inhibitory activity in one molecule has previously not been recognized. For many antidepressants in clinical use today, metabolism of a prodrug moiety is responsible for converting the molecule into a pharmacologically active compound.
Thus, it is suggested that imipramine is converted to desimipramine that also possesses significant pharmacological activity. In this way, the drug may attain a more desirable pharmacokinetic or pharmacodynamic profile. It is likely that this is taking place for numerous CNS agents in this class of therapeutics.
Thus, it is suggested that imipramine is converted to desimipramine that also possesses significant pharmacological activity. In this way, the drug may attain a more desirable pharmacokinetic or pharmacodynamic profile. It is likely that this is taking place for numerous CNS agents in this class of therapeutics.
[0006] Additional agents with pharmacological activity against CNS
neurotransmitter receptors and/or intracellular signaling events downstream of neurotransmitter receptor binding are needed. This present invention as described herein meets this and other needs.
BRIEF SUMMARY OF THE INVENTION
neurotransmitter receptors and/or intracellular signaling events downstream of neurotransmitter receptor binding are needed. This present invention as described herein meets this and other needs.
BRIEF SUMMARY OF THE INVENTION
[0007] In one embodiment, the present invention provides compounds of Formula X:
D¨(CH2)a¨J¨X A (CH2)b¨N¨(CH2)c E¨(CH2)d¨GR3 X
In Formula X, D is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; J is a direct bond or optionally combined with A
and X to form a 5-6 membered heterocylic ring, substituted with an Rl and an R2 group each independently selected from the group consisting of hydrogen and optionally substituted aryl, or optionally combined with D to form an optionally substituted aryl; X is a member selected from the group consisting of 0, N and S; A is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; E is a member selected from the group consisting of a direct bond and optionally substituted heterocylcoalkyl; G is a member selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl;
R3 is a member selected from the group consisting of hydrogen and C1-C6 alkyl, or optionally combined with G to form an optionally substituted heterocycloalkyl; each of subscript a, c and d is independently an integer from 0-6; and subscript b is an integer from 1-6; or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, prodrug or polymorph thereof.
D¨(CH2)a¨J¨X A (CH2)b¨N¨(CH2)c E¨(CH2)d¨GR3 X
In Formula X, D is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; J is a direct bond or optionally combined with A
and X to form a 5-6 membered heterocylic ring, substituted with an Rl and an R2 group each independently selected from the group consisting of hydrogen and optionally substituted aryl, or optionally combined with D to form an optionally substituted aryl; X is a member selected from the group consisting of 0, N and S; A is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; E is a member selected from the group consisting of a direct bond and optionally substituted heterocylcoalkyl; G is a member selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl;
R3 is a member selected from the group consisting of hydrogen and C1-C6 alkyl, or optionally combined with G to form an optionally substituted heterocycloalkyl; each of subscript a, c and d is independently an integer from 0-6; and subscript b is an integer from 1-6; or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, prodrug or polymorph thereof.
[0008] In other embodiments, the present invention provides a compound having Formula XI:
D¨(CH2)a¨S" ----(CH2)b¨N¨(CH2)6--G0 R3 XI
In still other embodiments, the compounds of Formula XI are those where G is hydrogen or combined with R3 to form a 5-6 membered heterocylcoalkyl containing 1-2 heteroatoms each independently selected from the group consisting of N and 0; and subscript b is 1-3. In another embodiment, the compounds of Formula XI are those where D is a member selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl and optionally substituted bi-phenyl; and subscript a is 0-3.
D¨(CH2)a¨S" ----(CH2)b¨N¨(CH2)6--G0 R3 XI
In still other embodiments, the compounds of Formula XI are those where G is hydrogen or combined with R3 to form a 5-6 membered heterocylcoalkyl containing 1-2 heteroatoms each independently selected from the group consisting of N and 0; and subscript b is 1-3. In another embodiment, the compounds of Formula XI are those where D is a member selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl and optionally substituted bi-phenyl; and subscript a is 0-3.
[0009] In other embodiments, the present invention provides compounds of Formula XII:
0 Nr(cH2),¨y,c,2>c_c- R3 0 XII
In Formula XII, D and G are both the same; subscripts a and d are both 0-3 and are the same;
and subscripts b and c are both 2.
100101 In further embodiments, the present invention provides a compound of Formula XIII:
D¨(CH2)a0--c y--(CH2)b¨N¨(CH2)---E¨(CH2)d¨GR2 XIII
Compounds of Formula XIII include those where E is an optionally substituted heterocylcoalkyl having at least from 1-3 nitrogen atoms; R1 is hydrogen or optionally combined with D to form an optionally substituted aryl; and R2 is a member selected from the group consisting of hydrogen and optionally substituted phenyl.
[0011] In yet other variations, the present invention provides a compound of Formula XIV:
D-0 A )¨(CH2)b¨N¨(CH2)E---E¨(CH2)d¨G 1, XIV
Compounds of Formula XIV include those where D is an optionally substituted phenyl; A is an optionally substituted phenyl; E is an optionally substituted heterocylcoalkyl having from 1-3 nitrogen atoms; G is an optionally substituted phenyl; subscripts b and c are each independently 1-6; and subscript d is 0.
[0012] Particularly preferred compounds of the present invention include compounds having dual inhibitory activity against serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme.
[0013] In another aspect, the present invention provides pharmaceutical compositions comprising a compound as described herein and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful in the treatment or prevention of a disease or disorder amenable to therapeutic or prophylactic intervention via inhibition of neurotransmitter reuptake and/or PDE4 activity. Diseases or disorders amenable to treatment or prevention using the pharmaceutical compositions of the present invention include, for example, depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, bipolar disorder, and neurodegenerative disease such as, e.g., Parkinson's Disease and Alzheimer's Disease.
[0014] In still another aspect, the present invention provides methods for the treatment preventions of a disease or disorder in a subject. In certain embodiments, the method includes the step of administering to a subject an effective amount of a compound as described herein, wherein said subject is suffering from a central nervous system (CNS) disease or disorder amenable to treatment or prevention by inhibition of at least one of serotonin reuptake and phosphodiesterase 4 (PDE4) activity. In some preferred variations, the compound is a dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity.
[0015] Diseases and disorders particularly amenable to treatment or prevention using the methods described herein include, for example, depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, bipolar disorder, memory loss, and cognitive impairment. In some embodiments, the compound has anti-neurodegenerative activity and is used for the treatment or prevention of a neurodegenerative disease or disorder (e.g., Parkinson's Disease or Alzheimer's Disease). Particularly suitable compounds for use in the present methods are compounds that induce non-addicting CNS stimulation in the subject.
[0016] In specific embodiments of the therapeutic and prophylactic methods, the subject has been diagnosed with the disease or disorder, is not suffering from a second disease or disorder, and/or is monitored for one or more symptoms of the disease or disorder.
DEFINITIONS
[0017] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and material similar to those described herein can be used in the practice or testing of the present invention, only exemplary methods and materials are described. For purposes of the present invention, the following terms are defined below.
[0018] The terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0019] The term "agent" refers generally to the compounds described herein;
accordingly, the terms "agent" and "compound" are used synonymously.
[0020] The term "hydrido" refers to a single hydrogen.
[0021] The term "alkyl" refers to saturated aliphatic groups including straight chain, branched chain, and cyclic groups, all of which may be optionally substituted.
Suitable alkyl groups include methyl, ethyl, propyl, sec-butyl, tert-butyl, cycloalkyl, cyclopentyl, and the like, and may be optionally substituted.
[0022] The term "alkenyl" refers to unsaturated groups which contain at least one carbon-carbon double bond and includes straight chain, branched chain, and cyclic groups, all of which may be optionally substituted. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, and isopropenyl and the like which may be optionally substituted.
[0023] The term "alkynyl" refers to unsaturated groups which contain at least one carbon-carbon triple bond and includes straight chain, branched chain, and cyclic groups, all of which may be optionally substituted. Suitable alkynyl groups include ethynyl, propynyl, butynyl and the like which may be optionally substituted.
[0024] The term "alkoxy" refers to the ether ¨OR where R is alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl.
[0025] The term "aryloxy" refers to the ether ¨OR where R is aryl or heteroaryl.
[0026] The term "alkenyloxy" refers to ether ¨OR where R is alkenyl.
[0027] The term "alkylthio" refers to ¨SR where R is akyl, alkenyl, alkynyl, aryl, aralkyl.
[0028] The term "alkylthioalkyl" refers to an alkylthio group attached to an alkyl radical of about one to twenty carbon atoms through a divalent sulfur atom.
[0029] The term "alkylsulfinyl" refers to ¨S(0)R where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0030] The term "sulfonyl" refers to a -S02-R group where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0031] The term "aminosulfonyl", "sulfamyl", "sulfonamidyl" refer to -SO2NRR' where R
and R' are independently selected from alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0032] The term "hydroxyalkyl" refers to linear or branched alkyl radicals having one to about twenty carbon atoms any one of which may be substituted with a hydroxyl group.
[0033] The term "cyanoalkyl" refers to linear or branched alkyl radicals having one to about twenty carbon atoms any one of which could be substituted with one or more cyano groups.
[0034] The term "alkoxyalkyl" refers to alkyl groups having one or more alkoxy radicals attached to the alkyl group. The alkoxy radical may be further substituted with one or more halo atoms. Preferred haloalkoxy groups may contain one to twenty carbons.
[0035] The term "oximinoalkoxy" refers to alkoxy radicals having one to about twenty carbon atoms, any one of which may be substituted with an oximino radical.
[0036] The term "aryl" refers to a 6-15 membered ring system wherein there can be a single ring or multiple rings that are fused or linked together. Exemplary aryl groups of the present invention include, but are not limited to, phenyl, naphthyl, anthracene, pyrene, and biphenyl, all of which may be optionally substituted.
[0037] The term "carbocyclic aryl" refers to groups wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic groups include phenyl and naphthyl groups which may be optionally substituted with 1 to 5 sub stituents such as alkyl, alkoxy, amino, amido, cyano, carboxylate ester, hydroxyl, halogen, acyl, nitro.
[0038] The term "aralkyl" refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl, and the like, and may be optionally substituted.
[0039] The term "aroyl" refers to ¨C(0)R where R is aryl group.
[0040] The term "alkoxycarbonyl" refers to ¨C(0)OR wherein R is alkyl, akenyl, alkynyl, aryl, aralkyl.
[0041] The term "acyl" refers to the alkanoyl group ¨C(0)R where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0042] The term "acyloxy" refers to the alkanoyl group ¨0C(0)R where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0043] The term "aminoalkyl" refers to alkyl which is substituted with amino groups.
[0044] The term "arylamino" refers to amino groups substituted with one or more aryl radicals.
[0045] The term "aminocarbonyl" or "amido" refers to ¨C(0)NRRI wherein R and R1 are independently selected from hydrogen, alkyl, akenyl, alkynyl, aryl, aralkyl.
[0046] The azidoalkyl refers to alkyl R which is substituted with azido -N3 [0047] The term "amino" refers to -NRRI where R and R1 are independently hydrogen, lower alkyl or are joined together to give a 5 or 6-membered ring such as pyrrolidine or piperidine rings which are optionally substituted.
[0048] The term "alkylamino" includes amino groups substituted with one or more alkyl groups.
[0049] The term "dialkylamino" refers to ¨NRRi R and R1 are independently lower alkyl groups or together form the rest of ring such as morpholino. Suitable dialkylamino groups include dimethylamino, diethylamino and morpholino.
[0050] The term "morpholinoalkyl" refers to alkyl R substituted with morpholine group.
[0051] The term "isocyanoalkyl" refers to alkyl R that is substituted with isocyano group ¨
NCO.
[0052] The term "isothiocyanoalkyl" refers to alkyl R that is substituted with isothiocyano group ¨NCS.
[0053] The term "isocyanoalkenyl" refers to alkenyl R that is substituted with isocyano group ¨NCO.
[0054] The term "isothiocyanoalkenyl" refers to alkenyl R that is substituted with isothiocyano group ¨NCS.
[0055] The term "isocyanoalkynyl" refers to alkynylyl R that is substituted with isocyano group ¨NCO.
[0056] The term "isothiocyanoalkynyl" refers to alkynyl R that is substituted with isothiocyano group ¨NCS.
[0057] The term "alkanoylamino" or "carbamoyl" refers to -NRC(0)0R1 where R
and R1 are independently hydrogen, lower alkyl, akenyl, alkynyl, aryl, aralkyl.
[0058] The term "formylalkyl" refers to alkyl R substituted with ¨CHO.
[0059] The term "optionally substituted" or "substituted" refers to groups substituted by one to five sub stituents, independently selected from lower alkyl (acyclic or cyclic), aryl (carboaryl or heteroaryl) alkenyl, alkynyl, alkoxy, halo, haloalkyl (including trihaloalkyl, such as trifluoromethyl), amino, mercapto, alkylthio, alkylsulfinyl, alkylsulfonyl, nitro, alkanoyl, alkanoyloxy, alkanoyloxyalkanoyl, alkoxycarboxy, (-COOR, where R is lower alkyl), aminocarbonyl (-CONRRI, where R and R1 are indepently lower alkyl), formyl, carboxyl, hydroxyl, cyano, azido, oxo, carbonyl, keto, and cyclic ketals thereof, alkanoylamido, heteroaryloxy, and heterocarbocyclicoxy.
[0060] The term "lower" refers herein in connection with organic radicals or compounds defines such as one up to and including ten, preferably up to and including six, and more preferably one to four carbon atoms. Such groups may be straight chain, branched chain, or cyclic.
[0061] The term "heterocyclic" refers to a 3-10 membered ring having 1-4 heteroatoms such as 0, N, S or P. The ring structure can be a single ring, or multiple rings fused together.
Exemplary heterocycles include, but are not limited to, thiazolidine, tetrahydrofuran, 1,4-dioxane, 1,3,5-trioxane, pyrrolidine, piperidine, quinuclidine, dithiane, tetrahydropyran, phthalzain-1-one and morpholine.
[0062] The term "heteroaryl" refers to carbon containing 5-14 membered cyclic unsaturated radicals containing one, two, three, or four 0, N, P, or S atoms and having 6, 10 or 14n electrons delocalized in one or more than one rings, e.g., pyridine, oxazole, indole, purine, pyrimidine, imidazole, benzimidazole, indazole, 2H-1,2-4-triazole, 1,2,3-triazole, 211-1,2,3,4-tetrazole, 1H-1,2,3,4-triazolebenztriazole, 1,2,3-triazolo[4,5-b]pyridine, thiazole, isoxazole, pyrazole, quinoline, cytosine, thymine, uracil, adenine, guanine, pyrazine, picoline, picolinic acid, furoic acid, furfural, furyl alcohol, carbazole, isoquinoline, pyrrole, thiophene, furan, phenoxazine, phthalazine and phenothiazine, each of which may be optionally substituted.
[0063] The term "salt" refers to a compound of the present invention formed by replacing all or part of the hydrogen ions of an acid with metal ions or electropositive radicals.
[0064] The term "hydrate" refers to the formation of a complex of a compound of the present invention and a water molecule. The complex can exist in a 1:1 ratio of compound to water, or 2:1, or 1:2. One of skill in the art will appreciate that other ratios of hydrates are also useful in the present invention.
[0065] The term "solvate" refers to the formation of a complex of a compound of the present invention and a solvent molecule. The complex can exist in a 1:1 ratio of compound to solvent, or 2:1, or 1:2, or others. Furthermore, the complex can use a combination of solvents. Solvents useful for formation of solvates of the present invention include, but are not limited to alcoholic solvents such as ethanol, methanol and propylene glycol; ethers such as tetrahydrofuran, dioxane, and diethyl ether; halogenated solvents such as methylene chloride, chloroform and carbon-tetrachloride; alkanes such as pentane, hexane and octane;
as well as solvents such as acetone, ethyl acetate, pyridine, dimethyl formamide, hexamethyl phosphoric acid, dimethylsulfoxide, as well as others. One of skill in the art will appreciate that other solvents are also useful in the present invention.
[0066] The term "stereoisomer" refers to compounds of the present invention having at least one stereocenter where the compounds are linked in the same order but have different spatial orientation. Specific stereoisomers include enantiomers and diastereomers.
[0067] The term "prodrug" refers to compounds that are combined with a biological substance such that when placed in the body, the prodrug reacts to produce a compound of the present invention.
[0068] The term "polymorph" refers to a compound of the present invention in one of several crystalline structures that the compound can adopt.
[0069] The term "modulate," in reference to compounds of the present invention, refers to an ability of a compound to regulate a physiological activity in vitro and/or in vivo. In certain embodiments of the present invention, compounds are modulators of cellular signaling events such as by inhibition or stimulation of cellular receptors and/or intracellular signaling molecules.
[0070] The term "modulator of CNS neurotransmitter" and "CNS modulator" are used synonymously herein to refer to a compound that is capable of modulating signaling via one or more neurotransmitters, such as by modulation of neurotransmitter reuptake or by modulation of intracellular signaling downstream of a neurotransmitter receptor. In accordance with certain embodiments of the compositions and methods of the present invention, CNS modulators are capable of inhibiting serotonin reuptake and/or enzymatic activity of phosphodiesterase 4 (PDE4). In some variations, CNS modulators are capable of stimulating one or more G protein-coupled receptor kinases (GRKs).
[0071] The term "inhibit" means to reduce by a measurable amount, or to prevent entirely.
[0072] "Treating," "treatment," or "therapy" of a disease or disorder means slowing, stopping, or reversing progression of the disease or disorder, as evidenced by a reduction or elimination of either clinical or diagnostic symptoms, using the compositions and methods of the present invention as described herein.
[0073] "Preventing," "prophylaxis," or "prevention" of a disease or disorder means prevention of the occurrence or onset of a disease or disorder or some or all of its symptoms.
[0074] "Addiction" as used herein refers to a disease or disorder characterized by a habitual psychological and physiologic dependence on a substance or practice that is substantially beyond voluntary control. Addictions amenable to treatment using the compounds and methods described herein include drug addictions.
[0075] The term "subject" as used herein means any mammalian patient to which the compositions of the present invention may be administered according to the methods described herein. Subjects specifically intended for treatment or prophylaxis using the methods of the present invention include humans.
[0076] The term "therapeutically effective regime" means that a pharmaceutical composition or combination thereof is administered in sufficient amount and frequency and by an appropriate route to reduce pain, or to at least detectably prevent, delay, inhibit, or reverse development of at least one symptom or biochemical marker of a disease or disorder amenable to treatment or prevention by inhibition of serotonin reuptake and/or inhibition of PDE4 activity.
[0077] The term "therapeutically effective amount" refers to an amount of an agent of the present invention, or a combination of an agent of the present invention with other agent(s), that is present to achieve a desired result, e.g., preventing, delaying, inhibiting, or reversing a symptom or biochemical marker of a disease or disorder amenable to treatment by inhibition of serotonin reuptake and/or inhibition of PDE4 activity, when administered in an appropriate regime.
0 Nr(cH2),¨y,c,2>c_c- R3 0 XII
In Formula XII, D and G are both the same; subscripts a and d are both 0-3 and are the same;
and subscripts b and c are both 2.
100101 In further embodiments, the present invention provides a compound of Formula XIII:
D¨(CH2)a0--c y--(CH2)b¨N¨(CH2)---E¨(CH2)d¨GR2 XIII
Compounds of Formula XIII include those where E is an optionally substituted heterocylcoalkyl having at least from 1-3 nitrogen atoms; R1 is hydrogen or optionally combined with D to form an optionally substituted aryl; and R2 is a member selected from the group consisting of hydrogen and optionally substituted phenyl.
[0011] In yet other variations, the present invention provides a compound of Formula XIV:
D-0 A )¨(CH2)b¨N¨(CH2)E---E¨(CH2)d¨G 1, XIV
Compounds of Formula XIV include those where D is an optionally substituted phenyl; A is an optionally substituted phenyl; E is an optionally substituted heterocylcoalkyl having from 1-3 nitrogen atoms; G is an optionally substituted phenyl; subscripts b and c are each independently 1-6; and subscript d is 0.
[0012] Particularly preferred compounds of the present invention include compounds having dual inhibitory activity against serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme.
[0013] In another aspect, the present invention provides pharmaceutical compositions comprising a compound as described herein and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful in the treatment or prevention of a disease or disorder amenable to therapeutic or prophylactic intervention via inhibition of neurotransmitter reuptake and/or PDE4 activity. Diseases or disorders amenable to treatment or prevention using the pharmaceutical compositions of the present invention include, for example, depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, bipolar disorder, and neurodegenerative disease such as, e.g., Parkinson's Disease and Alzheimer's Disease.
[0014] In still another aspect, the present invention provides methods for the treatment preventions of a disease or disorder in a subject. In certain embodiments, the method includes the step of administering to a subject an effective amount of a compound as described herein, wherein said subject is suffering from a central nervous system (CNS) disease or disorder amenable to treatment or prevention by inhibition of at least one of serotonin reuptake and phosphodiesterase 4 (PDE4) activity. In some preferred variations, the compound is a dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity.
[0015] Diseases and disorders particularly amenable to treatment or prevention using the methods described herein include, for example, depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, bipolar disorder, memory loss, and cognitive impairment. In some embodiments, the compound has anti-neurodegenerative activity and is used for the treatment or prevention of a neurodegenerative disease or disorder (e.g., Parkinson's Disease or Alzheimer's Disease). Particularly suitable compounds for use in the present methods are compounds that induce non-addicting CNS stimulation in the subject.
[0016] In specific embodiments of the therapeutic and prophylactic methods, the subject has been diagnosed with the disease or disorder, is not suffering from a second disease or disorder, and/or is monitored for one or more symptoms of the disease or disorder.
DEFINITIONS
[0017] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and material similar to those described herein can be used in the practice or testing of the present invention, only exemplary methods and materials are described. For purposes of the present invention, the following terms are defined below.
[0018] The terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0019] The term "agent" refers generally to the compounds described herein;
accordingly, the terms "agent" and "compound" are used synonymously.
[0020] The term "hydrido" refers to a single hydrogen.
[0021] The term "alkyl" refers to saturated aliphatic groups including straight chain, branched chain, and cyclic groups, all of which may be optionally substituted.
Suitable alkyl groups include methyl, ethyl, propyl, sec-butyl, tert-butyl, cycloalkyl, cyclopentyl, and the like, and may be optionally substituted.
[0022] The term "alkenyl" refers to unsaturated groups which contain at least one carbon-carbon double bond and includes straight chain, branched chain, and cyclic groups, all of which may be optionally substituted. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, and isopropenyl and the like which may be optionally substituted.
[0023] The term "alkynyl" refers to unsaturated groups which contain at least one carbon-carbon triple bond and includes straight chain, branched chain, and cyclic groups, all of which may be optionally substituted. Suitable alkynyl groups include ethynyl, propynyl, butynyl and the like which may be optionally substituted.
[0024] The term "alkoxy" refers to the ether ¨OR where R is alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl.
[0025] The term "aryloxy" refers to the ether ¨OR where R is aryl or heteroaryl.
[0026] The term "alkenyloxy" refers to ether ¨OR where R is alkenyl.
[0027] The term "alkylthio" refers to ¨SR where R is akyl, alkenyl, alkynyl, aryl, aralkyl.
[0028] The term "alkylthioalkyl" refers to an alkylthio group attached to an alkyl radical of about one to twenty carbon atoms through a divalent sulfur atom.
[0029] The term "alkylsulfinyl" refers to ¨S(0)R where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0030] The term "sulfonyl" refers to a -S02-R group where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0031] The term "aminosulfonyl", "sulfamyl", "sulfonamidyl" refer to -SO2NRR' where R
and R' are independently selected from alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0032] The term "hydroxyalkyl" refers to linear or branched alkyl radicals having one to about twenty carbon atoms any one of which may be substituted with a hydroxyl group.
[0033] The term "cyanoalkyl" refers to linear or branched alkyl radicals having one to about twenty carbon atoms any one of which could be substituted with one or more cyano groups.
[0034] The term "alkoxyalkyl" refers to alkyl groups having one or more alkoxy radicals attached to the alkyl group. The alkoxy radical may be further substituted with one or more halo atoms. Preferred haloalkoxy groups may contain one to twenty carbons.
[0035] The term "oximinoalkoxy" refers to alkoxy radicals having one to about twenty carbon atoms, any one of which may be substituted with an oximino radical.
[0036] The term "aryl" refers to a 6-15 membered ring system wherein there can be a single ring or multiple rings that are fused or linked together. Exemplary aryl groups of the present invention include, but are not limited to, phenyl, naphthyl, anthracene, pyrene, and biphenyl, all of which may be optionally substituted.
[0037] The term "carbocyclic aryl" refers to groups wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic groups include phenyl and naphthyl groups which may be optionally substituted with 1 to 5 sub stituents such as alkyl, alkoxy, amino, amido, cyano, carboxylate ester, hydroxyl, halogen, acyl, nitro.
[0038] The term "aralkyl" refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl, and the like, and may be optionally substituted.
[0039] The term "aroyl" refers to ¨C(0)R where R is aryl group.
[0040] The term "alkoxycarbonyl" refers to ¨C(0)OR wherein R is alkyl, akenyl, alkynyl, aryl, aralkyl.
[0041] The term "acyl" refers to the alkanoyl group ¨C(0)R where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0042] The term "acyloxy" refers to the alkanoyl group ¨0C(0)R where R is alkyl, alkenyl, alkynyl, aryl, aralkyl.
[0043] The term "aminoalkyl" refers to alkyl which is substituted with amino groups.
[0044] The term "arylamino" refers to amino groups substituted with one or more aryl radicals.
[0045] The term "aminocarbonyl" or "amido" refers to ¨C(0)NRRI wherein R and R1 are independently selected from hydrogen, alkyl, akenyl, alkynyl, aryl, aralkyl.
[0046] The azidoalkyl refers to alkyl R which is substituted with azido -N3 [0047] The term "amino" refers to -NRRI where R and R1 are independently hydrogen, lower alkyl or are joined together to give a 5 or 6-membered ring such as pyrrolidine or piperidine rings which are optionally substituted.
[0048] The term "alkylamino" includes amino groups substituted with one or more alkyl groups.
[0049] The term "dialkylamino" refers to ¨NRRi R and R1 are independently lower alkyl groups or together form the rest of ring such as morpholino. Suitable dialkylamino groups include dimethylamino, diethylamino and morpholino.
[0050] The term "morpholinoalkyl" refers to alkyl R substituted with morpholine group.
[0051] The term "isocyanoalkyl" refers to alkyl R that is substituted with isocyano group ¨
NCO.
[0052] The term "isothiocyanoalkyl" refers to alkyl R that is substituted with isothiocyano group ¨NCS.
[0053] The term "isocyanoalkenyl" refers to alkenyl R that is substituted with isocyano group ¨NCO.
[0054] The term "isothiocyanoalkenyl" refers to alkenyl R that is substituted with isothiocyano group ¨NCS.
[0055] The term "isocyanoalkynyl" refers to alkynylyl R that is substituted with isocyano group ¨NCO.
[0056] The term "isothiocyanoalkynyl" refers to alkynyl R that is substituted with isothiocyano group ¨NCS.
[0057] The term "alkanoylamino" or "carbamoyl" refers to -NRC(0)0R1 where R
and R1 are independently hydrogen, lower alkyl, akenyl, alkynyl, aryl, aralkyl.
[0058] The term "formylalkyl" refers to alkyl R substituted with ¨CHO.
[0059] The term "optionally substituted" or "substituted" refers to groups substituted by one to five sub stituents, independently selected from lower alkyl (acyclic or cyclic), aryl (carboaryl or heteroaryl) alkenyl, alkynyl, alkoxy, halo, haloalkyl (including trihaloalkyl, such as trifluoromethyl), amino, mercapto, alkylthio, alkylsulfinyl, alkylsulfonyl, nitro, alkanoyl, alkanoyloxy, alkanoyloxyalkanoyl, alkoxycarboxy, (-COOR, where R is lower alkyl), aminocarbonyl (-CONRRI, where R and R1 are indepently lower alkyl), formyl, carboxyl, hydroxyl, cyano, azido, oxo, carbonyl, keto, and cyclic ketals thereof, alkanoylamido, heteroaryloxy, and heterocarbocyclicoxy.
[0060] The term "lower" refers herein in connection with organic radicals or compounds defines such as one up to and including ten, preferably up to and including six, and more preferably one to four carbon atoms. Such groups may be straight chain, branched chain, or cyclic.
[0061] The term "heterocyclic" refers to a 3-10 membered ring having 1-4 heteroatoms such as 0, N, S or P. The ring structure can be a single ring, or multiple rings fused together.
Exemplary heterocycles include, but are not limited to, thiazolidine, tetrahydrofuran, 1,4-dioxane, 1,3,5-trioxane, pyrrolidine, piperidine, quinuclidine, dithiane, tetrahydropyran, phthalzain-1-one and morpholine.
[0062] The term "heteroaryl" refers to carbon containing 5-14 membered cyclic unsaturated radicals containing one, two, three, or four 0, N, P, or S atoms and having 6, 10 or 14n electrons delocalized in one or more than one rings, e.g., pyridine, oxazole, indole, purine, pyrimidine, imidazole, benzimidazole, indazole, 2H-1,2-4-triazole, 1,2,3-triazole, 211-1,2,3,4-tetrazole, 1H-1,2,3,4-triazolebenztriazole, 1,2,3-triazolo[4,5-b]pyridine, thiazole, isoxazole, pyrazole, quinoline, cytosine, thymine, uracil, adenine, guanine, pyrazine, picoline, picolinic acid, furoic acid, furfural, furyl alcohol, carbazole, isoquinoline, pyrrole, thiophene, furan, phenoxazine, phthalazine and phenothiazine, each of which may be optionally substituted.
[0063] The term "salt" refers to a compound of the present invention formed by replacing all or part of the hydrogen ions of an acid with metal ions or electropositive radicals.
[0064] The term "hydrate" refers to the formation of a complex of a compound of the present invention and a water molecule. The complex can exist in a 1:1 ratio of compound to water, or 2:1, or 1:2. One of skill in the art will appreciate that other ratios of hydrates are also useful in the present invention.
[0065] The term "solvate" refers to the formation of a complex of a compound of the present invention and a solvent molecule. The complex can exist in a 1:1 ratio of compound to solvent, or 2:1, or 1:2, or others. Furthermore, the complex can use a combination of solvents. Solvents useful for formation of solvates of the present invention include, but are not limited to alcoholic solvents such as ethanol, methanol and propylene glycol; ethers such as tetrahydrofuran, dioxane, and diethyl ether; halogenated solvents such as methylene chloride, chloroform and carbon-tetrachloride; alkanes such as pentane, hexane and octane;
as well as solvents such as acetone, ethyl acetate, pyridine, dimethyl formamide, hexamethyl phosphoric acid, dimethylsulfoxide, as well as others. One of skill in the art will appreciate that other solvents are also useful in the present invention.
[0066] The term "stereoisomer" refers to compounds of the present invention having at least one stereocenter where the compounds are linked in the same order but have different spatial orientation. Specific stereoisomers include enantiomers and diastereomers.
[0067] The term "prodrug" refers to compounds that are combined with a biological substance such that when placed in the body, the prodrug reacts to produce a compound of the present invention.
[0068] The term "polymorph" refers to a compound of the present invention in one of several crystalline structures that the compound can adopt.
[0069] The term "modulate," in reference to compounds of the present invention, refers to an ability of a compound to regulate a physiological activity in vitro and/or in vivo. In certain embodiments of the present invention, compounds are modulators of cellular signaling events such as by inhibition or stimulation of cellular receptors and/or intracellular signaling molecules.
[0070] The term "modulator of CNS neurotransmitter" and "CNS modulator" are used synonymously herein to refer to a compound that is capable of modulating signaling via one or more neurotransmitters, such as by modulation of neurotransmitter reuptake or by modulation of intracellular signaling downstream of a neurotransmitter receptor. In accordance with certain embodiments of the compositions and methods of the present invention, CNS modulators are capable of inhibiting serotonin reuptake and/or enzymatic activity of phosphodiesterase 4 (PDE4). In some variations, CNS modulators are capable of stimulating one or more G protein-coupled receptor kinases (GRKs).
[0071] The term "inhibit" means to reduce by a measurable amount, or to prevent entirely.
[0072] "Treating," "treatment," or "therapy" of a disease or disorder means slowing, stopping, or reversing progression of the disease or disorder, as evidenced by a reduction or elimination of either clinical or diagnostic symptoms, using the compositions and methods of the present invention as described herein.
[0073] "Preventing," "prophylaxis," or "prevention" of a disease or disorder means prevention of the occurrence or onset of a disease or disorder or some or all of its symptoms.
[0074] "Addiction" as used herein refers to a disease or disorder characterized by a habitual psychological and physiologic dependence on a substance or practice that is substantially beyond voluntary control. Addictions amenable to treatment using the compounds and methods described herein include drug addictions.
[0075] The term "subject" as used herein means any mammalian patient to which the compositions of the present invention may be administered according to the methods described herein. Subjects specifically intended for treatment or prophylaxis using the methods of the present invention include humans.
[0076] The term "therapeutically effective regime" means that a pharmaceutical composition or combination thereof is administered in sufficient amount and frequency and by an appropriate route to reduce pain, or to at least detectably prevent, delay, inhibit, or reverse development of at least one symptom or biochemical marker of a disease or disorder amenable to treatment or prevention by inhibition of serotonin reuptake and/or inhibition of PDE4 activity.
[0077] The term "therapeutically effective amount" refers to an amount of an agent of the present invention, or a combination of an agent of the present invention with other agent(s), that is present to achieve a desired result, e.g., preventing, delaying, inhibiting, or reversing a symptom or biochemical marker of a disease or disorder amenable to treatment by inhibition of serotonin reuptake and/or inhibition of PDE4 activity, when administered in an appropriate regime.
BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 depicts scheme 1 (of schemes 1 to 3) of a general method for synthesis of certain embodiments of the present invention.
[0079] Figure 2 depicts scheme 2 (of schemes 1 to 3) of a general method for synthesis of certain embodiments of the present invention.
[0080] Figure 3 depicts scheme 3 (of schemes 1 to 3) of a general method for synthesis of certain embodiments of the present invention.
[0081] Figure 4 depicts a scheme for a synthesis of (S)-2-alkyl pyrrolidines (compounds 25b and 25c).
[0082] Figure 5 depicts a scheme for a synthesis of monomethyl amine adducts for prodrugs of the primary amines.
[0083] Figure 6 depicts testing of exemplary compounds for GRK2 stimulation or inhibition.
[0084] Figure 7 depicts the effect of cocaine on horizontal activity counts/10 min as a function of dose (top to bottom panels) and time interval during an 8-hr session. Each panel shows one dose group compared with vehicle control. *p<0.05 Compared with saline for stimulant effect (0-30 min) [0085] Figure 8 depicts the effect of compound 31,646 on horizontal activity counts/10 min as a function of dose (top to bottom panels) and time interval during an 8-hr session. Each panel shows one dose group compared with vehicle control. *p<0.05 Compared with vehicle for depressant effect (0-30 min).
[0086] Figure 9 depicts a molecular dissection of cocaine to afford 2,5-disubstituted tetrahydrofuran compounds.
[0087] Figure 10 depicts a retros3mthesis of 2,5-disubstituted tetrahydrofuran compounds.
[0088] Figure 11 depicts an effect of acute treatment with fluoxetine (64.7 ptmol/kg, 20 mg/kg), compound 18k/1, (35.5 pmol/kg, 10 mg/kg) and compound 18o/p, (37.4 pmol/kg, 10 mg/kg), on immobility in the forced-swim test in Balb/c mice. Vehicle or compounds were injected i.p. 30 min prior to the test. n= 10-11.
[0078] Figure 1 depicts scheme 1 (of schemes 1 to 3) of a general method for synthesis of certain embodiments of the present invention.
[0079] Figure 2 depicts scheme 2 (of schemes 1 to 3) of a general method for synthesis of certain embodiments of the present invention.
[0080] Figure 3 depicts scheme 3 (of schemes 1 to 3) of a general method for synthesis of certain embodiments of the present invention.
[0081] Figure 4 depicts a scheme for a synthesis of (S)-2-alkyl pyrrolidines (compounds 25b and 25c).
[0082] Figure 5 depicts a scheme for a synthesis of monomethyl amine adducts for prodrugs of the primary amines.
[0083] Figure 6 depicts testing of exemplary compounds for GRK2 stimulation or inhibition.
[0084] Figure 7 depicts the effect of cocaine on horizontal activity counts/10 min as a function of dose (top to bottom panels) and time interval during an 8-hr session. Each panel shows one dose group compared with vehicle control. *p<0.05 Compared with saline for stimulant effect (0-30 min) [0085] Figure 8 depicts the effect of compound 31,646 on horizontal activity counts/10 min as a function of dose (top to bottom panels) and time interval during an 8-hr session. Each panel shows one dose group compared with vehicle control. *p<0.05 Compared with vehicle for depressant effect (0-30 min).
[0086] Figure 9 depicts a molecular dissection of cocaine to afford 2,5-disubstituted tetrahydrofuran compounds.
[0087] Figure 10 depicts a retros3mthesis of 2,5-disubstituted tetrahydrofuran compounds.
[0088] Figure 11 depicts an effect of acute treatment with fluoxetine (64.7 ptmol/kg, 20 mg/kg), compound 18k/1, (35.5 pmol/kg, 10 mg/kg) and compound 18o/p, (37.4 pmol/kg, 10 mg/kg), on immobility in the forced-swim test in Balb/c mice. Vehicle or compounds were injected i.p. 30 min prior to the test. n= 10-11.
[0089] Figure 12 depicts scheme 6 (of schemes 6 to 8) of a method for synthesis of certain embodiments of the present invention. (See Example 28.) [0090] Figure 13 depicts scheme 7 (of schemes 6 to 8) of a method for synthesis of certain embodiments of the present invention. (See Example 28.) [0091] Figure 14 depicts scheme 8 (of schemes 6 to 8) of a method for synthesis of certain embodiments of the present invention. (See Example 28.) [0092] Figure 15 depicts an effect of acute treatment of test compounds on immobility in the forced-swim test in ICR mice: (A) compound 14 (10 mg/kg, 371=01/kg and 30 mg/kg, 112 1=01/kg); (B) compound 19 (0.3 mg/kg, 1.0 mol/kg and 3 mg/kg, 10 mol/kg) and (C) compound 21 (0.3 mg/kg, 0.5 imol/kg and 3 mg/kg, 5 mol/kg). Vehicle (Veh) or test agent was injected i.p. 30 min prior to the test. n = 9-11; * P <0.05 vs. Veh.
[0093] Figure 16 depicts an effect of acute treatment with fluoxetine (20 mg/kg, 65 mol/kg), compound 14 (10 mg/kg, 37.4 mol/kg), and compound 15 (10 mg/kg, 35.5 mol/kg) on immobility in the forced-swim test in Balb/c mice. Vehicle or test agent was injected i.p. 30 min prior to the test. n = 10-11.
[0094] Figure 17 depicts an effect of subchronic administration of fluoxetine (10 mg/kg, 32.3 mol/kg), compound 14 (10 mg/kg, 37.4 mol/kg) and compound 21 (1.0 mg/kg, 1.6 mol/kg) on immobility in the forced-swim test in Balb/c mice. Vehicle or the test agent was injected i.p. 23, 5, and 1 hr prior to the test. n = 10-11; * P < 0.05 vs.
vehicle.
[0095] Figure 18 depicts depicts scheme 9 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0096] Figure 19 depicts depicts scheme 10 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0097] Figure 20 depicts depicts scheme 11 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0098] Figure 21 depicts depicts scheme 12 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0099] Figure 22 depicts depicts scheme 13 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0100] Figure 23 depicts an asymmetric synthesis of norfluoxetine.
[0101] Figure 24 depicts a synthesis of dual SSRI/PDE4 inhibitors (23(S) and 24(R)).
[0102] Figure 25 depicts a synthesis of a dual SSRUPDE4 dual inhibitor.
[0103] Figure 26 depicts a synthesis of urea diastereomers.
[0104] Figure 27 depicts a synthesis of Duloxetine.
[0105] Figure 28 depicts a synthesis of the Grignard reagent.
[0106] Figure 29 depicts a Grignard reaction with cis-1,2,3,6-tetrahydrophthalic anhydride.
[0107] Figure 30 depicts a synthesis of the phthalazinone.
[0108] Figure 31 depicts a synthesis of the 5 carbon linker.
[0109] Figure 32 depicts a Mitsunobu reaction with chiral alcohol.
[0110] Figure 33 depicts a synthesis of the phthalimide from the Mitsunobu product.
[0111] Figure 34 depicts a synthesis of (R) or (S)-norfluoxetine.
[0112] Figure 35 depicts a synthesis of PDE4/SSRI dual inhibitor with the phthalizinone and norfluoxetine.
[0113] Figure 36 depicts a synthesis of 4-(3,4-Dimethoxy-pheny1)-245-(2-{5-[2-(5-flouro-2-methoxy-pheny1)-ethyTthtrahydro-furan-2-yll - ethylamino)-penty1]-4,5,8,8a-tetrahydro-2H-phthalazin-l-one (21).
[0114] Figure 37 depicts a synthesis of 4-(3,4-Dimethoxy-pheny1)-245-(2- {5-[3-(5-fluoro-2-methoxy-pheny1)-propyThtetrahydro-furan-2-y1} -ethylamino)-penty1-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (22).
[0115] Figure 38 depicts a synthesis of N'-(R)41-(1-naphthyl)ethyli-N-(S)-344-(triflouromethyl)phenoxy]-3-phenylpropylurea.
[0116] Figure 39 depicts a synthesis of N'-(S)41-(1-maphthypethyll-N-(S)-344-(tiflouromethyl)phenoxy]-3-phenylpropylurea.
[0093] Figure 16 depicts an effect of acute treatment with fluoxetine (20 mg/kg, 65 mol/kg), compound 14 (10 mg/kg, 37.4 mol/kg), and compound 15 (10 mg/kg, 35.5 mol/kg) on immobility in the forced-swim test in Balb/c mice. Vehicle or test agent was injected i.p. 30 min prior to the test. n = 10-11.
[0094] Figure 17 depicts an effect of subchronic administration of fluoxetine (10 mg/kg, 32.3 mol/kg), compound 14 (10 mg/kg, 37.4 mol/kg) and compound 21 (1.0 mg/kg, 1.6 mol/kg) on immobility in the forced-swim test in Balb/c mice. Vehicle or the test agent was injected i.p. 23, 5, and 1 hr prior to the test. n = 10-11; * P < 0.05 vs.
vehicle.
[0095] Figure 18 depicts depicts scheme 9 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0096] Figure 19 depicts depicts scheme 10 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0097] Figure 20 depicts depicts scheme 11 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0098] Figure 21 depicts depicts scheme 12 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0099] Figure 22 depicts depicts scheme 13 (of schemes 9 to 13) of a method for synthesis of certain embodiments of the present invention. (See Example 29.) [0100] Figure 23 depicts an asymmetric synthesis of norfluoxetine.
[0101] Figure 24 depicts a synthesis of dual SSRI/PDE4 inhibitors (23(S) and 24(R)).
[0102] Figure 25 depicts a synthesis of a dual SSRUPDE4 dual inhibitor.
[0103] Figure 26 depicts a synthesis of urea diastereomers.
[0104] Figure 27 depicts a synthesis of Duloxetine.
[0105] Figure 28 depicts a synthesis of the Grignard reagent.
[0106] Figure 29 depicts a Grignard reaction with cis-1,2,3,6-tetrahydrophthalic anhydride.
[0107] Figure 30 depicts a synthesis of the phthalazinone.
[0108] Figure 31 depicts a synthesis of the 5 carbon linker.
[0109] Figure 32 depicts a Mitsunobu reaction with chiral alcohol.
[0110] Figure 33 depicts a synthesis of the phthalimide from the Mitsunobu product.
[0111] Figure 34 depicts a synthesis of (R) or (S)-norfluoxetine.
[0112] Figure 35 depicts a synthesis of PDE4/SSRI dual inhibitor with the phthalizinone and norfluoxetine.
[0113] Figure 36 depicts a synthesis of 4-(3,4-Dimethoxy-pheny1)-245-(2-{5-[2-(5-flouro-2-methoxy-pheny1)-ethyTthtrahydro-furan-2-yll - ethylamino)-penty1]-4,5,8,8a-tetrahydro-2H-phthalazin-l-one (21).
[0114] Figure 37 depicts a synthesis of 4-(3,4-Dimethoxy-pheny1)-245-(2- {5-[3-(5-fluoro-2-methoxy-pheny1)-propyThtetrahydro-furan-2-y1} -ethylamino)-penty1-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (22).
[0115] Figure 38 depicts a synthesis of N'-(R)41-(1-naphthyl)ethyli-N-(S)-344-(triflouromethyl)phenoxy]-3-phenylpropylurea.
[0116] Figure 39 depicts a synthesis of N'-(S)41-(1-maphthypethyll-N-(S)-344-(tiflouromethyl)phenoxy]-3-phenylpropylurea.
DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS
[0117] The present invention pertains generally to agents having pharmacological activity on cells, particularly cells of the central nervous system (CNS). In a specific aspect, the invention relates to compounds that selectively modulate neurotransmitter binding, uptake and release for use in human disorders of the CNS and other diseases. For example, in certain embodiments, the present invention relates to the selective inhibition of serotonin reuptake. In certain preferred embodiments, the present invention relates to combining the cAMP-modulating activity of a PDE4 inhibitor with a neurotransmitter reuptake inhibitor (e.g., a selective serotonin reuptake inhibitor (SSR1)) to produce a synergistic effect. In some variations, the present invention also relates to the modulation of G protein-coupled receptors (GRKs).
[0118] The compositions and methods are useful, for example, in the treatment of mood disorders, enhancement of memory and/or cognition, and providing neuroprotective effects.
Diseases and disorders amenable to treatment using the compositions and methods described herein include, for example, depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, bipolar disorder, memory loss, cognitive impairment, and neurodegenerative disease.
[0119] Compositions and methods are therefore provided herein for treating or preventing CNS diseases or disorders by the inhibition of neurotransmitter reuptake, as well as the dual inhibition of the reuptake of serotonin and/or other neurotransmitters combined with the inhibition of PDE4. In some embodiments, compounds as described herein and having SSRI
activity are used for the treatment or prevention of a CNS disease or disorder such as, e.g., bipolar disorder, through stimulation of one or more GRKs (e.g., GRK2 and/or GRK3).
[0120] With particular regard to dual inhibition of serotonin reuptake and PDE4 activity, dual PDE4 inhibitor/SSRIs offer an advantage beyond simple additive effects.
Dual PDE4 inhibitor/SSRIs offer the advantage of blocking the effect of the up-regulation of PDE4.
Thus, the overall increase in serotonin receptor-mediated cAMP signaling will be preserved with repeated treatment. In addition, the onset of pharmacological action will be much faster than traditional anti-depressants or SSRIs as well as have a longer sustained mechanism of action. When animals are treated repeatedly with SSR1s, PDE4 is up-regulated.
This may be a result of an increase in 5-HT receptor-mediated cAMP signaling. It has been shown that increased cAMP increases the expression of a number of PDE4 variants in neurons. Thus, in this case, the adaptation of PDE4 that occurs in response to repeated treatment with SSRIs is homeostatic and in opposition to the acute effect of the drugs. That is, with acute treatment, SSRIs will increase 5-HT receptor-mediated cAMP signaling. With repeated treatment, this effect will be blunted (i.e., some tolerance development), since PDE4 is up-regulated and cAMP hydrolysis is increased.
[0121] With respect to modulation of GRKs, G-protein coupled receptors (GPCRs) are responsible for many cell-signalling processes. In humans, genetic evidence suggests that individuals that have defective GRK3 have a higher prevalence of bipolar disorder than individuals with normal GRK3. Pharmacological stimulation of GRK3 can provide a means to upregulate GRK3 and serve as a therapy for, e.g., mood disorders such as bipolar disorder.
GRK2 and GRK3 are very similar proteins and very similar pharmacology is expected from stimulation of either protein. Small molecules that stimulate GRK2 are expected to also stimulate GRK3 and are useful for the treatment of, e.g., bipolar disorder.
Compounds [0122] In one embodiment, the present invention provides compounds of Formula X:
D¨(CH2)a¨J¨X A )---(CH2)b¨N¨(CH2)6--E¨(CH2)d¨GX
In Formula X, D is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; J is a direct bond or optionally combined with A
and X to form a 5-6 membered heterocylic ring, substituted with an R1 and an R2 group each independently selected from the group consisting of hydrogen and optionally substituted aryl, or optionally combined with D to form an optionally substituted aryl; X is a member selected from the group consisting of 0, N and S; A is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; E is a member selected from the group consisting of a direct bond and optionally substituted heterocylcoalkyl; G is a member selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl;
R3 is a member selected from the group consisting of hydrogen and C1-C6 alkyl, or optionally combined with G to form an optionally substituted heterocycloalkyl; each of subscript a, c and d is independently an integer from 0-6; and subscript b is an integer from 1-6; or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, prodtug or polymorph thereof.
[0123] In other embodiments, the present invention provides a compound having Formula XI:
D¨(cH2).¨ 0 )¨(cH2)b¨y¨(cH2),G
XI
[0124] In still other embodiments, the compounds of Formula XI are those where G is hydrogen or combined with R3 to form a 5-6 membered heterocylcoalkyl containing 1-2 heteroatoms each independently selected from the group consisting of N and 0;
and subscript b is 1-3. In another embodiment, the compounds of Formula XI are those where D
is a member selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl and optionally substituted bi-phenyl; and subscript a is 0-3.
[0125] In a further embodiment, the present invention provides compounds of Formula XI
such as:
2-(aminomethyl)-5-phenyltetrahydrofuran, 2-(aminomethyl)-5-(4'-chlorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxyphenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-t-butylphenyl)tetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-fluoro-4'-methylphenyptetrahydrofuran, 2-(aminomethyl)-5-cyclohexyltetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-naphthyl)tetrahydrofuran, 2-(aminoethyl)-5-phenyltetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-cyclohexyltetrahydrofuran, and 2-(aminoethyl)-5-(2'-furyptetrahydrofuran.
[0126] In still another embodiment, the present invention provides compounds of Formula XI such as:
2-(aminomethyl)-5-benzyltetrahydrofuran, 2-(aminoethyl)-5-benzyltetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran.
[0127] In further embodiments, the present invention provides compounds of Formula XI
such as:
2-(aminomethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-pyridylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-chloro-5'-trifluoromethylphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(pentafluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(3',4'-dimethoxyphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(-2'-tetrahydrofuryl-2'-ethyl)tetrahydrofuran, 2-(aminoethyl)-5-(phenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-hydroxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-trifluoromethoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-phenylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-fluoro-3'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(31-fluoro-4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(cyclohexylethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-pyridylethyptetrahydrofuran, 2-(aminoethyl)-5-(1'-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(2'-naphthylethyl)tetrahydrofuran, trans-2-piperidylmethy1-5-(2' -methoxy-5' -fluorophenethyl)tetrahydrofuran, trans-2-(N,N-diethylaminomethyl)-5-(2'-methoxy-5'-fluorophenethyptetrahydrofuran, and trans-2-(morpholinomethyl)-5 -(2' -methoxy-5' -fluorophenethyptetrahydrofuran.
[01281 In other embodiments, the present invention provides compounds of Formula XII:
D¨(CH2)a¨c.0 )¨(CH2)b¨y¨(CH2)c0¨c- y(CH2)d¨G XIIR3 In Formula XII, D and G are both the same; subscripts a and d are both 0-3 and are the same;
and subscripts b and c are both 2. In some embodiments, the present invention provides compounds of Formula XII such as:
NN- bis (5'-phenyl-2'-tetrahydrofurylethypamine, NN- his (5'-(p-fluoropheny1)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-bromopheny1)-2'-tetrahydrofurylethypamine, N,N- bis (5'-(p-t-butylpheny1)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-cyclohexy1-2'-tetrahydrofurylethypamine, NN- his (trans-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryl)ethyl)amine, N,N- his (cis-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofurypethypamine, 1V ,N- his (5'-benzy1-2'-tetrahydrofurylethyl)amine, NN- his (5'-phenethy1-2'-tetrahydrofurylethyl)amine, N,N- his (5'-phenethy1-2'-tetrahydrofury1ethyl)methy1amine, NN- his (5'-(p-hydroxyphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(m-fluoro-p-methylphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-fluoro-m-methylphenethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(5"-fluoro-2"-methoxyphenethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(3"-pyridylethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'41"-naphthethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(2"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(4"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, N,N-bis (trans-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranyl)ethyl)amine, N,N-bis (cis-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranyl)ethyl)amine, and N,N-bis (trans-5-(2"-methoxy-5"-fluoropheny1-3'-propy1-2'-tetrahydrofurypethyl)amine.
[0129] In a further embodiment, the present invention provides a compound of Formula XIII:
D¨(CH2)al ----(C112)b-11¨(CH2)E¨E¨(CH2)d¨G0 R2 XIII
Compounds of Formula XIII include those where E is an optionally substituted heterocylcoalkyl having at least from 1-3 nitrogen atoms; RI. is hydrogen or optionally combined with D to form an optionally substituted aryl; and R2 is a member selected from the group consisting of hydrogen and optionally substituted phenyl. In some embodiments, the present invention provides compounds of Formula XIII such as:
4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-ethyll-tetrahydrofuran-2-y1} -ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-, phthalazin-l-one, 4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-propy1]-tetrahydrofuran-2-y1}-ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-[5-(2- {5-[2-(5-fluoro-2-methoxy-pheny1)-ethyl]-tetrahydro-furan-2-yll -ethylamino)-p entyl] -pyrrolidin-2-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-[5-(2- {5-[3 -(5-fluoro-2-methoxy-pheny1)-propy1]-tetrahydro-furan-2-y1}-ethylamino)-pentyli-pyrrolidin-2-one, 2-(3- {544-(3,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-34-pentylaminol -propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 2-(3- {54443 -Cyclop entyloxy-4-methoxy-pheny1)-2-oxo-pyrrolidin-l-yl] -pentylamino } -propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 4-(3,4-Dimethoxy-pheny1)-2-(5- [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyl]-amino } -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-(5- [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyl]-amino -penty1)-pyrrolidin-2-one, 2- {5[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentyll dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 1- 15-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-p entyl} -4-(3-cyclopentyloxy-4-methoxy-phenyl)-pyrrolidin-2-one, 4-(3,4-Dimethoxy-phenyl)-2-(5- {[5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethy1]-amino -p enty1)-4a,5,8,8 a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- [5-(3-fluoro-4-methyl-phenyl)-tetrahydro-furan-2-ylmethy1]-amino -penty1)-pyrrolidin-2-one.
[0130] In another embodiment, the present invention provides a compound of Formula XIV:
D-0 A )---(CHA¨N¨(DE12)E¨E¨(CF12)d¨GR3 XIV
[0117] The present invention pertains generally to agents having pharmacological activity on cells, particularly cells of the central nervous system (CNS). In a specific aspect, the invention relates to compounds that selectively modulate neurotransmitter binding, uptake and release for use in human disorders of the CNS and other diseases. For example, in certain embodiments, the present invention relates to the selective inhibition of serotonin reuptake. In certain preferred embodiments, the present invention relates to combining the cAMP-modulating activity of a PDE4 inhibitor with a neurotransmitter reuptake inhibitor (e.g., a selective serotonin reuptake inhibitor (SSR1)) to produce a synergistic effect. In some variations, the present invention also relates to the modulation of G protein-coupled receptors (GRKs).
[0118] The compositions and methods are useful, for example, in the treatment of mood disorders, enhancement of memory and/or cognition, and providing neuroprotective effects.
Diseases and disorders amenable to treatment using the compositions and methods described herein include, for example, depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, bipolar disorder, memory loss, cognitive impairment, and neurodegenerative disease.
[0119] Compositions and methods are therefore provided herein for treating or preventing CNS diseases or disorders by the inhibition of neurotransmitter reuptake, as well as the dual inhibition of the reuptake of serotonin and/or other neurotransmitters combined with the inhibition of PDE4. In some embodiments, compounds as described herein and having SSRI
activity are used for the treatment or prevention of a CNS disease or disorder such as, e.g., bipolar disorder, through stimulation of one or more GRKs (e.g., GRK2 and/or GRK3).
[0120] With particular regard to dual inhibition of serotonin reuptake and PDE4 activity, dual PDE4 inhibitor/SSRIs offer an advantage beyond simple additive effects.
Dual PDE4 inhibitor/SSRIs offer the advantage of blocking the effect of the up-regulation of PDE4.
Thus, the overall increase in serotonin receptor-mediated cAMP signaling will be preserved with repeated treatment. In addition, the onset of pharmacological action will be much faster than traditional anti-depressants or SSRIs as well as have a longer sustained mechanism of action. When animals are treated repeatedly with SSR1s, PDE4 is up-regulated.
This may be a result of an increase in 5-HT receptor-mediated cAMP signaling. It has been shown that increased cAMP increases the expression of a number of PDE4 variants in neurons. Thus, in this case, the adaptation of PDE4 that occurs in response to repeated treatment with SSRIs is homeostatic and in opposition to the acute effect of the drugs. That is, with acute treatment, SSRIs will increase 5-HT receptor-mediated cAMP signaling. With repeated treatment, this effect will be blunted (i.e., some tolerance development), since PDE4 is up-regulated and cAMP hydrolysis is increased.
[0121] With respect to modulation of GRKs, G-protein coupled receptors (GPCRs) are responsible for many cell-signalling processes. In humans, genetic evidence suggests that individuals that have defective GRK3 have a higher prevalence of bipolar disorder than individuals with normal GRK3. Pharmacological stimulation of GRK3 can provide a means to upregulate GRK3 and serve as a therapy for, e.g., mood disorders such as bipolar disorder.
GRK2 and GRK3 are very similar proteins and very similar pharmacology is expected from stimulation of either protein. Small molecules that stimulate GRK2 are expected to also stimulate GRK3 and are useful for the treatment of, e.g., bipolar disorder.
Compounds [0122] In one embodiment, the present invention provides compounds of Formula X:
D¨(CH2)a¨J¨X A )---(CH2)b¨N¨(CH2)6--E¨(CH2)d¨GX
In Formula X, D is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; J is a direct bond or optionally combined with A
and X to form a 5-6 membered heterocylic ring, substituted with an R1 and an R2 group each independently selected from the group consisting of hydrogen and optionally substituted aryl, or optionally combined with D to form an optionally substituted aryl; X is a member selected from the group consisting of 0, N and S; A is a member selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl; E is a member selected from the group consisting of a direct bond and optionally substituted heterocylcoalkyl; G is a member selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocycloalkyl;
R3 is a member selected from the group consisting of hydrogen and C1-C6 alkyl, or optionally combined with G to form an optionally substituted heterocycloalkyl; each of subscript a, c and d is independently an integer from 0-6; and subscript b is an integer from 1-6; or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, prodtug or polymorph thereof.
[0123] In other embodiments, the present invention provides a compound having Formula XI:
D¨(cH2).¨ 0 )¨(cH2)b¨y¨(cH2),G
XI
[0124] In still other embodiments, the compounds of Formula XI are those where G is hydrogen or combined with R3 to form a 5-6 membered heterocylcoalkyl containing 1-2 heteroatoms each independently selected from the group consisting of N and 0;
and subscript b is 1-3. In another embodiment, the compounds of Formula XI are those where D
is a member selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl and optionally substituted bi-phenyl; and subscript a is 0-3.
[0125] In a further embodiment, the present invention provides compounds of Formula XI
such as:
2-(aminomethyl)-5-phenyltetrahydrofuran, 2-(aminomethyl)-5-(4'-chlorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxyphenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-t-butylphenyl)tetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-fluoro-4'-methylphenyptetrahydrofuran, 2-(aminomethyl)-5-cyclohexyltetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-naphthyl)tetrahydrofuran, 2-(aminoethyl)-5-phenyltetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-cyclohexyltetrahydrofuran, and 2-(aminoethyl)-5-(2'-furyptetrahydrofuran.
[0126] In still another embodiment, the present invention provides compounds of Formula XI such as:
2-(aminomethyl)-5-benzyltetrahydrofuran, 2-(aminoethyl)-5-benzyltetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran.
[0127] In further embodiments, the present invention provides compounds of Formula XI
such as:
2-(aminomethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-pyridylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-chloro-5'-trifluoromethylphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(pentafluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(3',4'-dimethoxyphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(-2'-tetrahydrofuryl-2'-ethyl)tetrahydrofuran, 2-(aminoethyl)-5-(phenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-hydroxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-trifluoromethoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-phenylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-fluoro-3'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(31-fluoro-4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(cyclohexylethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-pyridylethyptetrahydrofuran, 2-(aminoethyl)-5-(1'-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(2'-naphthylethyl)tetrahydrofuran, trans-2-piperidylmethy1-5-(2' -methoxy-5' -fluorophenethyl)tetrahydrofuran, trans-2-(N,N-diethylaminomethyl)-5-(2'-methoxy-5'-fluorophenethyptetrahydrofuran, and trans-2-(morpholinomethyl)-5 -(2' -methoxy-5' -fluorophenethyptetrahydrofuran.
[01281 In other embodiments, the present invention provides compounds of Formula XII:
D¨(CH2)a¨c.0 )¨(CH2)b¨y¨(CH2)c0¨c- y(CH2)d¨G XIIR3 In Formula XII, D and G are both the same; subscripts a and d are both 0-3 and are the same;
and subscripts b and c are both 2. In some embodiments, the present invention provides compounds of Formula XII such as:
NN- bis (5'-phenyl-2'-tetrahydrofurylethypamine, NN- his (5'-(p-fluoropheny1)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-bromopheny1)-2'-tetrahydrofurylethypamine, N,N- bis (5'-(p-t-butylpheny1)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-cyclohexy1-2'-tetrahydrofurylethypamine, NN- his (trans-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryl)ethyl)amine, N,N- his (cis-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofurypethypamine, 1V ,N- his (5'-benzy1-2'-tetrahydrofurylethyl)amine, NN- his (5'-phenethy1-2'-tetrahydrofurylethyl)amine, N,N- his (5'-phenethy1-2'-tetrahydrofury1ethyl)methy1amine, NN- his (5'-(p-hydroxyphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(m-fluoro-p-methylphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-fluoro-m-methylphenethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(5"-fluoro-2"-methoxyphenethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(3"-pyridylethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'41"-naphthethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(2"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(4"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, N,N-bis (trans-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranyl)ethyl)amine, N,N-bis (cis-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranyl)ethyl)amine, and N,N-bis (trans-5-(2"-methoxy-5"-fluoropheny1-3'-propy1-2'-tetrahydrofurypethyl)amine.
[0129] In a further embodiment, the present invention provides a compound of Formula XIII:
D¨(CH2)al ----(C112)b-11¨(CH2)E¨E¨(CH2)d¨G0 R2 XIII
Compounds of Formula XIII include those where E is an optionally substituted heterocylcoalkyl having at least from 1-3 nitrogen atoms; RI. is hydrogen or optionally combined with D to form an optionally substituted aryl; and R2 is a member selected from the group consisting of hydrogen and optionally substituted phenyl. In some embodiments, the present invention provides compounds of Formula XIII such as:
4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-ethyll-tetrahydrofuran-2-y1} -ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-, phthalazin-l-one, 4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-propy1]-tetrahydrofuran-2-y1}-ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-[5-(2- {5-[2-(5-fluoro-2-methoxy-pheny1)-ethyl]-tetrahydro-furan-2-yll -ethylamino)-p entyl] -pyrrolidin-2-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-[5-(2- {5-[3 -(5-fluoro-2-methoxy-pheny1)-propy1]-tetrahydro-furan-2-y1}-ethylamino)-pentyli-pyrrolidin-2-one, 2-(3- {544-(3,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-34-pentylaminol -propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 2-(3- {54443 -Cyclop entyloxy-4-methoxy-pheny1)-2-oxo-pyrrolidin-l-yl] -pentylamino } -propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 4-(3,4-Dimethoxy-pheny1)-2-(5- [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyl]-amino } -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-(5- [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyl]-amino -penty1)-pyrrolidin-2-one, 2- {5[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentyll dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 1- 15-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-p entyl} -4-(3-cyclopentyloxy-4-methoxy-phenyl)-pyrrolidin-2-one, 4-(3,4-Dimethoxy-phenyl)-2-(5- {[5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethy1]-amino -p enty1)-4a,5,8,8 a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- [5-(3-fluoro-4-methyl-phenyl)-tetrahydro-furan-2-ylmethy1]-amino -penty1)-pyrrolidin-2-one.
[0130] In another embodiment, the present invention provides a compound of Formula XIV:
D-0 A )---(CHA¨N¨(DE12)E¨E¨(CF12)d¨GR3 XIV
Compounds of Formula XIV include those where D is an optionally substituted phenyl; A is an optionally substituted phenyl; E is an optionally substituted heterocylcoalkyl having from 1-3 nitrogen atoms; G is an optionally substituted phenyl; subscripts b and c are each independently 1-6; and subscript d is 0. In other embodiments, the present invention provides compounds of Formula XIV such as:
4-(3,4-Dimethoxy-pheny1)-2- {543-pheny1-3-(4-trifluoromethyl-phenoxy)-propylaminol-pentyll -4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-{543-pheny1-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyll -pyrrolidin-2-one.
Other Embodiments of Compounds of the Present Invention [0131] In certain other embodiments, the present invention provides compounds of Formula I:
A¨ B
HSE
Compounds of Formula I useful in the present invention include those where A
and B
constitute part of a 5- or 6-member ring system from unsaturated, partially unsaturated or saturated heterocyclic and carbocyclic rings wherein A is optionally substituted with hydrido, acyl, halo, lower acyl, lower haloakyl, oxo, cyano, nitro, carboxyl, amino, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, alkylamino, arylamino, lower carboxyalkyl, lower cyanoalkyl, lower hydroxyalkyl, alkylthio, alkylsulfinyl and aryl, lower aralkylthio, lower alkylsulfinyl, lower alkylsulfonyl, arninosulfonyl, lower N-arylaminosulfonyl, lower arylsulfonyl, lower N-alkyl-N-arylaminosulfonyl; wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted with one or two substituents selected from halo, hydroxyl, amino, nitro, cyano, carbamoyl, lower alkyl, lower alkenyloxy, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylamino, lower dialkylamino, lower halo alkyl, lower alkoxycarbonyl, lower N-alkylcarbamoyl, lower N,N-dialkylcarbamoyl, lower alkanoylamino, lower cyanoalkoxy, lower carbamoylalkoxy, lower carbonylalkoxy;
wherein the acyl group is optionally substituted with a substituent selected from hydrido, alkyl, halo, and alkoxy.
[0132] In other embodiments, compounds of Formula I useful in the present invention include those where the A, B ring system is a radical selected from pyranyl, furyl, tetrahydrofuryl, tetrahydrothienyl, thienyl, oxazolyl, pyrolyl, thiazolyl, imidazolyl, isthiazolyl, isoxazoly, pyrazolyl, cyclopentyl, phenyl, and pyridyl.
[0133] In further embodiments, C, D, E, F, G, and H of Structure I are selected from aminoalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, heteroaralkyloxy, aroyl, aroylalkyl, aryloxy, aryloxyalkyl, hydrido, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, acyl, acylalkyl, acyloxy, acyloxyalkyl, halo, haloalkyl, cyano, cyanoalkyl, nitro, nitroalkyl, carboxyl, carboxylalkyl, amino, aminoalkyl, amino carbonyl, aminocarbonylalkyl, carbamoylalkyl, carbamoylalkoxy, iminoalkyl, imidoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylamino, alkylaminoalkyl, dialkylamino, dialkylaminoalkyl, arylamino, arylaminoalkyl, hydroxy, hydroxyalkyl, isocyano, isocyanoalkyl, isothiocyano, isothiocyanoalkyl, oximinoalkoxy, morpholino, morpholinoalkyl, azido, azidoalkyl, formyl, formylalkyl, alkylthio, alkylthioalkyl, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, amino sulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted. In addition, two adjacent groups can be together to form a part of a fused carbocyclic or heterocyclic ring system. For example, E and F may be part of a ring that is fused to the ring.
[0134] In some embodiments, the compounds of Formula I have a central ring system where the A and B substituents include, but are not limited to, pyrrolidine, piperidine, pip erazine, heptamethyleneimine, hexamethyleneimine, homopiperazine, perhydroindole, azetidine, 4-piperidinopiperidine, 1-azacycloheptane, perhydroisoquioline, decahydroquinoline, 1-phenylpiperazine. 4-phenylpiperidine, 1-(fluorophenyl)piperazine, 1,3,5-hexa-hydrotriazine, morpholine, phenylmorpholine, thiomorpholine, tetrahydrothiophene, thiazolidine, co-thiocaprolactam, 1,4-thioxane, 1,3-dithiane, 1,4,7-trithiacyclononane, 1,3,5-trithiane, tetrahydrofuran, tetramethyleneoxide, tetrahydropyran, 1,3,5-trioxane, oxepane and the like, optionally having one or two ring hydrogens substituted with substituents selected from Cl, Br, I, -0R4, -R5, -0C(0)R6, OC(0)NR7R8, -C(0)R9, -CN, -SR12, "S(0)R11; (0)2R14; "C(0)0R15; "S (0)2NR- -16R17; "R18-NR- -19R20 wherein R4;
R5; Rs, R7; R8, R9; R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 are the same or different and are branched or unbranched alkyl groups from one to eight carbon atoms or hydrogen radicals. When the above radicals are incorporated into the parent molecule, the present invention includes all possible stereochemical arrangements of the sub stituents. In addition, the optional agent includes racemic or stereochemically pure compounds.
[0135] In another embodiment, the compounds of the present invention include those of Formula II where A is carbon, oxygen, sulfur, nitrogen or phosphorus:
A
II
The compounds of the present invention of Formula II are those where A is oxygen, and E
and H are selected from aminoalkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydrido, alkyl, alkenyl, alkynyl, halo alkyl, cyano, cyanoalkyl, nitroalkyl, iminoalkyl, imidoalkyl, hydroxyalkyl, thioalkyl, alkylthioalkyl, isocyanoalkyl, isothiocyanoalkyl, oximinoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl, alkylthioalkyl, alkylsulfinylaminoalkyl, alkylsulfonylaminoalkyl; and F and G
are hydrogen.
In a further embodiment, E and H are selected from aminoalkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl, halo alkyl, cyanoalkyl, iminoalkyl, imidoalkyl, isothiocyanoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl. In still another embodiment, E or H is an aryl or heteroaryl.
[0136] In still other embodiments, the compounds of the present invention are those of Structure II where E and H are selected from N-methyl aminomethyl, N-methyl amino ethyl, aminomethyl, amino ethyl, aminopropyl, alkylaminomethyl, alkylamino ethyl, alkylaminopropyl, arylaminoethyl, dialkylaminomethyl, dialkylaminoethyl, dialkylaminopropyl, aryl, arylmethyl, arylethyl, arylpropyl, heteroaryl, heteroarylmethyl, heteroarylethyl, heteroarylpropyl, alkyl, halomethyl, thiomethyl, alkylthiomethyl, cyanomethyl, cyano ethyl, nitromethyl, nitro ethyl, iminomethyl, imino ethyl, iminopropyl, imidomethyl, hydroxymethyl, isocyanomethyl, isothiocyanomethyl, oximinomethyl, oximinoethyl, oximinopropyl, morpholinomethyl, azidomethyl, alkylsulfinylaminomethyl, alkylsulfmylaminoethyl, alkylsulfinylaminopropyl, alkylsulfonylaminomethyl, alkylsulfonylamino ethyl, alkylsulfonylaminopropyl; and F and G are hydrogen.
[0137] In some embodiments, the present invention provides the following compounds when E or H is an aryl or heteroaryl:
2-(aminomethyl)-5-phenyltetrahydrofuran, 2-(aminomethyl)-5-(4'-chlorophneyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxyphenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-t-butylphenyptetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-fluoro-4'-methylphenyl)tetrahydrofuran, 2-(aminomethyl)-5-cyclohexyltetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-naphthyptetrahydrofuran, 2-(aminoethyl)-5-phenyltetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophneyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenyptetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-cyclohexyltetrahydrofuran, and 2-(aminoethyl)-5-(2'-furyptetrahydrofuran.
[0138] In other embodiments, E or H of Formula II is an arylethyl or heteroaryl ethyl. In those embodiments, the present invention provides compounds such as:
2-(aminomethyl)-5-benzyltetrahydrofuran, 2-(aminoethyl)-5-benzyltetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran, cis-2-(aminomethy1)-5-(2-methoxy-5'-fluorobenzy1)tetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran.
[0139] In still other embodiments, the present invention provides compounds where E or H
of Formula II is an arylethyl or heteroarylethyl. In those embodiments, the present invention includes compounds such as:
2-(aminomethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-pyridylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-chloro-5'-trifluoromethylphenethyptetrahydrofilran, 2-(aminomethyl)-5-(pentafluorophenethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, 2-(aminoethyl)-5-(3',4'-dimethoxyphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-11-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(-2"-tetrahydrofuryl-2'-ethyptetrahydrofuran, 2-(aminoethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-hydroxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-trifluoromethoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-phenylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-fluoro-3'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(3'-fluoro-4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(cyclohexylethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-pyridylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(2t-naphthylethyl)tetrahydrofuran, trans-2-piperidylmethy1-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran, trans-2-(N,N-diethylaminomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran, and trans-2-(morpholinomethyl)-5-(2'-methoxy-5'-fluorophenethyptetrahydrofuran.
[0140] In certain embodiments, the present invention provides compounds where E or H of Formula II is an arylpropyl or heteroarylpropyl. In those embodiments, the present invention provides compounds such as:2-(aminomethyl)-5-(3'-phenylpropyl)tetrahydrofuran, 2-(aminoethyl)-5-(3'-phenylpropyptetrahydrofuran, trans-2-(aminomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)propyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(2"-methoxy-5"-fluoropheny1-3L
propyl)tetrahydrofuran, cis-2-(aminoethyl)-5-(2"-methoxy-5"-fluoropheny1-31-propyl)tetrahydrofuran, and trans-2-(piperidinomethyl)-5-(2"-methoxy-5"-fluoropheny1-3'-propyptetrahydrofuran.
[0141] In other embodiments, the present invention provides the following compounds:
cis-2-(phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, and trans-2-(phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran.
[0142] In another embodiment, the present invention provides a compound of Structure II
where A is a nitrogen, and E, and G are hydrogen and H is selected from aminoalkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl, halo alkyl, cyanoalkyl, iminoalkyl, imidoalkyl, isothiocyanoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl. In a further embodiment, Structure II provides compounds such as 1-Methyl-2-Styrenyl Pyrrolidine and 2-Styrenyl Pyrrolidine.
4-(3,4-Dimethoxy-pheny1)-2- {543-pheny1-3-(4-trifluoromethyl-phenoxy)-propylaminol-pentyll -4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-{543-pheny1-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyll -pyrrolidin-2-one.
Other Embodiments of Compounds of the Present Invention [0131] In certain other embodiments, the present invention provides compounds of Formula I:
A¨ B
HSE
Compounds of Formula I useful in the present invention include those where A
and B
constitute part of a 5- or 6-member ring system from unsaturated, partially unsaturated or saturated heterocyclic and carbocyclic rings wherein A is optionally substituted with hydrido, acyl, halo, lower acyl, lower haloakyl, oxo, cyano, nitro, carboxyl, amino, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, alkylamino, arylamino, lower carboxyalkyl, lower cyanoalkyl, lower hydroxyalkyl, alkylthio, alkylsulfinyl and aryl, lower aralkylthio, lower alkylsulfinyl, lower alkylsulfonyl, arninosulfonyl, lower N-arylaminosulfonyl, lower arylsulfonyl, lower N-alkyl-N-arylaminosulfonyl; wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted with one or two substituents selected from halo, hydroxyl, amino, nitro, cyano, carbamoyl, lower alkyl, lower alkenyloxy, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylamino, lower dialkylamino, lower halo alkyl, lower alkoxycarbonyl, lower N-alkylcarbamoyl, lower N,N-dialkylcarbamoyl, lower alkanoylamino, lower cyanoalkoxy, lower carbamoylalkoxy, lower carbonylalkoxy;
wherein the acyl group is optionally substituted with a substituent selected from hydrido, alkyl, halo, and alkoxy.
[0132] In other embodiments, compounds of Formula I useful in the present invention include those where the A, B ring system is a radical selected from pyranyl, furyl, tetrahydrofuryl, tetrahydrothienyl, thienyl, oxazolyl, pyrolyl, thiazolyl, imidazolyl, isthiazolyl, isoxazoly, pyrazolyl, cyclopentyl, phenyl, and pyridyl.
[0133] In further embodiments, C, D, E, F, G, and H of Structure I are selected from aminoalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, heteroaralkyloxy, aroyl, aroylalkyl, aryloxy, aryloxyalkyl, hydrido, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, acyl, acylalkyl, acyloxy, acyloxyalkyl, halo, haloalkyl, cyano, cyanoalkyl, nitro, nitroalkyl, carboxyl, carboxylalkyl, amino, aminoalkyl, amino carbonyl, aminocarbonylalkyl, carbamoylalkyl, carbamoylalkoxy, iminoalkyl, imidoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylamino, alkylaminoalkyl, dialkylamino, dialkylaminoalkyl, arylamino, arylaminoalkyl, hydroxy, hydroxyalkyl, isocyano, isocyanoalkyl, isothiocyano, isothiocyanoalkyl, oximinoalkoxy, morpholino, morpholinoalkyl, azido, azidoalkyl, formyl, formylalkyl, alkylthio, alkylthioalkyl, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, amino sulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted. In addition, two adjacent groups can be together to form a part of a fused carbocyclic or heterocyclic ring system. For example, E and F may be part of a ring that is fused to the ring.
[0134] In some embodiments, the compounds of Formula I have a central ring system where the A and B substituents include, but are not limited to, pyrrolidine, piperidine, pip erazine, heptamethyleneimine, hexamethyleneimine, homopiperazine, perhydroindole, azetidine, 4-piperidinopiperidine, 1-azacycloheptane, perhydroisoquioline, decahydroquinoline, 1-phenylpiperazine. 4-phenylpiperidine, 1-(fluorophenyl)piperazine, 1,3,5-hexa-hydrotriazine, morpholine, phenylmorpholine, thiomorpholine, tetrahydrothiophene, thiazolidine, co-thiocaprolactam, 1,4-thioxane, 1,3-dithiane, 1,4,7-trithiacyclononane, 1,3,5-trithiane, tetrahydrofuran, tetramethyleneoxide, tetrahydropyran, 1,3,5-trioxane, oxepane and the like, optionally having one or two ring hydrogens substituted with substituents selected from Cl, Br, I, -0R4, -R5, -0C(0)R6, OC(0)NR7R8, -C(0)R9, -CN, -SR12, "S(0)R11; (0)2R14; "C(0)0R15; "S (0)2NR- -16R17; "R18-NR- -19R20 wherein R4;
R5; Rs, R7; R8, R9; R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 are the same or different and are branched or unbranched alkyl groups from one to eight carbon atoms or hydrogen radicals. When the above radicals are incorporated into the parent molecule, the present invention includes all possible stereochemical arrangements of the sub stituents. In addition, the optional agent includes racemic or stereochemically pure compounds.
[0135] In another embodiment, the compounds of the present invention include those of Formula II where A is carbon, oxygen, sulfur, nitrogen or phosphorus:
A
II
The compounds of the present invention of Formula II are those where A is oxygen, and E
and H are selected from aminoalkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydrido, alkyl, alkenyl, alkynyl, halo alkyl, cyano, cyanoalkyl, nitroalkyl, iminoalkyl, imidoalkyl, hydroxyalkyl, thioalkyl, alkylthioalkyl, isocyanoalkyl, isothiocyanoalkyl, oximinoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl, alkylthioalkyl, alkylsulfinylaminoalkyl, alkylsulfonylaminoalkyl; and F and G
are hydrogen.
In a further embodiment, E and H are selected from aminoalkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl, halo alkyl, cyanoalkyl, iminoalkyl, imidoalkyl, isothiocyanoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl. In still another embodiment, E or H is an aryl or heteroaryl.
[0136] In still other embodiments, the compounds of the present invention are those of Structure II where E and H are selected from N-methyl aminomethyl, N-methyl amino ethyl, aminomethyl, amino ethyl, aminopropyl, alkylaminomethyl, alkylamino ethyl, alkylaminopropyl, arylaminoethyl, dialkylaminomethyl, dialkylaminoethyl, dialkylaminopropyl, aryl, arylmethyl, arylethyl, arylpropyl, heteroaryl, heteroarylmethyl, heteroarylethyl, heteroarylpropyl, alkyl, halomethyl, thiomethyl, alkylthiomethyl, cyanomethyl, cyano ethyl, nitromethyl, nitro ethyl, iminomethyl, imino ethyl, iminopropyl, imidomethyl, hydroxymethyl, isocyanomethyl, isothiocyanomethyl, oximinomethyl, oximinoethyl, oximinopropyl, morpholinomethyl, azidomethyl, alkylsulfinylaminomethyl, alkylsulfmylaminoethyl, alkylsulfinylaminopropyl, alkylsulfonylaminomethyl, alkylsulfonylamino ethyl, alkylsulfonylaminopropyl; and F and G are hydrogen.
[0137] In some embodiments, the present invention provides the following compounds when E or H is an aryl or heteroaryl:
2-(aminomethyl)-5-phenyltetrahydrofuran, 2-(aminomethyl)-5-(4'-chlorophneyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxyphenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-t-butylphenyptetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-fluoro-4'-methylphenyl)tetrahydrofuran, 2-(aminomethyl)-5-cyclohexyltetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-naphthyptetrahydrofuran, 2-(aminoethyl)-5-phenyltetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophneyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-bromophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenyptetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-cyclohexyltetrahydrofuran, and 2-(aminoethyl)-5-(2'-furyptetrahydrofuran.
[0138] In other embodiments, E or H of Formula II is an arylethyl or heteroaryl ethyl. In those embodiments, the present invention provides compounds such as:
2-(aminomethyl)-5-benzyltetrahydrofuran, 2-(aminoethyl)-5-benzyltetrahydrofuran, trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran, cis-2-(aminomethy1)-5-(2-methoxy-5'-fluorobenzy1)tetrahydrofuran, trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran, and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran.
[0139] In still other embodiments, the present invention provides compounds where E or H
of Formula II is an arylethyl or heteroarylethyl. In those embodiments, the present invention includes compounds such as:
2-(aminomethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-pyridylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-chloro-5'-trifluoromethylphenethyptetrahydrofilran, 2-(aminomethyl)-5-(pentafluorophenethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, 2-(aminoethyl)-5-(3',4'-dimethoxyphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(1'-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-11-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(-2"-tetrahydrofuryl-2'-ethyptetrahydrofuran, 2-(aminoethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-hydroxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-trifluoromethoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-phenylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-fluoro-3'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(3'-fluoro-4'-methylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(cyclohexylethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-pyridylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(2t-naphthylethyl)tetrahydrofuran, trans-2-piperidylmethy1-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran, trans-2-(N,N-diethylaminomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran, and trans-2-(morpholinomethyl)-5-(2'-methoxy-5'-fluorophenethyptetrahydrofuran.
[0140] In certain embodiments, the present invention provides compounds where E or H of Formula II is an arylpropyl or heteroarylpropyl. In those embodiments, the present invention provides compounds such as:2-(aminomethyl)-5-(3'-phenylpropyl)tetrahydrofuran, 2-(aminoethyl)-5-(3'-phenylpropyptetrahydrofuran, trans-2-(aminomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)propyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(2"-methoxy-5"-fluoropheny1-3L
propyl)tetrahydrofuran, cis-2-(aminoethyl)-5-(2"-methoxy-5"-fluoropheny1-31-propyl)tetrahydrofuran, and trans-2-(piperidinomethyl)-5-(2"-methoxy-5"-fluoropheny1-3'-propyptetrahydrofuran.
[0141] In other embodiments, the present invention provides the following compounds:
cis-2-(phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, and trans-2-(phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran.
[0142] In another embodiment, the present invention provides a compound of Structure II
where A is a nitrogen, and E, and G are hydrogen and H is selected from aminoalkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl, halo alkyl, cyanoalkyl, iminoalkyl, imidoalkyl, isothiocyanoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl. In a further embodiment, Structure II provides compounds such as 1-Methyl-2-Styrenyl Pyrrolidine and 2-Styrenyl Pyrrolidine.
[01431 hi a further embodiment, the present invention provides a compound of Formula III:
The compounds of the present invention of Formula III are those where E is as defined above, X is saturated carbon chains from C2-C8 and R is alkyl, akenyl, alkynyl, optionally substituted aryl and aralkyl. In another embodiment, X is ethylene and E is an aryl, aralkyl, heteroaryl, or heteroaralkyl.
[0144] In other embodiments, the present invention provides compounds of Structure III
such as:
NN- his (5'-phenyl-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(p-fluoropheny1)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(p-bromopheny1)-2'-tetrahydrofurylethyl)amine, NN- bis (5'-(p-t-butylpheny1)-2'-tetrahydrofurylethyl)amine, NN- his (5'-cyclohexy1-2'-tetrahydrofurylethypamine, N,N- his (trans-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryl)ethypamine, N,N- bis (cis-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryl)ethyl)amine, N,N- his (5'-benzy1-2'-tetrahydrofurylethypamine, NN- his (5'-phenethy1-2'-tetrahydrofurylethyl)amine, N,N- his (5'-phenethy1-2'-tetrahydrofurylethypmethylamine, NN- his (5'-(p-hydroxyphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(m-fluoro-p-methylphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-fluoro-m-methylphenethyl)-21-tetrahydrofurylethypamine, NN- his (5'-(5"-fluoro-2"-methoxyphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(3"-pyridylethyl)-2'-tetrahydrofurylethypamine, NN- his (5'-(1"-naphthethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(2"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, NN- his (5'-(4"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, N,N-bis (trans-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranypethyl)amine, N,N-bis (cis-51-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranyl)ethypamine, and /V,N-bis (trans-5-(2"-methoxy-5"-fluoropheny1-3'-propy1-2'-tetrahydrofuryl)ethyl)amine.
[0145] In other embodiments, the present invention provides a compound of Formula IV:
E______( X N X H J P N
K M
IV L .
Compounds of Formula IV are those where E is as defined above, X is a saturated carbon chain from C2-C8, and J and P constitute part of a 6-member ring system from unsaturated, partially unsaturated or saturated heterocyclic and carbocyclic rings wherein A is optionally substituted with hydrido, acyl, halo, lower acyl, lower haloakyl, oxo, cyano, nitro, carboxyl, amino, lower alkoxy, amino carbonyl, lower alkoxycarbonyl, alkylamino, arylamino, lower carboxyalkyl, lower cyanoalkyl, lower hydroxyalkyl, alkylthio, alkylsulfinyl and aryl, lower aralkylthio, lower alkylsulfinyl, lower alkylsulfonyl, aminosulfonyl, lower N-arylaminosulfonyl, lower arylsulfonyl, lower N-alkyl-N-arylaminosulfonyl;
wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted with one or two substituents selected from halo, hydroxyl, amino, nitro, cyano, carbamoyl, lower alkyl, lower alkenyloxy, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylamino, lower dialkylamino, lower haloalkyl, lower alkoxycarbonyl, lower N-alkylcarbamoyl, lower N,N-dialkylcarbamoyl, lower alkanoylamino, lower cyanoalkoxy, lower carbamoylalkoxy, lower carbonylalkoxy; wherein the acyl group is optionally substituted with a sub stituent selected from hydrido, alkyl, halo, and alkoxy.
[0146] In still other embodiments, compounds of Formula IV are those where the J and H
ring system is selected from the group consisting of phthalazinone, pyranyl, furyl, tetrahydrofuryl, tetrahydrothienyl, thienyl, oxazolyl, pyrolyl, thiazolyl, imidazolyl, isthiazolyl, isoxazoly, pyrazolyl, cyclopentyl, phenyl, and pyridyl.
The compounds of the present invention of Formula III are those where E is as defined above, X is saturated carbon chains from C2-C8 and R is alkyl, akenyl, alkynyl, optionally substituted aryl and aralkyl. In another embodiment, X is ethylene and E is an aryl, aralkyl, heteroaryl, or heteroaralkyl.
[0144] In other embodiments, the present invention provides compounds of Structure III
such as:
NN- his (5'-phenyl-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(p-fluoropheny1)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(p-bromopheny1)-2'-tetrahydrofurylethyl)amine, NN- bis (5'-(p-t-butylpheny1)-2'-tetrahydrofurylethyl)amine, NN- his (5'-cyclohexy1-2'-tetrahydrofurylethypamine, N,N- his (trans-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryl)ethypamine, N,N- bis (cis-5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryl)ethyl)amine, N,N- his (5'-benzy1-2'-tetrahydrofurylethypamine, NN- his (5'-phenethy1-2'-tetrahydrofurylethyl)amine, N,N- his (5'-phenethy1-2'-tetrahydrofurylethypmethylamine, NN- his (5'-(p-hydroxyphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(m-fluoro-p-methylphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-fluoro-m-methylphenethyl)-21-tetrahydrofurylethypamine, NN- his (5'-(5"-fluoro-2"-methoxyphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(3"-pyridylethyl)-2'-tetrahydrofurylethypamine, NN- his (5'-(1"-naphthethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(2"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, NN- his (5'-(4"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethyl)amine, N,N-bis (trans-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranypethyl)amine, N,N-bis (cis-51-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofuranyl)ethypamine, and /V,N-bis (trans-5-(2"-methoxy-5"-fluoropheny1-3'-propy1-2'-tetrahydrofuryl)ethyl)amine.
[0145] In other embodiments, the present invention provides a compound of Formula IV:
E______( X N X H J P N
K M
IV L .
Compounds of Formula IV are those where E is as defined above, X is a saturated carbon chain from C2-C8, and J and P constitute part of a 6-member ring system from unsaturated, partially unsaturated or saturated heterocyclic and carbocyclic rings wherein A is optionally substituted with hydrido, acyl, halo, lower acyl, lower haloakyl, oxo, cyano, nitro, carboxyl, amino, lower alkoxy, amino carbonyl, lower alkoxycarbonyl, alkylamino, arylamino, lower carboxyalkyl, lower cyanoalkyl, lower hydroxyalkyl, alkylthio, alkylsulfinyl and aryl, lower aralkylthio, lower alkylsulfinyl, lower alkylsulfonyl, aminosulfonyl, lower N-arylaminosulfonyl, lower arylsulfonyl, lower N-alkyl-N-arylaminosulfonyl;
wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted with one or two substituents selected from halo, hydroxyl, amino, nitro, cyano, carbamoyl, lower alkyl, lower alkenyloxy, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylamino, lower dialkylamino, lower haloalkyl, lower alkoxycarbonyl, lower N-alkylcarbamoyl, lower N,N-dialkylcarbamoyl, lower alkanoylamino, lower cyanoalkoxy, lower carbamoylalkoxy, lower carbonylalkoxy; wherein the acyl group is optionally substituted with a sub stituent selected from hydrido, alkyl, halo, and alkoxy.
[0146] In still other embodiments, compounds of Formula IV are those where the J and H
ring system is selected from the group consisting of phthalazinone, pyranyl, furyl, tetrahydrofuryl, tetrahydrothienyl, thienyl, oxazolyl, pyrolyl, thiazolyl, imidazolyl, isthiazolyl, isoxazoly, pyrazolyl, cyclopentyl, phenyl, and pyridyl.
[0147] In another embodiment, compounds of Formula IV are those where K, L, M, and N
are selected from amino alkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, heteroaralkyloxy, aroyl, aroylalkyl, aryloxy, aryloxyalkyl, hydrido, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, acyl, acylalkyl, acyloxy, acyloxyalkyl, halo, haloalkyl, cyano, cyanoalkyl, nitro, nitroalkyl, carboxyl, carboxylalkyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, carbamoylalkyl, carbamoylalkoxy, iminoalkyl, imidoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylamino, alkylaminoalkyl, catechol, dialkylamino, dialkylarninoalkyl, arylamino, arylaminoalkyl, hydroxy, hydroxyalkyl, isocyano, isocyanoalkyl, isothiocyano, isothiocyanoalkyl, oximinoalkoxy, morpholino, morpholinoalkyl, azido, azidoalkyl, formyl, formylalkyl, alkylthio, alkylthioalkyl, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, amino sulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted. In addition, two adjacent groups are joint together to form a part of a fused carbocyclic or heterocyclic ring system. In some embodiments, L and M may be part of a ring that is fused to the ring.
[0148] In still further embodiments, the present invention provides compounds such as:
4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-ethyl]-tetrahydrofuran-2-yll -ethylamino)-p entyl] -4a,5,8,8 a-tetrahydro-2H-phthalazin-l-one, 4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-propyll-tetrahydrofuran-2-yll -ethylamino)-penty11-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-[5-(2- {5-[2-(5-fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-y1}-ethylamino)-pentyll-pyrrolidin-2-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-145-(2- {543-(5-fluoro-2-methoxy-pheny1)-propyll-tetrahydro-furan-2-yll-ethylamino)-pentyli-pyrrolidin-2-one, 2-(3- {544-(3,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-111-phthalazin-2-y1]-pentylamino}-propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 2-(3- {544-(3-Cyclopentyloxy-4-methoxy-pheny1)-2-oxo-pyrrolidin-l-y11-pentylamino}-propy1)-244-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 4-(3,4-Dimethoxy-phenyl)-2-(5- {{5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyl] -amino} -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyThamino -penty1)-pyrrolidin-2-one, 2- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentyl}
dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 1- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentylf -4-(3-cyclopentyloxy-4-methoxy-pheny1)-pyrrolidin-2-one, 4-(3,4-Dimethoxy-pheny1)-2-(5- {{5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethyThamino -p enty1)-4a,5,8,8 a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- [5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethyl]-amino -p enty1)-p yrrolidin-2-one.
[0149] In certain other embodiments, the present invention provides a compound of Formula V:
A
Compounds of Formula V include those where A is nitrogen, E, F and G are hydrogen, and H V
is selected from amino alkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydrido, alkyl, alkenyl, alkynyl, haloalkyl, cyano, cyanoalkyl, nitroalkyl, iminoalkyl, imidoalkyl, hydroxyalkyl, thioalkyl, alkylthioalkyl, isocyanoalkyl, isothiocyanoalkyl, oximinoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl, alkylthioalkyl, alkylsulflnylaminoalkyl, and alkylsulfonylaminoalkyl.
are selected from amino alkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, heteroaralkyloxy, aroyl, aroylalkyl, aryloxy, aryloxyalkyl, hydrido, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, acyl, acylalkyl, acyloxy, acyloxyalkyl, halo, haloalkyl, cyano, cyanoalkyl, nitro, nitroalkyl, carboxyl, carboxylalkyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, carbamoylalkyl, carbamoylalkoxy, iminoalkyl, imidoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylamino, alkylaminoalkyl, catechol, dialkylamino, dialkylarninoalkyl, arylamino, arylaminoalkyl, hydroxy, hydroxyalkyl, isocyano, isocyanoalkyl, isothiocyano, isothiocyanoalkyl, oximinoalkoxy, morpholino, morpholinoalkyl, azido, azidoalkyl, formyl, formylalkyl, alkylthio, alkylthioalkyl, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, amino sulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; wherein aryl is selected from phenyl, biphenyl, and naphthyl, and 5- and 6-membered heteroaryl, wherein aryl is optionally substituted. In addition, two adjacent groups are joint together to form a part of a fused carbocyclic or heterocyclic ring system. In some embodiments, L and M may be part of a ring that is fused to the ring.
[0148] In still further embodiments, the present invention provides compounds such as:
4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-ethyl]-tetrahydrofuran-2-yll -ethylamino)-p entyl] -4a,5,8,8 a-tetrahydro-2H-phthalazin-l-one, 4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2-methoxypheny1)-propyll-tetrahydrofuran-2-yll -ethylamino)-penty11-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-[5-(2- {5-[2-(5-fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-y1}-ethylamino)-pentyll-pyrrolidin-2-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-145-(2- {543-(5-fluoro-2-methoxy-pheny1)-propyll-tetrahydro-furan-2-yll-ethylamino)-pentyli-pyrrolidin-2-one, 2-(3- {544-(3,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-111-phthalazin-2-y1]-pentylamino}-propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 2-(3- {544-(3-Cyclopentyloxy-4-methoxy-pheny1)-2-oxo-pyrrolidin-l-y11-pentylamino}-propy1)-244-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 4-(3,4-Dimethoxy-phenyl)-2-(5- {{5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyl] -amino} -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyThamino -penty1)-pyrrolidin-2-one, 2- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentyl}
dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 1- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentylf -4-(3-cyclopentyloxy-4-methoxy-pheny1)-pyrrolidin-2-one, 4-(3,4-Dimethoxy-pheny1)-2-(5- {{5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethyThamino -p enty1)-4a,5,8,8 a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- [5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethyl]-amino -p enty1)-p yrrolidin-2-one.
[0149] In certain other embodiments, the present invention provides a compound of Formula V:
A
Compounds of Formula V include those where A is nitrogen, E, F and G are hydrogen, and H V
is selected from amino alkyl, alkylaminoalkyl, arylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydrido, alkyl, alkenyl, alkynyl, haloalkyl, cyano, cyanoalkyl, nitroalkyl, iminoalkyl, imidoalkyl, hydroxyalkyl, thioalkyl, alkylthioalkyl, isocyanoalkyl, isothiocyanoalkyl, oximinoalkyl, morpholinoalkyl, azidoalkyl, formylalkyl, alkylthioalkyl, alkylsulflnylaminoalkyl, and alkylsulfonylaminoalkyl.
[0150] In other embodiments, the present invention provides compounds of Formula V
where E and H are selected from aminomethyl, amino ethyl, aminopropyl, alkylaminomethyl, alkylaminoethyl, alkylaminopropyl, arylamino ethyl, dialkylaminomethyl, dialkylamino ethyl, dialkylaminopropyl, aryl, aryhnethyl, arylethyl, arylpropyl, heteroaryl, heteroarylmethyl, heteroarylethyl, heteroarylpropyl, alkyl, halomethyl, thiomethyl, alkylthiomethyl, cyanomethyl, cyano ethyl, nitromethyl, nitro ethyl, iminomethyl, imino ethyl, iminopropyl, imidomethyl, hydroxymethyl, isocyanomethyl, isothiocyanomethyl, oximinomethyl, oximinoethyl, oximinopropyl, morpholinomethyl, azidomethyl, alkylsulfinylaminomethyl, alkylsulfinylaminoethyl, alkylsulfinylaminopropyl, alkylsulfonylaminomethyl, alkylsulfonylaminoethyl, and alkylsulfonylaminopropyl; and F and G are hydrogen.
[0151] One of skill in the art will recognize that the compounds of the present invention can also be present as the salt, hydrate, solvate, stereoisomer, prodrug, stereoisomer or polymorph thereof.
Preparation of Compounds of the Present Invention [0152] The compounds described in the invention may be prepared using conventional techniques and standard synthetic methods as described in books such as "Organic Synthesis"
or methods in journals such as "Journal of Organic Chemistry", "Journal of Medicinal Chemistry", or "Journal of American Chemical Society".
General Methods [0153] The general method for the preparation of the compounds in the invention is outlined in Scheme 1, Scheme 2, and Scheme 3 (see Figures 1-3, respectively).
The synthesis starts from the aryl substituted aldehyde. Some of these aldehydes are commercially available; others can be synthesized as illustrated in Scheme 1 (see Figure 1). The aldehydes 1 were treated with a Wittig reagent that was obtained from methoxyrnethyltriphenylphosphonium chloride and sodium hydride to give enol ethers 2 as mixtures of E- and Z-isomers. Hydrolysis of 2 produced the aldehydes 3.
Treatment of 1 with the commercially available Wittig reagent carbethoxytriphenylphosphorane gave the unsaturated esters 4 which was hydrogenated in the presence of palladium on activated carbon to produce the saturated esters 5. Reduction of 5 with DiBAL in toluene resulted in the formation of aldehydes 6. Combining the strategy for synthesis of 3 and 6 produced the aldehydes 9. The synthetic sequence presented here provides a general method for making the aryl-substituted aldehydes of any chain length.
where E and H are selected from aminomethyl, amino ethyl, aminopropyl, alkylaminomethyl, alkylaminoethyl, alkylaminopropyl, arylamino ethyl, dialkylaminomethyl, dialkylamino ethyl, dialkylaminopropyl, aryl, aryhnethyl, arylethyl, arylpropyl, heteroaryl, heteroarylmethyl, heteroarylethyl, heteroarylpropyl, alkyl, halomethyl, thiomethyl, alkylthiomethyl, cyanomethyl, cyano ethyl, nitromethyl, nitro ethyl, iminomethyl, imino ethyl, iminopropyl, imidomethyl, hydroxymethyl, isocyanomethyl, isothiocyanomethyl, oximinomethyl, oximinoethyl, oximinopropyl, morpholinomethyl, azidomethyl, alkylsulfinylaminomethyl, alkylsulfinylaminoethyl, alkylsulfinylaminopropyl, alkylsulfonylaminomethyl, alkylsulfonylaminoethyl, and alkylsulfonylaminopropyl; and F and G are hydrogen.
[0151] One of skill in the art will recognize that the compounds of the present invention can also be present as the salt, hydrate, solvate, stereoisomer, prodrug, stereoisomer or polymorph thereof.
Preparation of Compounds of the Present Invention [0152] The compounds described in the invention may be prepared using conventional techniques and standard synthetic methods as described in books such as "Organic Synthesis"
or methods in journals such as "Journal of Organic Chemistry", "Journal of Medicinal Chemistry", or "Journal of American Chemical Society".
General Methods [0153] The general method for the preparation of the compounds in the invention is outlined in Scheme 1, Scheme 2, and Scheme 3 (see Figures 1-3, respectively).
The synthesis starts from the aryl substituted aldehyde. Some of these aldehydes are commercially available; others can be synthesized as illustrated in Scheme 1 (see Figure 1). The aldehydes 1 were treated with a Wittig reagent that was obtained from methoxyrnethyltriphenylphosphonium chloride and sodium hydride to give enol ethers 2 as mixtures of E- and Z-isomers. Hydrolysis of 2 produced the aldehydes 3.
Treatment of 1 with the commercially available Wittig reagent carbethoxytriphenylphosphorane gave the unsaturated esters 4 which was hydrogenated in the presence of palladium on activated carbon to produce the saturated esters 5. Reduction of 5 with DiBAL in toluene resulted in the formation of aldehydes 6. Combining the strategy for synthesis of 3 and 6 produced the aldehydes 9. The synthetic sequence presented here provides a general method for making the aryl-substituted aldehydes of any chain length.
[0154] The aldehydes (1 or 3 or 6 or 9) that were obtained according to Scheme 1 were then treated with the commercially available 1-butenylmagnesium bromide to form the ring-closure precursor enols 10 (see Figure 2). 5-bromomethyl substituted tetrahydrofurans 11 were formed by treating 10 with N-bromosuccinimide (NBS) in CH2C12 (See id.).
Bromides 11 were treated with potassium phthalimide in DMSO catalyzed by Nal at 70 C to produce phthilimido derivatives 12. Hydrolysis of 12 with hydrazine hydrate gave the desired amines 13. The cyano compounds 14 were formed in a similar manner. The cyano compounds 14 were catalytically hydrogenated in the presence of Raney nickel and one atmosphere of H2 to give the desired primary amines 15 as the major products and secondary amines 16 as the minor products. Alternatively, amines 15 were synthesized by reducing 14 with sodium borohydride in the presence of Raney nickel.
[0155] The synthetic procedures used for the preparation of cis-( )-4a,5,8,8a-tetrahydro-2H-phthalazin- 1-ones that were linked to the 2,5-disubstituted tetrahydrofurans and derivatives thereof is depicted in Scheme 3 (see Figure 3). Nucleophilic addition of Grignard reagent, 3,4-dimethoxyphenylmagnesium bromide to cis-1,2,3,6-tetrahydrophthalic anhydride afforded 7-keto acid in moderate yield (40%). The 7-keto acid readily underwent cyclization upon treatment with hydrazine hydrate in Et0H to give the corresponding phthalazinone. A
five carbon linker is attached to the phthalazinone with NaH and 1,5-dibromopentane. This adduct is then linked to the 2,5-disubstituted tetrahydrofurans with CsOH in DMF.
Synthesis of (S)-2-alkyl Pyrrolidines, Compounds 25b-25c [0156] S-Proline was a useful starting material for the synthesis of 2-alkylpyrrolidines because it provided a 2-substituted pyrrolidine with the desired (S)-stereochemistry. Further elaboration of the 2-monosubstituted pyrrolidine was made via the Wittig reaction to form compound 25. Compound 23 was converted into 1-tBoc-2-formylpyrrolidine, compound 24, by an oxidative reaction sequence and as described below, the t-Boc was a useful protecting group.
[0157] Reduction of compound 23a with lithium aluminum hydride and then N-protection with a tBoc group afforded 2-pyrrolidine methanol, compound 23b. Oxidation of compound 23b by Swem oxidation gave 1-tBoc-2-formylpyrrolindine, compound 24. Compound was treated with benzyltriphenylphosphonium chloride under standard Wittig conditions to provide a double bond at the C-2 position, compound 25a. Compound 25a was then deprotected and methylated to produce compounds 25b and 25c as depicted in Scheme 4.
(See Figure 4.) [0158] Monomethyl amine adducts were prepared for prodrugs of the primary amines. The general synthesis is diagramed in Scheme 5 (see Figure 5) where the ethyl carbamate is made from the primary amine with ethyl chloroformate in THE. The carbamate is then reduced to the methyl group with LAH in THF to yield the monomethyl secondary amine.
Pharmaceutical Compositions and Methods of Administration [0159] The agents of the present invention are useful in a variety of applications relating to modulation of cellular signaling. For example, in a preferred aspect of the invention, the agents are useful for modulation of CNS neurotransmitter signaling. Modulation of CNS
neurotransmitter signaling can be achieved, e.g., by the ability of an agent to modulate neurotransmitter reuptake (e.g., selective inhibition of serotonin reuptake) and/or to modulate cellular signaling downstream of a neurotransmitter receptor (e.g., inhibition of phosphodiesterase 4 (1PDE4) activity or G protein-coupled receptor kinase activity). Thus, in certain embodiments, the agents of the present invention are useful for the treatment or prevention of disorders or diseases amenable to therapeutic or prophylactic intervention via modulation (e.g., inhibition) of neurotransmitter reuptake and/or neurotransmitter receptor intracellular signaling pathways. For example, the agents are particularly useful for the treatment or prevention of CNS disorders or diseases amenable to therapeutic or prophylactic intervention by inhibition of serotonin reuptake and/or inhibition of phosphodiesterase 4 (PDE4) enzyme activity. Disorders and diseases amenable to treatment or prevention in accordance with the present invention include, e.g., depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, and bipolar disorder. In other variations, the disease or disorder is a neurodegenerative disease or disorder. In typical embodiments, the compound induces non-addicting CNS stimulation in a subject.
[0160] Accordingly, the present invention further provides pharmaceutical compositions and methods for the treatment or prevention of CNS diseases or disorders. The CNS
modulators of the present invention can be delivered or administered to a mammal, e.g., human subject, alone, in the form of a pharmaceutically acceptable salt or hydrolysable precursor thereof, or in the form of a pharmaceutical composition wherein the compound is mixed with suitable carriers or excipient(s) in a therapeutically effective amount. When administered in an appropriate therapeutically effective regime, a sufficient amount of the agent is present to inhibit serotonM reuptake and/or to inhibit PDE4 activity in vivo so as to modulate neurotransmitter receptor signaling.
[0161] The CNS modulators that are used in the methods of the present invention can be administered as pharmaceutical compositions comprising the agent together with one or more other pharmaceutically acceptable components. Pharmaceutical compositions can be in the form of solids (such as, e.g., powders, granules, dragees, tablets, or pills), semi-solids (such as, e.g., gels, slurries, or ointments), liquids, or gases (such as, e.g., aerosols or inhalants).
[0162] Suitable formulations for use in the present invention are found in, for example, Remington's Pharmaceutical Sciences (Mack Publishing Company, Philadelphia, PA, 17th ed. 1985) and Langer, Science 249:1527-1533, 1990. The pharmaceutical compositions described herein can be manufactured in a conventional manner, e.g., mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
[0163] In preparing the formulations of the present invention, pharmaceutically recognized equivalents of each of the compounds can be alternatively used. These pharmaceutically recognized equivalents can be pharmaceutically acceptable esters, amides, or salts or pharmaceutically acceptable acid addition salts.
[0164] A pharmaceutically acceptable salt is a non-toxic metal, alkaline earth metal, or an ammonium salt commonly used in the pharmaceutical industry including, for example, a sodium, potassium, lithium, calcium, magnesium, barium, ammonium, and protamine zinc salt, which is prepared by methods well-known in the art. The term also includes a non-toxic acid addition salt, which is generally prepared by reacting the compounds of the present invention with a suitable organic or inorganic acid. Representative salts include, e.g., hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and napsylate.
[0165] A pharmaceutically acceptable acid addition salt is a salt that retains the biological effectiveness and properties of the free bases and that is not biologically or otherwise undesirable, formed with inorganic acids such as, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, menthanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like (see, e.g., Bundgaard ed., Design of Prodrugs (Elsevier Science Publishers, Amsterdam 1985)).
[0166] The CNS modulators can be formulated with common excipients, diluents, or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration. The CNS modulators can also be formulated as sustained release dosage forms and the like.
[0167] In order to exert the desired therapeutic or prophylactic effects associated with inhibition of serotonin reuptake and/or PDE4 activity, the agents of the present invention must reach brain cells and brain tissue, requiring their passage from the blood to the brain by crossing the blood brain barrier, comprising the microcapillary membranes of the cerebrovascular endothelium. The present invention provides methods for administering a therapeutically effective dosage regime of the CNS modulator to a peripheral tissue in a patient (i.e., tissues other than central nervous system tissues). This can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdennal, intratracheal, and intramuscular administration. Moreover, the agents can be administered in a local rather than systemic manner, in a depot or sustained release formulation. In addition, the agents can be administered in a vesicle, in particular a liposome (see, e.g., Langer, supra; Treat et al., In Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler eds., Liss, New York, pp. 353-365, 1989).
[0168] For injection, the CNS modulators of the present invention can be formulated into preparations by dissolving, suspending, or emulsifying them in an aqueous or nonaqueous solvent such as, e.g., vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids, or propylene glycol; and, if desired, with conventional additives such as, e.g., solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers, and preservatives. Preferably, for injection, the compounds of the present invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
Bromides 11 were treated with potassium phthalimide in DMSO catalyzed by Nal at 70 C to produce phthilimido derivatives 12. Hydrolysis of 12 with hydrazine hydrate gave the desired amines 13. The cyano compounds 14 were formed in a similar manner. The cyano compounds 14 were catalytically hydrogenated in the presence of Raney nickel and one atmosphere of H2 to give the desired primary amines 15 as the major products and secondary amines 16 as the minor products. Alternatively, amines 15 were synthesized by reducing 14 with sodium borohydride in the presence of Raney nickel.
[0155] The synthetic procedures used for the preparation of cis-( )-4a,5,8,8a-tetrahydro-2H-phthalazin- 1-ones that were linked to the 2,5-disubstituted tetrahydrofurans and derivatives thereof is depicted in Scheme 3 (see Figure 3). Nucleophilic addition of Grignard reagent, 3,4-dimethoxyphenylmagnesium bromide to cis-1,2,3,6-tetrahydrophthalic anhydride afforded 7-keto acid in moderate yield (40%). The 7-keto acid readily underwent cyclization upon treatment with hydrazine hydrate in Et0H to give the corresponding phthalazinone. A
five carbon linker is attached to the phthalazinone with NaH and 1,5-dibromopentane. This adduct is then linked to the 2,5-disubstituted tetrahydrofurans with CsOH in DMF.
Synthesis of (S)-2-alkyl Pyrrolidines, Compounds 25b-25c [0156] S-Proline was a useful starting material for the synthesis of 2-alkylpyrrolidines because it provided a 2-substituted pyrrolidine with the desired (S)-stereochemistry. Further elaboration of the 2-monosubstituted pyrrolidine was made via the Wittig reaction to form compound 25. Compound 23 was converted into 1-tBoc-2-formylpyrrolidine, compound 24, by an oxidative reaction sequence and as described below, the t-Boc was a useful protecting group.
[0157] Reduction of compound 23a with lithium aluminum hydride and then N-protection with a tBoc group afforded 2-pyrrolidine methanol, compound 23b. Oxidation of compound 23b by Swem oxidation gave 1-tBoc-2-formylpyrrolindine, compound 24. Compound was treated with benzyltriphenylphosphonium chloride under standard Wittig conditions to provide a double bond at the C-2 position, compound 25a. Compound 25a was then deprotected and methylated to produce compounds 25b and 25c as depicted in Scheme 4.
(See Figure 4.) [0158] Monomethyl amine adducts were prepared for prodrugs of the primary amines. The general synthesis is diagramed in Scheme 5 (see Figure 5) where the ethyl carbamate is made from the primary amine with ethyl chloroformate in THE. The carbamate is then reduced to the methyl group with LAH in THF to yield the monomethyl secondary amine.
Pharmaceutical Compositions and Methods of Administration [0159] The agents of the present invention are useful in a variety of applications relating to modulation of cellular signaling. For example, in a preferred aspect of the invention, the agents are useful for modulation of CNS neurotransmitter signaling. Modulation of CNS
neurotransmitter signaling can be achieved, e.g., by the ability of an agent to modulate neurotransmitter reuptake (e.g., selective inhibition of serotonin reuptake) and/or to modulate cellular signaling downstream of a neurotransmitter receptor (e.g., inhibition of phosphodiesterase 4 (1PDE4) activity or G protein-coupled receptor kinase activity). Thus, in certain embodiments, the agents of the present invention are useful for the treatment or prevention of disorders or diseases amenable to therapeutic or prophylactic intervention via modulation (e.g., inhibition) of neurotransmitter reuptake and/or neurotransmitter receptor intracellular signaling pathways. For example, the agents are particularly useful for the treatment or prevention of CNS disorders or diseases amenable to therapeutic or prophylactic intervention by inhibition of serotonin reuptake and/or inhibition of phosphodiesterase 4 (PDE4) enzyme activity. Disorders and diseases amenable to treatment or prevention in accordance with the present invention include, e.g., depression, drug addiction, anxiety, attention-deficit disorder, schizophrenia, and bipolar disorder. In other variations, the disease or disorder is a neurodegenerative disease or disorder. In typical embodiments, the compound induces non-addicting CNS stimulation in a subject.
[0160] Accordingly, the present invention further provides pharmaceutical compositions and methods for the treatment or prevention of CNS diseases or disorders. The CNS
modulators of the present invention can be delivered or administered to a mammal, e.g., human subject, alone, in the form of a pharmaceutically acceptable salt or hydrolysable precursor thereof, or in the form of a pharmaceutical composition wherein the compound is mixed with suitable carriers or excipient(s) in a therapeutically effective amount. When administered in an appropriate therapeutically effective regime, a sufficient amount of the agent is present to inhibit serotonM reuptake and/or to inhibit PDE4 activity in vivo so as to modulate neurotransmitter receptor signaling.
[0161] The CNS modulators that are used in the methods of the present invention can be administered as pharmaceutical compositions comprising the agent together with one or more other pharmaceutically acceptable components. Pharmaceutical compositions can be in the form of solids (such as, e.g., powders, granules, dragees, tablets, or pills), semi-solids (such as, e.g., gels, slurries, or ointments), liquids, or gases (such as, e.g., aerosols or inhalants).
[0162] Suitable formulations for use in the present invention are found in, for example, Remington's Pharmaceutical Sciences (Mack Publishing Company, Philadelphia, PA, 17th ed. 1985) and Langer, Science 249:1527-1533, 1990. The pharmaceutical compositions described herein can be manufactured in a conventional manner, e.g., mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
[0163] In preparing the formulations of the present invention, pharmaceutically recognized equivalents of each of the compounds can be alternatively used. These pharmaceutically recognized equivalents can be pharmaceutically acceptable esters, amides, or salts or pharmaceutically acceptable acid addition salts.
[0164] A pharmaceutically acceptable salt is a non-toxic metal, alkaline earth metal, or an ammonium salt commonly used in the pharmaceutical industry including, for example, a sodium, potassium, lithium, calcium, magnesium, barium, ammonium, and protamine zinc salt, which is prepared by methods well-known in the art. The term also includes a non-toxic acid addition salt, which is generally prepared by reacting the compounds of the present invention with a suitable organic or inorganic acid. Representative salts include, e.g., hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and napsylate.
[0165] A pharmaceutically acceptable acid addition salt is a salt that retains the biological effectiveness and properties of the free bases and that is not biologically or otherwise undesirable, formed with inorganic acids such as, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, menthanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like (see, e.g., Bundgaard ed., Design of Prodrugs (Elsevier Science Publishers, Amsterdam 1985)).
[0166] The CNS modulators can be formulated with common excipients, diluents, or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration. The CNS modulators can also be formulated as sustained release dosage forms and the like.
[0167] In order to exert the desired therapeutic or prophylactic effects associated with inhibition of serotonin reuptake and/or PDE4 activity, the agents of the present invention must reach brain cells and brain tissue, requiring their passage from the blood to the brain by crossing the blood brain barrier, comprising the microcapillary membranes of the cerebrovascular endothelium. The present invention provides methods for administering a therapeutically effective dosage regime of the CNS modulator to a peripheral tissue in a patient (i.e., tissues other than central nervous system tissues). This can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdennal, intratracheal, and intramuscular administration. Moreover, the agents can be administered in a local rather than systemic manner, in a depot or sustained release formulation. In addition, the agents can be administered in a vesicle, in particular a liposome (see, e.g., Langer, supra; Treat et al., In Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler eds., Liss, New York, pp. 353-365, 1989).
[0168] For injection, the CNS modulators of the present invention can be formulated into preparations by dissolving, suspending, or emulsifying them in an aqueous or nonaqueous solvent such as, e.g., vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids, or propylene glycol; and, if desired, with conventional additives such as, e.g., solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers, and preservatives. Preferably, for injection, the compounds of the present invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
[0169] For oral administration, the CNS modulator can be formulated readily by combining with pharmaceutically acceptable carriers that are well-known in the art. Such carriers enable the compounds to be formulated as tablets, pills, dragees, capsules, emulsions, lipophilic and hydrophilic suspensions, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a subject to be treated. Pharmaceutial preparations for oral use can be obtained by mixing the compounds with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Particularly suitable excipients include fillers such as, for example, sugars (e.g., lactose, sucrose, mannitol, or sorbitol), cellulose preparations (e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone (PVP). If desired, disintegrating agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as, e.g., sodium alginate.
[0170] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions, and/or suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[0171] Pharmaceutical preparations that can be used orally include, for example, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as, e.g., glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as, for example, lactose, binders (e.g., starches), and/or lubricants (e.g., talc or magnesium stearate) and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as, e.g., fatty oils, liquid paraffin, or liquid polyethylene glycol.
[0172] For buccal administration, the compositions can take the form of tablets or lozenges formulated in a conventional manner.
[0173] For administration by inhalation, the compounds for use in accordance with the present invention are conveniently delivered in the form of an aerosol spray preparation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetraflouroethane, carbon dioxide or other suitable gas, or from propellant-free, dry-powder inhalers. In the case of a pressurized aerosol the dosage unit can be determined by, for example, providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as, for example, lactose or starch.
[0174] CNS modulators of the present invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative. The compositions can take such forms as, e.g., suspensions, solutions, or emulsions in oil-based or aqueous vehicles, and can contain formulator agents such as, for example, suspending, stabilizing, and/or dispersing agents.
[0175] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Alternatively, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils (e.g., sesame oil), synthetic fatty acid esters (e.g., ethyl oleate or triglycerides), or liposomes. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as, for example, sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0176] CNS modulators as described herein can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as, for example, cocoa butter, carbowaxes, polyethylene glycols, or other glycerides, all of which melt at body temperature, yet are solidified at room temperature.
[0177] In addition to the formulations described previously, the compounds can also be formulated as a depot preparation. Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
Accordingly, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., a sparingly soluble salt).
[0170] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions, and/or suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[0171] Pharmaceutical preparations that can be used orally include, for example, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as, e.g., glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as, for example, lactose, binders (e.g., starches), and/or lubricants (e.g., talc or magnesium stearate) and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as, e.g., fatty oils, liquid paraffin, or liquid polyethylene glycol.
[0172] For buccal administration, the compositions can take the form of tablets or lozenges formulated in a conventional manner.
[0173] For administration by inhalation, the compounds for use in accordance with the present invention are conveniently delivered in the form of an aerosol spray preparation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetraflouroethane, carbon dioxide or other suitable gas, or from propellant-free, dry-powder inhalers. In the case of a pressurized aerosol the dosage unit can be determined by, for example, providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as, for example, lactose or starch.
[0174] CNS modulators of the present invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative. The compositions can take such forms as, e.g., suspensions, solutions, or emulsions in oil-based or aqueous vehicles, and can contain formulator agents such as, for example, suspending, stabilizing, and/or dispersing agents.
[0175] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Alternatively, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils (e.g., sesame oil), synthetic fatty acid esters (e.g., ethyl oleate or triglycerides), or liposomes. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as, for example, sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0176] CNS modulators as described herein can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as, for example, cocoa butter, carbowaxes, polyethylene glycols, or other glycerides, all of which melt at body temperature, yet are solidified at room temperature.
[0177] In addition to the formulations described previously, the compounds can also be formulated as a depot preparation. Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
Accordingly, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., a sparingly soluble salt).
[0178] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds can be employed. Liposomes and emulsions are well-known examples of delivery vehicles or carriers for hydrophobic drugs. In some methods, long-circulating, e.g., stealth, liposomes can be employed. Such liposomes are generally described in U.S. Patent No.
5,013,556 to Woodle et a/.
[0179] The compounds of the present invention can also be administered by controlled release means and/or delivery devices. In certain variations, a pump is used (see, e.g., Langer, supra; Sefton, CRC Crit. Ref Biomed. Eng. 14:201, 1987; Buchwald et al., Surgery 88:507, 1980; Saudek et al., N. Engl. I Med. 321:574, 1989). In other embodiments, polymeric materials are used (see, e.g., Medical Applications of Controlled Release, Langer and Wise eds., CRC Pres., Boca Raton, Florida, 1974; Controlled Drug Bioavailability, Drug Product Design and Pelformatzee, Smolen and Bull eds., Wiley, New York, 1984;
Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61, 1983; see also Levy et al., Science 228:190, 1985; During et al., Ann. Neurol. 25:351, 1989; Howard et al., J.
Neurosurg. 71:105, 1989). Controlled release means and delivery devices are also described in, e.g., U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719.
[0180] Certain organic solvents such as, e.g., dimethylsulfoxide (DMSO) also can be employed, although usually at the cost of greater toxicity. Additionally, the compounds can be delivered using a sustained-release system such as, for example, semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established. Sustained-release capsules can, depending on their chemical nature, release the compounds for a few hours up to over 100 days.
[0181] The pharmaceutical compositions can also comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as, e.g., polyethylene glycols.
[0182] For treatment or prevention of drug addiction, compounds of the present invention may also be administered by incorporating the agent into a drag-containing product (for example, in the case of nicotine ingestion, a tobacco product such as, e.g., a cigarette). For example, in certain embodiments, a compound of the present invention is sprayed or otherwise applied onto the drug-containing product prior to ingestion.
5,013,556 to Woodle et a/.
[0179] The compounds of the present invention can also be administered by controlled release means and/or delivery devices. In certain variations, a pump is used (see, e.g., Langer, supra; Sefton, CRC Crit. Ref Biomed. Eng. 14:201, 1987; Buchwald et al., Surgery 88:507, 1980; Saudek et al., N. Engl. I Med. 321:574, 1989). In other embodiments, polymeric materials are used (see, e.g., Medical Applications of Controlled Release, Langer and Wise eds., CRC Pres., Boca Raton, Florida, 1974; Controlled Drug Bioavailability, Drug Product Design and Pelformatzee, Smolen and Bull eds., Wiley, New York, 1984;
Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61, 1983; see also Levy et al., Science 228:190, 1985; During et al., Ann. Neurol. 25:351, 1989; Howard et al., J.
Neurosurg. 71:105, 1989). Controlled release means and delivery devices are also described in, e.g., U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719.
[0180] Certain organic solvents such as, e.g., dimethylsulfoxide (DMSO) also can be employed, although usually at the cost of greater toxicity. Additionally, the compounds can be delivered using a sustained-release system such as, for example, semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established. Sustained-release capsules can, depending on their chemical nature, release the compounds for a few hours up to over 100 days.
[0181] The pharmaceutical compositions can also comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as, e.g., polyethylene glycols.
[0182] For treatment or prevention of drug addiction, compounds of the present invention may also be administered by incorporating the agent into a drag-containing product (for example, in the case of nicotine ingestion, a tobacco product such as, e.g., a cigarette). For example, in certain embodiments, a compound of the present invention is sprayed or otherwise applied onto the drug-containing product prior to ingestion.
[0183] Pharmaceutical compositions suitable for use in accordance with the present invention include compositions wherein the active ingredients are contained in a therapeutically effective amount. The therapeutically effective amounts for the methods of the present invention can depend on a variety of factors, including, e.g., age, body weight, general health, sex, diet, time and manner of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular affliction being treated. The amount of active agent will also depend upon the specific activity of the CNS modulator and whether that agent is co-administered with any other therapeutic or prophylactic ingredients.
[0184] Typically, a subject treated in accordance with the methods provided herein has been diagnosed with a disease or disorder amenable to treatment using a compound of the present invention; has been identified as at risk of a disease or disorder amenable to prophylaxis using the compound; or has otherwise been identified as a subject that will obtain a physiological benefit using the compound. In certain variations, the subject has not been diagnosed with a second disease or disorder (for example, another disease or disorder amenable to treatment using the compounds of the present invention). Further, in some embodiments, the subject is monitored during treatment for a physiological and/or clinical effect. For example, a subject can be monitored for one or more symptoms associated with the disease or disorder (e.g., for the treatment of depression, anxiety, bipolar disorder, attention deficit disorder, or schizophrenia in a subject, the subject can be monitored for one or more symptoms of depression, anxiety, bipolar disorder, attention deficit disorder, or schizophrenia, respectively).
EXAMPLES
[0185] The following examples are offered to illustrate but not to limit the claimed invention.
[0186] (Note: relative to the compound numbering scheme used elsewhere herein, each of Examples 28, 29, and 30 (and corresponding Figures and Tables) uses different compound reference designations.) Example 1: Trans-2-(Aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran [0187] 1-(2'-Methoxy-5'-fluorophenyl)pent-4-en-1-ol: To a solution of 2-methoxy-5-fluorobenzaldehyde (3.0 g, 19.5 mmol) in THF (20 mL) at 0 C was added a solution 1-butenylmagnesium bromide (0.5 M in THF, 45 mL, 22.5 mmol) dropwise for 15 min.
Then the reaction mixture was poured to a solution of saturated ammonium chloride (80 mL) in a separatory funnel. The organic fraction was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (10% Et0Ac in hexane, Rf = 0.11) to give the product as an oil (3.27 g, 93%).
[0188] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran: To a solution of 1-(2'-methoxy-5'-fluorophenyl)pent-4-en-1-ol (3.24 g, 18.0 rrunol) in dry CH2C12 (50 mL) at 0 C was added portionwise N-bromosuccinimide (NBS, 3.56 g, 20.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. Solvent was then removed in vacuo and the residue was purified by flash column chromatography (10% Et0Ac in Hexane, Rf = 0.28) to give the product (2.28 g, 44%) as an oil.
[0189] 2-(N-Phthalimidomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran:
To a vial under Ar(g) was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (1.28 g, 4.44 mmol), NaI (100 mg), potassium phthalimide (2.05 g, 11.1 mmol), and dry DMSO (10 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h.
After it was cooled to room temperature, the reaction mixture was poured in to a separatory funnel containing sodium bicarbonate aqueous solution (sat. NaHCO3: H20=1:1, 70 mL).
The organic fraction was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (20% Et0Ac in hexane, Rf = 0.12) to give the product (about 2:1 of trans:
cis isomers, 1.14 g, 72%) as an oil.
[0190] Trans-2-Aminomethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran: To a vial under Ar(g) was added 2-(N-phthalimidomethyl)-5-(21-methoxy-5'-fluorophenyl)tetrahydrofuran (225 mg, 0.63 mmol), hydrazine hydrate (150 mg, 4.9 mmol), and methanol (10 mL). The mixture thus obtained was stirred at room temperature for 12 h.
The solvent was then removed in vacuo and the crude product thus obtained was purified by column flash chromatography (10% methanol in CH2C12, 0.25 % triethylamine) to give the title compound (41 mg, 30%, Rf 0.08, trans: cis = 0.95:0.05).
10191] Similar methods were used to prepare: 2-(aminomethyl)-5-phenyltetrahydrofuran, 2-(aminomethyl)-5-(4'-chlorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-bromophenyptetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxyphenyptetrahydrofuran, 2-(aminomethyl)-5-(4'-t-butylphenyptetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-fluoro-4'-methylphenyl)tetrahydrofuran, 2-(aminomethyl)-5-cyclohexyltetrahydrofuran, 2-(aminomethyl)-5-(1'-naphethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-11-naphethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-naphethy1)tetrahydrofuran, 2-(aminomethyl)-5-(3'-quinoline)tetrahydrofuran, trans-2-(aminomethyl)-5-(2'-pyridyptetrahydrofuran.
Example 2: Cis-2-Aminoethy1-5-(T-methoxy-5'-fluorophenyptetrahydrofuran and N,N-Bis (5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryflethyDamine [0192] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran and cis-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran: To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofitran (1.23 g, 4.3 mmol), NaI (100 mg), potassium cyanide (0.7 g, 10.6 mmol), and dry DMSO (15 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured in to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: 1120=1:1, 80 mL). The organics were extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacua and crude product thus obtained was purified by flash column chromatography (20%
Et0Ac in hexane, Rf = 0.20). Careful analysis and collection of early fractions resulted in isolation of the trans isomer (HJX-I-30, 0.55 g, 55%); The rest of the fractions were collected and upon removal of the solvents, a white colored solid was formed. Further purification of this solid by triturating with hexane resulted in the cis isomer (HJX-I-30B, 250 mg, 25%);
[0193] /V,N-Bis (cis-5'-(2"-methoxy-5"-fluorophenyl-2'-tetrahydrofuranypethyl)amine and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran: To a vial under Ar(g) was added Raney Ni that was washed with ethanol (100%, 3 times) and cis-(cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (100 mg, 0.43 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated and purged with H2 three times each. Then a balloon was attached to the flask and the reaction was charged in 112 and allowed to go for 6 days at room temperature. The reaction mixture wasTM
then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10% Me0H in CH2C12, 1%
1'EA Rf =
0.31) to result in N,N-Bis (cis-5'-(2"-methoxy-5"-fluorophenyl-T-tetrahydrofuryl)ethyl)amine (HJX-I-40A) (11 mg, 6%) as a 1:1 diastereomers; and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (43 mg, 42%, Rf = 0.09).
[0194] Similar methods were used to prepare: 2-(aminoethyl)-5-phenyltetrahydrofuran, 2-(arninoethyl)-5-(4'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-bromophenyptetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(T-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-cyclohexyltetrahydrofuran, 2-(aminoethyl)-5-(21-furyptetrahydrofuran, and 1V
,N- bis (5'-phenyl-2'-tetrahydrof-urylethyl)amine, N,N- bis (5'-(p-fluoropheny1)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(p-bromopheny1)-2'-tetrahydrofurylethyl)amine, NN- bis (5'-(p-t-butylpheny1)-2'-tetrahydrofurylethyl)amine, NN- bis (5'-cyclohexy1-2'-tetrahydrofurylethyl)amine, N,N- bis (trans-5'-(2"-methoxy-5"-fluorophenyl-2'-tetrahydrofurypethyl)amine, NN- bis (5'-(2"-naphthy1-2'-tetrahydrofuryl)ethyl)amine.
Example 3: Trans-2-(aminomethyl)-5-(5'-fluoro-2'-methoxybenzyptetrahydrofuran [0195] 5-Fluoro-2-methoxyphenacetaldehyde: To a suspension of methoxymethyltriphenylphosphonium chloride (10.0 g, 30.0 mmol) in THF (30 mL) under Ar(g) was added NaH (60% in mineral oil, 1.2 g, 30 mmol) and the mixture thus obtained was heated to reflux for 1 h. The orange suspension thus obtained was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (4.2 g, 26.0 mmol) was added and the reaction was continued for 12 h while warmed to room temperature. The reaction mixture was poured in to a separatory funnel containing ammonium chloride aqueous solution (sat. NH4 Cl:
1120=1:1, 100 mL). The organic fraction was extracted with ethyl acetate (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over sodium sulfate. The solvent was then removed in vacuo and crude product thus obtained was dissolved in acetone (50 mL) and 1-12SO4 (1 M, 1.5 mL) was added and the mixture thus obtained was heated to reflux for 6 h. It was then cooled to room temperature and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10%
ethyl acetate in hexane, Rf = 0.15) to give the product (2.63 g, 66%) as an oil.
[0196] 1-(2'-Methoxy-5'-fluorophenyl)hex-5-en-2-ol: To a solution of 1-butenylmagnesium bromide (0.5 M in THF, 9 mL, 4.5 mmol) at 0 C was added a solution of 5-fluoro-2-methoxyphenylacetaldehyde (635 m g, 3.8 mmol) in THF (10 mL) dropwise for min. Then the reaction mixture was poured in to a solution of saturated ammonium chloride (40 mL) in a separatory funnel. The organics were extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent was removed in vacuo and crude product thus obtained was 10 purified by flash column chromatography (12.5% Et0Ac in hexane, Rf = 0.18) to give the product as an oil (642 mg, 74%).
[0197] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenylmethyl)tetrahydrofuran (trans, cis, mixture): To a solution of 1-(2'-methoxy-5'-fluorophenyl)hex-5-en-2-ol (1.35 g, 6.0 mmol) in dry CH2C12 (30 mL) at 0 C was added N-bromosuccinimide (NBS, 1.30 g, 7.2 15 mmol) portionwise and the reaction was warmed to room temperature for 12 h.
Solvent was then removed in vacuo and the residue was purified by flash column chromatography (5%
Et0Ac in Hexane, Rf = 0.12) to give in the trans isomer (663 mg, 36%) as an oil.
[0198] Trans-2-(N-Phthalimidomethyl)-5-(2'-methoxy-5'-fluorobenzAtetra-hydrofuran: To a vial under Ar(g) was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran (0.45 g, 1.48 mmol), NaI (80 mg), potassium phthalimide (0.7 g, 3.7 mrnol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarbonate aqueous solution (sat. NaHCO3:
H20=1:1, 50 mL). The organic fraction was extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate.
The solvent then was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (15% Et0Ac in hexane, Rf = 0.10) to give the product (385 mg, 70%) as an oil.
[0199] Trans-2-Aminomethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran: To a vial under Ar was added trans-2-(N-phthalimidomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran (100 mg, 0.27 mmol), hydrazine hydrate (100 mg, 3.5 mmol), and methanol (5 mL). The mixture thus obtained was stirred at room temperature for 6 h.
[0184] Typically, a subject treated in accordance with the methods provided herein has been diagnosed with a disease or disorder amenable to treatment using a compound of the present invention; has been identified as at risk of a disease or disorder amenable to prophylaxis using the compound; or has otherwise been identified as a subject that will obtain a physiological benefit using the compound. In certain variations, the subject has not been diagnosed with a second disease or disorder (for example, another disease or disorder amenable to treatment using the compounds of the present invention). Further, in some embodiments, the subject is monitored during treatment for a physiological and/or clinical effect. For example, a subject can be monitored for one or more symptoms associated with the disease or disorder (e.g., for the treatment of depression, anxiety, bipolar disorder, attention deficit disorder, or schizophrenia in a subject, the subject can be monitored for one or more symptoms of depression, anxiety, bipolar disorder, attention deficit disorder, or schizophrenia, respectively).
EXAMPLES
[0185] The following examples are offered to illustrate but not to limit the claimed invention.
[0186] (Note: relative to the compound numbering scheme used elsewhere herein, each of Examples 28, 29, and 30 (and corresponding Figures and Tables) uses different compound reference designations.) Example 1: Trans-2-(Aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran [0187] 1-(2'-Methoxy-5'-fluorophenyl)pent-4-en-1-ol: To a solution of 2-methoxy-5-fluorobenzaldehyde (3.0 g, 19.5 mmol) in THF (20 mL) at 0 C was added a solution 1-butenylmagnesium bromide (0.5 M in THF, 45 mL, 22.5 mmol) dropwise for 15 min.
Then the reaction mixture was poured to a solution of saturated ammonium chloride (80 mL) in a separatory funnel. The organic fraction was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (10% Et0Ac in hexane, Rf = 0.11) to give the product as an oil (3.27 g, 93%).
[0188] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran: To a solution of 1-(2'-methoxy-5'-fluorophenyl)pent-4-en-1-ol (3.24 g, 18.0 rrunol) in dry CH2C12 (50 mL) at 0 C was added portionwise N-bromosuccinimide (NBS, 3.56 g, 20.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. Solvent was then removed in vacuo and the residue was purified by flash column chromatography (10% Et0Ac in Hexane, Rf = 0.28) to give the product (2.28 g, 44%) as an oil.
[0189] 2-(N-Phthalimidomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran:
To a vial under Ar(g) was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (1.28 g, 4.44 mmol), NaI (100 mg), potassium phthalimide (2.05 g, 11.1 mmol), and dry DMSO (10 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h.
After it was cooled to room temperature, the reaction mixture was poured in to a separatory funnel containing sodium bicarbonate aqueous solution (sat. NaHCO3: H20=1:1, 70 mL).
The organic fraction was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (20% Et0Ac in hexane, Rf = 0.12) to give the product (about 2:1 of trans:
cis isomers, 1.14 g, 72%) as an oil.
[0190] Trans-2-Aminomethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran: To a vial under Ar(g) was added 2-(N-phthalimidomethyl)-5-(21-methoxy-5'-fluorophenyl)tetrahydrofuran (225 mg, 0.63 mmol), hydrazine hydrate (150 mg, 4.9 mmol), and methanol (10 mL). The mixture thus obtained was stirred at room temperature for 12 h.
The solvent was then removed in vacuo and the crude product thus obtained was purified by column flash chromatography (10% methanol in CH2C12, 0.25 % triethylamine) to give the title compound (41 mg, 30%, Rf 0.08, trans: cis = 0.95:0.05).
10191] Similar methods were used to prepare: 2-(aminomethyl)-5-phenyltetrahydrofuran, 2-(aminomethyl)-5-(4'-chlorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-bromophenyptetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxyphenyptetrahydrofuran, 2-(aminomethyl)-5-(4'-t-butylphenyptetrahydrofuran, cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-fluoro-4'-methylphenyl)tetrahydrofuran, 2-(aminomethyl)-5-cyclohexyltetrahydrofuran, 2-(aminomethyl)-5-(1'-naphethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-11-naphethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-naphethy1)tetrahydrofuran, 2-(aminomethyl)-5-(3'-quinoline)tetrahydrofuran, trans-2-(aminomethyl)-5-(2'-pyridyptetrahydrofuran.
Example 2: Cis-2-Aminoethy1-5-(T-methoxy-5'-fluorophenyptetrahydrofuran and N,N-Bis (5'-(2"-methoxy-5"-fluoropheny1-2'-tetrahydrofuryflethyDamine [0192] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran and cis-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran: To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofitran (1.23 g, 4.3 mmol), NaI (100 mg), potassium cyanide (0.7 g, 10.6 mmol), and dry DMSO (15 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured in to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: 1120=1:1, 80 mL). The organics were extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacua and crude product thus obtained was purified by flash column chromatography (20%
Et0Ac in hexane, Rf = 0.20). Careful analysis and collection of early fractions resulted in isolation of the trans isomer (HJX-I-30, 0.55 g, 55%); The rest of the fractions were collected and upon removal of the solvents, a white colored solid was formed. Further purification of this solid by triturating with hexane resulted in the cis isomer (HJX-I-30B, 250 mg, 25%);
[0193] /V,N-Bis (cis-5'-(2"-methoxy-5"-fluorophenyl-2'-tetrahydrofuranypethyl)amine and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran: To a vial under Ar(g) was added Raney Ni that was washed with ethanol (100%, 3 times) and cis-(cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (100 mg, 0.43 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated and purged with H2 three times each. Then a balloon was attached to the flask and the reaction was charged in 112 and allowed to go for 6 days at room temperature. The reaction mixture wasTM
then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10% Me0H in CH2C12, 1%
1'EA Rf =
0.31) to result in N,N-Bis (cis-5'-(2"-methoxy-5"-fluorophenyl-T-tetrahydrofuryl)ethyl)amine (HJX-I-40A) (11 mg, 6%) as a 1:1 diastereomers; and cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (43 mg, 42%, Rf = 0.09).
[0194] Similar methods were used to prepare: 2-(aminoethyl)-5-phenyltetrahydrofuran, 2-(arninoethyl)-5-(4'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-bromophenyptetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenyl)tetrahydrofuran, trans-2-(aminoethyl)-5-(T-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-cyclohexyltetrahydrofuran, 2-(aminoethyl)-5-(21-furyptetrahydrofuran, and 1V
,N- bis (5'-phenyl-2'-tetrahydrof-urylethyl)amine, N,N- bis (5'-(p-fluoropheny1)-2'-tetrahydrofurylethyl)amine, N,N- bis (5'-(p-bromopheny1)-2'-tetrahydrofurylethyl)amine, NN- bis (5'-(p-t-butylpheny1)-2'-tetrahydrofurylethyl)amine, NN- bis (5'-cyclohexy1-2'-tetrahydrofurylethyl)amine, N,N- bis (trans-5'-(2"-methoxy-5"-fluorophenyl-2'-tetrahydrofurypethyl)amine, NN- bis (5'-(2"-naphthy1-2'-tetrahydrofuryl)ethyl)amine.
Example 3: Trans-2-(aminomethyl)-5-(5'-fluoro-2'-methoxybenzyptetrahydrofuran [0195] 5-Fluoro-2-methoxyphenacetaldehyde: To a suspension of methoxymethyltriphenylphosphonium chloride (10.0 g, 30.0 mmol) in THF (30 mL) under Ar(g) was added NaH (60% in mineral oil, 1.2 g, 30 mmol) and the mixture thus obtained was heated to reflux for 1 h. The orange suspension thus obtained was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (4.2 g, 26.0 mmol) was added and the reaction was continued for 12 h while warmed to room temperature. The reaction mixture was poured in to a separatory funnel containing ammonium chloride aqueous solution (sat. NH4 Cl:
1120=1:1, 100 mL). The organic fraction was extracted with ethyl acetate (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over sodium sulfate. The solvent was then removed in vacuo and crude product thus obtained was dissolved in acetone (50 mL) and 1-12SO4 (1 M, 1.5 mL) was added and the mixture thus obtained was heated to reflux for 6 h. It was then cooled to room temperature and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10%
ethyl acetate in hexane, Rf = 0.15) to give the product (2.63 g, 66%) as an oil.
[0196] 1-(2'-Methoxy-5'-fluorophenyl)hex-5-en-2-ol: To a solution of 1-butenylmagnesium bromide (0.5 M in THF, 9 mL, 4.5 mmol) at 0 C was added a solution of 5-fluoro-2-methoxyphenylacetaldehyde (635 m g, 3.8 mmol) in THF (10 mL) dropwise for min. Then the reaction mixture was poured in to a solution of saturated ammonium chloride (40 mL) in a separatory funnel. The organics were extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent was removed in vacuo and crude product thus obtained was 10 purified by flash column chromatography (12.5% Et0Ac in hexane, Rf = 0.18) to give the product as an oil (642 mg, 74%).
[0197] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenylmethyl)tetrahydrofuran (trans, cis, mixture): To a solution of 1-(2'-methoxy-5'-fluorophenyl)hex-5-en-2-ol (1.35 g, 6.0 mmol) in dry CH2C12 (30 mL) at 0 C was added N-bromosuccinimide (NBS, 1.30 g, 7.2 15 mmol) portionwise and the reaction was warmed to room temperature for 12 h.
Solvent was then removed in vacuo and the residue was purified by flash column chromatography (5%
Et0Ac in Hexane, Rf = 0.12) to give in the trans isomer (663 mg, 36%) as an oil.
[0198] Trans-2-(N-Phthalimidomethyl)-5-(2'-methoxy-5'-fluorobenzAtetra-hydrofuran: To a vial under Ar(g) was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran (0.45 g, 1.48 mmol), NaI (80 mg), potassium phthalimide (0.7 g, 3.7 mrnol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarbonate aqueous solution (sat. NaHCO3:
H20=1:1, 50 mL). The organic fraction was extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate.
The solvent then was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (15% Et0Ac in hexane, Rf = 0.10) to give the product (385 mg, 70%) as an oil.
[0199] Trans-2-Aminomethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran: To a vial under Ar was added trans-2-(N-phthalimidomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran (100 mg, 0.27 mmol), hydrazine hydrate (100 mg, 3.5 mmol), and methanol (5 mL). The mixture thus obtained was stirred at room temperature for 6 h.
The solvent was then removed in vacuo and the crude product thus obtained was purified by flash column chromatography (10% methanol in CH2C12, 0.25 % triethylamine, Rf = 0.09) to give the product (54 mg, 60%, Rf = 0.10) as a viscous oil.
Example 4: Trans-2-(Aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran and N,N-Bis (trans-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofurany1)-2-ethyl)amine [0200] Trans-2-(Cyanomethyl)-5-(2' -methoxy-5' -fluorobenzyl)tetrahydrofuran:
To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran (0.76 g, 2.5 mmol), NaI (80 mg), potassium cyanide (0.4 g, 6.3 mmol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 40 mL). The organic fraction was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (10%
Et0Ac in hexane). Careful analysis and collection of early fractions resulted in the trans isomer (170 mg, 27%).
[0201] N,N-Bis (trans-5' -(2" -methoxy-5"-fluorobenzy1-2'-tetrahydrofury1)-2-ethyl)amine and trans-2-aminoethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran: To a vial under Ar(g) was added Raney Ni that was washed with ethanol (100%, 3 times) and trans-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran (88.8 mg, 0.36 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated and purged with H2 three times each. Then a H2 balloon was attached to the flask and charged with H2 and the reaction was allowed to go for 6 days at room temperature. The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10% Me0H
in CH2C12, 1% TEA Rf = 0.30) to result in (11 mg, 6%) as a 1:1 diastereomers;
and (41 mg, 45%, Rf = 0.09).
[0202] Similar methods were used to prepare: Cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran and N,N-bis (cis-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofurany1)-2-ethyl)amine.
Example 5: Trans-2-(Aminomethy1-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran [0203] Ethyl-3-(5'-fluoro-2'-methoxyphenyl)acrylate: To a solution of 5-fluoro-methoxybenzaldehyde (4.3 g, 28 mmol) in dry CH2C12 (40 mL) at 0 C was added carbethoxymethylenetriphenylphosphorane (10.7 g, 30 mmol) portionwise and the reaction was warmed to room temperature for 12 h. The solvent was then removed in vacuo and the residue was purified by flash column chromatography (8% Et0Ac in Hexane, Rf =
0.20) to yield the product (4 g, 95%) as an oil.
[0204] Ethyl-3-(5'-fluoro-2'-methoxyphenyl)propionate: To a solution of ethy1-3-(5'-fluoro-2'-methoxyphenyl)acrylate (6.0 g, 27 mmol) in ethanol (100%, 80 mL) under Ar was added Pd/C (10%, 250 mg) very carefully and the flask containing the mixture was evacuated and purged with H2 three time each. Then a H2 balloon was attached to the flask and charged with H2 and the reaction was allowed to go for 20 h at room temperature. Then the reaction mixture was filtered through a pad of silica eluted with mixed solvent of Et0Ac and Hexane (1:1). The crude product that obtained by removal of the solvent in vacuo was purified by flash column chromatography (10% Et0Ac in hexane, Rf = 0.20) to give the product (5.8 g, 95%).
[0205] 3-(5'-Fluoro-2'-methoxyphenyl)propionaldehyde: To a solution of ethy1-3-(5'-fluoro-2'-methoxyphenyl)propionate (5.8 g, 25.7 mmol) in dry toluene (40 mL) under Ar was added DIBAL solution (1 M in toluene, 30 mL, 30 mmol) at ¨78 C. The reaction was stirred at this temperature for 2 h. Methanol (2 mL) was added to the reaction mixture and the reaction was allowed to warm to 0 C. The reaction mixture was then poured into a separatory funnel containing HC1 solution (1 N, 150 mL). The organic function was extracted with ethyl acetate (3 x 100 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product that was obtained after removal of the solvent in vacuo was purified by flash column chromatography (20% Et0Ac in hexane, Rf = 0.20) to give the product (3.1 g, 66%).
[0206] 1-(2'-Methoxy-5'-fluorophenyl)hept-5-en-3-ol: To a solution of 1-butenylmagnesium bromide (0.5 M in THF, 18 mL, 9.0 mmol) at 0 C was added a solution of 3-(5'-fluoro-2'-methoxyphenyl)propionaldehyde (3.0 g, 16.5 mmol) in THF (30 mL) dropwise for 15 min. The reaction mixture was poured into a solution of saturated ammonium chloride (80 mL) in a separatory funnel. The organic function was extracted with ethyl acetate (3 x 80 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (15% Et0Ac in hexane, Rf 0.20) to give the product as an oil (3.7 g, 94%).
[0207] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenethAtetrahydrofuran (trans, cis): To a solution of 1-(2'-methoxy-5'-fluorophenyl)hept-5-en-3-ol (3.5 g, 14.7 mmol) in dry CH2C12 (90 mL) at 0 C was added N-bromosuccinimide (NBS, 3.15 g, 17.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. Solvent was then removed in vacuo and the residue was purified by flash column chromatography (5% Et0Ac in Hexane, Rf 0.12) to result in the trans isomer (2.05 g, 44%) as an oil; and the cis isomer (743 mg, 16%) as an oil; and mixture of both isomers (1.35 g, 29%).
[0208] Trans-2-(N-phthalimidomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahy-drofuran: To a vial under Ar(o was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (1.0 g, 3.2 mmol), NaI (75 mg), potassium phthalimide (1.5 g, 8 mmol), and dry DMSO (10 mL). The mixture thus obtained was heated to 70 C
under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat.
NaHCO3:
H20=1:1, 70 mL). The organics were extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (20% Et0Ac in hexane, Rf = 0.12) to give the product (0.695g, 57%).
[0209] Trans-2-(Aminomethy1-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran:
To a vial under Ar(g) was added trans-2-(N-phthalimidomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (380 mg, 1.0 mmol), hydrazine hydrate (287 mg, 9 mmol), and methanol (10 mL). The mixture thus obtained was stirred at room temperature for 12 h.
The solvent was then removed in vacuo and the crude product thus obtained was purified by column flash chromatography (10% methanol in CH2C12, 0.25 % triethylamine) to give the title compound (197 mg, 78%, Rf = 0.08, trans: cis = 0.95:0.05).
[0210] Similar methods were used to prepare: 2-(aminomethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-pyridylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-chloro-5'-trifluoromethylphenethyptetrahydrofuran, 2-(aminomethyl)-5-(pentafluorophenethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(3',4'-dimethoxyphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(11-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(-2"-tetrahydrofuryl-2'-ethyl)tetrahydrofuran.
Example 6: Trans-2-(Aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran and /V,/V--l3is (trans-5-(2'-methoxy-5'-fluorophenethy1-2-tetrahydrofiuyflethyl)amine [0211] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran:
To a vial under Ar(g) was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahy-drofuran (0.67 g, 2.1 mmol), NaI (70 mg), potassium cyanide (0.35 g, 5.3 mmol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h.
After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 40 mL). The organic function was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane) to result in the title product (448 mg, 86%).
[0212] /V,N-Bis(trans-5'-(2"-methoxy-5"-fluorophenethy11-2'-tetrahydrofurany1)-ethy1)amine and trans-2-(aminoethy1)-5-(2'-methoxy-5'-fluorophenethy1)tetrahydro furan: To a vial under Ar was added Raney Ni that was washed with ethanol (200 proof, 3 times) and trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenethyl) tetrahydro furan (448 mg, 1.8 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated and purged with H2 three times each. Then a H2 balloon was attached to the flask and charged with H2 and the reaction was allowed to go for 4 days at room temperature. The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10% Me0H in CH2C12, 1% TEA Rf = 0.30) to result in (114 mg, 24%) as a 1:1 diastereomers; and (192 mg, 40%, Rf = 0.09).
[0213] Similar methods were used to prepare: 2-(aminoethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-aminoethy1-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-hydroxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-trifluoromethoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-phenylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-fluoro-3'-methylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-fluoro-4'-methylphenethyl)tetrahydrofiu-an, 2-(aminoethyl)-5-(cyclohexylethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-pyridylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-pyridylethyptetrahydrofuran, 2-(aminoethyl)-5-(11-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(2'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxy-1 '-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(2'-naphthylethyl)tetrahydrofuran, and N,N- his (5'-phenethy1-2'-tetrahydrofurylethypamine, N,N- his (5'-phenethy1-2'-tetrahydrofurylethypmethylamine, N,N- bis (5'-(p-hydroxyphenethyl)-21-tetrahydrofurylethyl)amine, N,N- his (5'-(m-fluoro-p-methylphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-fluoro-m-methylphenethyl)-21-tetrahydrofurylethyl)amine, N,N- his (5'-(5"-fluoro-2"-methoxyphenethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(3"-pyridylethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(4"-pyridylethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(1"-naphthethyl)-T-tetrahydrofurylethypamine, N,N- his (5'-(2"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(4"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethypamine and related compounds.
Example 7: Trans-2-(Aminomethyl)-54 (2"-methoxy-5"-fluoropheny1)-3' propyl)tetrahydrofuran [0214] Ethyl-4-(5'-fluoro-2'-methoxyphenyl)butyrate: To a solution of ethy1-3-(5'-fluoro-2'-methoxybenzyl)acrylate (2.36 g, 10.0 mmol) in ethanol (100%, 40 mL) under Ar(g) was added Pd/C (10%, 200 mg) very carefully and the flask containing the mixture was evacuated and purged with H2 three time each. Then a balloon was attached to the flask and the reaction was allowed to go for 15 h at room temperature. The reaction mixture was filtered through a pad of silica eluted with mixed solvent of Et0Ac and Hexane (1:1). The crude product that obtained by removal of the solvent in vacuo was purified by a flash column chromatography (10% Et0Ac in hexane, Rf = 0.20) to give the product (2.25 g, 95%).
[0215] 4-(5'-Fluoro-2'-methoxyphenyl)butyraldehyde: To a solution of ethyl-4-(5'-fluoro-T-methoxyphenyl)butyrate (2.25 g, 9.4 mmol) in dry toluene (30 mL) under Ar(g) was added DMAL solution (1 M in toluene, 11 mL, 11 mmol) at ¨78 C. Then the reaction was stirred at this temperature for 2 h. Methanol (2 mL) was then added to the reaction mixture and the reaction was allowed to warm to 0 C. The reaction mixture was poured into a separatory funnel containing HC1 solution (1 N, 100 mL). The organic function was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product that obtained by removal of the solvent in vacuo was purified by flash column chromatography (10% Et0Ac in hexane, Rf = 0.10) to give the product (1.30 g, 70%).
[0216] 8-(5'-Fluoro-2'-methoxyphenyl)oct-1-en-5-ol: To a solution of 4-(5'-fluoro-2'-methoxyphenyl)butyraldehyde (1.30 g, 6.6 mmol) in THF (15 mL) at 0 C was added a solution 1-butenylmagnesium bromide (0.5 M in THF, 15 mL, 7.5 mmol) dropwise for 5 min.
Then the reaction mixture was poured to a solution of saturated ammonium chloride (60 mL) in a separatory funnel. The organics were extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with brine (40 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (12.5% Et0Ac in hexane, Rf = 0.15) to give the product as a colorless oil (1.06 g, 61%).
[0217] Trans-2-(Bromomethyl)-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran: To a solution of 8-(5'-fluoro-2'-methoxyphenyl)oct-1-en-5-ol (1.01 g, 4.01 mmol) in dry CH2C12 (30 mL) at 0 C under Ar(g) was added N-bromosuccinimide (NB 5, 890 mg, 5.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. Solvent was then removed in vacuo and the residue was purified by flash column chromatography (5% Et0Ac in hexane, Rf = 0.10) to result in the cis isomer enriched product (530 mg, >85% of cis-isomer, 40%) as a colorless oil.
[0218] 2-(N-Phthalimidomethyl)-542"-methoxy-5"-fluoropheny1)-31-propyl)tetrahydrofuran: To a vial under Ar was added trans-2-(bromomethyl)-542"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran (221 mg, 0.61 mmol), NaI
(50 mg), potassium phthilimide (300 mg, 1.50 mmol), and dry DMSO (4 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 30 mL). The organic function was extracted with ethyl acetate (3 x 30 mL) and the combined organic layers were washed with brine (30 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane, Rf =
0.09) to give the product (151 mg, 62%) as an oil.
[0219] Trans-2-Aminomethy1-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran: To a vial under Ar was added 2-(N-phthilimidomethyl)-542"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran (72 mg, 0.18 mmol), hydrazine hydrate (70 mg, 2.4 mmol), and methanol (4 mL). The mixture thus obtained was stirred at room temperature for 12 h. The solvent was then removed in vacuo and the crude product thus obtained was purified by flash column chromatography (12.5% methanol in CH2C12, 1 %
triethylamine Rf = 0.09) to give the product (42 mg, 87%) as a viscous oil.
[0220] Similar methods were used to prepare: cis-2-(aminomethyl)-542"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran.
Example 8: Trans-2-(Aminoethyl)-5(2"-methoxy-5"-fluoropheny1-3'-propyl)tetrahydrofuran and /V,N-Bis (trans-5-(2"-methoxy-5"-fluoropheny1-3'-propyl-T-tetrahydrofuryl)ethyDamine [0221] Trans-2-(Cyanomethyl)-5-(2"-methoxy-5"-fluoropheny1-3'-propyl)tetrahy-drofuran: To a vial under Ar was added 2-(bromomethyl)-5-(2"-methoxy-5"-fluoropheny1-31-propyl)tetrahydrofuran (0.10 g, 0.3 mmol), Nal (20 mg), potassium cyanide (0.15 g, 2.5 mmol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70' C
under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat.
NaHCO3:
H20=1:1, 40 mL). The organic function was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane) to result in the title product (71 mg, 89%).
Example 4: Trans-2-(Aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran and N,N-Bis (trans-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofurany1)-2-ethyl)amine [0200] Trans-2-(Cyanomethyl)-5-(2' -methoxy-5' -fluorobenzyl)tetrahydrofuran:
To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran (0.76 g, 2.5 mmol), NaI (80 mg), potassium cyanide (0.4 g, 6.3 mmol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 40 mL). The organic fraction was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (10%
Et0Ac in hexane). Careful analysis and collection of early fractions resulted in the trans isomer (170 mg, 27%).
[0201] N,N-Bis (trans-5' -(2" -methoxy-5"-fluorobenzy1-2'-tetrahydrofury1)-2-ethyl)amine and trans-2-aminoethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran: To a vial under Ar(g) was added Raney Ni that was washed with ethanol (100%, 3 times) and trans-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorobenzyptetrahydrofuran (88.8 mg, 0.36 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated and purged with H2 three times each. Then a H2 balloon was attached to the flask and charged with H2 and the reaction was allowed to go for 6 days at room temperature. The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10% Me0H
in CH2C12, 1% TEA Rf = 0.30) to result in (11 mg, 6%) as a 1:1 diastereomers;
and (41 mg, 45%, Rf = 0.09).
[0202] Similar methods were used to prepare: Cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran and N,N-bis (cis-5'-(2"-methoxy-5"-fluorobenzy1-2'-tetrahydrofurany1)-2-ethyl)amine.
Example 5: Trans-2-(Aminomethy1-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran [0203] Ethyl-3-(5'-fluoro-2'-methoxyphenyl)acrylate: To a solution of 5-fluoro-methoxybenzaldehyde (4.3 g, 28 mmol) in dry CH2C12 (40 mL) at 0 C was added carbethoxymethylenetriphenylphosphorane (10.7 g, 30 mmol) portionwise and the reaction was warmed to room temperature for 12 h. The solvent was then removed in vacuo and the residue was purified by flash column chromatography (8% Et0Ac in Hexane, Rf =
0.20) to yield the product (4 g, 95%) as an oil.
[0204] Ethyl-3-(5'-fluoro-2'-methoxyphenyl)propionate: To a solution of ethy1-3-(5'-fluoro-2'-methoxyphenyl)acrylate (6.0 g, 27 mmol) in ethanol (100%, 80 mL) under Ar was added Pd/C (10%, 250 mg) very carefully and the flask containing the mixture was evacuated and purged with H2 three time each. Then a H2 balloon was attached to the flask and charged with H2 and the reaction was allowed to go for 20 h at room temperature. Then the reaction mixture was filtered through a pad of silica eluted with mixed solvent of Et0Ac and Hexane (1:1). The crude product that obtained by removal of the solvent in vacuo was purified by flash column chromatography (10% Et0Ac in hexane, Rf = 0.20) to give the product (5.8 g, 95%).
[0205] 3-(5'-Fluoro-2'-methoxyphenyl)propionaldehyde: To a solution of ethy1-3-(5'-fluoro-2'-methoxyphenyl)propionate (5.8 g, 25.7 mmol) in dry toluene (40 mL) under Ar was added DIBAL solution (1 M in toluene, 30 mL, 30 mmol) at ¨78 C. The reaction was stirred at this temperature for 2 h. Methanol (2 mL) was added to the reaction mixture and the reaction was allowed to warm to 0 C. The reaction mixture was then poured into a separatory funnel containing HC1 solution (1 N, 150 mL). The organic function was extracted with ethyl acetate (3 x 100 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product that was obtained after removal of the solvent in vacuo was purified by flash column chromatography (20% Et0Ac in hexane, Rf = 0.20) to give the product (3.1 g, 66%).
[0206] 1-(2'-Methoxy-5'-fluorophenyl)hept-5-en-3-ol: To a solution of 1-butenylmagnesium bromide (0.5 M in THF, 18 mL, 9.0 mmol) at 0 C was added a solution of 3-(5'-fluoro-2'-methoxyphenyl)propionaldehyde (3.0 g, 16.5 mmol) in THF (30 mL) dropwise for 15 min. The reaction mixture was poured into a solution of saturated ammonium chloride (80 mL) in a separatory funnel. The organic function was extracted with ethyl acetate (3 x 80 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (15% Et0Ac in hexane, Rf 0.20) to give the product as an oil (3.7 g, 94%).
[0207] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenethAtetrahydrofuran (trans, cis): To a solution of 1-(2'-methoxy-5'-fluorophenyl)hept-5-en-3-ol (3.5 g, 14.7 mmol) in dry CH2C12 (90 mL) at 0 C was added N-bromosuccinimide (NBS, 3.15 g, 17.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. Solvent was then removed in vacuo and the residue was purified by flash column chromatography (5% Et0Ac in Hexane, Rf 0.12) to result in the trans isomer (2.05 g, 44%) as an oil; and the cis isomer (743 mg, 16%) as an oil; and mixture of both isomers (1.35 g, 29%).
[0208] Trans-2-(N-phthalimidomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahy-drofuran: To a vial under Ar(o was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (1.0 g, 3.2 mmol), NaI (75 mg), potassium phthalimide (1.5 g, 8 mmol), and dry DMSO (10 mL). The mixture thus obtained was heated to 70 C
under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat.
NaHCO3:
H20=1:1, 70 mL). The organics were extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (20% Et0Ac in hexane, Rf = 0.12) to give the product (0.695g, 57%).
[0209] Trans-2-(Aminomethy1-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran:
To a vial under Ar(g) was added trans-2-(N-phthalimidomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (380 mg, 1.0 mmol), hydrazine hydrate (287 mg, 9 mmol), and methanol (10 mL). The mixture thus obtained was stirred at room temperature for 12 h.
The solvent was then removed in vacuo and the crude product thus obtained was purified by column flash chromatography (10% methanol in CH2C12, 0.25 % triethylamine) to give the title compound (197 mg, 78%, Rf = 0.08, trans: cis = 0.95:0.05).
[0210] Similar methods were used to prepare: 2-(aminomethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(3'-pyridylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(2'-chloro-5'-trifluoromethylphenethyptetrahydrofuran, 2-(aminomethyl)-5-(pentafluorophenethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran, 2-(aminoethyl)-5-(3',4'-dimethoxyphenethyl)tetrahydrofuran, 2-(aminomethyl)-5-(11-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(2'-methoxy-1'-naphthylethyptetrahydrofuran, 2-(aminomethyl)-5-(4'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminomethyl)-5-(-2"-tetrahydrofuryl-2'-ethyl)tetrahydrofuran.
Example 6: Trans-2-(Aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran and /V,/V--l3is (trans-5-(2'-methoxy-5'-fluorophenethy1-2-tetrahydrofiuyflethyl)amine [0211] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran:
To a vial under Ar(g) was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahy-drofuran (0.67 g, 2.1 mmol), NaI (70 mg), potassium cyanide (0.35 g, 5.3 mmol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h.
After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 40 mL). The organic function was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane) to result in the title product (448 mg, 86%).
[0212] /V,N-Bis(trans-5'-(2"-methoxy-5"-fluorophenethy11-2'-tetrahydrofurany1)-ethy1)amine and trans-2-(aminoethy1)-5-(2'-methoxy-5'-fluorophenethy1)tetrahydro furan: To a vial under Ar was added Raney Ni that was washed with ethanol (200 proof, 3 times) and trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenethyl) tetrahydro furan (448 mg, 1.8 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated and purged with H2 three times each. Then a H2 balloon was attached to the flask and charged with H2 and the reaction was allowed to go for 4 days at room temperature. The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10% Me0H in CH2C12, 1% TEA Rf = 0.30) to result in (114 mg, 24%) as a 1:1 diastereomers; and (192 mg, 40%, Rf = 0.09).
[0213] Similar methods were used to prepare: 2-(aminoethyl)-5-(phenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-fluorophenethyl)tetrahydrofuran, 2-aminoethy1-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-hydroxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-trifluoromethoxyphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-methylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(4'-phenylphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-t-butylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(5'-fluoro-2'-methoxyphenethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-fluoro-3'-methylphenethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-fluoro-4'-methylphenethyl)tetrahydrofiu-an, 2-(aminoethyl)-5-(cyclohexylethyptetrahydrofuran, 2-(aminoethyl)-5-(3'-pyridylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-pyridylethyptetrahydrofuran, 2-(aminoethyl)-5-(11-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(2'-methoxy-1'-naphthylethyl)tetrahydrofuran, 2-(aminoethyl)-5-(4'-methoxy-1 '-naphthylethyptetrahydrofuran, 2-(aminoethyl)-5-(2'-naphthylethyl)tetrahydrofuran, and N,N- his (5'-phenethy1-2'-tetrahydrofurylethypamine, N,N- his (5'-phenethy1-2'-tetrahydrofurylethypmethylamine, N,N- bis (5'-(p-hydroxyphenethyl)-21-tetrahydrofurylethyl)amine, N,N- his (5'-(m-fluoro-p-methylphenethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(p-fluoro-m-methylphenethyl)-21-tetrahydrofurylethyl)amine, N,N- his (5'-(5"-fluoro-2"-methoxyphenethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(3"-pyridylethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(4"-pyridylethyl)-2'-tetrahydrofurylethyl)amine, N,N- his (5'-(1"-naphthethyl)-T-tetrahydrofurylethypamine, N,N- his (5'-(2"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethypamine, N,N- his (5'-(4"-methoxy-1"-naphthethyl)-2'-tetrahydrofurylethypamine and related compounds.
Example 7: Trans-2-(Aminomethyl)-54 (2"-methoxy-5"-fluoropheny1)-3' propyl)tetrahydrofuran [0214] Ethyl-4-(5'-fluoro-2'-methoxyphenyl)butyrate: To a solution of ethy1-3-(5'-fluoro-2'-methoxybenzyl)acrylate (2.36 g, 10.0 mmol) in ethanol (100%, 40 mL) under Ar(g) was added Pd/C (10%, 200 mg) very carefully and the flask containing the mixture was evacuated and purged with H2 three time each. Then a balloon was attached to the flask and the reaction was allowed to go for 15 h at room temperature. The reaction mixture was filtered through a pad of silica eluted with mixed solvent of Et0Ac and Hexane (1:1). The crude product that obtained by removal of the solvent in vacuo was purified by a flash column chromatography (10% Et0Ac in hexane, Rf = 0.20) to give the product (2.25 g, 95%).
[0215] 4-(5'-Fluoro-2'-methoxyphenyl)butyraldehyde: To a solution of ethyl-4-(5'-fluoro-T-methoxyphenyl)butyrate (2.25 g, 9.4 mmol) in dry toluene (30 mL) under Ar(g) was added DMAL solution (1 M in toluene, 11 mL, 11 mmol) at ¨78 C. Then the reaction was stirred at this temperature for 2 h. Methanol (2 mL) was then added to the reaction mixture and the reaction was allowed to warm to 0 C. The reaction mixture was poured into a separatory funnel containing HC1 solution (1 N, 100 mL). The organic function was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product that obtained by removal of the solvent in vacuo was purified by flash column chromatography (10% Et0Ac in hexane, Rf = 0.10) to give the product (1.30 g, 70%).
[0216] 8-(5'-Fluoro-2'-methoxyphenyl)oct-1-en-5-ol: To a solution of 4-(5'-fluoro-2'-methoxyphenyl)butyraldehyde (1.30 g, 6.6 mmol) in THF (15 mL) at 0 C was added a solution 1-butenylmagnesium bromide (0.5 M in THF, 15 mL, 7.5 mmol) dropwise for 5 min.
Then the reaction mixture was poured to a solution of saturated ammonium chloride (60 mL) in a separatory funnel. The organics were extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with brine (40 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by a flash column chromatography (12.5% Et0Ac in hexane, Rf = 0.15) to give the product as a colorless oil (1.06 g, 61%).
[0217] Trans-2-(Bromomethyl)-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran: To a solution of 8-(5'-fluoro-2'-methoxyphenyl)oct-1-en-5-ol (1.01 g, 4.01 mmol) in dry CH2C12 (30 mL) at 0 C under Ar(g) was added N-bromosuccinimide (NB 5, 890 mg, 5.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. Solvent was then removed in vacuo and the residue was purified by flash column chromatography (5% Et0Ac in hexane, Rf = 0.10) to result in the cis isomer enriched product (530 mg, >85% of cis-isomer, 40%) as a colorless oil.
[0218] 2-(N-Phthalimidomethyl)-542"-methoxy-5"-fluoropheny1)-31-propyl)tetrahydrofuran: To a vial under Ar was added trans-2-(bromomethyl)-542"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran (221 mg, 0.61 mmol), NaI
(50 mg), potassium phthilimide (300 mg, 1.50 mmol), and dry DMSO (4 mL). The mixture thus obtained was heated to 70 C under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 30 mL). The organic function was extracted with ethyl acetate (3 x 30 mL) and the combined organic layers were washed with brine (30 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane, Rf =
0.09) to give the product (151 mg, 62%) as an oil.
[0219] Trans-2-Aminomethy1-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran: To a vial under Ar was added 2-(N-phthilimidomethyl)-542"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran (72 mg, 0.18 mmol), hydrazine hydrate (70 mg, 2.4 mmol), and methanol (4 mL). The mixture thus obtained was stirred at room temperature for 12 h. The solvent was then removed in vacuo and the crude product thus obtained was purified by flash column chromatography (12.5% methanol in CH2C12, 1 %
triethylamine Rf = 0.09) to give the product (42 mg, 87%) as a viscous oil.
[0220] Similar methods were used to prepare: cis-2-(aminomethyl)-542"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran.
Example 8: Trans-2-(Aminoethyl)-5(2"-methoxy-5"-fluoropheny1-3'-propyl)tetrahydrofuran and /V,N-Bis (trans-5-(2"-methoxy-5"-fluoropheny1-3'-propyl-T-tetrahydrofuryl)ethyDamine [0221] Trans-2-(Cyanomethyl)-5-(2"-methoxy-5"-fluoropheny1-3'-propyl)tetrahy-drofuran: To a vial under Ar was added 2-(bromomethyl)-5-(2"-methoxy-5"-fluoropheny1-31-propyl)tetrahydrofuran (0.10 g, 0.3 mmol), Nal (20 mg), potassium cyanide (0.15 g, 2.5 mmol), and dry DMSO (5 mL). The mixture thus obtained was heated to 70' C
under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat.
NaHCO3:
H20=1:1, 40 mL). The organic function was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane) to result in the title product (71 mg, 89%).
[0222] /V,N-Bis(trans-5-(2"-methoxy-5"-fluoropheny1-3'-propy1-2'-tetrahydrofuryl)ethyl)amine and trans-2-(aminoethyl)-5-(2"-methoxy-5"-fluorophenyl-3'-propyl)tetrahydrofuran: To a vial under Ar was added Raney Ni that was washed with ethanol (100%, 3 times) and trans-2-(cyanomethyl)-5-(2"-methoxy-5"-fluoropheny1-31-propyl)tetrahydrofuran (71 mg, 0.27 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated and purged with 112 three times each.
Then a balloon was attached to the flask and the reaction was allowed to go for 4 days at room temperature.
The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10%
Me0H in CH2C12, 1% TEA Rf = 0.30) to result in (7 mg, 19%) as a 1:1 diastereomers; and (36 mg, 50%, Rf = 0.09).
[0223] Similar methods were used to prepare: cis-2-aminoethy1-5-(2"-methoxy-5"-fluoropheny1-3'-propyptetrahydrofuran.
Example 9: Cis-2-(Phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran [0224] Cis-2-(Phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran:
To a vial under Ar was added phenylacetaldehyde (18 mg, 0.15 mmol), cis-2-aminoethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (30 mg, 0.13 mmol) and Me0H (5 mL) and the mixture thus obtained was stirred at room temperature for 30 min. NaCNBH3 (20 mg, 0.30 mg) was added and the reaction was continued for 12 h. Solvent was removed and the product was purified by flash column chromatography (5% Me0H in CH2C12, 0.1%
TEA, Rf = 0.3) resulted in the product (14 mg, 31%).
[0225] Similar methods were used to prepare: cis-2-(phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, trans-2-(dimethylaminomethyl)-5-(T-methoxy-5'-fluorophenyl)tetrahydrofuran, N,N- bis (5'-phenethy1-2'-tetrahydrofurylethyl)methylamine.
Example 10: Trans-2-(Morpholinomethyl)-5-(2'-methoxy-5'-fluorophenylethyl) tetrahydrofuran [0226] To a flask under Ar was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (43 mg, 0.136 mmol), Nal (30 mg), morpholine(65 mg, 0.75 mmol), NaHCO3 (130 mg) and dry DMSO (2.5 mL) and dry THF (4 mL). The mixture thus obtained was heated to reflux under Ar(g) for 12 h. After it was cooled to room temperature, the reaction mixture was poured to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 30 mL). The organic function was extracted with ethyl acetate (3 x 30 mL) and the combined organic layers were washed with brine (30 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (2% Me0H in CH2C12, 0.1%
TEA, Rf= 0.21) to give the product (29 mg, 66%) as an oil.
[0227] Similar methods were used to prepare: , trans-2-(piperidinomethyl)-5-(2"-methoxy-5"-fluoropheny1-31-propyptetrahydrofuran, trans-2-piperidylmethy1-5-(2-methoxy-5'-fluorophenylethyl)tetrahydrofuran.
Example 11: Trans-2-(N,N-diethylaminomethyl)-5-(2'-methoxy-5'-fluorophenethyl) tetrahydrofuran [0228] To a vial under Ar was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (50 mg, 0.16 mmol), NaI (30 mg), diethylamine (55 mg, 0.75 mmol), NaHCO3 (120 mg), and dry DMSO (4 mL). The mixture thus obtained was heated to 50 C under Ar for 72 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarbonate aqueous solution (sat. NaHCO3: H20=1:1, 30 mL). The organic function was extracted with ethyl acetate (3 x mL) and the combined organic layers were washed with brine (30 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane, Rf = 0.09) to give the product (14 mg, 28%) as an oil.
Example 12: Trans-2-asothiocyanomethyl)-5-(2'-methoxy-5'-fluorophenethyl) tetrahydrofuran [0229] To a solution of trans-2-(bromomethyl)-5-(21-methoxy-5'-fluorophenethyl)tetrahydrofuran (33 mg, 0.13 mmol) in CHC13 (6 mL) was added a solution of NaHCO3 (50 mg, in 3 mL of water) and the mixture was cooled to 0 C. A
solution of thiophosgene (30 mg, 0.26 mmol) in CHC13 (1 mL) was added and the reaction was stirred for 2 h. then the reaction mixture was partitioned between water (20 mL) and CH2Q2 (30 mL) and the organic layer was collected and dried over Na2SO4. The solvent was removed in vacuo and the crude product thus obtained was purified by flash chromatography (22 mg, 57%).
Example 13: 3,4-Dimethoxyphenylmagnesium bromide [0230] In a flame dried round bottom flask with magnetic stir bar was put anhydrous THF
(150 mL) and Mg(s) turnings (1.43g, 58.8 mmol, 1.0 eq). The flask was then fitted with a pressure equalizing addition funnel containing 4-bromo-1,2-dimethoxybenzene (12.7g, 59 mmol, 1.03 eq) in THF (50mL). The 4-bromo-1,2-dimethoxybenzene solution was then added dropwise over a period of 45 min while stirring at room temperature.
Once the addition was complete 12 (500mg) was added and then the reaction was brought to reflux for 12 hr. The Grignard reagent was then used immediately to make the 6-(3,4-dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid.
Example 14: 6-(3,4-dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid [0231] A solution of 3,4-dimethoxypehnylmagnesium bromide (59 mmol, 0.29 M) in THF
was added dropwise to an ice-cooled solution of cis-1,2,3,6-tetrahydrophthalic anhydride in THF (120mL) over a 1 h period. After the addition was complete, the resulting mixture was stirred for another 30 min at 0 C. The reaction mixture was allowed to warm to room temperature overnight. The reaction was quenched with sat. NH4C1(aq) and then the pH was adjusted to 2 with concentrated HC1(aq) and extracted with diethyl ether. The combined organic extracts were washed with water and subsequently extracted with 1 M
Na011(aq). The combined aqueous extracts were neutralized with conc. HC100 and extracted with Et0Ac.
The combined organic extracts were dried over MgSO4, filtered through paper, and concentrated under reduced pressure to give an oil. The oil was dissolved in CH2C12 and filtered through silica to remove any dicarboxylic acid formed during the reaction work up.
The product was recrystalized in diethyl ether to afford a white solid (1.62g, 5.58 mmol, 10%).
Then a balloon was attached to the flask and the reaction was allowed to go for 4 days at room temperature.
The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (10%
Me0H in CH2C12, 1% TEA Rf = 0.30) to result in (7 mg, 19%) as a 1:1 diastereomers; and (36 mg, 50%, Rf = 0.09).
[0223] Similar methods were used to prepare: cis-2-aminoethy1-5-(2"-methoxy-5"-fluoropheny1-3'-propyptetrahydrofuran.
Example 9: Cis-2-(Phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran [0224] Cis-2-(Phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran:
To a vial under Ar was added phenylacetaldehyde (18 mg, 0.15 mmol), cis-2-aminoethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (30 mg, 0.13 mmol) and Me0H (5 mL) and the mixture thus obtained was stirred at room temperature for 30 min. NaCNBH3 (20 mg, 0.30 mg) was added and the reaction was continued for 12 h. Solvent was removed and the product was purified by flash column chromatography (5% Me0H in CH2C12, 0.1%
TEA, Rf = 0.3) resulted in the product (14 mg, 31%).
[0225] Similar methods were used to prepare: cis-2-(phenethylaminoethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrofuran, trans-2-(dimethylaminomethyl)-5-(T-methoxy-5'-fluorophenyl)tetrahydrofuran, N,N- bis (5'-phenethy1-2'-tetrahydrofurylethyl)methylamine.
Example 10: Trans-2-(Morpholinomethyl)-5-(2'-methoxy-5'-fluorophenylethyl) tetrahydrofuran [0226] To a flask under Ar was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (43 mg, 0.136 mmol), Nal (30 mg), morpholine(65 mg, 0.75 mmol), NaHCO3 (130 mg) and dry DMSO (2.5 mL) and dry THF (4 mL). The mixture thus obtained was heated to reflux under Ar(g) for 12 h. After it was cooled to room temperature, the reaction mixture was poured to a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20=1:1, 30 mL). The organic function was extracted with ethyl acetate (3 x 30 mL) and the combined organic layers were washed with brine (30 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (2% Me0H in CH2C12, 0.1%
TEA, Rf= 0.21) to give the product (29 mg, 66%) as an oil.
[0227] Similar methods were used to prepare: , trans-2-(piperidinomethyl)-5-(2"-methoxy-5"-fluoropheny1-31-propyptetrahydrofuran, trans-2-piperidylmethy1-5-(2-methoxy-5'-fluorophenylethyl)tetrahydrofuran.
Example 11: Trans-2-(N,N-diethylaminomethyl)-5-(2'-methoxy-5'-fluorophenethyl) tetrahydrofuran [0228] To a vial under Ar was added trans-2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (50 mg, 0.16 mmol), NaI (30 mg), diethylamine (55 mg, 0.75 mmol), NaHCO3 (120 mg), and dry DMSO (4 mL). The mixture thus obtained was heated to 50 C under Ar for 72 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarbonate aqueous solution (sat. NaHCO3: H20=1:1, 30 mL). The organic function was extracted with ethyl acetate (3 x mL) and the combined organic layers were washed with brine (30 mL) and dried over sodium sulfate. The solvent then was removed in vacuo and crude product thus obtained was purified by flash column chromatography (15% Et0Ac in hexane, Rf = 0.09) to give the product (14 mg, 28%) as an oil.
Example 12: Trans-2-asothiocyanomethyl)-5-(2'-methoxy-5'-fluorophenethyl) tetrahydrofuran [0229] To a solution of trans-2-(bromomethyl)-5-(21-methoxy-5'-fluorophenethyl)tetrahydrofuran (33 mg, 0.13 mmol) in CHC13 (6 mL) was added a solution of NaHCO3 (50 mg, in 3 mL of water) and the mixture was cooled to 0 C. A
solution of thiophosgene (30 mg, 0.26 mmol) in CHC13 (1 mL) was added and the reaction was stirred for 2 h. then the reaction mixture was partitioned between water (20 mL) and CH2Q2 (30 mL) and the organic layer was collected and dried over Na2SO4. The solvent was removed in vacuo and the crude product thus obtained was purified by flash chromatography (22 mg, 57%).
Example 13: 3,4-Dimethoxyphenylmagnesium bromide [0230] In a flame dried round bottom flask with magnetic stir bar was put anhydrous THF
(150 mL) and Mg(s) turnings (1.43g, 58.8 mmol, 1.0 eq). The flask was then fitted with a pressure equalizing addition funnel containing 4-bromo-1,2-dimethoxybenzene (12.7g, 59 mmol, 1.03 eq) in THF (50mL). The 4-bromo-1,2-dimethoxybenzene solution was then added dropwise over a period of 45 min while stirring at room temperature.
Once the addition was complete 12 (500mg) was added and then the reaction was brought to reflux for 12 hr. The Grignard reagent was then used immediately to make the 6-(3,4-dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid.
Example 14: 6-(3,4-dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid [0231] A solution of 3,4-dimethoxypehnylmagnesium bromide (59 mmol, 0.29 M) in THF
was added dropwise to an ice-cooled solution of cis-1,2,3,6-tetrahydrophthalic anhydride in THF (120mL) over a 1 h period. After the addition was complete, the resulting mixture was stirred for another 30 min at 0 C. The reaction mixture was allowed to warm to room temperature overnight. The reaction was quenched with sat. NH4C1(aq) and then the pH was adjusted to 2 with concentrated HC1(aq) and extracted with diethyl ether. The combined organic extracts were washed with water and subsequently extracted with 1 M
Na011(aq). The combined aqueous extracts were neutralized with conc. HC100 and extracted with Et0Ac.
The combined organic extracts were dried over MgSO4, filtered through paper, and concentrated under reduced pressure to give an oil. The oil was dissolved in CH2C12 and filtered through silica to remove any dicarboxylic acid formed during the reaction work up.
The product was recrystalized in diethyl ether to afford a white solid (1.62g, 5.58 mmol, 10%).
Example 15: 4-(3,4-Dimethoxy-phenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one [0232] A mixture of 6-(3,4-dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid (112mg, 0.39 mmol, 1.0 eq) and hydrazine hydrate (3 lmg, 0.96 mmol, 2.5 eq) in Et0H
(3mL) was refluxed for 4 hr. The reaction was then cooled to room temperature and then concentrated under reduced pressure to oil. The oil was dissolved in Et0Ac and washed with water followed by brine. The organic layer was then dried over Na2SO4, filtered through paper, and concentrated under reduced pressure to oil. The product was recrystallized in Et0H to yield a white solid.
Example 16: 245-Bromo-penty1)-4-(3,4-dimethoxypheny1)-4a,5,8,8a-tetrahydro-2H-phthalaxin-1-one [0233] Sodium hydride (60% dispersion in oil, 44mg, 1.1 mmol, 1.1 eq) was added to a solution of 4-(3,4-dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (287 mg, 1.0 mmol, 1.0 eq). The mixture was stirred for 30 min whereupon it took on a slight yellow color and then 1,5-dibromopentane (600mg, 2.6 mmol, 2.6 eq)was added via syringe. After 30 min the yellow color had diminished and the reaction was poured into water.
The solution was extracted with Et20 and washed with brine. The organic layer was dried over MgSO4, filtered through paper, and concentrated under reduced pressure to provide a clear oil. The product was chromatographed through silica with CH2C12 to afford a clear oil.
Example 17: 4-(3,4-Dimethoxypheny1)-245-(2-{542-(5-fluoro-2-methoxypheny1)-ethyl]-tetrahydrofuran-2-yll -ethylamino)-p enty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-l-one [0234] Cesium hydroxide monohydrate (23mg, 0.14 mmol, 1.0 eq) and DMF (0.5mL) was stirred in a flame dried round bottom flask under Ar(g) for 30 min at room temperature. Then 2-aminoethy1-5-(2'-methoxy-5'-fluoro phenethyltetrahydro furan (37mg, 0.14 mmol, 1.0 eq) in DMF (0.3mL) was added via syringe and stirred at room temperature for 30 min. 245-Bromo-penty1)-4-(3,4-dimethoxypheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (72mg, 0.16 mmol, 1.2 eq) in DMF (0.3mL) was added and continued to stir for 24 hr at room temperature. The reaction was filtered through paper with Et0Ac (30mL) and then the filtrate was washed with water in a seperatory funnel. The organic layer was dried with Na2SO4, filtered through paper, and concentrated to give an oil. The product was purified with prep TLC eluted with 5% Me0H in CH2C12 to afford a yellow oil (27mg, 0.04 mmol, 31%).
[0235] Similar methods were used to prepare 4-(3,4-Dimethoxypheny1)-245-(2-{54245-fluoro-2-methoxypheny1)-propylHetrahydrofuran-2-yll - ethylamino)-p enty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-[5-(2-{54245-fluoro-2-methoxy-pheny1)-ethyTtetrahydro-furan-2-y1}-ethylamino)-pentylkpyrrolidin-2-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-[5-(2-1543-(5-fluoro-2-methoxy-pheny1)-propyll-tetrahydro-furan-2-yll-ethylamino)-pentyll-pyrrolidin-2-one, 4-(3,4-Dimethoxy-pheny1)-2- {5[3-pheny1-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyll -4a,5,8,8 a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-1543-pheny1-3-(4-trifluoromethyl-phenoxy)-propylaminol-pentyll-pyrrolidin-2-one, 2-(3-{54443,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-y11-pentylamino}-propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 2-(3-{5-[4-(3-Cyclopentyloxy-4-methoxy-pheny1)-2-oxo-pyrroliclin-1-y1]-pentylaminof -propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 4-(3,4-Dimethoxy-pheny1)-2-(5-1[5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylinethyl]-amino}-penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclop entyloxy-4-methoxy-pheny1)-1-(5- 1[5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyTaminof -penty1)-pyrrolidin-2-one, 2-15-[(5-Cyclohexyl-tetrahydro-furan-ylmethyl)-amino]-pentyl} -4-(3,4-dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 1- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentylf -4-(3-cyclopentyloxy-4-methoxy-pheny1)-pyrrolidin-2-one, 4-(3,4-Dimethoxy-phenyl)-2-(5- { [543 -fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethy1]-amino} -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- { [5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethyThamino}-penty1)-pyrrolidin-2-one.
Example 18: (S)-2-Pyrrolidine Methanol [0236] A suspension of lithium aluminium hydride (3.8 g, 0.1 mol) in 160 mL
THF was refluxed for 15 min. (S)-Proline (7.4 g, 0.06 mol) was added in small portions to the refluxing mixture at a rate to keep the reaction under reflux without external heating. The mixture was refluxed for an additional 1 hr. The reaction was stopped by careful addition of potassium hydroxide solution (1.8 g in 7.2 mL 1120) with reduced heat. The mixture was then refluxed for 15 min and the hot solution was filtered. The precipitate was refluxed with THF for an hour and filtered once more. The combined filtrates were concentrated under reduced pressure and used for the next step without further purification in quantitative yield.
Example 19: 1-tBoc-2-Hydroxymethyl Pyrrolidine [0237] Pyrrolidine methanol (2 g, 20 mmol) in 20 mL dichloromethane was placed in a round bottom flask. To the dichloromethane solution, di-t-butyldicarbonate (4.8 g, 2.2 mmol) in 10 mL dichloromethane was slowly added at 0 C. The mixture was stirred for 30 min at 0 C and the reaction was stopped by addition of 30 mL saturated sodium carbonate at 0 C.
The aqueous layer was separated and extracted three times with 30 mL
dichloromethane.
The organic layers were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography Me0H/CH2C12 (5:95, v:v) to give 1-tBoc-2-hydroxymethyl pyrrolidine in 92% yield.
Example 20: 1-tBoc-2-Formyl Pyrrolidine [0238] Dimethyl sulfoxide (2.66 mL, 37.5 mmol) in 6 mL dichloromethane was added dropwise to oxalyl chloride (2.1 g, 16.5 mmol) in 30 mL dichloromethane at -78 C. After 5 min, 1-tBoc-2-hydroxymethyl pyrrolidine (3 g, 15 mmol) was added dropwise to the solution.
After another 15 min, 10 mL of triethylamine was added dropwise to the solution and the mixture was stirred for 5 min. The mixture was brought to 25 C and the reaction was stopped by the addition of 50 mL water. The aqueous layer was separated and extracted three times with 50 mL dichloromethane. The organic layers were combined and washed with 100 mL each of water, 5% sodium carbonate, water, and saturated sodium chloride.
The organic solution was then dried over sodium sulfate, filtered, and concentrated in vacuo to give 1-tBoc-2-formyl pyrrolidine. The product was used for the next step without further purification: 52% yield.
Example 21: 1-tBoc-2-Styrenyl Pyrrolidine [0239] Benzyltriphenylphosphonium chloride (3.89 g, 10 mmol) in 10 mL diethyl ether was placed in a round bottom flask. The solution was cooled to -78 C and nBuLi (4 mL of 2.5M nBuLi in hexane, 10 mmol) was added dropwise to the solution. After 30 min, the suspension was added dropwise to 1-tBoc-2-formyl pyrrolidine (2 g, 10 mmol) in 10 mL
diethyl ether at -78 C and the mixture was stirred for 3 hours. The reaction was stopped with 50 mL H20, the organic layer was separated from the aqueous layer, and the aqueous layer was extracted 3 times with 50 mL diethyl ether. The combined organic layer was washed with H20 until the pH of the aqueous layer was 7, dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by silica column chromatography Et0Ac/
hexane (10:90, v:v), 1.1 g, 40% yield.
Example 22: 2-Styrenyl Pyrrolidine [0240] A solution of 1-tBoc-2-phenethyl pyrrolidine (230 mg, 0.84 mmol) in 5 mL
trifiuoroacetic acid was stirred for 30 min at 0 C. The trifluoroacetic acid was removed under reduced pressure. The residue was dissolved in 5 mL diethyl ether and the ethereal solution was washed with 5 mL saturated Na2CO3 and extracted twice with 2 mL
of 1N HC1.
The combined HC1 solution was then basicified with saturated Na2CO3 to pH = 10 and extracted three times with 5 mL dichloromethane. The combined dichloromethane layers were washed with 10 mL saturated NaCl, dried over Na2SO4, filtered, and concentrated in vacuum. The residue was purified on thin layer chromatography to give 2-phenethyl pyrrolidine: 120 mg, 82% yield.
Example 23: 1-Methyl-2-Styrenyl Pyrrolidine [0241] Sodium cyanoborohydride (17.4 mg, 0.27 mmol) was added portion-wise to a stirred solution of 2-phenethyl pyrrolidine (30 mg, 0.17 mmol) and 37% aqueous formaldehyde (0.07 mL, 0.87 mmol) in 1.5 mL acetonitrile at 25 C. The mixture was stirred for 15 min, acetic acid was added dropwise until the reaction was neutral, and the mixture was stirred for an additional 2 hours. The solvent was removed under reduced pressure. The residue was dissolved in 10 mL diethyl ether and the ethereal solution was washed with 10 mL of saturated Na2CO3 and extracted twice with 5 mL of 1N HC1. The combined solutions were then basicified with saturated Na2CO3 to obtain a pH = 10 and extracted three times with 10 mL dichloromethane. The combined dichloromethane layers were washed with 10 mL of saturated NaC1, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified on thin layer chromatography to give 1-methyl-2-phenethyl pyrrolidine free base; 18 mg, 55% yield.
Example 24: (2- {542-(5-Fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-111-ethyl)-carbamic ethyl ester [0242] In a flame dried 20 mL scintillation vial was placed K2CO3 (239mg, 1.73 mmol, 6.0 eq) and of anhydrous THF (5.0 mL). The vial was purged with Ar(g) and then chilled in an ice bath. Ethyl chloroformate (156 mg, 1.44 mmol, 5.0 eq) was then added via syringe followed by a slow addition of the primary amine (77 mg, 0.29 mmol, 1.0 eq) dissolved in THF (1.5 mL). The reaction stirred at 0 C for 0.5 hrs and then let warm to rt and let stir an additional 3 hrs. The reaction was then quenched with sat. NaHCO3(aq) and extracted with Et0Ac (3 x 20 mL). The organic layer was washed with brine and dried over Na2SO4, filtered through paper, and concentrated under reduced pressure to yield crude product that was a mixture of cis and trans and used in the next step of the synthesis.
[0243] Similar methods were used to prepare (2- {543-(5-Fluoro-2-methoxy-pheny1)-propyThtetrahydro-furan-2-y1}-ethyl)-carbamic acid ethyl ester.
Example 25: N-Methyl-2-aminoethy1-5-(2'-methoxy-5'-fluoro phenethyltetrahydro furan [0244] In a flame dried round bottom flask, purged with Ar(g), was put the carbamate (112 mg, 0.33 mmol, 1.0 eq) and anhydrous THF (1.6 mL). The flask was then cooled with an ice bath while stirring for 15 min. LAB (1.0 M, 1.32 mL, 1.32 mmol, 4.0 eq) was then slowly added via a syringe over a period of 5 mm. The reaction was allowed to warm to rt and stirred an additional 4 hrs. The reaction was then quenched with ice cold Me0H
and then stirred at rt for an additional 15 min. The resulting solution was transferred to a beaker with the aid of 1N HC1(aq) and then made basic with 10M Na01-1(ao. The basic solution was then extracted with Et20 (3 x 20 mL) and then the organic layer was washed with brine. The Et20 layer was dried over Mg2SO4 for 15 min and then filtered through paper and concentrated to oil under reduced pressure to afford the crude product. The oil was purified with PTLC and MeOH:CH2C12 (5:95) in 45% yield.
(3mL) was refluxed for 4 hr. The reaction was then cooled to room temperature and then concentrated under reduced pressure to oil. The oil was dissolved in Et0Ac and washed with water followed by brine. The organic layer was then dried over Na2SO4, filtered through paper, and concentrated under reduced pressure to oil. The product was recrystallized in Et0H to yield a white solid.
Example 16: 245-Bromo-penty1)-4-(3,4-dimethoxypheny1)-4a,5,8,8a-tetrahydro-2H-phthalaxin-1-one [0233] Sodium hydride (60% dispersion in oil, 44mg, 1.1 mmol, 1.1 eq) was added to a solution of 4-(3,4-dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (287 mg, 1.0 mmol, 1.0 eq). The mixture was stirred for 30 min whereupon it took on a slight yellow color and then 1,5-dibromopentane (600mg, 2.6 mmol, 2.6 eq)was added via syringe. After 30 min the yellow color had diminished and the reaction was poured into water.
The solution was extracted with Et20 and washed with brine. The organic layer was dried over MgSO4, filtered through paper, and concentrated under reduced pressure to provide a clear oil. The product was chromatographed through silica with CH2C12 to afford a clear oil.
Example 17: 4-(3,4-Dimethoxypheny1)-245-(2-{542-(5-fluoro-2-methoxypheny1)-ethyl]-tetrahydrofuran-2-yll -ethylamino)-p enty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-l-one [0234] Cesium hydroxide monohydrate (23mg, 0.14 mmol, 1.0 eq) and DMF (0.5mL) was stirred in a flame dried round bottom flask under Ar(g) for 30 min at room temperature. Then 2-aminoethy1-5-(2'-methoxy-5'-fluoro phenethyltetrahydro furan (37mg, 0.14 mmol, 1.0 eq) in DMF (0.3mL) was added via syringe and stirred at room temperature for 30 min. 245-Bromo-penty1)-4-(3,4-dimethoxypheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (72mg, 0.16 mmol, 1.2 eq) in DMF (0.3mL) was added and continued to stir for 24 hr at room temperature. The reaction was filtered through paper with Et0Ac (30mL) and then the filtrate was washed with water in a seperatory funnel. The organic layer was dried with Na2SO4, filtered through paper, and concentrated to give an oil. The product was purified with prep TLC eluted with 5% Me0H in CH2C12 to afford a yellow oil (27mg, 0.04 mmol, 31%).
[0235] Similar methods were used to prepare 4-(3,4-Dimethoxypheny1)-245-(2-{54245-fluoro-2-methoxypheny1)-propylHetrahydrofuran-2-yll - ethylamino)-p enty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-[5-(2-{54245-fluoro-2-methoxy-pheny1)-ethyTtetrahydro-furan-2-y1}-ethylamino)-pentylkpyrrolidin-2-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-[5-(2-1543-(5-fluoro-2-methoxy-pheny1)-propyll-tetrahydro-furan-2-yll-ethylamino)-pentyll-pyrrolidin-2-one, 4-(3,4-Dimethoxy-pheny1)-2- {5[3-pheny1-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyll -4a,5,8,8 a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-1543-pheny1-3-(4-trifluoromethyl-phenoxy)-propylaminol-pentyll-pyrrolidin-2-one, 2-(3-{54443,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-y11-pentylamino}-propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 2-(3-{5-[4-(3-Cyclopentyloxy-4-methoxy-pheny1)-2-oxo-pyrroliclin-1-y1]-pentylaminof -propy1)-2-(4-fluoro-pheny1)-2,3-dihydro-benzofuran-6-carbonitrile, 4-(3,4-Dimethoxy-pheny1)-2-(5-1[5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylinethyl]-amino}-penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclop entyloxy-4-methoxy-pheny1)-1-(5- 1[5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyTaminof -penty1)-pyrrolidin-2-one, 2-15-[(5-Cyclohexyl-tetrahydro-furan-ylmethyl)-amino]-pentyl} -4-(3,4-dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 1- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-amino]-pentylf -4-(3-cyclopentyloxy-4-methoxy-pheny1)-pyrrolidin-2-one, 4-(3,4-Dimethoxy-phenyl)-2-(5- { [543 -fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethy1]-amino} -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- { [5-(3-fluoro-4-methyl-pheny1)-tetrahydro-furan-2-ylmethyThamino}-penty1)-pyrrolidin-2-one.
Example 18: (S)-2-Pyrrolidine Methanol [0236] A suspension of lithium aluminium hydride (3.8 g, 0.1 mol) in 160 mL
THF was refluxed for 15 min. (S)-Proline (7.4 g, 0.06 mol) was added in small portions to the refluxing mixture at a rate to keep the reaction under reflux without external heating. The mixture was refluxed for an additional 1 hr. The reaction was stopped by careful addition of potassium hydroxide solution (1.8 g in 7.2 mL 1120) with reduced heat. The mixture was then refluxed for 15 min and the hot solution was filtered. The precipitate was refluxed with THF for an hour and filtered once more. The combined filtrates were concentrated under reduced pressure and used for the next step without further purification in quantitative yield.
Example 19: 1-tBoc-2-Hydroxymethyl Pyrrolidine [0237] Pyrrolidine methanol (2 g, 20 mmol) in 20 mL dichloromethane was placed in a round bottom flask. To the dichloromethane solution, di-t-butyldicarbonate (4.8 g, 2.2 mmol) in 10 mL dichloromethane was slowly added at 0 C. The mixture was stirred for 30 min at 0 C and the reaction was stopped by addition of 30 mL saturated sodium carbonate at 0 C.
The aqueous layer was separated and extracted three times with 30 mL
dichloromethane.
The organic layers were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography Me0H/CH2C12 (5:95, v:v) to give 1-tBoc-2-hydroxymethyl pyrrolidine in 92% yield.
Example 20: 1-tBoc-2-Formyl Pyrrolidine [0238] Dimethyl sulfoxide (2.66 mL, 37.5 mmol) in 6 mL dichloromethane was added dropwise to oxalyl chloride (2.1 g, 16.5 mmol) in 30 mL dichloromethane at -78 C. After 5 min, 1-tBoc-2-hydroxymethyl pyrrolidine (3 g, 15 mmol) was added dropwise to the solution.
After another 15 min, 10 mL of triethylamine was added dropwise to the solution and the mixture was stirred for 5 min. The mixture was brought to 25 C and the reaction was stopped by the addition of 50 mL water. The aqueous layer was separated and extracted three times with 50 mL dichloromethane. The organic layers were combined and washed with 100 mL each of water, 5% sodium carbonate, water, and saturated sodium chloride.
The organic solution was then dried over sodium sulfate, filtered, and concentrated in vacuo to give 1-tBoc-2-formyl pyrrolidine. The product was used for the next step without further purification: 52% yield.
Example 21: 1-tBoc-2-Styrenyl Pyrrolidine [0239] Benzyltriphenylphosphonium chloride (3.89 g, 10 mmol) in 10 mL diethyl ether was placed in a round bottom flask. The solution was cooled to -78 C and nBuLi (4 mL of 2.5M nBuLi in hexane, 10 mmol) was added dropwise to the solution. After 30 min, the suspension was added dropwise to 1-tBoc-2-formyl pyrrolidine (2 g, 10 mmol) in 10 mL
diethyl ether at -78 C and the mixture was stirred for 3 hours. The reaction was stopped with 50 mL H20, the organic layer was separated from the aqueous layer, and the aqueous layer was extracted 3 times with 50 mL diethyl ether. The combined organic layer was washed with H20 until the pH of the aqueous layer was 7, dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by silica column chromatography Et0Ac/
hexane (10:90, v:v), 1.1 g, 40% yield.
Example 22: 2-Styrenyl Pyrrolidine [0240] A solution of 1-tBoc-2-phenethyl pyrrolidine (230 mg, 0.84 mmol) in 5 mL
trifiuoroacetic acid was stirred for 30 min at 0 C. The trifluoroacetic acid was removed under reduced pressure. The residue was dissolved in 5 mL diethyl ether and the ethereal solution was washed with 5 mL saturated Na2CO3 and extracted twice with 2 mL
of 1N HC1.
The combined HC1 solution was then basicified with saturated Na2CO3 to pH = 10 and extracted three times with 5 mL dichloromethane. The combined dichloromethane layers were washed with 10 mL saturated NaCl, dried over Na2SO4, filtered, and concentrated in vacuum. The residue was purified on thin layer chromatography to give 2-phenethyl pyrrolidine: 120 mg, 82% yield.
Example 23: 1-Methyl-2-Styrenyl Pyrrolidine [0241] Sodium cyanoborohydride (17.4 mg, 0.27 mmol) was added portion-wise to a stirred solution of 2-phenethyl pyrrolidine (30 mg, 0.17 mmol) and 37% aqueous formaldehyde (0.07 mL, 0.87 mmol) in 1.5 mL acetonitrile at 25 C. The mixture was stirred for 15 min, acetic acid was added dropwise until the reaction was neutral, and the mixture was stirred for an additional 2 hours. The solvent was removed under reduced pressure. The residue was dissolved in 10 mL diethyl ether and the ethereal solution was washed with 10 mL of saturated Na2CO3 and extracted twice with 5 mL of 1N HC1. The combined solutions were then basicified with saturated Na2CO3 to obtain a pH = 10 and extracted three times with 10 mL dichloromethane. The combined dichloromethane layers were washed with 10 mL of saturated NaC1, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified on thin layer chromatography to give 1-methyl-2-phenethyl pyrrolidine free base; 18 mg, 55% yield.
Example 24: (2- {542-(5-Fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-111-ethyl)-carbamic ethyl ester [0242] In a flame dried 20 mL scintillation vial was placed K2CO3 (239mg, 1.73 mmol, 6.0 eq) and of anhydrous THF (5.0 mL). The vial was purged with Ar(g) and then chilled in an ice bath. Ethyl chloroformate (156 mg, 1.44 mmol, 5.0 eq) was then added via syringe followed by a slow addition of the primary amine (77 mg, 0.29 mmol, 1.0 eq) dissolved in THF (1.5 mL). The reaction stirred at 0 C for 0.5 hrs and then let warm to rt and let stir an additional 3 hrs. The reaction was then quenched with sat. NaHCO3(aq) and extracted with Et0Ac (3 x 20 mL). The organic layer was washed with brine and dried over Na2SO4, filtered through paper, and concentrated under reduced pressure to yield crude product that was a mixture of cis and trans and used in the next step of the synthesis.
[0243] Similar methods were used to prepare (2- {543-(5-Fluoro-2-methoxy-pheny1)-propyThtetrahydro-furan-2-y1}-ethyl)-carbamic acid ethyl ester.
Example 25: N-Methyl-2-aminoethy1-5-(2'-methoxy-5'-fluoro phenethyltetrahydro furan [0244] In a flame dried round bottom flask, purged with Ar(g), was put the carbamate (112 mg, 0.33 mmol, 1.0 eq) and anhydrous THF (1.6 mL). The flask was then cooled with an ice bath while stirring for 15 min. LAB (1.0 M, 1.32 mL, 1.32 mmol, 4.0 eq) was then slowly added via a syringe over a period of 5 mm. The reaction was allowed to warm to rt and stirred an additional 4 hrs. The reaction was then quenched with ice cold Me0H
and then stirred at rt for an additional 15 min. The resulting solution was transferred to a beaker with the aid of 1N HC1(aq) and then made basic with 10M Na01-1(ao. The basic solution was then extracted with Et20 (3 x 20 mL) and then the organic layer was washed with brine. The Et20 layer was dried over Mg2SO4 for 15 min and then filtered through paper and concentrated to oil under reduced pressure to afford the crude product. The oil was purified with PTLC and MeOH:CH2C12 (5:95) in 45% yield.
[0245] Similar methods were used to prepare N-Methy1-2-aminoethy1-5-((2"-methoxy-5"-fluoropheny1)-3'-propyptetrahydrofuran.
Example 26: High Throughput Kinase Assay for Identifying Stimulators of GRK2 [0246] A homogenous KinaseGlo assay was developed and conducted in a 96-well format.
Briefly, the assay design allowed large numbers of tests to be done in a high throughput fashion using a 96-well plate reader system. The KinaseGlo assay involved transfer of phosphate from [3P]ATP by GRK2 to tubulin. The assay was robust and efficient.
was chosen as our target protein for several important reasons including: a) GRK2 was available in highly purified form from our collaborator (Professor Benovic, Thomas Jefferson University), b) GRK2 and GRK3 are highly homologous and are anticipated to be stimulated similarly by ligands, c) the crystal structure of GRK2 was recently solved and allows the modeling of difficult-to-predict distal sites that could stimulate the enzyme and d) GRK3 was scheduled to be produced commercially.
[0247] Stimulators of GRK2, as well as of GRK3, have been identified. Figure 6 summarizes results of testing of compounds for GRK2 stimulation and inhibition.
Compound 28 (Table 1) and 2-(pyridine-3-yl)cyclopropanamine were potent stimulators of GRK2. Epinephrine hydroxylamine was a very potent inhibitor of GRK2 and is also expected to be useful in ameliorating CNS diseases.
Example 27: Results of Biological Studies In vitro Methods Antagonism of Neurotransmitter Transporters and Release [0248] Chemical compounds were tested for their ability to inhibit uptake, displace radioligand and modulate release from human embryonic kidney (HEK) cells that contain the human dopamine (DAT), human serotonin (SERT), and human norepinephrine (NET) transporters. Nine concentrations were used with the highest concentrations being in the high micromolar range (where possible). Three independent experiments for each compound were done.
Example 26: High Throughput Kinase Assay for Identifying Stimulators of GRK2 [0246] A homogenous KinaseGlo assay was developed and conducted in a 96-well format.
Briefly, the assay design allowed large numbers of tests to be done in a high throughput fashion using a 96-well plate reader system. The KinaseGlo assay involved transfer of phosphate from [3P]ATP by GRK2 to tubulin. The assay was robust and efficient.
was chosen as our target protein for several important reasons including: a) GRK2 was available in highly purified form from our collaborator (Professor Benovic, Thomas Jefferson University), b) GRK2 and GRK3 are highly homologous and are anticipated to be stimulated similarly by ligands, c) the crystal structure of GRK2 was recently solved and allows the modeling of difficult-to-predict distal sites that could stimulate the enzyme and d) GRK3 was scheduled to be produced commercially.
[0247] Stimulators of GRK2, as well as of GRK3, have been identified. Figure 6 summarizes results of testing of compounds for GRK2 stimulation and inhibition.
Compound 28 (Table 1) and 2-(pyridine-3-yl)cyclopropanamine were potent stimulators of GRK2. Epinephrine hydroxylamine was a very potent inhibitor of GRK2 and is also expected to be useful in ameliorating CNS diseases.
Example 27: Results of Biological Studies In vitro Methods Antagonism of Neurotransmitter Transporters and Release [0248] Chemical compounds were tested for their ability to inhibit uptake, displace radioligand and modulate release from human embryonic kidney (HEK) cells that contain the human dopamine (DAT), human serotonin (SERT), and human norepinephrine (NET) transporters. Nine concentrations were used with the highest concentrations being in the high micromolar range (where possible). Three independent experiments for each compound were done.
[0249] Stable transfections: Stable transfections of HEK293 cells were carried out by seeding exponentially growing cells in 10 mL DMEM/10 cm plates and incubating overnight.
Plasmid DNA, including pcDNAl-hDAT, pcDNA-hSERT, or pcDNAl-hNET and pBabePuro, which confers resistance to puromycin, was mixed with 0.5 mL of 0.25M CaCl2.
An equal volume of 2x BES-buffered saline is added, and the mixture was incubated at room temperature for 20 minutes before the dropwise addition to the medium in the plates. Cells were incubated overnight in a 3% CO2 environment. The next day, medium was removed and replaced with DMEM supplemented with 5% FCS and 5% BCS; cells were incubated in a 10% CO2 environment. Puromycin-resistant cells have been isolated by selection at a concentration of 2 vig/mL, a concentration that kills control HEK293 cells within one week.
[0250] Radioligand Binding: Cells were grown on 150 mm diameter tissue culture dishes.
Medium was poured off the plate, the plate was washed with 10 mL of phosphate buffered saline and 10 mL of lysis buffer (2 mM HEPES, 1 mM EDTA) was added. After 10 min, cells were scraped from plates and poured into centrifuge tubes and centrifuged for 20 mM at 30,000 x g. Supernatant was removed, and the pellet was resuspended in 20 mL
0.32 M
sucrose with a Polytron at setting 7 for 10 sec.
[0251] Assay: Each assay contained 50 [IL membrane preparation (approximately 501.1.g protein), 251AL of the individual compound, and 25 iAL of [1251]RTI-55 (40-80 pMol) in a fmal volume of 250 pl. Krebs HEPES was used for assays. Membranes were preincubated with individual compounds for 10 min prior to addition of [1251]1211-55. The reaction was incubated for 90 min at room temperature in the dark and was terminated by filtration onto GF/C filters using a Tomtech harvester. Radioactivity remaining on the filter was determined using a Wallac (3-plate reader. Competition experiments were conducted with duplicate determinations. Data was analyzed using GraphPad Prism, with IC50 values converted to Ki values using the Cheng-Prusoff equation. For binding to HEKhNET cells [3H]nisoxetine was used instead of [1251]R.T1-55, and the rest of the assay was identical.
[0252] [3111Neurotransmitter Uptake: For experiments involving uptake of [3H]dopamine by HEKhDAT cells, [3H]5HT uptake by HEKhSERT cells, or [3H]NE uptake by HEKhNET
cells, the medium was removed from the cells and 2.5 mL of calcium-magnesium-free phosphate buffered saline was added to 10 cm plates, and cells were removed by gentle scraping. Aliquots (50 }IL) of the cell suspension was added in triplicate to tubes containing Krebs HEPES (25 mM HEPES, 122 mM NaCl, 5 mM KC1, 1.2 mM MgSO4, 2.5 mM CaCl2, 1pM pargyline, 0.2g/100 mL glucose, 0.02g/100 mL ascorbic acid, pH 7.4) and individual compounds in a final volume of 0.5 mL. Uptake was initiated by the addition of [3H]dopamine, for example, (20 nM, specific activity 20-53 Ci/mmol) in a final volume of 500 L. Mazindol (5 M) was used to define nonspecific uptake. Cells were pre-incubated for 10 min with the desired compound before addition of radioligand. Uptake was terminated after a 10 min incubation (depending on the cell line) by filtration of the contents of each tube over Whatman GF/C filters that have been soaked in 0.05% polyethylenimine, using a Tomtech 96-well cell harvester. Radioactivity remaining on the filters was determined with a Wallac (3-plate reader. Ki and IC50 values were organized and inactive and active compounds were identified. All Ki and IC50 experiments were conducted with triplicate determinations.
Multiple concentrations of many of the individual compounds were used to determine the t112, the time point at which 50% of a drugs maximal effect is observed. Dose-response curves were conducted at time points approximating the t112 for each drug. Data was analyzed using the nonlinear curve fitting computer program GraphPAD. ANOVA was used to determine significant differences among previously described drug groups. Triplicate determinations allowed us to present the results the standard error of the mean.
[0253] Transporter-Mediated Release. C-6 hDAT cells were used for these experiments because there is a clear quantitative difference in the effects of drugs on Ca2+-independent release of neurotransmitter from these cells. When cells are confluent in 24 well plates, [31-1]-MPP+ (20 nM) in Krebs-HEPE buffer, 1 M pargyline, 2 mg/mL glucose and 0.2 mg/mL
ascorbic acid) was added to each well. Loading of the cells was conducted for 20 min at room temperature at which time the intracellular [3H-MPP+] concentration reaches steady state. Nonspecific binding was defined as the difference in uptake observed in the absence of sodium or in the presence of 5 M mazindol. The loading buffer was removed and cells were quickly washed with ice-cold release buffer which is the same as loading buffer except it lacks Ca2+. Release buffer, ice cold, was added to the plates and initiated by placing the incubations in a 37 C water bath. At each time point, the buffer was aspirated from each well. TCA, 3%, was added and radioactivity remaining in the cells was determined by liquid scintillation counting. All experiments were conducted in triplicate. Multiple concentrations were used to determine the tn. Subsequent dose-response curves were conducted at time points approximating the ti/2 for each compound. Data was analyzed using the nonlinear curve fitting computer program GraphPAD. ANOVA was used to determine significant differences among previously described drug groups. Triplicate determinations allowed us to present the results the standard error of the mean.
10254] Binding and Reuptake Inhibition of Dual PDE4 inhibitor/SSRIs in HEK
Cells.
The dual inhibitors were evaluated for inhibition of [1251]-RTI-55 binding in human embryonic kidney (HEK) cells containing either DAT, SERT or NET (n = 3) and separately as reuptake inhibitors. Results shown in Table 3 shows that the dual PDE4 inhibitor/SSRIs retained potency and selectivity for the hSERT. The data cannot be directly compared with Table 1 because the compounds of Table 3 were mixtures of diastereomers and isomers at all centers of chirality. Compared with the dual PDE4 inhibitor/SSRIs, the PDE4 inhibitor, 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, and the alkyl bromide derivative showed no transporter inhibition potency.
[0255] Inhibition of PDE4 with dual SSRIs/PDE4 inhibitors. The measurement of inhibitor interaction with high- and low-affinity rolipram binding sites on PDE4 was done as follows: Two radioligands were used to label high- and low-affinity rolipram binding sites on PDE4 and to determine Ki values for the interaction of inhibitors with these sites (Jacobitz et al., 1996). 31I-rolipram is used to label the high-affinity site. IC50 values for inhibitor interaction with this site were calculated by nonlinear regression analysis of competition curves for unlabeled PDE4 inhibitors; Ki values were determined according to the method of Cheng and Prusoff (1973). Although, 3H-rolipram can be used to label the low-affinity site, this involves the use of equilibrium filtration assays that are too cumbersome and variable for routine use. 3H-piclamilast was used to label the low affinity site (and high-affinity site; see below); this radioligand has equal affinity for both the high- and low-affinity rolipram binding site on PDE4. This radioligand binds specifically to PDE4, but, in contrast to rolipram, it is not selective for the two binding sites for PDE4 inhibitors (i.e., the rolipram binding sites). Competition curves for the PDE4 inhibitors were subjected to nonlinear regression analysis and IC50 values with which the inhibitors bind to each of the binding sites was determined; K1 values were determined according to the method of Cheng and Prusoff (1973). Density of the high-affinity rolipram binding site was determined using saturation isotherms with 3H-rolipram. The density of the combined low-affinity and high-affinity rolipram binding site was determined directly using saturation isotherms with 3H-piclamilast.
Density of the low-affinity rolipram binding site was determined by subtracting 3H-rolipram binding from 3H-piclamilast binding. Inhibitor interaction with the high-affinity rolipram binding site was determined using competition experiments with unlabeled inhibitor and 3H-rolipram. Inhibitor interaction with the low-affinity rolipram binding site was determined in two ways. Nonlinear regression analysis of competition curves generated using unlabeled inhibitor and 3H-piclamilast showed affinity for the low- and high-affinity rolipram binding sites. Second, potency for inhibiting 3H-piclamilast binding with 1 uM
rolipram (to block 3H-piclamilast binding to the high-affinity state) showed its affinity for the low-affmity site.
The inhibition results are listed in Table 4.
[0256] Preparation of human PDE 4D3 with dual SSRIs/PDE4 inhibitors. The PDE
construct was transfected into Cos 7 cells in round culture dish (100x20 mm).
The cells were then harvested and homogenized with lysis buffer. The crude homogenate was spun at maximum speed in a microfuge. The supernatant fluid was saved as an extract.
Cold ethylene glycol was added to make a final concentration of 33% and then stored at -20 C.
Inhibition of human PDE 4D3 with dual SSRIs/PDE4 inhibitors is shown in Table 5. The PDE construct and Cos 7 cells were a kind gift from Dr. Conti at the Stanford University School of Medicine.
Results [0257] Table 1 and Table 2 present the data for the binding assays described in the methods section above. Ki is the parameter that describes the inhibition of binding of radioligand to the transporter by the test compound. Kr is the parameter that describes the inhibition of re-uptake of radioligand to the transporter by the test compound. Table 3 shows the data for binding and reuptake of the dual SSRIs/PDE4 inhibitors in HEK cells. Table 4 is the data for inhibition of PDE4 with dual SSRIs/PDE4 inhibitors. Table 5 is the data for inhibition of highly purified human PDE4D3 with dual SSRIs/PDE4 inhibitors.
Plasmid DNA, including pcDNAl-hDAT, pcDNA-hSERT, or pcDNAl-hNET and pBabePuro, which confers resistance to puromycin, was mixed with 0.5 mL of 0.25M CaCl2.
An equal volume of 2x BES-buffered saline is added, and the mixture was incubated at room temperature for 20 minutes before the dropwise addition to the medium in the plates. Cells were incubated overnight in a 3% CO2 environment. The next day, medium was removed and replaced with DMEM supplemented with 5% FCS and 5% BCS; cells were incubated in a 10% CO2 environment. Puromycin-resistant cells have been isolated by selection at a concentration of 2 vig/mL, a concentration that kills control HEK293 cells within one week.
[0250] Radioligand Binding: Cells were grown on 150 mm diameter tissue culture dishes.
Medium was poured off the plate, the plate was washed with 10 mL of phosphate buffered saline and 10 mL of lysis buffer (2 mM HEPES, 1 mM EDTA) was added. After 10 min, cells were scraped from plates and poured into centrifuge tubes and centrifuged for 20 mM at 30,000 x g. Supernatant was removed, and the pellet was resuspended in 20 mL
0.32 M
sucrose with a Polytron at setting 7 for 10 sec.
[0251] Assay: Each assay contained 50 [IL membrane preparation (approximately 501.1.g protein), 251AL of the individual compound, and 25 iAL of [1251]RTI-55 (40-80 pMol) in a fmal volume of 250 pl. Krebs HEPES was used for assays. Membranes were preincubated with individual compounds for 10 min prior to addition of [1251]1211-55. The reaction was incubated for 90 min at room temperature in the dark and was terminated by filtration onto GF/C filters using a Tomtech harvester. Radioactivity remaining on the filter was determined using a Wallac (3-plate reader. Competition experiments were conducted with duplicate determinations. Data was analyzed using GraphPad Prism, with IC50 values converted to Ki values using the Cheng-Prusoff equation. For binding to HEKhNET cells [3H]nisoxetine was used instead of [1251]R.T1-55, and the rest of the assay was identical.
[0252] [3111Neurotransmitter Uptake: For experiments involving uptake of [3H]dopamine by HEKhDAT cells, [3H]5HT uptake by HEKhSERT cells, or [3H]NE uptake by HEKhNET
cells, the medium was removed from the cells and 2.5 mL of calcium-magnesium-free phosphate buffered saline was added to 10 cm plates, and cells were removed by gentle scraping. Aliquots (50 }IL) of the cell suspension was added in triplicate to tubes containing Krebs HEPES (25 mM HEPES, 122 mM NaCl, 5 mM KC1, 1.2 mM MgSO4, 2.5 mM CaCl2, 1pM pargyline, 0.2g/100 mL glucose, 0.02g/100 mL ascorbic acid, pH 7.4) and individual compounds in a final volume of 0.5 mL. Uptake was initiated by the addition of [3H]dopamine, for example, (20 nM, specific activity 20-53 Ci/mmol) in a final volume of 500 L. Mazindol (5 M) was used to define nonspecific uptake. Cells were pre-incubated for 10 min with the desired compound before addition of radioligand. Uptake was terminated after a 10 min incubation (depending on the cell line) by filtration of the contents of each tube over Whatman GF/C filters that have been soaked in 0.05% polyethylenimine, using a Tomtech 96-well cell harvester. Radioactivity remaining on the filters was determined with a Wallac (3-plate reader. Ki and IC50 values were organized and inactive and active compounds were identified. All Ki and IC50 experiments were conducted with triplicate determinations.
Multiple concentrations of many of the individual compounds were used to determine the t112, the time point at which 50% of a drugs maximal effect is observed. Dose-response curves were conducted at time points approximating the t112 for each drug. Data was analyzed using the nonlinear curve fitting computer program GraphPAD. ANOVA was used to determine significant differences among previously described drug groups. Triplicate determinations allowed us to present the results the standard error of the mean.
[0253] Transporter-Mediated Release. C-6 hDAT cells were used for these experiments because there is a clear quantitative difference in the effects of drugs on Ca2+-independent release of neurotransmitter from these cells. When cells are confluent in 24 well plates, [31-1]-MPP+ (20 nM) in Krebs-HEPE buffer, 1 M pargyline, 2 mg/mL glucose and 0.2 mg/mL
ascorbic acid) was added to each well. Loading of the cells was conducted for 20 min at room temperature at which time the intracellular [3H-MPP+] concentration reaches steady state. Nonspecific binding was defined as the difference in uptake observed in the absence of sodium or in the presence of 5 M mazindol. The loading buffer was removed and cells were quickly washed with ice-cold release buffer which is the same as loading buffer except it lacks Ca2+. Release buffer, ice cold, was added to the plates and initiated by placing the incubations in a 37 C water bath. At each time point, the buffer was aspirated from each well. TCA, 3%, was added and radioactivity remaining in the cells was determined by liquid scintillation counting. All experiments were conducted in triplicate. Multiple concentrations were used to determine the tn. Subsequent dose-response curves were conducted at time points approximating the ti/2 for each compound. Data was analyzed using the nonlinear curve fitting computer program GraphPAD. ANOVA was used to determine significant differences among previously described drug groups. Triplicate determinations allowed us to present the results the standard error of the mean.
10254] Binding and Reuptake Inhibition of Dual PDE4 inhibitor/SSRIs in HEK
Cells.
The dual inhibitors were evaluated for inhibition of [1251]-RTI-55 binding in human embryonic kidney (HEK) cells containing either DAT, SERT or NET (n = 3) and separately as reuptake inhibitors. Results shown in Table 3 shows that the dual PDE4 inhibitor/SSRIs retained potency and selectivity for the hSERT. The data cannot be directly compared with Table 1 because the compounds of Table 3 were mixtures of diastereomers and isomers at all centers of chirality. Compared with the dual PDE4 inhibitor/SSRIs, the PDE4 inhibitor, 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, and the alkyl bromide derivative showed no transporter inhibition potency.
[0255] Inhibition of PDE4 with dual SSRIs/PDE4 inhibitors. The measurement of inhibitor interaction with high- and low-affinity rolipram binding sites on PDE4 was done as follows: Two radioligands were used to label high- and low-affinity rolipram binding sites on PDE4 and to determine Ki values for the interaction of inhibitors with these sites (Jacobitz et al., 1996). 31I-rolipram is used to label the high-affinity site. IC50 values for inhibitor interaction with this site were calculated by nonlinear regression analysis of competition curves for unlabeled PDE4 inhibitors; Ki values were determined according to the method of Cheng and Prusoff (1973). Although, 3H-rolipram can be used to label the low-affinity site, this involves the use of equilibrium filtration assays that are too cumbersome and variable for routine use. 3H-piclamilast was used to label the low affinity site (and high-affinity site; see below); this radioligand has equal affinity for both the high- and low-affinity rolipram binding site on PDE4. This radioligand binds specifically to PDE4, but, in contrast to rolipram, it is not selective for the two binding sites for PDE4 inhibitors (i.e., the rolipram binding sites). Competition curves for the PDE4 inhibitors were subjected to nonlinear regression analysis and IC50 values with which the inhibitors bind to each of the binding sites was determined; K1 values were determined according to the method of Cheng and Prusoff (1973). Density of the high-affinity rolipram binding site was determined using saturation isotherms with 3H-rolipram. The density of the combined low-affinity and high-affinity rolipram binding site was determined directly using saturation isotherms with 3H-piclamilast.
Density of the low-affinity rolipram binding site was determined by subtracting 3H-rolipram binding from 3H-piclamilast binding. Inhibitor interaction with the high-affinity rolipram binding site was determined using competition experiments with unlabeled inhibitor and 3H-rolipram. Inhibitor interaction with the low-affinity rolipram binding site was determined in two ways. Nonlinear regression analysis of competition curves generated using unlabeled inhibitor and 3H-piclamilast showed affinity for the low- and high-affinity rolipram binding sites. Second, potency for inhibiting 3H-piclamilast binding with 1 uM
rolipram (to block 3H-piclamilast binding to the high-affinity state) showed its affinity for the low-affmity site.
The inhibition results are listed in Table 4.
[0256] Preparation of human PDE 4D3 with dual SSRIs/PDE4 inhibitors. The PDE
construct was transfected into Cos 7 cells in round culture dish (100x20 mm).
The cells were then harvested and homogenized with lysis buffer. The crude homogenate was spun at maximum speed in a microfuge. The supernatant fluid was saved as an extract.
Cold ethylene glycol was added to make a final concentration of 33% and then stored at -20 C.
Inhibition of human PDE 4D3 with dual SSRIs/PDE4 inhibitors is shown in Table 5. The PDE construct and Cos 7 cells were a kind gift from Dr. Conti at the Stanford University School of Medicine.
Results [0257] Table 1 and Table 2 present the data for the binding assays described in the methods section above. Ki is the parameter that describes the inhibition of binding of radioligand to the transporter by the test compound. Kr is the parameter that describes the inhibition of re-uptake of radioligand to the transporter by the test compound. Table 3 shows the data for binding and reuptake of the dual SSRIs/PDE4 inhibitors in HEK cells. Table 4 is the data for inhibition of PDE4 with dual SSRIs/PDE4 inhibitors. Table 5 is the data for inhibition of highly purified human PDE4D3 with dual SSRIs/PDE4 inhibitors.
Table 1. Binding and Re-uptake of Primary Amines and Related Compounds Names Structures Binding (Ki, n1V1) Reuptake (Kr, niVI) bDAT hSERT hNET hDAT hSERT bNET
trans-2-aminomethyl- OMe o 7328 0.8 8541 5-((2"-methoxy-5"-fluoropheny1)-3'-F
propyl)tetrahydrofuran 2-aminoethy1-5((2"- OMe 7307.0 1.1 10600.0 16987 2.3 1930.0 methoxy-5"- o fluoropheny1)-31- 40 NH2 propyl)tetrahydrofuran F
2-aminomethy1-5-(2'- ocH3 >10k 609 1658 887 1.64 methoxy-5'- 0 0 NH2 fluorophenethyl F
tetrahydrofuran 27 2-aminoethy1-5-(2'- ocH3 >10k 4.5 6452 >10k 3.1 methoxy-5'-fluoro dlik o NH2 phenethyltetrahydro F
furan 28 2-(aminomethyl)-5- 0 >10k 18.5 >10k - --(r-naphethyl)tetra II, NH2 hydrofuran ir trans-2-aminoethy1-5- OMe -(T-methoxy-5'- 0 fluorobenzyl) tetrahydrofuran F
cis-2-aminoethy1-5- OMe -(2'-methoxy-5'- 0 NH2 fluorobenzyl) 40 tetrahydrofuran F
2-(aminoethyl)-5-(1'- = o NH2 9298 30 8059 >10 k 73 >10 k naphethyl) -tetrahydrofuran 2-(aminomethyl)-5- 41 0 phenyltetrahydrofuran NH2 2-(aminomethyl)-5-512 45 >10k 28 4 (2'-naphthyl)tetra 110 di 0 hydrofuran NH2 2-(aminoethyl)-5- 0 o)___¨_¨NH2 4066 54 >10 K 1463 --phenyltetrahydrofuran 2-(aminomethyl)-5- 41 0 -(phenethyl) NH2 tetrahydrofuran 2-(aminoethyl)-5-(2'- ocH3 >10 k 86 >10 k - --methoxy-11-naphethyl) Pi o NH2 tetrahydrofuran, IIP
trans-2-aminomethyl- OMe o 7328 0.8 8541 5-((2"-methoxy-5"-fluoropheny1)-3'-F
propyl)tetrahydrofuran 2-aminoethy1-5((2"- OMe 7307.0 1.1 10600.0 16987 2.3 1930.0 methoxy-5"- o fluoropheny1)-31- 40 NH2 propyl)tetrahydrofuran F
2-aminomethy1-5-(2'- ocH3 >10k 609 1658 887 1.64 methoxy-5'- 0 0 NH2 fluorophenethyl F
tetrahydrofuran 27 2-aminoethy1-5-(2'- ocH3 >10k 4.5 6452 >10k 3.1 methoxy-5'-fluoro dlik o NH2 phenethyltetrahydro F
furan 28 2-(aminomethyl)-5- 0 >10k 18.5 >10k - --(r-naphethyl)tetra II, NH2 hydrofuran ir trans-2-aminoethy1-5- OMe -(T-methoxy-5'- 0 fluorobenzyl) tetrahydrofuran F
cis-2-aminoethy1-5- OMe -(2'-methoxy-5'- 0 NH2 fluorobenzyl) 40 tetrahydrofuran F
2-(aminoethyl)-5-(1'- = o NH2 9298 30 8059 >10 k 73 >10 k naphethyl) -tetrahydrofuran 2-(aminomethyl)-5- 41 0 phenyltetrahydrofuran NH2 2-(aminomethyl)-5-512 45 >10k 28 4 (2'-naphthyl)tetra 110 di 0 hydrofuran NH2 2-(aminoethyl)-5- 0 o)___¨_¨NH2 4066 54 >10 K 1463 --phenyltetrahydrofuran 2-(aminomethyl)-5- 41 0 -(phenethyl) NH2 tetrahydrofuran 2-(aminoethyl)-5-(2'- ocH3 >10 k 86 >10 k - --methoxy-11-naphethyl) Pi o NH2 tetrahydrofuran, IIP
Names Structures Binding (Kb nM) Reuptake (Kõ nM) hDAT hSERT hNET hDAT hSERT hNET
2-(aminomethyl)-5- a >10 k 92 9460 - --(2'-chloro-5'- . o NH2 trifluoromethylphenet Fsc hyl)tetrahydrouran 38 2-(aminoethyl)-5-(4'- H,o0 0 >10k 93 >10 k methoxy- V-naphthylethyl) tetrahydrofuran 39 cis-2-(aminomethyl)- OMe -5-(5'-fluoro-2'- 0 NH2 methoxybenzyl) 40 tetrahydrofuran F
2-(aminomethyl)-5- . 0 (r-naphethyptetra NH2 hydro furan 110 trans-2- OMe -(aminomethyl)-5-(5'- . o '''''''''''' fluoro-T-methoxybenzyl) F
tetrahydrofuran 42 2-(aminomethyl)-5- ocH3 >10 k 228 >10 k - --(2'-methoxy-l'- Atik o NH2 naphethyl) 11, tetrahydrofuran 43 2-(aminomethyl)-5- F* 0 (4'-fluoro-3'- NH2 methylphenethyl) tetrahydrouran 44 2-(aminomethyl)-5- 0 NH2 -(3'-phenylpropyl) tetrahydrofuran 45 2-(aminoethyl)-5-(2'- 0* o NH2 naphthylethyl) tetrahydrofuran 46 2-(aminoethyl)-5-(4'- F . 0 NH2 >10k 538 >10k 3280 278 >10k fluorophenethyl) tetrahydrofuran 47 2-(aminoethy1)-5-(4LF 4, o NH2 fluoro-3'- H3c methylphenethyl) tetrahydrofuran 48 2-(aminomethyl)-5- OMe >10 k 843 439 603 78 (2'-methoxy-l'- 0 0 naphethyl) NH2 tetrahydrofuran 2-(aminoethyl)-5-(4'- Br . 0NH2 >10 k 944 >10 k - --bromophenyl) tetrahydrofuran 50 2-(aminoethyl)-5- o NH2 27 1094 409 2314 di (phenethyl) tetrahydrofuran fumaric salt Names Structures Binding (Ki, nIVI) Reuptake (Kr, 1-1M) hDAT hSERT hNET _ hDAT hSERT hNET
2-(aminomethyD-5- CI . o 6830 1105 (4'-chlorophenyl) NH2 tetrahydrafuran -2-(aminomethyl)-5- Br . 0 6117 1114 >10k (4'-bromophenyl) NH2 tetrahydrofuran MM-II-152C . = NH2 5106 2727 6375 2697 2-(aminoethyl)-5-(phenethyl) 54 tetrahydrofuran 2-(aminoethyl)-5- 0 NH2 1334 1362 2443 1007 _ _ *
(phenethyl)tetrahydrof uran 55 2-(aminoethyl)-5-(3'-H 3c do 0 NH2 8844 1487 fluoro-4'-F
methylphenethyl) tetrahydrafuran 2-(aminoethyl)-5-(4'- F3c 4 0 NH2 >10 k 1796 >10 k >10 k 519 >10 k trifluoromethoxyphen ethyl)tetrahydrafuran 57 trans-2-(aminoethyl)- F 32934 1808 27495 >10k 1046 >10k 5-(2'-methoxy-5'- 41111 0 ..-------NH2 fluorophenyl) OMe tetrahydrofuran 58 2-(aminomethyl)-5- F F >10k 2126 (pentafluorophenethyl F 41 0 r--"NH2 )tetrahydrofuran F F
2-(aminoethyl)-5-(4'- H3co 0 0 NH2 >10k 2517 6013 >10k 628 >10k methoxyphenethyl) tetrahydrofuran 60 2-(aminomethyl)-5- F 6852 2665 H3c . o (3'-fluoro-4'-methylphenyl) tetrahydrofuran 61 2-(aminoethyl)-5-(41- diNH2 7897 3587 phenylphenethyl) ilir tetrahydrofuran 62 fumaric salt 2-(aminoethyl)-5-(4'- H3c 4 0 NH2 7610 3740 >10 k >10 k 3763 919 methylphenethyl) tetrahydrofuran 63 2-(aminoethy1-5- 46 o NH2 >10k 3822 >10k _ _ _ benzyltetrahydrofuran µ1"
2-(aminomethyl)-5- H3co 7920 4521 (31,4'dimethoxyphenet H3co 0 o hyl) tetrahydrofuran 2-(aminomethyl)-5- >10k 4546 8517 >10k 2548 >10k (3'-pyridylethyl) N
tetrahydrofuran 662 Names Structures Binding (Ki, nM) Reuptake (Kr, nM) hDAT hSERT bNET hDAT hSERT bNET _ cis-2-(aminoethyl)-5- F >10K 4772 48874 >10K
2411 >10K
(2'-methoxy-5'- 0 o NH2 fluorophenyl) .Me tetrahydrofuran o NH2 >10k 5691 5345 >10k 6685 >10k 2-(aminoethyl)-5-(3'-O-"--------r------pyridylethyl) N
tetrahydrofuran 68 trans-2- 0 .04 62205 5857 'NH2 (aminomethyl)-5-(3'- el N
quinoline) tetrahydrofuran trans-2- F >10k 6307 71991 >10k 1939 >10k (aminomethyl)-5-(2'-methoxy-5'-ome fluorophenyl) tetrahydrofuran 2-(aminoMethyl)-5- H3C0 . 0 >10k 6877 methoxyphenyl)tetrah ydrofuran F
2-(aminomethyl)-5- 42764 6886 57016 >10k 8452 >10k (2'-methoxy-5'- 0) o fluorophenyl) OMe trans:cis = 0.58:0.42 tetrahydrofuran 2-(aminoethyl)-5-(4'- HO Air 0 NH2 5498 7483 TIP
hydroxyphenethyl)tetr ahydrofuran 73 2-(aminomethyl)-5- F dik o >10k 9190 >10k - - -(4'-fluorophenethyl) tetrahydrofuran 74 2-(aminomethyl)-54- 142265 10296 72075 >10k >10k >10k 2"-tetrahydrofury1-2'-ethyl)tetrahydrofuran. 75 2-(aMinomethyl)-5- o 63720 11370 22740 -- -el ''., (3?-quino1ine) N
tetrahydrofuran cis:trans=2:1 2-(aminoethyl)-5-(21- ((5,--_--NH2 89441 12145 50646 >10 k >10 k >10 k o furyl)tetrahydrofuran 77 _ Cis-2- F 3350 13790 (Phenethylaminoethyl) 0 0 H
-5-(2'-methoxy-5'-eMe fluorophenyl) tetrohydrofuran _ 2-(aminoethyl)-5-(4'- N' \ NH2 55163 15433 pyridylethyl) trans:cis=2: 1 tetrahydrofuran, 79 Cis-2- F 3139 17466 (Phenethylaminoethyl) ,a, H
w o N---------...ph -5-(2'-methoxy-5'-.Me fluorophenyl) tetrahydrofuran Names Structures Binding (Ki, MVI) Reuptake (Kr, n1q) hDAT hSERT bNET hDAT hSERT bNET
2-(aminomethyl)-5- NI \ 0 145733 18578 57448 _ _ _ (4'-pyridylethyl) trans:cis=2:1 NH2 tetrahydrofuran trans-2- 483667 78170 93411 - --(aminomethyl)-5-(2'- 0--= ).." 'NH2 pyridyl) tetrahydrofuran. 82 2-(aminomethyl)-5- >10k >10k 405 2573 939 317 cyclohexyl NH2 tetrahydrofuran 2-(aminomethyl)-5- 0 1760 >10 k 1905 876 --benzyltetrahydrofitran .
2-(aminomethyl)-5- >10k >10k 4543 4301 637 2322 (41-t-butylphenyl) = 0 NH2 tetrahydrofuran 2-(aminoethyl)-5- 0 y-._NH2 >10k >10 k >10 k - --phenyltetrahydrofuran 86 _ 2-(aminoethyl)-544'_ F 0 0 NH2 >10 k >10 k >10 k - --fluorophenyl) tetrahydrofuran 87 2-(aminoethyl)-5- >10k >10k >10k - --0------0__N H2 cyclohexyl tetrahydrofuran, 2-(aminoethyl)-5-(4?-t- NH2 >10k >10k >10k >10k >10k 556 butylphenethyl) = o tetrahydrofuran 89 2-(aminoethyl)-5- >10k >10k >10k >10k 217 >10k (cyclohexylethyl) tetrahydrofuran 90 2-(aminoethy1)-5-(4'-t- >10 k >10 k >10 k - --butylphenyl) ilk o NH, tetrahydrofuran 91 .
2-(aminomethyl)-5- H3c0 . o - - - 2112 53 (4'-methoxy-l'- NH2 naphthylethyl) .
tetrahydrofuran 92 Table 2. Binding and Re-uptake of Seconary Amines and Related compounds Names Structures Binding (ki, nIVI) Reuptake (kup, BM) hDAT hSERT bNET hDAT hSERT bNET
N,N-bis (cis-5'-(2"- 1441 methoxy-5"- Ma 0 ENI = .Me fluorobenzyl-T- F 0F
tetrahydrofury1)-2- 93 ethyl)amine N,N-bis (5'-(p- 709 fluoropheny1)-2'-tetrahydrofurylethyl) 94 Amine N,N-Bis (trans-5-(2"- 2390 methoxy-5"-fluorobenzy1-2'-tetrahydrofury1)-2- 95 ethyl)amine NN-bis (5'-(5"-fluoro- , 236 2 "-methoxyphenethyl)- ...)_____11 2'-tetrahydrofurylethyl) me Amine N,N- bis (5'-phenethyl- CL_c_o_y 30 T-tetrahydrofurylethyl) 18 Amine 97 N,N- bis (S'-(p- 443 bromopheny1)-T-tetrahydrofurylethyl) 98 Amine N,N-bis (trans-5'-(2"- 1386 F
methoxy-5"-fluoropheny1-2'- ( el = OMe ''---)P
tetrahydrofuryl)ethyl) 99 Amine N,N-bis (cis-5'-(2"- 2654 F
methoxy-5"-( C.6:L.5......)_Nry fluorophenyl-T- Me 2 tetrahydrofuryl)ethyl) 100 Amine N,N- bis (5'42% 75 naphthyl-T-tetrahydrofuryl)ethyl) 101 Amine N,N- bis (5'-(1"- 1075 283 4337 >10K 718 >10K
s¨,_(oy naphthethyl)-2'-tetrahydrofurylethyl) 102 amine .
N,N- bis (51-(p- 36 hydroxyphenethyl)-2'- Ho '01,-.5_¨_--I oHNI-__-- -.y70'' tetrahydrofurylethyl) 103 amine N,N- bis (5'-phenethyl- 0 N.......y.,,,,..-0 84 2'-tetrahydrofurylethyl) methylamine 104 N,N- bis (5'-(p-fluoro- F F 798 743 m-methylphenethyl)-2'-tetrahydrofurylethyl) 105 amine N,N- bis (5'-(3"- 0-----,5 -11...õ3,----) 12339 886 7752 >10k 1788 >10k _ Names Structures Binding (1d, n1\4) Reuptake (kup, nlVl) hDAT hSERT hNET hDAT hSERT hNET
pyridylethyl)-21- 106 tetrahydrofurylethyl) amine N,N-bis (5'-benzyl-T- 1310 937 605 564 2260 tetrahydrofury1)-2-ethyl)amine 107 N,N- bis (5'-phenyl-2'- 970 1089 777 609 2016 tetrahydrofurylethyl) amine 108 N,N- bis (5'-(2"- 5512 2032 >10 K -methoxy-1"-naphthethyl)-21- ome LIom.
tetrahydrofurylethyl) 109 amine N,N- bis (5'-(m-fluoro- 474 2578 4099 p-methylphenethyl)-2'-tetrahydrofurylethyl) 110 amine N,N- bis (5'-(4"- 5672 3671 >10 K -methoxy-1"- Mo0 OMe naphthethyl)-2'- 0 N
tetrahydrofurylethyl) 111 amine NN- his (5'-(4"- 9329 6614 1617 pyridylethyl)-2'-tetrahydrofurylethyl) 112 amine N,N- bis (5'- 5960 6762 8430 cyclohexy1-2'-tetrahydrofurylethyl) 113 amine N,N- bis (5' -(p-t- 8893 >10K >10K -butylpheny1)-2'-tetrahydrofurylethyl) 114 amine Table 3. Binding and reuptake of the dual SSRIs/PDE4 inhibitors in HEK cells Binding (Ki, nM) _ Reuptake (IC50, nlVI) Names Structures hDAT hSERT _ 13NET hDAT , hSERT 13NET
Hp) Am so 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a- H3co 1 >100 >100 >100 >100 >100 >100 tetrahydro-2H- N,N 0 UM
UM UM uM uM uM
phthalazin-l-one H
443,4- OMe Dimethoxypheny1)-2-[542- {5-[2-(5-fluoro- F ill 2-methoxypheny1)- Me0 =40 o 872 1 8I:W7 1450 5388 286 1808 ethyl]-tetrahydrofuran-2-yll - Me0 1 ethylamino)-penty1]- N'N 0 NH
4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 115 4-(3,4- Me0 ., F
Dimethoxypheny1)-2- H300 [542- {5-[2-(5-fluoro- 40 io 2-methoxypheny1)- H3co 1 N 5340 194 7441 5340 194 + 7441 propy1]- 1,1 0 0 tetrahydrofuran-2-yll -ethylamino)-penty1]- -7Th\I
4a,5,8,8a-tetrahydro- H
2H-phthalazin-1-one 21 Table 4. Inhibition of rodent PDE4 with dual SSRIs/PDE4 inhibitors Number Structures pIC5o H3co Ain so 4-(3,4-Dimethoxy-phenyl)-H3co 41111 4a,5,8,8a-tetrahydro-2H- N
' N o 6.7 H
phthalazin-l-one OMe 4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2- Me0 g& 40 F
methoxypheny1)-ethyl]-tetrahydrofuran-2-yll - Me0 IIV 1 6.6 N'N 0 NH
ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 115 4-(3,4-Dimethoxypheny1)-2[5-Me0 = F
H3c0 ifir 40 (2- {5-[2-(5-fluoro-2-H3co wr methoxypheny1)-propyl]- NI'N 0 0 6.3 tetrahydrofuran-2-yll -ethylamino)-penty1]-4a,5,8,8a- aN
H
tetrahydro-2H-phthalazin-1-one 21 Table 5. Inhibition of recombinant human PDE 4D3 with dual SSRls/PDB4 inhibitors Names Structures pICso K nM
H3co al 4-(3,4-Dimethoxy-phenyl)-H3co I
4a,5,8,8a-tetrahydro-2H-N 'N 0 -2.2 6.3 phthalazin-l-one OMe 4-(3,4-Dimethoxypheny1)-245-(2-{542-(5-fluoro-2-methoxypheny1)-ethy1]- Me0 i&
Me0 -2.7 tetrahydrofuran-2-yll-N'LJN 0 NH
ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 4-(3,4-Dimethoxypheny1)-245-(2-Me0 H3co An so {5-[2-(5-fluoro-2-H3C0 q'F
methoxypheny1)-propy1]-NI=N o 0 -2.9 1.2 tetrahydrofuran-2-yll-ethylamino)-penty1]-4a,5,8,8a-ar4 tetrahydro-2H-phthalazin-1-one Table 6. Inhibition of radioligand binding and uptake inhibition in HEK-hDAT, HEK-hSERT and EIBK-hNET by monomethyl disubstituted tetrahydrofuran and pyrrolidine derivatives Names Structures Binding (Ki, nM) Reuptake (IC50, nM) hDAT hSERT hNET hDAT hSERT hNET
="µ"c 2-Styrenyl Pyrrolidine 4130 4580 >10k 1270 1-Methyl-2-Styrenyl Pyrrolidine CH3 3240 >10k 2780 1030 ND 250 N-Methyl-2- OMe aminoethy1-5-(21-methoxy-5'-fluoro F
NHCH3 >10k 21.2 >10k >10k 18.4 >10k phenethyltetrahydro furan 118 Names Structures Binding (KJ, 111\4) Reuptake (IC50, nIVI) bDAT hSERT hNET hDAT hSERT hNET
N-Methyl-2- OMe aminoethy1-54(2"-methoxy-5"- F >10k 4.5 >10k >10k 3.1 >10k fluoropheny1)-3I- NH2 propyl)tetrahydrofuran 128 Table 7. Dual SSRI/PDFA inhibtors to treat depression and memory and cognition-enhancement functional activity Name Structure 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-115-(2-{542-(5-fluoro-2-methoxy-phenyl)-ethyl]-tetrahydro-furan-2-yll-ethylamino)-pentyll- 0 OMe pyrrolidin-2-one F
OMe N
4-(3-Cyclopentyloxy-4-methoxy-pheny1)-115-(2-{543-(5-fluoro-2-methoxy-pheny1)-propy1]-tetrahydro-furan-2-yll-ethylamino)-pentyl]- 0 OMe pyrrolidin-2-one OMe N) 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-{5-[3-pheny1-3-(4-trifluoromethyl-phenoxy)-propylaminoi-pentyll-pyrrolidin-2-one 0 OMe F F
F
4-(3,4-Dimethoxy-phenyl)-2-{543-pheny1-3-(4- F F
trifluoromethyl-phenoxy)-propylamino]-penty1}- F
OMe 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 0 OMe 401 NWN'I\I
2-(3-{544-(3,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-y1]- 0 F
pentylamino}-propy1)-2-(4-fluoro-phenyl)-2,3-dihydro-benzofuran-6-carbonitrile Me0 N. 0 *
ON
OMe Name Structure 2-(3- {544-(3-Cyclopentyloxy-4-methoxy-phenyl)-CN
2-oxo-pyrrolidin-1-A-pentylamino} -propy1)-2-(4- F
* 0 *
fluoro-phenyl)-2,3-dihydro-benzofuran-6- Me0 A
carbonitrile Table 8. Dual norepinephrin3 reuptake inhibitors/PDE4 inhibtors Name Structure 4-(3,4-Dimethoxy-phenyl)-2-(5- [5-(4-methoxy-OMe phenyl)-tetrahydro-furan-2-ylmethyl]-amino }-OMe penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one Me0 0 N
NEN, 4-(3-Cyc lop entyloxy-4-methoxy-pheny1)-1-(5-{ [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyll-Cr amino} -penty1)-pyrrolidin-2-one Me() OMe HN¨\____\_0 JN
2- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-OMe amino]-penty1}-4-(3,4-dimethoxy-phenyl)-OMe 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 1- {5- [(5-Cyclohexyl-tetrahydro-furan-2-y1methyl)-amino]-penty11-4-(3-cyclopentyloxy-4-methoxy-OL) phenyl)-pyrrolidin-2-one el OMe ac5.71 0 N¨ \
4-(3,4-Dimethoxy-phenyl)-2-(5- [5-(3-fluoro-4-OMe methyl-phenyl)-tetrahydro-furan-2-ylmethyl]-OMe amino} -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin- H3C
1-one NwN'N
2-(aminomethyl)-5- a >10 k 92 9460 - --(2'-chloro-5'- . o NH2 trifluoromethylphenet Fsc hyl)tetrahydrouran 38 2-(aminoethyl)-5-(4'- H,o0 0 >10k 93 >10 k methoxy- V-naphthylethyl) tetrahydrofuran 39 cis-2-(aminomethyl)- OMe -5-(5'-fluoro-2'- 0 NH2 methoxybenzyl) 40 tetrahydrofuran F
2-(aminomethyl)-5- . 0 (r-naphethyptetra NH2 hydro furan 110 trans-2- OMe -(aminomethyl)-5-(5'- . o '''''''''''' fluoro-T-methoxybenzyl) F
tetrahydrofuran 42 2-(aminomethyl)-5- ocH3 >10 k 228 >10 k - --(2'-methoxy-l'- Atik o NH2 naphethyl) 11, tetrahydrofuran 43 2-(aminomethyl)-5- F* 0 (4'-fluoro-3'- NH2 methylphenethyl) tetrahydrouran 44 2-(aminomethyl)-5- 0 NH2 -(3'-phenylpropyl) tetrahydrofuran 45 2-(aminoethyl)-5-(2'- 0* o NH2 naphthylethyl) tetrahydrofuran 46 2-(aminoethyl)-5-(4'- F . 0 NH2 >10k 538 >10k 3280 278 >10k fluorophenethyl) tetrahydrofuran 47 2-(aminoethy1)-5-(4LF 4, o NH2 fluoro-3'- H3c methylphenethyl) tetrahydrofuran 48 2-(aminomethyl)-5- OMe >10 k 843 439 603 78 (2'-methoxy-l'- 0 0 naphethyl) NH2 tetrahydrofuran 2-(aminoethyl)-5-(4'- Br . 0NH2 >10 k 944 >10 k - --bromophenyl) tetrahydrofuran 50 2-(aminoethyl)-5- o NH2 27 1094 409 2314 di (phenethyl) tetrahydrofuran fumaric salt Names Structures Binding (Ki, nIVI) Reuptake (Kr, 1-1M) hDAT hSERT hNET _ hDAT hSERT hNET
2-(aminomethyD-5- CI . o 6830 1105 (4'-chlorophenyl) NH2 tetrahydrafuran -2-(aminomethyl)-5- Br . 0 6117 1114 >10k (4'-bromophenyl) NH2 tetrahydrofuran MM-II-152C . = NH2 5106 2727 6375 2697 2-(aminoethyl)-5-(phenethyl) 54 tetrahydrofuran 2-(aminoethyl)-5- 0 NH2 1334 1362 2443 1007 _ _ *
(phenethyl)tetrahydrof uran 55 2-(aminoethyl)-5-(3'-H 3c do 0 NH2 8844 1487 fluoro-4'-F
methylphenethyl) tetrahydrafuran 2-(aminoethyl)-5-(4'- F3c 4 0 NH2 >10 k 1796 >10 k >10 k 519 >10 k trifluoromethoxyphen ethyl)tetrahydrafuran 57 trans-2-(aminoethyl)- F 32934 1808 27495 >10k 1046 >10k 5-(2'-methoxy-5'- 41111 0 ..-------NH2 fluorophenyl) OMe tetrahydrofuran 58 2-(aminomethyl)-5- F F >10k 2126 (pentafluorophenethyl F 41 0 r--"NH2 )tetrahydrofuran F F
2-(aminoethyl)-5-(4'- H3co 0 0 NH2 >10k 2517 6013 >10k 628 >10k methoxyphenethyl) tetrahydrofuran 60 2-(aminomethyl)-5- F 6852 2665 H3c . o (3'-fluoro-4'-methylphenyl) tetrahydrofuran 61 2-(aminoethyl)-5-(41- diNH2 7897 3587 phenylphenethyl) ilir tetrahydrofuran 62 fumaric salt 2-(aminoethyl)-5-(4'- H3c 4 0 NH2 7610 3740 >10 k >10 k 3763 919 methylphenethyl) tetrahydrofuran 63 2-(aminoethy1-5- 46 o NH2 >10k 3822 >10k _ _ _ benzyltetrahydrofuran µ1"
2-(aminomethyl)-5- H3co 7920 4521 (31,4'dimethoxyphenet H3co 0 o hyl) tetrahydrofuran 2-(aminomethyl)-5- >10k 4546 8517 >10k 2548 >10k (3'-pyridylethyl) N
tetrahydrofuran 662 Names Structures Binding (Ki, nM) Reuptake (Kr, nM) hDAT hSERT bNET hDAT hSERT bNET _ cis-2-(aminoethyl)-5- F >10K 4772 48874 >10K
2411 >10K
(2'-methoxy-5'- 0 o NH2 fluorophenyl) .Me tetrahydrofuran o NH2 >10k 5691 5345 >10k 6685 >10k 2-(aminoethyl)-5-(3'-O-"--------r------pyridylethyl) N
tetrahydrofuran 68 trans-2- 0 .04 62205 5857 'NH2 (aminomethyl)-5-(3'- el N
quinoline) tetrahydrofuran trans-2- F >10k 6307 71991 >10k 1939 >10k (aminomethyl)-5-(2'-methoxy-5'-ome fluorophenyl) tetrahydrofuran 2-(aminoMethyl)-5- H3C0 . 0 >10k 6877 methoxyphenyl)tetrah ydrofuran F
2-(aminomethyl)-5- 42764 6886 57016 >10k 8452 >10k (2'-methoxy-5'- 0) o fluorophenyl) OMe trans:cis = 0.58:0.42 tetrahydrofuran 2-(aminoethyl)-5-(4'- HO Air 0 NH2 5498 7483 TIP
hydroxyphenethyl)tetr ahydrofuran 73 2-(aminomethyl)-5- F dik o >10k 9190 >10k - - -(4'-fluorophenethyl) tetrahydrofuran 74 2-(aminomethyl)-54- 142265 10296 72075 >10k >10k >10k 2"-tetrahydrofury1-2'-ethyl)tetrahydrofuran. 75 2-(aMinomethyl)-5- o 63720 11370 22740 -- -el ''., (3?-quino1ine) N
tetrahydrofuran cis:trans=2:1 2-(aminoethyl)-5-(21- ((5,--_--NH2 89441 12145 50646 >10 k >10 k >10 k o furyl)tetrahydrofuran 77 _ Cis-2- F 3350 13790 (Phenethylaminoethyl) 0 0 H
-5-(2'-methoxy-5'-eMe fluorophenyl) tetrohydrofuran _ 2-(aminoethyl)-5-(4'- N' \ NH2 55163 15433 pyridylethyl) trans:cis=2: 1 tetrahydrofuran, 79 Cis-2- F 3139 17466 (Phenethylaminoethyl) ,a, H
w o N---------...ph -5-(2'-methoxy-5'-.Me fluorophenyl) tetrahydrofuran Names Structures Binding (Ki, MVI) Reuptake (Kr, n1q) hDAT hSERT bNET hDAT hSERT bNET
2-(aminomethyl)-5- NI \ 0 145733 18578 57448 _ _ _ (4'-pyridylethyl) trans:cis=2:1 NH2 tetrahydrofuran trans-2- 483667 78170 93411 - --(aminomethyl)-5-(2'- 0--= ).." 'NH2 pyridyl) tetrahydrofuran. 82 2-(aminomethyl)-5- >10k >10k 405 2573 939 317 cyclohexyl NH2 tetrahydrofuran 2-(aminomethyl)-5- 0 1760 >10 k 1905 876 --benzyltetrahydrofitran .
2-(aminomethyl)-5- >10k >10k 4543 4301 637 2322 (41-t-butylphenyl) = 0 NH2 tetrahydrofuran 2-(aminoethyl)-5- 0 y-._NH2 >10k >10 k >10 k - --phenyltetrahydrofuran 86 _ 2-(aminoethyl)-544'_ F 0 0 NH2 >10 k >10 k >10 k - --fluorophenyl) tetrahydrofuran 87 2-(aminoethyl)-5- >10k >10k >10k - --0------0__N H2 cyclohexyl tetrahydrofuran, 2-(aminoethyl)-5-(4?-t- NH2 >10k >10k >10k >10k >10k 556 butylphenethyl) = o tetrahydrofuran 89 2-(aminoethyl)-5- >10k >10k >10k >10k 217 >10k (cyclohexylethyl) tetrahydrofuran 90 2-(aminoethy1)-5-(4'-t- >10 k >10 k >10 k - --butylphenyl) ilk o NH, tetrahydrofuran 91 .
2-(aminomethyl)-5- H3c0 . o - - - 2112 53 (4'-methoxy-l'- NH2 naphthylethyl) .
tetrahydrofuran 92 Table 2. Binding and Re-uptake of Seconary Amines and Related compounds Names Structures Binding (ki, nIVI) Reuptake (kup, BM) hDAT hSERT bNET hDAT hSERT bNET
N,N-bis (cis-5'-(2"- 1441 methoxy-5"- Ma 0 ENI = .Me fluorobenzyl-T- F 0F
tetrahydrofury1)-2- 93 ethyl)amine N,N-bis (5'-(p- 709 fluoropheny1)-2'-tetrahydrofurylethyl) 94 Amine N,N-Bis (trans-5-(2"- 2390 methoxy-5"-fluorobenzy1-2'-tetrahydrofury1)-2- 95 ethyl)amine NN-bis (5'-(5"-fluoro- , 236 2 "-methoxyphenethyl)- ...)_____11 2'-tetrahydrofurylethyl) me Amine N,N- bis (5'-phenethyl- CL_c_o_y 30 T-tetrahydrofurylethyl) 18 Amine 97 N,N- bis (S'-(p- 443 bromopheny1)-T-tetrahydrofurylethyl) 98 Amine N,N-bis (trans-5'-(2"- 1386 F
methoxy-5"-fluoropheny1-2'- ( el = OMe ''---)P
tetrahydrofuryl)ethyl) 99 Amine N,N-bis (cis-5'-(2"- 2654 F
methoxy-5"-( C.6:L.5......)_Nry fluorophenyl-T- Me 2 tetrahydrofuryl)ethyl) 100 Amine N,N- bis (5'42% 75 naphthyl-T-tetrahydrofuryl)ethyl) 101 Amine N,N- bis (5'-(1"- 1075 283 4337 >10K 718 >10K
s¨,_(oy naphthethyl)-2'-tetrahydrofurylethyl) 102 amine .
N,N- bis (51-(p- 36 hydroxyphenethyl)-2'- Ho '01,-.5_¨_--I oHNI-__-- -.y70'' tetrahydrofurylethyl) 103 amine N,N- bis (5'-phenethyl- 0 N.......y.,,,,..-0 84 2'-tetrahydrofurylethyl) methylamine 104 N,N- bis (5'-(p-fluoro- F F 798 743 m-methylphenethyl)-2'-tetrahydrofurylethyl) 105 amine N,N- bis (5'-(3"- 0-----,5 -11...õ3,----) 12339 886 7752 >10k 1788 >10k _ Names Structures Binding (1d, n1\4) Reuptake (kup, nlVl) hDAT hSERT hNET hDAT hSERT hNET
pyridylethyl)-21- 106 tetrahydrofurylethyl) amine N,N-bis (5'-benzyl-T- 1310 937 605 564 2260 tetrahydrofury1)-2-ethyl)amine 107 N,N- bis (5'-phenyl-2'- 970 1089 777 609 2016 tetrahydrofurylethyl) amine 108 N,N- bis (5'-(2"- 5512 2032 >10 K -methoxy-1"-naphthethyl)-21- ome LIom.
tetrahydrofurylethyl) 109 amine N,N- bis (5'-(m-fluoro- 474 2578 4099 p-methylphenethyl)-2'-tetrahydrofurylethyl) 110 amine N,N- bis (5'-(4"- 5672 3671 >10 K -methoxy-1"- Mo0 OMe naphthethyl)-2'- 0 N
tetrahydrofurylethyl) 111 amine NN- his (5'-(4"- 9329 6614 1617 pyridylethyl)-2'-tetrahydrofurylethyl) 112 amine N,N- bis (5'- 5960 6762 8430 cyclohexy1-2'-tetrahydrofurylethyl) 113 amine N,N- bis (5' -(p-t- 8893 >10K >10K -butylpheny1)-2'-tetrahydrofurylethyl) 114 amine Table 3. Binding and reuptake of the dual SSRIs/PDE4 inhibitors in HEK cells Binding (Ki, nM) _ Reuptake (IC50, nlVI) Names Structures hDAT hSERT _ 13NET hDAT , hSERT 13NET
Hp) Am so 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a- H3co 1 >100 >100 >100 >100 >100 >100 tetrahydro-2H- N,N 0 UM
UM UM uM uM uM
phthalazin-l-one H
443,4- OMe Dimethoxypheny1)-2-[542- {5-[2-(5-fluoro- F ill 2-methoxypheny1)- Me0 =40 o 872 1 8I:W7 1450 5388 286 1808 ethyl]-tetrahydrofuran-2-yll - Me0 1 ethylamino)-penty1]- N'N 0 NH
4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 115 4-(3,4- Me0 ., F
Dimethoxypheny1)-2- H300 [542- {5-[2-(5-fluoro- 40 io 2-methoxypheny1)- H3co 1 N 5340 194 7441 5340 194 + 7441 propy1]- 1,1 0 0 tetrahydrofuran-2-yll -ethylamino)-penty1]- -7Th\I
4a,5,8,8a-tetrahydro- H
2H-phthalazin-1-one 21 Table 4. Inhibition of rodent PDE4 with dual SSRIs/PDE4 inhibitors Number Structures pIC5o H3co Ain so 4-(3,4-Dimethoxy-phenyl)-H3co 41111 4a,5,8,8a-tetrahydro-2H- N
' N o 6.7 H
phthalazin-l-one OMe 4-(3,4-Dimethoxypheny1)-245-(2- {542-(5-fluoro-2- Me0 g& 40 F
methoxypheny1)-ethyl]-tetrahydrofuran-2-yll - Me0 IIV 1 6.6 N'N 0 NH
ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 115 4-(3,4-Dimethoxypheny1)-2[5-Me0 = F
H3c0 ifir 40 (2- {5-[2-(5-fluoro-2-H3co wr methoxypheny1)-propyl]- NI'N 0 0 6.3 tetrahydrofuran-2-yll -ethylamino)-penty1]-4a,5,8,8a- aN
H
tetrahydro-2H-phthalazin-1-one 21 Table 5. Inhibition of recombinant human PDE 4D3 with dual SSRls/PDB4 inhibitors Names Structures pICso K nM
H3co al 4-(3,4-Dimethoxy-phenyl)-H3co I
4a,5,8,8a-tetrahydro-2H-N 'N 0 -2.2 6.3 phthalazin-l-one OMe 4-(3,4-Dimethoxypheny1)-245-(2-{542-(5-fluoro-2-methoxypheny1)-ethy1]- Me0 i&
Me0 -2.7 tetrahydrofuran-2-yll-N'LJN 0 NH
ethylamino)-penty1]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 4-(3,4-Dimethoxypheny1)-245-(2-Me0 H3co An so {5-[2-(5-fluoro-2-H3C0 q'F
methoxypheny1)-propy1]-NI=N o 0 -2.9 1.2 tetrahydrofuran-2-yll-ethylamino)-penty1]-4a,5,8,8a-ar4 tetrahydro-2H-phthalazin-1-one Table 6. Inhibition of radioligand binding and uptake inhibition in HEK-hDAT, HEK-hSERT and EIBK-hNET by monomethyl disubstituted tetrahydrofuran and pyrrolidine derivatives Names Structures Binding (Ki, nM) Reuptake (IC50, nM) hDAT hSERT hNET hDAT hSERT hNET
="µ"c 2-Styrenyl Pyrrolidine 4130 4580 >10k 1270 1-Methyl-2-Styrenyl Pyrrolidine CH3 3240 >10k 2780 1030 ND 250 N-Methyl-2- OMe aminoethy1-5-(21-methoxy-5'-fluoro F
NHCH3 >10k 21.2 >10k >10k 18.4 >10k phenethyltetrahydro furan 118 Names Structures Binding (KJ, 111\4) Reuptake (IC50, nIVI) bDAT hSERT hNET hDAT hSERT hNET
N-Methyl-2- OMe aminoethy1-54(2"-methoxy-5"- F >10k 4.5 >10k >10k 3.1 >10k fluoropheny1)-3I- NH2 propyl)tetrahydrofuran 128 Table 7. Dual SSRI/PDFA inhibtors to treat depression and memory and cognition-enhancement functional activity Name Structure 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-115-(2-{542-(5-fluoro-2-methoxy-phenyl)-ethyl]-tetrahydro-furan-2-yll-ethylamino)-pentyll- 0 OMe pyrrolidin-2-one F
OMe N
4-(3-Cyclopentyloxy-4-methoxy-pheny1)-115-(2-{543-(5-fluoro-2-methoxy-pheny1)-propy1]-tetrahydro-furan-2-yll-ethylamino)-pentyl]- 0 OMe pyrrolidin-2-one OMe N) 4-(3-Cyclopentyloxy-4-methoxy-pheny1)-1-{5-[3-pheny1-3-(4-trifluoromethyl-phenoxy)-propylaminoi-pentyll-pyrrolidin-2-one 0 OMe F F
F
4-(3,4-Dimethoxy-phenyl)-2-{543-pheny1-3-(4- F F
trifluoromethyl-phenoxy)-propylamino]-penty1}- F
OMe 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 0 OMe 401 NWN'I\I
2-(3-{544-(3,4-Dimethoxy-pheny1)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-y1]- 0 F
pentylamino}-propy1)-2-(4-fluoro-phenyl)-2,3-dihydro-benzofuran-6-carbonitrile Me0 N. 0 *
ON
OMe Name Structure 2-(3- {544-(3-Cyclopentyloxy-4-methoxy-phenyl)-CN
2-oxo-pyrrolidin-1-A-pentylamino} -propy1)-2-(4- F
* 0 *
fluoro-phenyl)-2,3-dihydro-benzofuran-6- Me0 A
carbonitrile Table 8. Dual norepinephrin3 reuptake inhibitors/PDE4 inhibtors Name Structure 4-(3,4-Dimethoxy-phenyl)-2-(5- [5-(4-methoxy-OMe phenyl)-tetrahydro-furan-2-ylmethyl]-amino }-OMe penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one Me0 0 N
NEN, 4-(3-Cyc lop entyloxy-4-methoxy-pheny1)-1-(5-{ [5-(4-methoxy-pheny1)-tetrahydro-furan-2-ylmethyll-Cr amino} -penty1)-pyrrolidin-2-one Me() OMe HN¨\____\_0 JN
2- {5-[(5-Cyclohexyl-tetrahydro-furan-2-ylmethyl)-OMe amino]-penty1}-4-(3,4-dimethoxy-phenyl)-OMe 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one 1- {5- [(5-Cyclohexyl-tetrahydro-furan-2-y1methyl)-amino]-penty11-4-(3-cyclopentyloxy-4-methoxy-OL) phenyl)-pyrrolidin-2-one el OMe ac5.71 0 N¨ \
4-(3,4-Dimethoxy-phenyl)-2-(5- [5-(3-fluoro-4-OMe methyl-phenyl)-tetrahydro-furan-2-ylmethyl]-OMe amino} -penty1)-4a,5,8,8a-tetrahydro-2H-phthalazin- H3C
1-one NwN'N
Name Structure 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(5- { [5-(3 -fluoro-4-methyl-pheny1)-tetrahydro-furan-2- 0 ylmethyl]- amino} -penty1)-pyrrolidin-2-one H3C
oMe In vivo 10258] 2-(Aminoethyl)-5-(phenethyl) tetrahydrofuran was studied in vivo as described below. In this study this compound is also referred to as compound 54 (see Table 1) or compound 31,646 (see, e.g., Figure 8).
Summary [0259] Treatment with compound 54 resulted in time- and dose-dependent depression of locomotor activity following 30 and 100 mg/kg. Depressant effects of 30 and 100 mg/kg occurred within 10 minutes following injection and lasted 50 to 100 minutes.
An 11)50 of 39.8 mg/kg was estimated based on a 30-minute time period in which maximal depressant effects occurred (0 to 30 minutes following injection). Note: The vehicle used in this study was 2%
methylcellulose. Cocaine was used as a control stimulant.
Cocaine alone study Method [0260] A time course/dose response study of cocaine-induced locomotor stimulation was conducted beginning 02/21/00, according to a locomotor activity studies time course protocol. The study was conducted using 40 Dig/scan locomotor activity testing chambers (40.5 X 40.5 X 30.5cm) housed in sets of two, within sound-attenuating chambers. A panel of infrared beams (16 beams) and corresponding photodetectors were located in the horizontal direction along the sides of each activity chamber. A 7.5-W
incandescent light above each chamber provided dim illumination. Fans provided an 80-dB ambient noise level within the chamber. Separate groups of 8 non-habituated male Swiss-Webster mice (Hsd:ND4, aged 2-3 mo.) were injected via the intra peritoneal (IP) route with either vehicle (0.9% saline) or cocaine (5, 10, 20, or 40 mg/kg), immediately prior to locomotor activity testing. In all studies, horizontal activity (interruption of photocell beams) was measured for 8 hours within 10-nun periods, beginning at 0800 hrs (2 hours after lights on). Testing was conducted with one mouse per activity chamber.
Results [0261] Figure 7 shows average horizontal activity counts/10 mm as a function of time (0-8 hr) and dose of cocaine (top to bottom panels). Treatment with cocaine resulted in time- and dose-dependent stimulation of locomotor activity in doses from 10 to 40 mg/kg.
Stimulant effects of 10 and 20 mg/kg occurred within 10 minutes following injection and lasted 80 to 210 minutes. The period 0-30 mm was selected for analysis of dose-response data because this was the time period in which cocaine produced maximal effects. Using TableCurve 2D
v2.03 software (Jandel Scientific), the mean average horizontal activity counts for this 30-mm period were fit to a 3-parameter logistic peak function of log10 dose (with the constant set to 3224, the mean of the saline-treated group), and the maximum was estimated from the resulting curve (maximum = 5520 counts/10 min at 23.4 mg/kg). The ED50 (dose producing 1/2 maximal stimulant activity, where maximal stimulant activity = maximum -mean control counts/10 min) was estimated at 5.8 mg/kg from a linear regression against log10 dose of the ascending portion of the dose-effect curve (5-20 mg/kg cocaine).
[0262] A two-way analysis of variance conducted on horizontal activity counts/10 min indicated significant effects of Treatment F(4,35)=3.36, p=.02, 10-Minute Periods F(47,1645)=95.22, p<.001, and the interaction of those factors F(188,1645)=2.02, p<.001. A
one-way analysis of variance conducted on log10 horizontal activity counts for the 0-30 mm time period (maximal stimulant effect) indicated a significant effect of Treatment F(4,35)=4.90, p=.003, and planned comparisons (a priori contrast) against the vehicle group showed a significant stimulant effect for 10,20 and 40 mg/kg (ps <.05 denoted on Figure 7 with an asterisk).
Compound 31,646 alone study Method [0263] A time course/dose response study of compound 31,646-induced locomotor depression was conducted under the same conditions as outlined for the cocaine alone study described above. Separate groups of 8 mice were injected with either vehicle (2%
methylcellulose) or compound 31,646 (3, 10, 30 or 100 mg/kg), immediately prior to locomotor activity testing. Behavioral observations were recorded on each mouse at 30, 120 and 480 minutes following 100 mg/kg compound 31,646.
Results [0264] Figure 8 shows average horizontal activity counts/10 min as a function of time (0-8 hr) and dose of compound 31,646 (top to bottom panels). Treatment with compound 31,646 resulted in time- and dose-dependent depression of locomotor activity following 30 and 100 mg/kg. Depressant effects of 30 and 100 mg/kg occurred within 10 minutes following injection and lasted 50 to 100 minutes. The period 0-30 min was selected for analysis of dose-response data because this was the time period in which maximal suppression first appeared as a function of dose. The mean average horizontal activity counts/10 min for this 30-min period were fit to a linear function of logio dose of the descending portion of the dose-effect curve (3 to 100 mg/kg dose range). The 11)50 (dose producing 1/2 maximal depressant activity, where maximal depression = 0 counts/30 min) was calculated as 39.8 mg/kg. A small stimulant effect was apparent during the third hour following 10 mg/kg 31,646, although these differences were not statistically significant.
[0265] A two-way analysis of variance conducted on horizontal activity counts/10 min indicated significant effects of Treatment F(4,35)=3.84, p=.01 1, 10-Minute Periods F(47,1645)=59.93, p<.001. and the interaction of Periods and Treatment F(188,1645)=3.81, p<.001. A one-way analysis of variance conducted on logio horizontal activity counts for the 0-30 mm time period (maximal depressant effect) indicated a significant effect of Treatment F(4,35)=21.39, p<.001, and planned comparisons (a priori contrast) against the vehicle group showed a significant depressant effect for 30 and 100 mg/kg (ps <.05 denoted on Figure 8 with an asterisk).
[0266] Other Observations. No unusual effects were observed following 100 mg/kg of compound 31,646.
Conclusion [0267] Compound 31,646 as a representative member of the CNS agents synthesized and described herein was tested in an animal model of locomotor activity. Compound 31,646 did not cause CNS stimulation but in fact, depressed CNS stimulant activity. The data suggests that compound 31,646 and congeners readily penetrates into the brain and are CNS active but do not cause CNS stimulation.
oMe In vivo 10258] 2-(Aminoethyl)-5-(phenethyl) tetrahydrofuran was studied in vivo as described below. In this study this compound is also referred to as compound 54 (see Table 1) or compound 31,646 (see, e.g., Figure 8).
Summary [0259] Treatment with compound 54 resulted in time- and dose-dependent depression of locomotor activity following 30 and 100 mg/kg. Depressant effects of 30 and 100 mg/kg occurred within 10 minutes following injection and lasted 50 to 100 minutes.
An 11)50 of 39.8 mg/kg was estimated based on a 30-minute time period in which maximal depressant effects occurred (0 to 30 minutes following injection). Note: The vehicle used in this study was 2%
methylcellulose. Cocaine was used as a control stimulant.
Cocaine alone study Method [0260] A time course/dose response study of cocaine-induced locomotor stimulation was conducted beginning 02/21/00, according to a locomotor activity studies time course protocol. The study was conducted using 40 Dig/scan locomotor activity testing chambers (40.5 X 40.5 X 30.5cm) housed in sets of two, within sound-attenuating chambers. A panel of infrared beams (16 beams) and corresponding photodetectors were located in the horizontal direction along the sides of each activity chamber. A 7.5-W
incandescent light above each chamber provided dim illumination. Fans provided an 80-dB ambient noise level within the chamber. Separate groups of 8 non-habituated male Swiss-Webster mice (Hsd:ND4, aged 2-3 mo.) were injected via the intra peritoneal (IP) route with either vehicle (0.9% saline) or cocaine (5, 10, 20, or 40 mg/kg), immediately prior to locomotor activity testing. In all studies, horizontal activity (interruption of photocell beams) was measured for 8 hours within 10-nun periods, beginning at 0800 hrs (2 hours after lights on). Testing was conducted with one mouse per activity chamber.
Results [0261] Figure 7 shows average horizontal activity counts/10 mm as a function of time (0-8 hr) and dose of cocaine (top to bottom panels). Treatment with cocaine resulted in time- and dose-dependent stimulation of locomotor activity in doses from 10 to 40 mg/kg.
Stimulant effects of 10 and 20 mg/kg occurred within 10 minutes following injection and lasted 80 to 210 minutes. The period 0-30 mm was selected for analysis of dose-response data because this was the time period in which cocaine produced maximal effects. Using TableCurve 2D
v2.03 software (Jandel Scientific), the mean average horizontal activity counts for this 30-mm period were fit to a 3-parameter logistic peak function of log10 dose (with the constant set to 3224, the mean of the saline-treated group), and the maximum was estimated from the resulting curve (maximum = 5520 counts/10 min at 23.4 mg/kg). The ED50 (dose producing 1/2 maximal stimulant activity, where maximal stimulant activity = maximum -mean control counts/10 min) was estimated at 5.8 mg/kg from a linear regression against log10 dose of the ascending portion of the dose-effect curve (5-20 mg/kg cocaine).
[0262] A two-way analysis of variance conducted on horizontal activity counts/10 min indicated significant effects of Treatment F(4,35)=3.36, p=.02, 10-Minute Periods F(47,1645)=95.22, p<.001, and the interaction of those factors F(188,1645)=2.02, p<.001. A
one-way analysis of variance conducted on log10 horizontal activity counts for the 0-30 mm time period (maximal stimulant effect) indicated a significant effect of Treatment F(4,35)=4.90, p=.003, and planned comparisons (a priori contrast) against the vehicle group showed a significant stimulant effect for 10,20 and 40 mg/kg (ps <.05 denoted on Figure 7 with an asterisk).
Compound 31,646 alone study Method [0263] A time course/dose response study of compound 31,646-induced locomotor depression was conducted under the same conditions as outlined for the cocaine alone study described above. Separate groups of 8 mice were injected with either vehicle (2%
methylcellulose) or compound 31,646 (3, 10, 30 or 100 mg/kg), immediately prior to locomotor activity testing. Behavioral observations were recorded on each mouse at 30, 120 and 480 minutes following 100 mg/kg compound 31,646.
Results [0264] Figure 8 shows average horizontal activity counts/10 min as a function of time (0-8 hr) and dose of compound 31,646 (top to bottom panels). Treatment with compound 31,646 resulted in time- and dose-dependent depression of locomotor activity following 30 and 100 mg/kg. Depressant effects of 30 and 100 mg/kg occurred within 10 minutes following injection and lasted 50 to 100 minutes. The period 0-30 min was selected for analysis of dose-response data because this was the time period in which maximal suppression first appeared as a function of dose. The mean average horizontal activity counts/10 min for this 30-min period were fit to a linear function of logio dose of the descending portion of the dose-effect curve (3 to 100 mg/kg dose range). The 11)50 (dose producing 1/2 maximal depressant activity, where maximal depression = 0 counts/30 min) was calculated as 39.8 mg/kg. A small stimulant effect was apparent during the third hour following 10 mg/kg 31,646, although these differences were not statistically significant.
[0265] A two-way analysis of variance conducted on horizontal activity counts/10 min indicated significant effects of Treatment F(4,35)=3.84, p=.01 1, 10-Minute Periods F(47,1645)=59.93, p<.001. and the interaction of Periods and Treatment F(188,1645)=3.81, p<.001. A one-way analysis of variance conducted on logio horizontal activity counts for the 0-30 mm time period (maximal depressant effect) indicated a significant effect of Treatment F(4,35)=21.39, p<.001, and planned comparisons (a priori contrast) against the vehicle group showed a significant depressant effect for 30 and 100 mg/kg (ps <.05 denoted on Figure 8 with an asterisk).
[0266] Other Observations. No unusual effects were observed following 100 mg/kg of compound 31,646.
Conclusion [0267] Compound 31,646 as a representative member of the CNS agents synthesized and described herein was tested in an animal model of locomotor activity. Compound 31,646 did not cause CNS stimulation but in fact, depressed CNS stimulant activity. The data suggests that compound 31,646 and congeners readily penetrates into the brain and are CNS active but do not cause CNS stimulation.
In Vivo Activity of Dual PDE4 inhibitor/SSRI
[0268] Compounds 19 and 115 were tested in a Morris water maze test. The escape latency (time to climb onto a hidden platform) for each mouse was recorded as a memory test.
Previously, it has been shown that rolipram (a PDE4 inhibitor) increases memory and restores cognitive function in a stroke model in rats. Compared to a group of control mice, compound 19 and 115 caused a 30% improvement in memory at 3 mg/kg. The effect was dose-dependent as a 0.3 mg/kg dose produced a significantly lower response.
Compound 28 showed only about a 10% improvement in memory at 3 mg/kg. This is not completely unexpected as SSRIs often require repeated dosing to see a large and significant effect. The data shows that despite the large molecular weight, the compounds get into the brain and are pharmacologically active in vivo. Multiple dosing likely will increase the efficacy of the compounds tested. In contrast to simple SSRIs, the in vivo pharmacological effects had a very fast onset of action.
Example 28: 2,5-Disubstituted Tetrahydrofurans as Selective Serotonin Reuptake Inhibitors [0269] On the basis of molecular dissection of cocaine, a series of 2,5-disubstituted tetrahydrofurans were synthesized. The compounds were evaluated for their ability of compete with radiolabelled RTI-55 binding and to inhibit reuptake of neurotransmitters at the human dopamine, serotonin and norepinephrine transporters. Highly potent (i.e.
K= 800 pM) and selective (IC50 ratios for human dopamine:serotonin or norepinephrine:serotonin, 1397) functional activity suggested efficacious selective serotonin reuptake inhibitors were identified. Factors playing a dominant role in binding avidity and reuptake inhibition included substitution on the aromatic moiety, relative stereochemistry of the 2,5-disubstituted tetrahydrofuran portion, and the carbon chain length between the amine and the aromatic group. Two selective serotonin transporter inhibitors were evaluated in vivo, and acute administration for one agent suggested a tendency for activity in the forced swim test, but the result did not reach significance.
Introduction [0270] Serotonin systems and related transporters are important in modulating motor, endocrine and emotional functions (Broekkamp et al., J.Med. Chem., 38:4615-4633 (1995)).
Serotonin (5-HT) is altered in neurological and psychiatric disorders associated with depression and other conditions including depression and drug abuse (Broekkamp et al., J.Med. Chem., 38:4615-4633 (1995)). Brain 5-HT may play a role in normal and neurological and psychiatric disorders. New agents provide insight into new structure-activity relationships, and may lead to more selective ligands for improved understanding of differences in potency and selectivity at different transporters and for understanding 5-HT in brain physiology and disease (Blough et al., 1 Med. Chem., 40:3861-3864 (1997)). Synthesis of novel, highly potent and selective reuptake inhibitors of hSERT could provide a significant amount of structure activity information required for producing more effective antidepressants with fewer side effects. This may also lead to highly potent ligands needed for brain tomography studies that could help to elucidate the pathophysiological mechanism of 5-HT neurotransmission and the relationship between hSERT occupancy and central nervous system drug action (Oya, S. et aL, I Med. Chem., 42:333-335 (1999)).
[0271] Cocaine blocks the reuptake of dopamine (DA), serotonin (5-HT) and nor epinephrine (NE) (Eshleman et al., J PharmacoL Exp. Ther., 289:877-885 (1999)). Cocaine is more potent than DA at inhibiting 5-HT uptake and influences 5-HT
neurotransmission (Carroll et aL, I Med. Chem., 35:969 - 981 (1992); Wolf et al., Neurochem.
Int., 18:33-38 (1991)). Cocaine was utilized as a starting point to develop selective serotonin reuptake inhibitors (SSRls). Theoretically, molecular dissection of cocaine (Figure 9) via cleavage of the 2,3-carbon bond or cleavage of the 6,7-carbon bond leads to 5- and 6-membered ring systems (i.e., E and D, respectively, see Figure 9) (Feng, X. et al., Bioorg.
Med. Chem., 11:775-780 (2003); Tamiz et aL, I Med. Chem., 43:1215-1222 (2000)). Taking advantage of the observation that aryltropanes (Holmquist et al., I Med. Chem., 39:4139-4141 (1996)) or "WIN Compounds" (Clarke et al., I Med. Chem., 16:1260-1267 (1973)) were more metabolically stable than cocaine analogs that possess aryl ester functionality, metabolically stable compounds derived from molecular dissection of aryltropanes were designed and synthesized. The observation that oxa (Meltzer et al., I Med. Chem., 40:2661-2673 (1997)) or carbon (Meltzer et al., I Med. Chem., 42:2982-2991 (2000); Javanmard et al., J. Med.
Chem., 42:4836-4843 (1999)) analogs of aryltropanes (structure C, see Figure 9) were potent ligands for neurotransmitter transporters (Boja et al., I Med. Chem., 37, 1220-1223 (1994)) and that nortropanes (Blough et al., J. Med. Chem., 40:3861-3864 (1997)) possessed greater binding selectivity for the serotonin transporter (SERT) prompted the synthesis of 2,5-disubstituted tetrahydrofuran analogues (structure E, see Figure 9). During the process of identifying highly potent and selective human SERT reuptake inhibitors, the process of dynamic medicinal chemistry was employed where metabolic stability considerations were built into the design and synthesis of increasingly more potent and selective compounds. As observed previously, it was also noted that certain alkyl- and halogen-substitutions of the aromatic moiety of aryltropanes led to significant increases in affinity for the human SERT
(Blough et al., J. Med. Chem., 40:3861-3864 (1997)). While our investigations of substituents of aromatic ring analogues of 2,5-disubstituted tetrahydrofurans was not exhaustive, it supported the hypothesis that appropriate substitution markedly enhanced the potency and selectivity of reuptake inhibitors for the human SERT. Herein is described the synthesis and characterization of a new class of 2,5-disubstituted tetrahydrofurans that show potent, selective reuptake inhibition of hSERT and low affinity for hDAT and hNET. Studies in small animal models suggest that the compounds possess in vivo efficacy.
Results:
[0272] The approach to the identification of highly potent and selective SSRIs utilized molecular dissection and dynamic medicinal chemistry. Molecular dissection of (-)-cocaine derivatives (i.e., "WIN Compounds" or aryltropanes) afforded 2,5-disubstituted tetrahydofurans. When appropriately substituted, 2,5-disubstituted tetrahydrofurans afforded potent and selective reuptake inhibitors of the human serotonin transporter (hSERT). High throughput chemical synthesis was combined with a strategy to decrease metabolism of the lead compounds (i.e., dynamic medicinal chemistry) to produce metabolically stable, potent SSRIs.
Lead Discovery [0273] Chemical synthesis of a mixture of cis and trans 2,5-disubstituted tetrahydrofurans was done by liquid phase parallel synthesis. To accelerate the lead compound discovery process, a mixture of cis and trans diastereomers was carried through to the final products and pharmacologically tested in vitro. The ratio of diastereomers was determined by high resolution 1H NMR and in most cases, the diastereomer ratio was cis:trans =
1:2. Binding affinity (i.e., Ki value) was measured for each compound by assessing the potency of inhibition of binding radiolabeled RTI-55 to the human dopamine transporter (hDAT), human SERT (hSERT) and human norepinephrine transporter (hNET). In vitro functional potency was measured by determining the reuptake inhibition (i.e., IC50 value) of [3f1]--DA, [31-1]-5-HT
or [311]-NE at the recombinant hDAT, hSERT or hNET in the presence of HEK-293 cells transfected with the respective cDNA. In the series of 2,5-disubstituted tetrahydrofuran analogs examined, both the unsubstituted- and methoxy-substituted naphthyl compounds (e.g., 15a, Ki = 18.5 nM, ICso = 23.3 nM, 15c, Ki = 45 nM, ICso = 4.1 nM, 17a, K = 85.6 nM, 17b, K = 92.3 nM, and 15e, K1 = 174 nM) showed good to modest potency at blocking hSERT binding and reuptake (see Table 9). Unsubstituted phenyl compounds (e.g., 15b, Ki=
43.0 nM, ICso = 1714 nM, 15d, K = 68 nM, ICso = 129 nM, and 17d, K1 = 3822 nM) showed modest to poor potency at blocking radioligand binding to hSERT, and poor potency at blocking reuptake of [3E1] 5-HT via the hSERT. Aryl compounds with electron withdrawing groups (e.g., 15f, Ki = 1105 nM, ICso = 31.9 nM, 15g, K1= 1114 nM, ICso = 50.3 nM, and 15h, K= 2126 nM, IC50= 225 nM) all had poor potency at blocking binding to the hSERT, but were fairly potent at blocking reuptake by the transporter. Aryl compounds with electron donating groups (15j, Ki = 6877 nM, ICso = 617 nM, 17e, K1 = 7483 nM, ICso =
4041 nM and 15k, K = >10k nM, 636 nM) were also generally more potent at blocking reuptake by the hSERT as compared to their potencies at blocking binding. Aromatic groups with heteroatoms (e.g., 15i, K1= 4546 nM, ICso = 2721 nM and 171, K1 = >10k nM, ICso = >10k nM) also possessed poor potency for blocking hSERT binding and were also not very potent at blocking uptake by the hSERT. Substituents on the aryl group that contained both electron donating and electron withdrawing groups (e.g., 17c, K = 688 nM, ICso = 30 nM) were potent at blocking reuptake via the hSERT, but had low potency at blocking binding to the hSERT.
[0274] Generally, the 2,5-disubstituted tetrahydrofurans examined possessed very poor potency for inhibition of binding of radiolabeled RTI 55 to hDAT (i.e., range 512 to >10,000 nM) or to hNET (i.e., 634 to > 10,000 nM). However, in some cases, (i.e., 15b, 15c, 15f and 15g for the hNET and 15b and 15c for the hDAT) the compounds possessed considerable potency at blocking transporter reuptake. Lead discovery activity was focused on compounds that potently interacted with the hSERT.
Structure Activity Studies [0275] During the lead discovery phase, it was observed that methoxy substituents increased the affinity of the compounds for the hSERT (e.g., 17a). The fluoro methoxy disubstituted aryl analogs 18a-r were synthesized to further investigate the structure activity relationship for this series. Human SERT binding and reuptake inhibition was dependent on both the chain length between the aryl moiety and amine group and the cis/trans orientation of the 2,5-disubsituted tetrahydrofuran ring (see Table 10). Overall, the trans orientation (e.g., 18k, K= 0.8 nM, IC50 = 2.5) provided compounds that were more potent than the compound with the cis orientation (e.g., 181, Ki = 19.3 nM, IC50 = 17.5 nM).
Generally, the trans orientation increased the potency in the binding and reuptake assays approximately 7-fold compared to the corresponding cis compound. By increasing the chain length between the aryl group and tetrahydrofuran ring, the potency was increased (e.g., 18a, RI1= 6307 nM, 1050 = 2071 nM to 18m, K= 0.8 nM, IC50= 2.1 nM). Based on the compounds tested thus far, a three carbon atom span between the aryl group and the tetrahydrofuran was optimal.
Functional activity was also dependent on the number of carbon atoms between the tetrahydrofuran moiety and the terminal amine with two carbon atoms generally being superior to one carbon atom. The overall chain length between the substituted aryl group, tetrahydrofuran, and the terminal amine was optimal with a total of five carbon atoms (i.e., 18o, K1 = 1.1 nM, IC50 = 2.3 nM, cis/trans 1:2.5). Analogs 18a-r were also tested for binding and reuptake inhibition against hDAT and hNET, and these results are listed in Table 10.
Generally, 18a-r possessed very low affinity for the hDAT values in the range 6,288-41,257 nM) and very low affinity for the hNET values in the range 481-10,000 nM).
Thus, the selectivity for interacting with the hSERT was great. The selectivity ratios for inhibition of binding and reuptake of biogenic amines by these compounds are listed in Table 11. Potency for binding inhibition and reuptake inhibition at the hSERT
correlated very well for the most active compounds such as 18a-18p (i.e., average reuptake (IC50)/binding (Ki) correlation = 1.04). However, reuptake (IC50)/binding (Ki) correlations calculated for 18q (IC50/K1 = 21.0) and 18r (IC50/K1 = 15.5) suggested that the properties controlling binding and reuptake for these latter compounds were not exactly the same.
[0276] The selectivity of 18k, 18m and 18p for hSERT versus other biogenic amine transporters expressed as ratios of binding (Kis) or reuptake (IC50s) values listed in Table 11 showed that the most potent compounds possessed excellent transporter selectivity (Ki ratios ranging from 1162 to 10,676 or 1050 ratios ranging from 192 to 11,140) for hDAT/hSERT
and hNET/hSERT, respectively.
In Vivo Efficacy Studies [0277] Balb/c mice have been reported to exhibit a relatively high immobility baseline and have shown sensitivity to fluoxetine challenge in the forced-swim test (FST) (Lucki et al., Psychopharmacol.,155:315-322 (2001)). Fluoxetine and a 1:2 cis:trans ratio of compounds 18k/1 and 18o/p were examined in the FST. Acute administration of fluoxetine (20 mg/kg), 18k/1 (10 mg/kg), or 18o/p (10 mg/kg) the latter two compounds as a mixture of 1:2 cis:trans diastereomers, did not significantly alter the duration of immobility in the FST in Balb/c mice although there was a tendency for 18o/p to show an effect (Fig. 3). In contrast, subchronic administration of a lower dose of fluoxetine (10 mg/kg) significantly decreased immobility (P
<0.05) (data not shown) but subchronic treatment with 18k/1 (10 mg/kg) did not change immobility compared to the vehicle control (data not shown).
In Vitro Metabolic Stability Studies [0278] Metabolic stability tests were done with 18k/1 in the presence of both mouse and rat liver microsomes supplemented with NADPH using a general protocol described before (Denton etal., J. Med Chem. 48:224-239 (2004)). Compound 18k/1 was more stable in the presence of rat liver microsomes (i.e., half life of 106 min) than in the presence of mouse liver microsomes (i.e., a half life of 56 min). The N-methyl amine, compound 20, was synthesized to potentially increase metabolic stability and act as a pro-drug.
In vitro microsomal metabolism studies of compound 20 showed an increase in the metabolic stability in the presence of rat liver microsomes (i.e., a half life of 129 min). However, compound 20 was not more stable than 18k/1 and had a half life of 58.5 min in the presence of mouse liver microsomes.
Discussion [0279] Based on molecular dissection of cocaine and the closely related aryltropane structures, 5- and 6-membered compounds were prepared. 2,5-Disubstituted tetrahydrofuran compounds with 0, 1, 2, or 3 carbons between the tetrahydrofuran ring and various substituted or unsubstituted aryl or naphthyl groups as well as compounds with carbon chains of 1 or 2 carbon atoms between the tetrahydrofuran ring and the amine were tested for binding and reuptake inhibition at hDAT, hSERT, and hNET. In general, low binding potency and reuptake inhibition potency for the 2,5-disubstituted tetrahydrofurans were observed for the hDAT and hNET. For certain 2,5-disubstituted tetrahydrofurans, significant reuptake inhibition of the hSERT was observed and this was explored in detail.
Unsubstituted phenyl compounds possessed modest potency. Compounds with electron withdrawing or electron donating groups on the aryl group showed decreased affinity towards the hSERT. Binding affinity was decreased with bulky substituents on the aryl ring but affinity was maintained when large aromatic groups such as 1- or 2-naphthyl groups were present. Affinity for the hSERT was decreased when a heteroaryl group (i.e., furan or pyridine) was introduced as a replacement for the aryl group. When 2-methoxy 5-fluorophenyl substituents were present in the aryl portion of the molecule, highly potent and selective hSERT reuptake inhibitors were observed. It is possible that the methoxy and furan oxygen atoms work together to coordinate cations and facilitate hSERT
mechanism of action.
However, this was not examined in detail in this study. Nevertheless, synthesis of additional compounds with various carbon atom side chains with a 2-methoxy 5-fluorophenyl moiety present afforded highly potent compounds. The most potent hSERT reuptake inhibitors contained side chains of a total of 5 carbon atoms in length. In the 2-methoxy 5-fluorophenyl 2,5-disubstituted tetrahydrofuran series, compounds with the trans configuration at the 2,5-tetrahydrofuran junction afforded on average, about 7-fold more potency than the corresponding cis diastereomers. However, the absolute stereochemistry at the 2,5-position of the tetrahydrofuran was not investigated.
[0280] Acute treatment of mice with 18k/I at doses of 10 and 30 mg/kg or 18o/p tended to decrease immobility, but it was not statistically significant. (See Figure 11.) Subchronic treatment of mice with 18k/1 at doses of 10 mg/kg did not change immobility compared to the vehicle control. Under the same conditions, fluoxetine (10 mg/kg) did cause significantly decreased immobility in the FST. These in vivo results could be due to relatively rapid metabolism of the primary amine to inactive metabolites or the amount and duration of the dose.
Experimental Section:
[0281] General. Commercially available reagents were purchased from Aldrich chemical company or VWR and were used as received. All moisture sensitive reactions were carried out in flame-dried glassware under an argon atmosphere. Tetrahydrofuran (THF) and toluene were freshly distilled from calcium hydride under an argon atmosphere.
Methanol (CH3OH) was passed through a column of neutral alumina and stored over 3A molecular sieves prior to use.
[0282] Analytical thin-layer chromatography (TLC) was done on K6F silica gel (Whatman) glass-backed plates. Compounds were detected using UV absorption at 254 nm and/or stained with 12 (iodine). Flash chromatography was done on Merck (60 A) pore silica.
NMR spectra were recorded at 500 MHz by NuMega Resonance Labs, Inc., (San Diego, CA) or at 300 MHz by the Human BioMolecular Research Institute using the solvent specified.
Chemical shifts were reported in parts per million (ppm, 8) using residual solvent signals as internal standards. Low resolution mass spectroscopy (LRMS) was done with an mass spectrometer at HT Laboratories (San Diego, CA) using electrospray ionization (ESI) or at the Human BioMolecular Research Institute on a Hitachi M-8000 3DQMS (ion trap) mass spectrometer using ESI. High resolution mass spectroscopy (HRMS) was done with a Micromass LCT time of flight mass spectrometer at the University of Montana Mass Spectrometry Facility (Missoula, MT) using ESI.
[0283] The 2,5-disubstituted tetrahydrofuran analogues were characterized by 1H NMR, LRMS, HRMS and their purities (> 95%) were determined by HPLC in two distinct solvent systems. Analytical HPLC measurements were run on a Hitachi L-6200 system equipped with a Hitachi L-7400 UV detector. Separations were done (straight-phase) with an Axxi-chrom silica column (4.6 mm x 250 mm, 511m) or (reverse-phase) with a Supelco pentafluorophenyl column (4.6 mm x 250 mm, 5tim). Standard conditions utilized an isocratic, ternary-solvent system consisting of solvents A (methanol), B
(isopropanol), C
(acetonitrile), and D (HC104) set at a flow rate of 1.5 mL/min (straight-phase), or A, E
(water) and F (HCO2H) set at a flow rate of 1.0 mL/min (reverse-phase), X =
254 nm with retention times (tR) evaluated in minutes. Typical analyses involved two distinct isocratic elutions per compound of interest. Solvent conditions for the isocratic elutions were varied depending on the compound and its specific chromatographic properties. 1H NMR
and mass spectra are consistent with the assigned structures.
[0284] Transporter Binding and Reuptake Inhibition Assays. For [125I]RTI-55 binding studies, the HEK-hDAT, -hSERT, or hNET cells were grown as described previously (Eshleman et al., J. Pharmacol. Exp. Ther., 289:877-885 (1999)). Binding studies were done as described before (Eshleman et aL, J. Pharmacol. Exper. Ther., 274:276-283 (1995)). Two or three independent competition experiments were done with duplicate determinations.
GraphPad Prism was used to analyze the data with ICso values converted to Ki SEM values using the Cheng-Prusoff equation. For uptake inhibition assays, Krebs-HEPES
and test compound were added to cells described above. The assay was initiated by addition of tritiated neurotransmitter (20 nM final concentration). Specific uptake was defined as the difference in uptake observed in the presence and absence of 5 ,M mazindol or 5 tiM
imipramine (i.e., for the hSERT). Filtration of the cells through a filter and calculation of ICso values were as described before (Fandrick et al., Biorganic Med. Chem.
Lett., 13:2151-2154 (2003)). Triplicate determinations from curves made up of six drug concentrations each afforded each ICso value SEM.
[0268] Compounds 19 and 115 were tested in a Morris water maze test. The escape latency (time to climb onto a hidden platform) for each mouse was recorded as a memory test.
Previously, it has been shown that rolipram (a PDE4 inhibitor) increases memory and restores cognitive function in a stroke model in rats. Compared to a group of control mice, compound 19 and 115 caused a 30% improvement in memory at 3 mg/kg. The effect was dose-dependent as a 0.3 mg/kg dose produced a significantly lower response.
Compound 28 showed only about a 10% improvement in memory at 3 mg/kg. This is not completely unexpected as SSRIs often require repeated dosing to see a large and significant effect. The data shows that despite the large molecular weight, the compounds get into the brain and are pharmacologically active in vivo. Multiple dosing likely will increase the efficacy of the compounds tested. In contrast to simple SSRIs, the in vivo pharmacological effects had a very fast onset of action.
Example 28: 2,5-Disubstituted Tetrahydrofurans as Selective Serotonin Reuptake Inhibitors [0269] On the basis of molecular dissection of cocaine, a series of 2,5-disubstituted tetrahydrofurans were synthesized. The compounds were evaluated for their ability of compete with radiolabelled RTI-55 binding and to inhibit reuptake of neurotransmitters at the human dopamine, serotonin and norepinephrine transporters. Highly potent (i.e.
K= 800 pM) and selective (IC50 ratios for human dopamine:serotonin or norepinephrine:serotonin, 1397) functional activity suggested efficacious selective serotonin reuptake inhibitors were identified. Factors playing a dominant role in binding avidity and reuptake inhibition included substitution on the aromatic moiety, relative stereochemistry of the 2,5-disubstituted tetrahydrofuran portion, and the carbon chain length between the amine and the aromatic group. Two selective serotonin transporter inhibitors were evaluated in vivo, and acute administration for one agent suggested a tendency for activity in the forced swim test, but the result did not reach significance.
Introduction [0270] Serotonin systems and related transporters are important in modulating motor, endocrine and emotional functions (Broekkamp et al., J.Med. Chem., 38:4615-4633 (1995)).
Serotonin (5-HT) is altered in neurological and psychiatric disorders associated with depression and other conditions including depression and drug abuse (Broekkamp et al., J.Med. Chem., 38:4615-4633 (1995)). Brain 5-HT may play a role in normal and neurological and psychiatric disorders. New agents provide insight into new structure-activity relationships, and may lead to more selective ligands for improved understanding of differences in potency and selectivity at different transporters and for understanding 5-HT in brain physiology and disease (Blough et al., 1 Med. Chem., 40:3861-3864 (1997)). Synthesis of novel, highly potent and selective reuptake inhibitors of hSERT could provide a significant amount of structure activity information required for producing more effective antidepressants with fewer side effects. This may also lead to highly potent ligands needed for brain tomography studies that could help to elucidate the pathophysiological mechanism of 5-HT neurotransmission and the relationship between hSERT occupancy and central nervous system drug action (Oya, S. et aL, I Med. Chem., 42:333-335 (1999)).
[0271] Cocaine blocks the reuptake of dopamine (DA), serotonin (5-HT) and nor epinephrine (NE) (Eshleman et al., J PharmacoL Exp. Ther., 289:877-885 (1999)). Cocaine is more potent than DA at inhibiting 5-HT uptake and influences 5-HT
neurotransmission (Carroll et aL, I Med. Chem., 35:969 - 981 (1992); Wolf et al., Neurochem.
Int., 18:33-38 (1991)). Cocaine was utilized as a starting point to develop selective serotonin reuptake inhibitors (SSRls). Theoretically, molecular dissection of cocaine (Figure 9) via cleavage of the 2,3-carbon bond or cleavage of the 6,7-carbon bond leads to 5- and 6-membered ring systems (i.e., E and D, respectively, see Figure 9) (Feng, X. et al., Bioorg.
Med. Chem., 11:775-780 (2003); Tamiz et aL, I Med. Chem., 43:1215-1222 (2000)). Taking advantage of the observation that aryltropanes (Holmquist et al., I Med. Chem., 39:4139-4141 (1996)) or "WIN Compounds" (Clarke et al., I Med. Chem., 16:1260-1267 (1973)) were more metabolically stable than cocaine analogs that possess aryl ester functionality, metabolically stable compounds derived from molecular dissection of aryltropanes were designed and synthesized. The observation that oxa (Meltzer et al., I Med. Chem., 40:2661-2673 (1997)) or carbon (Meltzer et al., I Med. Chem., 42:2982-2991 (2000); Javanmard et al., J. Med.
Chem., 42:4836-4843 (1999)) analogs of aryltropanes (structure C, see Figure 9) were potent ligands for neurotransmitter transporters (Boja et al., I Med. Chem., 37, 1220-1223 (1994)) and that nortropanes (Blough et al., J. Med. Chem., 40:3861-3864 (1997)) possessed greater binding selectivity for the serotonin transporter (SERT) prompted the synthesis of 2,5-disubstituted tetrahydrofuran analogues (structure E, see Figure 9). During the process of identifying highly potent and selective human SERT reuptake inhibitors, the process of dynamic medicinal chemistry was employed where metabolic stability considerations were built into the design and synthesis of increasingly more potent and selective compounds. As observed previously, it was also noted that certain alkyl- and halogen-substitutions of the aromatic moiety of aryltropanes led to significant increases in affinity for the human SERT
(Blough et al., J. Med. Chem., 40:3861-3864 (1997)). While our investigations of substituents of aromatic ring analogues of 2,5-disubstituted tetrahydrofurans was not exhaustive, it supported the hypothesis that appropriate substitution markedly enhanced the potency and selectivity of reuptake inhibitors for the human SERT. Herein is described the synthesis and characterization of a new class of 2,5-disubstituted tetrahydrofurans that show potent, selective reuptake inhibition of hSERT and low affinity for hDAT and hNET. Studies in small animal models suggest that the compounds possess in vivo efficacy.
Results:
[0272] The approach to the identification of highly potent and selective SSRIs utilized molecular dissection and dynamic medicinal chemistry. Molecular dissection of (-)-cocaine derivatives (i.e., "WIN Compounds" or aryltropanes) afforded 2,5-disubstituted tetrahydofurans. When appropriately substituted, 2,5-disubstituted tetrahydrofurans afforded potent and selective reuptake inhibitors of the human serotonin transporter (hSERT). High throughput chemical synthesis was combined with a strategy to decrease metabolism of the lead compounds (i.e., dynamic medicinal chemistry) to produce metabolically stable, potent SSRIs.
Lead Discovery [0273] Chemical synthesis of a mixture of cis and trans 2,5-disubstituted tetrahydrofurans was done by liquid phase parallel synthesis. To accelerate the lead compound discovery process, a mixture of cis and trans diastereomers was carried through to the final products and pharmacologically tested in vitro. The ratio of diastereomers was determined by high resolution 1H NMR and in most cases, the diastereomer ratio was cis:trans =
1:2. Binding affinity (i.e., Ki value) was measured for each compound by assessing the potency of inhibition of binding radiolabeled RTI-55 to the human dopamine transporter (hDAT), human SERT (hSERT) and human norepinephrine transporter (hNET). In vitro functional potency was measured by determining the reuptake inhibition (i.e., IC50 value) of [3f1]--DA, [31-1]-5-HT
or [311]-NE at the recombinant hDAT, hSERT or hNET in the presence of HEK-293 cells transfected with the respective cDNA. In the series of 2,5-disubstituted tetrahydrofuran analogs examined, both the unsubstituted- and methoxy-substituted naphthyl compounds (e.g., 15a, Ki = 18.5 nM, ICso = 23.3 nM, 15c, Ki = 45 nM, ICso = 4.1 nM, 17a, K = 85.6 nM, 17b, K = 92.3 nM, and 15e, K1 = 174 nM) showed good to modest potency at blocking hSERT binding and reuptake (see Table 9). Unsubstituted phenyl compounds (e.g., 15b, Ki=
43.0 nM, ICso = 1714 nM, 15d, K = 68 nM, ICso = 129 nM, and 17d, K1 = 3822 nM) showed modest to poor potency at blocking radioligand binding to hSERT, and poor potency at blocking reuptake of [3E1] 5-HT via the hSERT. Aryl compounds with electron withdrawing groups (e.g., 15f, Ki = 1105 nM, ICso = 31.9 nM, 15g, K1= 1114 nM, ICso = 50.3 nM, and 15h, K= 2126 nM, IC50= 225 nM) all had poor potency at blocking binding to the hSERT, but were fairly potent at blocking reuptake by the transporter. Aryl compounds with electron donating groups (15j, Ki = 6877 nM, ICso = 617 nM, 17e, K1 = 7483 nM, ICso =
4041 nM and 15k, K = >10k nM, 636 nM) were also generally more potent at blocking reuptake by the hSERT as compared to their potencies at blocking binding. Aromatic groups with heteroatoms (e.g., 15i, K1= 4546 nM, ICso = 2721 nM and 171, K1 = >10k nM, ICso = >10k nM) also possessed poor potency for blocking hSERT binding and were also not very potent at blocking uptake by the hSERT. Substituents on the aryl group that contained both electron donating and electron withdrawing groups (e.g., 17c, K = 688 nM, ICso = 30 nM) were potent at blocking reuptake via the hSERT, but had low potency at blocking binding to the hSERT.
[0274] Generally, the 2,5-disubstituted tetrahydrofurans examined possessed very poor potency for inhibition of binding of radiolabeled RTI 55 to hDAT (i.e., range 512 to >10,000 nM) or to hNET (i.e., 634 to > 10,000 nM). However, in some cases, (i.e., 15b, 15c, 15f and 15g for the hNET and 15b and 15c for the hDAT) the compounds possessed considerable potency at blocking transporter reuptake. Lead discovery activity was focused on compounds that potently interacted with the hSERT.
Structure Activity Studies [0275] During the lead discovery phase, it was observed that methoxy substituents increased the affinity of the compounds for the hSERT (e.g., 17a). The fluoro methoxy disubstituted aryl analogs 18a-r were synthesized to further investigate the structure activity relationship for this series. Human SERT binding and reuptake inhibition was dependent on both the chain length between the aryl moiety and amine group and the cis/trans orientation of the 2,5-disubsituted tetrahydrofuran ring (see Table 10). Overall, the trans orientation (e.g., 18k, K= 0.8 nM, IC50 = 2.5) provided compounds that were more potent than the compound with the cis orientation (e.g., 181, Ki = 19.3 nM, IC50 = 17.5 nM).
Generally, the trans orientation increased the potency in the binding and reuptake assays approximately 7-fold compared to the corresponding cis compound. By increasing the chain length between the aryl group and tetrahydrofuran ring, the potency was increased (e.g., 18a, RI1= 6307 nM, 1050 = 2071 nM to 18m, K= 0.8 nM, IC50= 2.1 nM). Based on the compounds tested thus far, a three carbon atom span between the aryl group and the tetrahydrofuran was optimal.
Functional activity was also dependent on the number of carbon atoms between the tetrahydrofuran moiety and the terminal amine with two carbon atoms generally being superior to one carbon atom. The overall chain length between the substituted aryl group, tetrahydrofuran, and the terminal amine was optimal with a total of five carbon atoms (i.e., 18o, K1 = 1.1 nM, IC50 = 2.3 nM, cis/trans 1:2.5). Analogs 18a-r were also tested for binding and reuptake inhibition against hDAT and hNET, and these results are listed in Table 10.
Generally, 18a-r possessed very low affinity for the hDAT values in the range 6,288-41,257 nM) and very low affinity for the hNET values in the range 481-10,000 nM).
Thus, the selectivity for interacting with the hSERT was great. The selectivity ratios for inhibition of binding and reuptake of biogenic amines by these compounds are listed in Table 11. Potency for binding inhibition and reuptake inhibition at the hSERT
correlated very well for the most active compounds such as 18a-18p (i.e., average reuptake (IC50)/binding (Ki) correlation = 1.04). However, reuptake (IC50)/binding (Ki) correlations calculated for 18q (IC50/K1 = 21.0) and 18r (IC50/K1 = 15.5) suggested that the properties controlling binding and reuptake for these latter compounds were not exactly the same.
[0276] The selectivity of 18k, 18m and 18p for hSERT versus other biogenic amine transporters expressed as ratios of binding (Kis) or reuptake (IC50s) values listed in Table 11 showed that the most potent compounds possessed excellent transporter selectivity (Ki ratios ranging from 1162 to 10,676 or 1050 ratios ranging from 192 to 11,140) for hDAT/hSERT
and hNET/hSERT, respectively.
In Vivo Efficacy Studies [0277] Balb/c mice have been reported to exhibit a relatively high immobility baseline and have shown sensitivity to fluoxetine challenge in the forced-swim test (FST) (Lucki et al., Psychopharmacol.,155:315-322 (2001)). Fluoxetine and a 1:2 cis:trans ratio of compounds 18k/1 and 18o/p were examined in the FST. Acute administration of fluoxetine (20 mg/kg), 18k/1 (10 mg/kg), or 18o/p (10 mg/kg) the latter two compounds as a mixture of 1:2 cis:trans diastereomers, did not significantly alter the duration of immobility in the FST in Balb/c mice although there was a tendency for 18o/p to show an effect (Fig. 3). In contrast, subchronic administration of a lower dose of fluoxetine (10 mg/kg) significantly decreased immobility (P
<0.05) (data not shown) but subchronic treatment with 18k/1 (10 mg/kg) did not change immobility compared to the vehicle control (data not shown).
In Vitro Metabolic Stability Studies [0278] Metabolic stability tests were done with 18k/1 in the presence of both mouse and rat liver microsomes supplemented with NADPH using a general protocol described before (Denton etal., J. Med Chem. 48:224-239 (2004)). Compound 18k/1 was more stable in the presence of rat liver microsomes (i.e., half life of 106 min) than in the presence of mouse liver microsomes (i.e., a half life of 56 min). The N-methyl amine, compound 20, was synthesized to potentially increase metabolic stability and act as a pro-drug.
In vitro microsomal metabolism studies of compound 20 showed an increase in the metabolic stability in the presence of rat liver microsomes (i.e., a half life of 129 min). However, compound 20 was not more stable than 18k/1 and had a half life of 58.5 min in the presence of mouse liver microsomes.
Discussion [0279] Based on molecular dissection of cocaine and the closely related aryltropane structures, 5- and 6-membered compounds were prepared. 2,5-Disubstituted tetrahydrofuran compounds with 0, 1, 2, or 3 carbons between the tetrahydrofuran ring and various substituted or unsubstituted aryl or naphthyl groups as well as compounds with carbon chains of 1 or 2 carbon atoms between the tetrahydrofuran ring and the amine were tested for binding and reuptake inhibition at hDAT, hSERT, and hNET. In general, low binding potency and reuptake inhibition potency for the 2,5-disubstituted tetrahydrofurans were observed for the hDAT and hNET. For certain 2,5-disubstituted tetrahydrofurans, significant reuptake inhibition of the hSERT was observed and this was explored in detail.
Unsubstituted phenyl compounds possessed modest potency. Compounds with electron withdrawing or electron donating groups on the aryl group showed decreased affinity towards the hSERT. Binding affinity was decreased with bulky substituents on the aryl ring but affinity was maintained when large aromatic groups such as 1- or 2-naphthyl groups were present. Affinity for the hSERT was decreased when a heteroaryl group (i.e., furan or pyridine) was introduced as a replacement for the aryl group. When 2-methoxy 5-fluorophenyl substituents were present in the aryl portion of the molecule, highly potent and selective hSERT reuptake inhibitors were observed. It is possible that the methoxy and furan oxygen atoms work together to coordinate cations and facilitate hSERT
mechanism of action.
However, this was not examined in detail in this study. Nevertheless, synthesis of additional compounds with various carbon atom side chains with a 2-methoxy 5-fluorophenyl moiety present afforded highly potent compounds. The most potent hSERT reuptake inhibitors contained side chains of a total of 5 carbon atoms in length. In the 2-methoxy 5-fluorophenyl 2,5-disubstituted tetrahydrofuran series, compounds with the trans configuration at the 2,5-tetrahydrofuran junction afforded on average, about 7-fold more potency than the corresponding cis diastereomers. However, the absolute stereochemistry at the 2,5-position of the tetrahydrofuran was not investigated.
[0280] Acute treatment of mice with 18k/I at doses of 10 and 30 mg/kg or 18o/p tended to decrease immobility, but it was not statistically significant. (See Figure 11.) Subchronic treatment of mice with 18k/1 at doses of 10 mg/kg did not change immobility compared to the vehicle control. Under the same conditions, fluoxetine (10 mg/kg) did cause significantly decreased immobility in the FST. These in vivo results could be due to relatively rapid metabolism of the primary amine to inactive metabolites or the amount and duration of the dose.
Experimental Section:
[0281] General. Commercially available reagents were purchased from Aldrich chemical company or VWR and were used as received. All moisture sensitive reactions were carried out in flame-dried glassware under an argon atmosphere. Tetrahydrofuran (THF) and toluene were freshly distilled from calcium hydride under an argon atmosphere.
Methanol (CH3OH) was passed through a column of neutral alumina and stored over 3A molecular sieves prior to use.
[0282] Analytical thin-layer chromatography (TLC) was done on K6F silica gel (Whatman) glass-backed plates. Compounds were detected using UV absorption at 254 nm and/or stained with 12 (iodine). Flash chromatography was done on Merck (60 A) pore silica.
NMR spectra were recorded at 500 MHz by NuMega Resonance Labs, Inc., (San Diego, CA) or at 300 MHz by the Human BioMolecular Research Institute using the solvent specified.
Chemical shifts were reported in parts per million (ppm, 8) using residual solvent signals as internal standards. Low resolution mass spectroscopy (LRMS) was done with an mass spectrometer at HT Laboratories (San Diego, CA) using electrospray ionization (ESI) or at the Human BioMolecular Research Institute on a Hitachi M-8000 3DQMS (ion trap) mass spectrometer using ESI. High resolution mass spectroscopy (HRMS) was done with a Micromass LCT time of flight mass spectrometer at the University of Montana Mass Spectrometry Facility (Missoula, MT) using ESI.
[0283] The 2,5-disubstituted tetrahydrofuran analogues were characterized by 1H NMR, LRMS, HRMS and their purities (> 95%) were determined by HPLC in two distinct solvent systems. Analytical HPLC measurements were run on a Hitachi L-6200 system equipped with a Hitachi L-7400 UV detector. Separations were done (straight-phase) with an Axxi-chrom silica column (4.6 mm x 250 mm, 511m) or (reverse-phase) with a Supelco pentafluorophenyl column (4.6 mm x 250 mm, 5tim). Standard conditions utilized an isocratic, ternary-solvent system consisting of solvents A (methanol), B
(isopropanol), C
(acetonitrile), and D (HC104) set at a flow rate of 1.5 mL/min (straight-phase), or A, E
(water) and F (HCO2H) set at a flow rate of 1.0 mL/min (reverse-phase), X =
254 nm with retention times (tR) evaluated in minutes. Typical analyses involved two distinct isocratic elutions per compound of interest. Solvent conditions for the isocratic elutions were varied depending on the compound and its specific chromatographic properties. 1H NMR
and mass spectra are consistent with the assigned structures.
[0284] Transporter Binding and Reuptake Inhibition Assays. For [125I]RTI-55 binding studies, the HEK-hDAT, -hSERT, or hNET cells were grown as described previously (Eshleman et al., J. Pharmacol. Exp. Ther., 289:877-885 (1999)). Binding studies were done as described before (Eshleman et aL, J. Pharmacol. Exper. Ther., 274:276-283 (1995)). Two or three independent competition experiments were done with duplicate determinations.
GraphPad Prism was used to analyze the data with ICso values converted to Ki SEM values using the Cheng-Prusoff equation. For uptake inhibition assays, Krebs-HEPES
and test compound were added to cells described above. The assay was initiated by addition of tritiated neurotransmitter (20 nM final concentration). Specific uptake was defined as the difference in uptake observed in the presence and absence of 5 ,M mazindol or 5 tiM
imipramine (i.e., for the hSERT). Filtration of the cells through a filter and calculation of ICso values were as described before (Fandrick et al., Biorganic Med. Chem.
Lett., 13:2151-2154 (2003)). Triplicate determinations from curves made up of six drug concentrations each afforded each ICso value SEM.
Animal testing [0285] Forty Balb/c male mice weighing 22.4 0.1 g were used in the experiment and were housed in a temperature-controlled room (22-23 C) and maintained on a 12-hour on /12-hour off light cycle (lights on at 6:00 AM). The study was conducted according to a standard operation procedure and in accordance with all Federal regulations. Water and food were freely available in the home cages. The mice were randomly divided into four groups:
Vehicle (saline containing 5% DMSO), (B) fluoxetine 20 mg/kg, (C) 1810 10 mg/kg and 18o/p 10 mg/kg. The forced-swim test (FST) was carried out as described previously (Zhang et al., Neuropsychopharmacol., 27:587-595 (2002)). Mice were given a swimming pretest session, once a day-for two successive days. Twenty-four hours after the last session, mice were injected i.p. with vehicle or the lower dose of each drug 30 min prior to the FST.
During the pretest and test sessions, each mouse was placed for 6 min in a plastic cylinder (45 cm high x 20 cm diameter), which was filled to a depth of 28 cm with water (23 1 C). The duration of immobility, which was defined as floating in an upright position without additional activity other than that necessary for the animal to keep its head above water, was recorded. For the subchronic administration tests, the animals were separated as above and vehicle or chemicals were given by i.p. administration 23, 5 and 1 hr before the FST. The subchronic experiments were done similar to the study described above except for the pretest training that was not carried out.
Mouse and Rat Liver Microsome Stability Assay.
[0286] A typical assay mixture contained either mouse or rat liver microsomes (0.5 mg of protein), 100 uM potassium phosphate buffer (pH 7.4), 40 uM test compounds, 0.5 mM
NADP+, 0.5 mM glucose-6-phosphate, 5 IU/mL glucose-6-phosphate dehydrogenase, mg/mL diethylenetriaminepentaacetic acid (DETAPAC) and 5 mM MgCl2 in a final incubation volume of 0.1 mL. After 0, 10, 25, 40 and 60 min, the incubations were stopped by the addition of 1 ml CH2C12/2-propanol (3:1 v:v). The mixture was centrifuged at 12,000 x g for 1 min, and the organic layer was separated from the aqueous fraction.
The organic fraction was evaporated with a stream of argon and the residue was taken up in methanol (200 L) and injected into the HPLC system described above.
Vehicle (saline containing 5% DMSO), (B) fluoxetine 20 mg/kg, (C) 1810 10 mg/kg and 18o/p 10 mg/kg. The forced-swim test (FST) was carried out as described previously (Zhang et al., Neuropsychopharmacol., 27:587-595 (2002)). Mice were given a swimming pretest session, once a day-for two successive days. Twenty-four hours after the last session, mice were injected i.p. with vehicle or the lower dose of each drug 30 min prior to the FST.
During the pretest and test sessions, each mouse was placed for 6 min in a plastic cylinder (45 cm high x 20 cm diameter), which was filled to a depth of 28 cm with water (23 1 C). The duration of immobility, which was defined as floating in an upright position without additional activity other than that necessary for the animal to keep its head above water, was recorded. For the subchronic administration tests, the animals were separated as above and vehicle or chemicals were given by i.p. administration 23, 5 and 1 hr before the FST. The subchronic experiments were done similar to the study described above except for the pretest training that was not carried out.
Mouse and Rat Liver Microsome Stability Assay.
[0286] A typical assay mixture contained either mouse or rat liver microsomes (0.5 mg of protein), 100 uM potassium phosphate buffer (pH 7.4), 40 uM test compounds, 0.5 mM
NADP+, 0.5 mM glucose-6-phosphate, 5 IU/mL glucose-6-phosphate dehydrogenase, mg/mL diethylenetriaminepentaacetic acid (DETAPAC) and 5 mM MgCl2 in a final incubation volume of 0.1 mL. After 0, 10, 25, 40 and 60 min, the incubations were stopped by the addition of 1 ml CH2C12/2-propanol (3:1 v:v). The mixture was centrifuged at 12,000 x g for 1 min, and the organic layer was separated from the aqueous fraction.
The organic fraction was evaporated with a stream of argon and the residue was taken up in methanol (200 L) and injected into the HPLC system described above.
Chemical Synthesis [0287] 5-Fluoro-2-methoxyphenylacetaldehyde (2a): To a suspension of methoxymethyltriphenylphosphonium chloride (10.0 g, 30.0 nunol) in THF (30 mL) under Ar was added NaH (60% in mineral oil, 1.2 g, 30 mmol) and then heated to reflux for 1 h.
The orange colored suspension was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (4.2 g, 26.0 mmol) was added and the mixture was stirred for 12 h at room temperature. The reaction mixture was then poured into a separatory funnel containing ammonium chloride aqueous solution (sat. NH4C1/H20, 1:1, v:v, 100 mL). The organic material was extracted with ethyl acetate (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over Na2SO4. The solvent was then removed in vacuo and the crude product (2a) obtained was dissolved in acetone (50 mL). H2SO4 (1 M, 1.5 mL) was then added and the mixture obtained was heated to reflux for 6 h while stirring. The reaction was then cooled to room temperature and the solvent was removed in vacuo to obtain the crude product that was then purified by flash column chromatography (Rf = 0.15, Et0Ac/Hexane, 10:90, v:v) to afford the product (2.63 g, 66%) as an oil: 1H NMR (CDC13, 500 MHz): 6 9.68 (s, 1 H), 6.97 (dt, J= 3.1, 8.7 Hz, 1 H), 6.89 (dd, J= 3.1, 8.7 Hz, 1 H), 6.83 (dd, J= 4.3, 8.7 Hz, 1 H), 3.80 (s, 3 H), 3.63 (d, J= 1.7 Hz, 2 H).
[0288] Ethyl-3-(5'-fluoro-2'-methoxypheny1)-2-propenoate (4a): To a solution of 5-fluoro-2-methoxybenzaldehyde (4.3 g, 28.0 mmol) in CH2C12 (30 mL) at 0 C was added portionwise carbethoxymethylenetriphenylphosphorane (10.7 g, 30.1 mmol). The mixture was then warmed to room temperature and stirred for 12 h. The solvent was removed in vacuo and the residue was purified by flash column chromatography (Rf = 0.2, Et0Ac/Hexane, 10:90, v:v) to provide the product (6.0 g, 95%) as oil in a 4:1 mixture of tran : cis isomers; 1H NMR (CDC13, 500 MHz): ö 7.93 (d, J= 16.2 Hz, 0.8 H), 7.33 (dd, J= 3.1, 9.2 Hz, 0.2 H), 7.21 (dd, .1= 3.1, 9.2, Hz, 0.8 H), 7.08 (d, J= 12.5 Hz, 0.2 H), 7.03 (dt, J=
3.0, 8.8 Hz, 0.8 H), 6.99 (dt, J= 3.0, 8.8 Hz, 0.2 H), 6.84 (dd, J= 3.1, 8.6 Hz, 0.8 H), 6.79 (dd, J= 3.3, 9.1 Hz, 0.2 H), 6.47 (d, J= 16.2 Hz, 0.8 H), 5.99 (d, J= 12.5 hz, 0.2 H), 4.25 (q, J= 7.1 Hz, 1.6 H), 4.15 (q, J= 7.0 Hz, 0.4 H), 3.86 (s, 2.4 H), 3.81 (s, 0.6 H), 1.34 (t, J= 7.1 Hz, 2.4 H), 1.22 (t, J= 7.0 Hz, 0.6 H).
(Rf = 0.4, Et0Ac/Hexane, 6:94, v:v) [0289] The following compounds were prepared in a similar fashion as that for compound 4a.
The orange colored suspension was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (4.2 g, 26.0 mmol) was added and the mixture was stirred for 12 h at room temperature. The reaction mixture was then poured into a separatory funnel containing ammonium chloride aqueous solution (sat. NH4C1/H20, 1:1, v:v, 100 mL). The organic material was extracted with ethyl acetate (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over Na2SO4. The solvent was then removed in vacuo and the crude product (2a) obtained was dissolved in acetone (50 mL). H2SO4 (1 M, 1.5 mL) was then added and the mixture obtained was heated to reflux for 6 h while stirring. The reaction was then cooled to room temperature and the solvent was removed in vacuo to obtain the crude product that was then purified by flash column chromatography (Rf = 0.15, Et0Ac/Hexane, 10:90, v:v) to afford the product (2.63 g, 66%) as an oil: 1H NMR (CDC13, 500 MHz): 6 9.68 (s, 1 H), 6.97 (dt, J= 3.1, 8.7 Hz, 1 H), 6.89 (dd, J= 3.1, 8.7 Hz, 1 H), 6.83 (dd, J= 4.3, 8.7 Hz, 1 H), 3.80 (s, 3 H), 3.63 (d, J= 1.7 Hz, 2 H).
[0288] Ethyl-3-(5'-fluoro-2'-methoxypheny1)-2-propenoate (4a): To a solution of 5-fluoro-2-methoxybenzaldehyde (4.3 g, 28.0 mmol) in CH2C12 (30 mL) at 0 C was added portionwise carbethoxymethylenetriphenylphosphorane (10.7 g, 30.1 mmol). The mixture was then warmed to room temperature and stirred for 12 h. The solvent was removed in vacuo and the residue was purified by flash column chromatography (Rf = 0.2, Et0Ac/Hexane, 10:90, v:v) to provide the product (6.0 g, 95%) as oil in a 4:1 mixture of tran : cis isomers; 1H NMR (CDC13, 500 MHz): ö 7.93 (d, J= 16.2 Hz, 0.8 H), 7.33 (dd, J= 3.1, 9.2 Hz, 0.2 H), 7.21 (dd, .1= 3.1, 9.2, Hz, 0.8 H), 7.08 (d, J= 12.5 Hz, 0.2 H), 7.03 (dt, J=
3.0, 8.8 Hz, 0.8 H), 6.99 (dt, J= 3.0, 8.8 Hz, 0.2 H), 6.84 (dd, J= 3.1, 8.6 Hz, 0.8 H), 6.79 (dd, J= 3.3, 9.1 Hz, 0.2 H), 6.47 (d, J= 16.2 Hz, 0.8 H), 5.99 (d, J= 12.5 hz, 0.2 H), 4.25 (q, J= 7.1 Hz, 1.6 H), 4.15 (q, J= 7.0 Hz, 0.4 H), 3.86 (s, 2.4 H), 3.81 (s, 0.6 H), 1.34 (t, J= 7.1 Hz, 2.4 H), 1.22 (t, J= 7.0 Hz, 0.6 H).
(Rf = 0.4, Et0Ac/Hexane, 6:94, v:v) [0289] The following compounds were prepared in a similar fashion as that for compound 4a.
[0290] Ethyl 3-pentafluoropheny1-2-propenoate (4b): The product (6.64 g, 94%) was obtained by chromatography on silica as oil; (Rf = 0.39, Et0Ac/Hexane, 6:94, v:v); 1H NMR
(CDC13, 500 MHz): a 7.64 (d, J= 16.6 Hz, 1 H), 6.73 (d, J= 16.5 Hz, 1 H), 4.29 (q, J= 7.2 Hz, 2 H), 1.35 (t, J= 7.2 Hz, 3 H).
[0291] Ethyl-3-(3-pyridine) 2-propenoate (4c): The product as an oil (5.3 g, quantitative yield) was obtained by chromatography on silica; (Rf = 0.24, Et0Ac/Hexane, 50:50, v:v); 1H
NMR (500 MHz, CDC13) a 8.70 (d, J= 1.9 Hz, 1 H), 8.55 (t, J= 5.2 Hz, 1 H), 7.79 (d, J-9.8 Hz, 1 H), 7.63 (d, J= 18.9 Hz, 1 H), 7.28 (dd, J= 5.3, 4.7 Hz, 1 H), 6.45 (d, J= 15.6 Hz, 1 H), 4.23 (q, J= 7.2 Hz, 2 H), 1.30 (t, J= 7.2 Hz, 3 H).
[0292] Ethyl 3-(1-naphthyl)-2-propenoate (4d): The product as an oil (14.3 g, 98.4%) was obtained by chromatography on silica; (Rf = 0.61, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) a 8.53 (d, J= 15.9 Hz, 1 H), 8.20 (d, J= 8.4 Hz, 1 H), 7.88 (t, J= 7.5 Hz, 2 H), 7.74 (d, J= 7.2 Hz, 1 H), 7.58 (t, J= 5.6 Hz, 1 H), 7.53 (t, J= 7.0 Hz, 1 H), 7.47 (t, J=
7.8 Hz, 1 H), 6.53 (d, J= 15.6 Hz, 1 H), 4.34 (q, J= 7.2 Hz, 2 H), 1.40 (t, J=
7.1 Hz, 3 H).
[0293] Ethyl 3-(2'-methoxy-1'-naphthyl)-2-propenoate (4e): The product as an oil (6.32 g, 93%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v);
1H NMR (500 MHz, CDC13) a 8.35 (d, J= 15.8 Hz, 1 H), 8.19 (d, J= 8.6 Hz, 1 H), 7.85 (d, J
= 9.1 Hz, 1 H), 7.79 (d, J= 7.9 Hz, 1 H), 7.52 (m, 1 H), 7.38 (t, J= 7.7 Hz, 1 H), 7.29 (d, J=
8.8 Hz, 1 H), 6.76 (d, J= 15.6 Hz, 1 H), 3.95 (s, 3 H), 3.42 (t, J= 7.7 Hz, 3 H), 2.74 (td, J-7.7, 1.9 Hz, 3 H).
[0294] Ethyl 3-(4'-methoxy-1'-naphthyl)-2-propenoate (41): The product as an oil (4.3 g, 92%) was obtained by chromatography on silica; (Rf = 0.55, Et0Ac/Hexane, 25:75, v:v);
1H NMR (300 MHz, CDC13) a 8.48 (d, J= 15.6 Hz, 1 H), 8.32 (d, J= 8.7 Hz, 1 H), 8.18 (d, J
= 8.7 Hz, 1 H), 7.73 (d, J= 7.8 Hz, 1 H), 7.63-7.50 (m, 2 H), 6.82 (d, J= 8.4 Hz, 1 H), 6.46 (d, J= 15.6 Hz, 1 H), 4.32 (q, J= 7.2 Hz, 2 H), 4.02 (s, 3 H), 1.38 (t, J= 7.2 Hz, 3 H).
[0295] Ethyl 3-(4'-flouro-3'-methylpheny1)-2-propenoate (4g): The product as an oil (4.53 g, 99%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v); 1H NMR (300 MHz, CDC13) a 7.58 (d, J= 16.2 Hz, 1 H), 7.34-7.28 (m, 2 H), 6.98 (t, J
= 9.3 Hz, 1 H), 6.31 (d, J= 16.2 Hz, 1 H), 4.23 (q, J= 7.2 Hz, 2 H), 2.26 (s, 3 H), 1.31 (t, J=
7.2 Hz, 3 H).
(CDC13, 500 MHz): a 7.64 (d, J= 16.6 Hz, 1 H), 6.73 (d, J= 16.5 Hz, 1 H), 4.29 (q, J= 7.2 Hz, 2 H), 1.35 (t, J= 7.2 Hz, 3 H).
[0291] Ethyl-3-(3-pyridine) 2-propenoate (4c): The product as an oil (5.3 g, quantitative yield) was obtained by chromatography on silica; (Rf = 0.24, Et0Ac/Hexane, 50:50, v:v); 1H
NMR (500 MHz, CDC13) a 8.70 (d, J= 1.9 Hz, 1 H), 8.55 (t, J= 5.2 Hz, 1 H), 7.79 (d, J-9.8 Hz, 1 H), 7.63 (d, J= 18.9 Hz, 1 H), 7.28 (dd, J= 5.3, 4.7 Hz, 1 H), 6.45 (d, J= 15.6 Hz, 1 H), 4.23 (q, J= 7.2 Hz, 2 H), 1.30 (t, J= 7.2 Hz, 3 H).
[0292] Ethyl 3-(1-naphthyl)-2-propenoate (4d): The product as an oil (14.3 g, 98.4%) was obtained by chromatography on silica; (Rf = 0.61, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) a 8.53 (d, J= 15.9 Hz, 1 H), 8.20 (d, J= 8.4 Hz, 1 H), 7.88 (t, J= 7.5 Hz, 2 H), 7.74 (d, J= 7.2 Hz, 1 H), 7.58 (t, J= 5.6 Hz, 1 H), 7.53 (t, J= 7.0 Hz, 1 H), 7.47 (t, J=
7.8 Hz, 1 H), 6.53 (d, J= 15.6 Hz, 1 H), 4.34 (q, J= 7.2 Hz, 2 H), 1.40 (t, J=
7.1 Hz, 3 H).
[0293] Ethyl 3-(2'-methoxy-1'-naphthyl)-2-propenoate (4e): The product as an oil (6.32 g, 93%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v);
1H NMR (500 MHz, CDC13) a 8.35 (d, J= 15.8 Hz, 1 H), 8.19 (d, J= 8.6 Hz, 1 H), 7.85 (d, J
= 9.1 Hz, 1 H), 7.79 (d, J= 7.9 Hz, 1 H), 7.52 (m, 1 H), 7.38 (t, J= 7.7 Hz, 1 H), 7.29 (d, J=
8.8 Hz, 1 H), 6.76 (d, J= 15.6 Hz, 1 H), 3.95 (s, 3 H), 3.42 (t, J= 7.7 Hz, 3 H), 2.74 (td, J-7.7, 1.9 Hz, 3 H).
[0294] Ethyl 3-(4'-methoxy-1'-naphthyl)-2-propenoate (41): The product as an oil (4.3 g, 92%) was obtained by chromatography on silica; (Rf = 0.55, Et0Ac/Hexane, 25:75, v:v);
1H NMR (300 MHz, CDC13) a 8.48 (d, J= 15.6 Hz, 1 H), 8.32 (d, J= 8.7 Hz, 1 H), 8.18 (d, J
= 8.7 Hz, 1 H), 7.73 (d, J= 7.8 Hz, 1 H), 7.63-7.50 (m, 2 H), 6.82 (d, J= 8.4 Hz, 1 H), 6.46 (d, J= 15.6 Hz, 1 H), 4.32 (q, J= 7.2 Hz, 2 H), 4.02 (s, 3 H), 1.38 (t, J= 7.2 Hz, 3 H).
[0295] Ethyl 3-(4'-flouro-3'-methylpheny1)-2-propenoate (4g): The product as an oil (4.53 g, 99%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v); 1H NMR (300 MHz, CDC13) a 7.58 (d, J= 16.2 Hz, 1 H), 7.34-7.28 (m, 2 H), 6.98 (t, J
= 9.3 Hz, 1 H), 6.31 (d, J= 16.2 Hz, 1 H), 4.23 (q, J= 7.2 Hz, 2 H), 2.26 (s, 3 H), 1.31 (t, J=
7.2 Hz, 3 H).
[0296] Ethyl-4-(5'-fluoro-2'-methoxyphenyl)propanoate (5a): To a solution of 4a (6.0 g, 27.0 mmol) in ethanol (200 proof, 40 mL) under Ar was added 10% Pd/C (250 mg). The flask containing the mixture was then evacuated and purged with H2 three times. A balloon containing H2 gas was attached to the flask and the reaction was allowed to stir for 15 h at room temperature. Then the reaction mixture was filtered through celite with ethanol. The crude product obtained by removal of the solvent in vacuo was purified by flash column chromatography (Rf = 0.27, Et0Ac/Hexane, 10:90, v:v) to give the product as an oil (5.8 g, 95%); 1H NMR (CDC13, 500 MHz): 6 6.89-6.84 (m, 2 H), 6.74 (dd, J= 4.7, 9.8 Hz, 1 H), 4.12 (q, J= 7.1 Hz, 2 H), 3.79 (s, 3 H), 2.91 (t, J= 7.7 Hz, 2 H), 2.59 (t, J=
7.7 Hz, 2 H), 1.24 (t, J= 7.2 Hz, 3 H).
[0297] The following compounds were prepared in a similar fashion as that for compound 5a.
[0298] Ethyl 3-pentafluoropheny1-2-propanoate (5b): The product as an oil (6.5 g, 96%) was obtained by chromatography on silica; (Rf = 0.65, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) 6 4.14 (q, J= 7.2 Hz, 2 H), 3.02 (t, J= 7.7 Hz, 2 H), 2.60 (q, J= 8.0 Hz, 2 H), 1.25 (t, J= 7.2 Hz, 3 H).
[0299] Ethyl 3-(3'-pyridine)propanoate (5c): The product as an oil (5.4 g, quantitative yield) was obtained by chromatography on silica; (Rf = 0.33, Et0Ac/Hexane, 40:60, v:v); 1H
NMR (500 MHz, CDC13) 6 8.48 (s, 1 H), 8.46, (d, J= 4.7 Hz, 1 H), 7.53 (d, J=
7.8 Hz, 1 H), 7.21 (m, 1 H), 4.12 (q, J= 7.2 Hz, 2 H), 2.95 (t, J= 7.6 Hz, 2 H), 2.63 (t, J=
7.6 Hz, 2 H), 1.23 (t, J= 7.2 Hz, 3 H).
[0300] Ethyl 3-(1-napthyl)-propanoate (5d): The product as an oil (12.4 g, 86.2%) was obtained by chromatography on silica; (Rf= 0.50, Et0Ac/Hexane, 20:80, v:v); 1H
NMR (500 MHz, CDC13) 6 8.05 (d, J= 8.3 Hz, 1 H), 7.87 (d, J= 1 H), 7.74 (d, J= 8.0 Hz, 1 H), 7.55 (t, J= 7.2 Hz, 1 H), 7.50 (t, J= 6.9 Hz, 1 H), 7.42 (t, J= 7.3 Hz, 1 H), 7.37 (d, J= 6.8 Hz, 1 H), 4.18 (t, J= 7.1 Hz, 2 H), 3.45 (t, J= 8.0 Hz, 2 H), 2.78 (q, J= 8.2 Hz, 2 H), 1.25 (t, J= 7.2 Hz, 3 H).
[0301] Ethyl 3-(2'-methoxy-1'-naphthyl)-2-propanoate: The product as an oil (4.42 g, 91%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (300 MHz, CDC13) 6 7.98 (d, J= 8.7 Hz, 1 H), 7.89 (d, J= 8.2 Hz, 1 H), 7.75 (d, J=
8.9 Hz, 1 H), 7.50 (t, J= 7.7 Hz, 1 H), 7.34 (t, J= 7.5 Hz, 1 H), 7.26 (m, 1 H), 4.16 (q, J-7 .1 Hz, 2 H), 3.96 (s, 3 H), 3.42 (t, J= 7.7 Hz, 2 H), 2.61 (m, 2 H), 1.26 (m, 3 H).
7.7 Hz, 2 H), 1.24 (t, J= 7.2 Hz, 3 H).
[0297] The following compounds were prepared in a similar fashion as that for compound 5a.
[0298] Ethyl 3-pentafluoropheny1-2-propanoate (5b): The product as an oil (6.5 g, 96%) was obtained by chromatography on silica; (Rf = 0.65, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) 6 4.14 (q, J= 7.2 Hz, 2 H), 3.02 (t, J= 7.7 Hz, 2 H), 2.60 (q, J= 8.0 Hz, 2 H), 1.25 (t, J= 7.2 Hz, 3 H).
[0299] Ethyl 3-(3'-pyridine)propanoate (5c): The product as an oil (5.4 g, quantitative yield) was obtained by chromatography on silica; (Rf = 0.33, Et0Ac/Hexane, 40:60, v:v); 1H
NMR (500 MHz, CDC13) 6 8.48 (s, 1 H), 8.46, (d, J= 4.7 Hz, 1 H), 7.53 (d, J=
7.8 Hz, 1 H), 7.21 (m, 1 H), 4.12 (q, J= 7.2 Hz, 2 H), 2.95 (t, J= 7.6 Hz, 2 H), 2.63 (t, J=
7.6 Hz, 2 H), 1.23 (t, J= 7.2 Hz, 3 H).
[0300] Ethyl 3-(1-napthyl)-propanoate (5d): The product as an oil (12.4 g, 86.2%) was obtained by chromatography on silica; (Rf= 0.50, Et0Ac/Hexane, 20:80, v:v); 1H
NMR (500 MHz, CDC13) 6 8.05 (d, J= 8.3 Hz, 1 H), 7.87 (d, J= 1 H), 7.74 (d, J= 8.0 Hz, 1 H), 7.55 (t, J= 7.2 Hz, 1 H), 7.50 (t, J= 6.9 Hz, 1 H), 7.42 (t, J= 7.3 Hz, 1 H), 7.37 (d, J= 6.8 Hz, 1 H), 4.18 (t, J= 7.1 Hz, 2 H), 3.45 (t, J= 8.0 Hz, 2 H), 2.78 (q, J= 8.2 Hz, 2 H), 1.25 (t, J= 7.2 Hz, 3 H).
[0301] Ethyl 3-(2'-methoxy-1'-naphthyl)-2-propanoate: The product as an oil (4.42 g, 91%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (300 MHz, CDC13) 6 7.98 (d, J= 8.7 Hz, 1 H), 7.89 (d, J= 8.2 Hz, 1 H), 7.75 (d, J=
8.9 Hz, 1 H), 7.50 (t, J= 7.7 Hz, 1 H), 7.34 (t, J= 7.5 Hz, 1 H), 7.26 (m, 1 H), 4.16 (q, J-7 .1 Hz, 2 H), 3.96 (s, 3 H), 3.42 (t, J= 7.7 Hz, 2 H), 2.61 (m, 2 H), 1.26 (m, 3 H).
[0302] Ethyl 3-(4'-methoxy-1'-naphthyl)-2-propanOate: The product as an oil (2.59g, 94%) was obtained by chromatography on silica; (Rf = 0.22, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (300 MHz, CDC13) 6 8.31 (d, J= 8.2 Hz, 1 H), 7.96 (d, J= 8.4 Hz, 1 H), 7.54 (m, 1 H), 7.49 (t, J= 7.8 Hz, 1 H), 7.25 (d, J= 7.8 Hz, 1 H), 6.73 (d, J= 8.1 Hz, 1 H), 4.15 (q, J= 7.2 Hz, 2 H), 3.99 (s, 3 H), 3.34 (t, J= 8.0 Hz, 2 H), 2.72 (t, J= 7.9 Hz, 2 H), 1.25 (t, J= 7.2 Hz, 3H).
[0303] Ethyl 3-(4'-flouro-3'-methylpheny1)-2-propanoate: The product as an oil (4.32 g, 95%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (300 MHz, CDC13) 6 7.00-6.86 (m, 3 H), 4.11 (q, J= 7.2 Hz, 2 H), 2.87 (t, J= 7.5 Hz, 2 H), 2.57 (t, J= 7.5 Hz, 2 H), 2.23 (s, 3 H), 1.22 (t, J= 7.2 Hz, 3 H).
[0304] 3-(5'-Fluoro-2'-methoxyphenyl)propanal (6a): To a solution of ethy1-3-(5'-fluoro-2'-methoxyphenybpropionate (5.8 g, 25.7 mmol) in dry toluene (40 mL) under Ar was added DIBAL solution (1 M in toluene, 30 mL, 30 mmol) at -78 C. The reaction was then stirred at this temperature for 2 h. Methanol (2 mL) was added to the reaction mixture and the reaction was allowed to warm to 0 C. The reaction mixture was then poured into a separatory funnel containing an HC1 solution (1 N, 100 mL). The organic material was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product obtained by removal of the solvent in vacuo was purified by a flash column chromatography (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v) to give the product (3.1 g, 66%); 1H NMR (CDC13, 500 MHz): 6 9.80 (s, 1 H), 6.88-6.86 (m, 2 H), 6.75 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.91 (t, J= 7.4 Hz, 2 H), 2.72 (t, J= 7.4 Hz, 2H).
[0305] The following compounds were prepared in a similar manner from 6a.
[0306] 3-Pentafluorophenylpropanal (6b): The product as an oil (1.60 g, 30%) was obtained by chromatography on silica; (Rf = 0.30, Et0Ac/Hexane, 5:95, v:v); 1H
NMR (500 MHz, CDC13) 6 9.81 (s, 1 H), 3.02 (t, J= 7.3 Hz, 2 H), 2.79 (t, J= 7.3 Hz, 2 H).
[0307] 3-(3-Pyridine) propanal (6e): The product as an oil (0.50 g, 67%) was obtained by chromatography on silica; (Rf = 0.29, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) 6 9.83 (s, 1 H), 8.48 (s, 1 H), 8.46 (d, J= 4.7 Hz, 1 H), 7.52 (d, J=
7.8 Hz, 1 H), 7.22 (m, 1 H), 2.96 (t, J= 7.5 Hz, 2 H), 2.82 (t, J= 7.5 Hz, 2 H).
NMR (300 MHz, CDC13) 6 8.31 (d, J= 8.2 Hz, 1 H), 7.96 (d, J= 8.4 Hz, 1 H), 7.54 (m, 1 H), 7.49 (t, J= 7.8 Hz, 1 H), 7.25 (d, J= 7.8 Hz, 1 H), 6.73 (d, J= 8.1 Hz, 1 H), 4.15 (q, J= 7.2 Hz, 2 H), 3.99 (s, 3 H), 3.34 (t, J= 8.0 Hz, 2 H), 2.72 (t, J= 7.9 Hz, 2 H), 1.25 (t, J= 7.2 Hz, 3H).
[0303] Ethyl 3-(4'-flouro-3'-methylpheny1)-2-propanoate: The product as an oil (4.32 g, 95%) was obtained by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (300 MHz, CDC13) 6 7.00-6.86 (m, 3 H), 4.11 (q, J= 7.2 Hz, 2 H), 2.87 (t, J= 7.5 Hz, 2 H), 2.57 (t, J= 7.5 Hz, 2 H), 2.23 (s, 3 H), 1.22 (t, J= 7.2 Hz, 3 H).
[0304] 3-(5'-Fluoro-2'-methoxyphenyl)propanal (6a): To a solution of ethy1-3-(5'-fluoro-2'-methoxyphenybpropionate (5.8 g, 25.7 mmol) in dry toluene (40 mL) under Ar was added DIBAL solution (1 M in toluene, 30 mL, 30 mmol) at -78 C. The reaction was then stirred at this temperature for 2 h. Methanol (2 mL) was added to the reaction mixture and the reaction was allowed to warm to 0 C. The reaction mixture was then poured into a separatory funnel containing an HC1 solution (1 N, 100 mL). The organic material was extracted with ethyl acetate (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product obtained by removal of the solvent in vacuo was purified by a flash column chromatography (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v) to give the product (3.1 g, 66%); 1H NMR (CDC13, 500 MHz): 6 9.80 (s, 1 H), 6.88-6.86 (m, 2 H), 6.75 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.91 (t, J= 7.4 Hz, 2 H), 2.72 (t, J= 7.4 Hz, 2H).
[0305] The following compounds were prepared in a similar manner from 6a.
[0306] 3-Pentafluorophenylpropanal (6b): The product as an oil (1.60 g, 30%) was obtained by chromatography on silica; (Rf = 0.30, Et0Ac/Hexane, 5:95, v:v); 1H
NMR (500 MHz, CDC13) 6 9.81 (s, 1 H), 3.02 (t, J= 7.3 Hz, 2 H), 2.79 (t, J= 7.3 Hz, 2 H).
[0307] 3-(3-Pyridine) propanal (6e): The product as an oil (0.50 g, 67%) was obtained by chromatography on silica; (Rf = 0.29, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) 6 9.83 (s, 1 H), 8.48 (s, 1 H), 8.46 (d, J= 4.7 Hz, 1 H), 7.52 (d, J=
7.8 Hz, 1 H), 7.22 (m, 1 H), 2.96 (t, J= 7.5 Hz, 2 H), 2.82 (t, J= 7.5 Hz, 2 H).
[0308] 3-(1'-Naphthyl) propanal (6d): The product as an oil (4.10 g, 74%) was obtained by chromatography on silica; (Rf = 0.32, Et0Ac/Hexane, 15:85, v:v); 1H NMR
(500 MHz, CDC13) 6 9.88 (s, 1 H), 7.99 (d, J= 8.3 Hz, 1 H), 7.88 (d, J= 8.0 Hz, 1 H), 7.75 (d, J= 8.2 Hz, 1 H), 7.55 (t, J= 7.2 Hz, 1 H), 7.51 (t, J= 6.9 Hz, 1 H), 7.41 (t, J= 7.3 Hz, 1 H), 7.35 (d, J= 7.0 Hz, 1 H), 3.43 (t, J= 7.8 Hz, 2 H), 2.91 (t, J= 8.1 Hz, 2 H).
[0309] 3-(21-Methoxy-1'-naphthyl) propanal (6e): The product as an oil (3.18 g, 94%) was obtained by chromatography on silica; (Rf = 0.43, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) 6 9.87 (s, 1 H), 7.90 (d, J= 8.7 Hz, 1 H), 7.81 (d, J= 8.2 Hz, 1 H), 7.77 (d, J= 8.9 Hz, 1 H), 7.49 (m 1 H), 7.35 (m, 1 H), 7.27 (d, J= 9.2 Hz, 1 H), 3.95 (s, 3 H), 3.41 (m, 2 H), 2.74 (td, J= 7.7, 1.9 Hz, 2 H).
[0310] 3-(4'IVIethoxy-l'-naphthyl) propanal (60: The product as an oil (1.70 g, 84%) was obtained by chromatography on silica; (Rf = 0.33, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) 6 9.87 (s, 1 H), 8.32 (d, J= 8.1 Hz, 1 H), 7.91 (d, J= 8.4 Hz, 1 H), 7.55 (m, 1 H), 7.49 (t, J= 7.9 Hz, 1 H), 7.24 (d, J= 7.7 Hz, 1 H), 6.74 (d, J= 7.9 Hz, 1 H), 3.99 (s, 3 H), 3.34 (t, J= 7.6 Hz, 2 H), 2.74 (m, 2 H).
[0311] 3-(4'-Flouro-3'-methylphenethyl)propanal (6g): The product as an oil (2.64 g, 77%) was obtained by chromatography on silica; (Rf = 0.37, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (500 MHz, CDC13) 6 9.81 (s, 1 H), 7.00-6.88 (m, 3 H), 2.89 (t, J= 7.4 Hz, 2 H), 2.75 (t, J= 7.2 Hz, 2 H), 2.24 (s, 3 H).
[0312] 1-(5'-Fluoro-2'-methoxypheny1)-4-ethylenedioxy-1-butene (7): To a suspension of 2-(1,3-dioxolan-2-ypethyltriphenylphosphonium bromide (5.0 g, 11.3 mmol) in THF (30 mL) under Ar was added NaH (60% in mineral oil, 0.48 g, 11.3 mmol). The reaction was heated to reflux for 1 h. The resulting orange colored suspension was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (1.54 g, 10.0 mmol) was added and the reaction was stirred for 12 h at room temperature. The mixture was poured to a separatory funnel containing ammonium chloride aqueous solution (sat. NH4C1/H20 = 1:1, v:v, 30 mL). The organics were extracted with Et0Ac (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over Na2SO4. The solvent was removed in vacuo and product was purified by flash column chromatography (Rf = 0.15, Et0Ac/Hexane, 7:93, v:v) to result in the product (2.63 g, 66%) as a mixture of cis and trans (cis:trans = 4:1): 1H
NMR (the major isomer): (CDC13, 500 MHz): 6 7.08 (dd, J= 3.1, 8.7 Hz, 1 H), 6.93 (dt, J= 3.1, 8.7 Hz, 1 H), 6.78 (dd, J= 4.3, 8.7 Hz, 1 H), 6.63 (d, J= 11.9 Hz, 1 H), 5.83 (td, J= 7.3 Hz, 11.9 Hz, 1 H), 4.99 (t, J= 4.6 Hz, 1 H), 4.02-3.99 (m, 2 H), 3.90-3.87 (m, 2 H), 3.80 (s, 3 H), 2.64-2.62 (m, 2H).
[0313] 4-(5'-Fluoro-T-methoxypheny1)-1-ethylenedioxybutane (8): To a solution (1.75 g, 7.3 mmol) in ethanol (200 proof, 80 mL) under Ar was added Pd/C (10%, 300 mg).
The flask containing the mixture was evacuated to the point of boiling and purged with H2 three times. Then a H2 balloon was attached to the flask and the reaction was stirred for 72 h at room temperature. The reaction mixture was then filtered through a pad of Celite eluted with Et0H. The crude product was obtained by removal of the solvent in vacua.
(CDC13, 500 MHz): 6 6.87-6.72 (m, 3 H), 4.87 (t, J= 3.8 Hz, 1 H), 3.97-3.95 (m, 2 H), 3.86-3.83 (m, 2 H), 3.79 (s, 3 H), 2.64-2.62 (m, 2 H), 2.44 (td, J= 1.7, 7.2 Hz, 2 H), 1.92 (quintet, J= 7.5 Hz, 2 H).
[0314] 4-(5'-Fluoro-2'-methoxyphenyl)butyraldehyde (9): To a solution of 8 (1.7g, 7.0 mmol) in THF (60 mL) was added HC1 (1 N, 3 mL) and the reaction was stirred at room temperature for 48 h. The reaction mixture was then poured into a separatory funnel containing water (60 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over Na2SO4.
The crude product obtained by removal of the solvent in vacua was purified by flash column chromatography (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v) to give the product (1.03 g, 53%
from 3a) as oil; 11-1 NMR (CDC13, 500 MHz): 6 9.76 (s, 1 H), 6.88-6.83 (m, 2 H), 6.75 (dd, J
= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.63 (t, J= 7.4 Hz, 2 H), 2.44 (t, J= 7.4 Hz, 2 H), 1.92 (quintet, J= 7.4 Hz, 2 H).
[0315] 5-(5'-Fluoro-2'-methoxypheny1)-1-pentene methyl ether (10): To a suspension of methoxymethyltriphenylphosphonium chloride (2.0 g, 5.8 mmol) in THF (20 mL) under Ar was added NaH (60% in mineral oil, 0.27 g, 6.7 mmol). The reaction was heated to reflux for 1 h. The resulting orange colored suspension was cooled to 0 C and 4-(5'-fluoro-2'-methoxyphenyl)butyraldehyde (9) (0.92 g, 4.7 mmol) was added and the mixture was stirred for 12 h at room temperature. The reaction mixture was poured to a separatory funnel containing ammonium chloride aqueous solution (sat. NH4C1: H20= 1:1, 50 mL).
The organics were extracted with Et0Ac (3 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The solvent was then removed in vacuo and crude product was purified by flash column chromatography on silica (Rf =
0.30, Et0Ac/Hexane, 5:95, v:v) to result in the product (0.46, 43%) as an oil and a mixture of cis and trans (cis:trans = 1 :2) : 1H NMR (CDC13, 500 MHz): 6 6.87-6.72(m, 3 H), 6.30 (d, J=
12.5 Hz, 0.66 H), 5.90 (d, J.= 6.2 Hz, 0.33 H), 4.75 (td, J= 7.2, 12.5 Hz, 0.66 H), 4.36 (m, 0.33 H), 3.79 (s, 3 H), 3.59 (s, 1 H), 3.51 (s, 2 H), 2.61-2.57 (m, 2 H), 2.11 (q, J= 7.2 Hz, 0.66 H), 1.97 (q, J= 7.2 Hz, 1.34 H), 1.65-1.58 (m, 2 H).
[0316] 5-(5'-Fluoro-2`-methoxyphenyl)pentanal (11): To a solution of 9 (0.46 g, 2.0 mmol) in acetone (20 mL) was added H2SO4 (5%, 2 mL) and the reaction was heated to reflux for 1.6 h. After the reaction was cooled to room temperature, most of the solvent was then removed in vacuo. A solution of NaHCO3 (sat. 40 mL) was added and the organics were extracted with Et0Ac (3 x 40 mL) and the combined organic layers were washed with brine (30 mL) and dried over Na2SO4. The crude product obtained by removal of the solvent in vacuo was purified by flash column chromatography on silica (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v) to give the product (0.20 g, 50%) as oil; 1H NMR (CDC13, 500 MHz):
c5 9.76 (s, 1 H), 6.88-6.82 (m, 2 H), 6.74 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.61 (t, J= 7.3 Hz, 2 H), 2.45 (m, 2 H), 1.69-1.60 (m, 4 H).
[0317] 1-(2'-Methoxy-5'-fluorophenyl)pent-4-en-1-ol (12a): To a solution of 2-methoxy-5-fluorobenzaldehyde (3.0 g, 19.5 mmol) in THF (20 mL) at 0 C was added a solution 1-butenylmagnesium bromide (0.5 M in THF, 45 mL, 22.5 mmol) dropwise for 15 mm.
Then the reaction mixture was poured into a separatory funnel containing solution of saturated ammonium chloride (80 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4.
The solvent then was removed in vacuo and crude product was purified by flash column chromatography (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v) on silica to afford the product as oil (3.27 g, 93%); 1H NMR (CDC13, 500 MHz): 6 7.07 (dd, J= 3.1, 9.2 Hz, 1 H), 6.91 (dt, J=
3.1, 9.0 Hz, 1 H), 6.79 (dd, J= 4.2, 8.5 Hz, 1 H), 5.85 (m, 1 H), 5.04 (d, J=
18.0 Hz, 1 H), 4.97 (d, J= 13.5 Hz, 1 H), 4.90 (t, J= 6.3 Hz, 1 H), 3.83 (s, 3 H), 2.42 (bs, 1 H), 2.23-2.13 (m, 2 H), 1.84 (q, J= 7.7 Hz, 2 H).
[0318] The following compounds were prepared in a similar manner as 12a.
[0319] 5-Phenyl-1-penten-5-ol (12b): The product (1.14 g, 82%) was obtained as a yellow oil by chromatography on silica; (Rf = 0.36, Et0Ac/Hexane, 20:80, v:v);
(500 MHz, CDC13) 6 7.36-7.27 (m, 5H), 5.83 (m, 1 H), 5.04 (dt, J= 15.7, 1.8 Hz, 1 H), 4.98 (d, J= 10.4 Hz, 1 H), 4.70 (t, J= 6.5 Hz, 1 H), 2.21-1.80 (m, 5H).
(500 MHz, CDC13) 6 9.88 (s, 1 H), 7.99 (d, J= 8.3 Hz, 1 H), 7.88 (d, J= 8.0 Hz, 1 H), 7.75 (d, J= 8.2 Hz, 1 H), 7.55 (t, J= 7.2 Hz, 1 H), 7.51 (t, J= 6.9 Hz, 1 H), 7.41 (t, J= 7.3 Hz, 1 H), 7.35 (d, J= 7.0 Hz, 1 H), 3.43 (t, J= 7.8 Hz, 2 H), 2.91 (t, J= 8.1 Hz, 2 H).
[0309] 3-(21-Methoxy-1'-naphthyl) propanal (6e): The product as an oil (3.18 g, 94%) was obtained by chromatography on silica; (Rf = 0.43, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) 6 9.87 (s, 1 H), 7.90 (d, J= 8.7 Hz, 1 H), 7.81 (d, J= 8.2 Hz, 1 H), 7.77 (d, J= 8.9 Hz, 1 H), 7.49 (m 1 H), 7.35 (m, 1 H), 7.27 (d, J= 9.2 Hz, 1 H), 3.95 (s, 3 H), 3.41 (m, 2 H), 2.74 (td, J= 7.7, 1.9 Hz, 2 H).
[0310] 3-(4'IVIethoxy-l'-naphthyl) propanal (60: The product as an oil (1.70 g, 84%) was obtained by chromatography on silica; (Rf = 0.33, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(500 MHz, CDC13) 6 9.87 (s, 1 H), 8.32 (d, J= 8.1 Hz, 1 H), 7.91 (d, J= 8.4 Hz, 1 H), 7.55 (m, 1 H), 7.49 (t, J= 7.9 Hz, 1 H), 7.24 (d, J= 7.7 Hz, 1 H), 6.74 (d, J= 7.9 Hz, 1 H), 3.99 (s, 3 H), 3.34 (t, J= 7.6 Hz, 2 H), 2.74 (m, 2 H).
[0311] 3-(4'-Flouro-3'-methylphenethyl)propanal (6g): The product as an oil (2.64 g, 77%) was obtained by chromatography on silica; (Rf = 0.37, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (500 MHz, CDC13) 6 9.81 (s, 1 H), 7.00-6.88 (m, 3 H), 2.89 (t, J= 7.4 Hz, 2 H), 2.75 (t, J= 7.2 Hz, 2 H), 2.24 (s, 3 H).
[0312] 1-(5'-Fluoro-2'-methoxypheny1)-4-ethylenedioxy-1-butene (7): To a suspension of 2-(1,3-dioxolan-2-ypethyltriphenylphosphonium bromide (5.0 g, 11.3 mmol) in THF (30 mL) under Ar was added NaH (60% in mineral oil, 0.48 g, 11.3 mmol). The reaction was heated to reflux for 1 h. The resulting orange colored suspension was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (1.54 g, 10.0 mmol) was added and the reaction was stirred for 12 h at room temperature. The mixture was poured to a separatory funnel containing ammonium chloride aqueous solution (sat. NH4C1/H20 = 1:1, v:v, 30 mL). The organics were extracted with Et0Ac (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over Na2SO4. The solvent was removed in vacuo and product was purified by flash column chromatography (Rf = 0.15, Et0Ac/Hexane, 7:93, v:v) to result in the product (2.63 g, 66%) as a mixture of cis and trans (cis:trans = 4:1): 1H
NMR (the major isomer): (CDC13, 500 MHz): 6 7.08 (dd, J= 3.1, 8.7 Hz, 1 H), 6.93 (dt, J= 3.1, 8.7 Hz, 1 H), 6.78 (dd, J= 4.3, 8.7 Hz, 1 H), 6.63 (d, J= 11.9 Hz, 1 H), 5.83 (td, J= 7.3 Hz, 11.9 Hz, 1 H), 4.99 (t, J= 4.6 Hz, 1 H), 4.02-3.99 (m, 2 H), 3.90-3.87 (m, 2 H), 3.80 (s, 3 H), 2.64-2.62 (m, 2H).
[0313] 4-(5'-Fluoro-T-methoxypheny1)-1-ethylenedioxybutane (8): To a solution (1.75 g, 7.3 mmol) in ethanol (200 proof, 80 mL) under Ar was added Pd/C (10%, 300 mg).
The flask containing the mixture was evacuated to the point of boiling and purged with H2 three times. Then a H2 balloon was attached to the flask and the reaction was stirred for 72 h at room temperature. The reaction mixture was then filtered through a pad of Celite eluted with Et0H. The crude product was obtained by removal of the solvent in vacua.
(CDC13, 500 MHz): 6 6.87-6.72 (m, 3 H), 4.87 (t, J= 3.8 Hz, 1 H), 3.97-3.95 (m, 2 H), 3.86-3.83 (m, 2 H), 3.79 (s, 3 H), 2.64-2.62 (m, 2 H), 2.44 (td, J= 1.7, 7.2 Hz, 2 H), 1.92 (quintet, J= 7.5 Hz, 2 H).
[0314] 4-(5'-Fluoro-2'-methoxyphenyl)butyraldehyde (9): To a solution of 8 (1.7g, 7.0 mmol) in THF (60 mL) was added HC1 (1 N, 3 mL) and the reaction was stirred at room temperature for 48 h. The reaction mixture was then poured into a separatory funnel containing water (60 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over Na2SO4.
The crude product obtained by removal of the solvent in vacua was purified by flash column chromatography (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v) to give the product (1.03 g, 53%
from 3a) as oil; 11-1 NMR (CDC13, 500 MHz): 6 9.76 (s, 1 H), 6.88-6.83 (m, 2 H), 6.75 (dd, J
= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.63 (t, J= 7.4 Hz, 2 H), 2.44 (t, J= 7.4 Hz, 2 H), 1.92 (quintet, J= 7.4 Hz, 2 H).
[0315] 5-(5'-Fluoro-2'-methoxypheny1)-1-pentene methyl ether (10): To a suspension of methoxymethyltriphenylphosphonium chloride (2.0 g, 5.8 mmol) in THF (20 mL) under Ar was added NaH (60% in mineral oil, 0.27 g, 6.7 mmol). The reaction was heated to reflux for 1 h. The resulting orange colored suspension was cooled to 0 C and 4-(5'-fluoro-2'-methoxyphenyl)butyraldehyde (9) (0.92 g, 4.7 mmol) was added and the mixture was stirred for 12 h at room temperature. The reaction mixture was poured to a separatory funnel containing ammonium chloride aqueous solution (sat. NH4C1: H20= 1:1, 50 mL).
The organics were extracted with Et0Ac (3 x 50 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The solvent was then removed in vacuo and crude product was purified by flash column chromatography on silica (Rf =
0.30, Et0Ac/Hexane, 5:95, v:v) to result in the product (0.46, 43%) as an oil and a mixture of cis and trans (cis:trans = 1 :2) : 1H NMR (CDC13, 500 MHz): 6 6.87-6.72(m, 3 H), 6.30 (d, J=
12.5 Hz, 0.66 H), 5.90 (d, J.= 6.2 Hz, 0.33 H), 4.75 (td, J= 7.2, 12.5 Hz, 0.66 H), 4.36 (m, 0.33 H), 3.79 (s, 3 H), 3.59 (s, 1 H), 3.51 (s, 2 H), 2.61-2.57 (m, 2 H), 2.11 (q, J= 7.2 Hz, 0.66 H), 1.97 (q, J= 7.2 Hz, 1.34 H), 1.65-1.58 (m, 2 H).
[0316] 5-(5'-Fluoro-2`-methoxyphenyl)pentanal (11): To a solution of 9 (0.46 g, 2.0 mmol) in acetone (20 mL) was added H2SO4 (5%, 2 mL) and the reaction was heated to reflux for 1.6 h. After the reaction was cooled to room temperature, most of the solvent was then removed in vacuo. A solution of NaHCO3 (sat. 40 mL) was added and the organics were extracted with Et0Ac (3 x 40 mL) and the combined organic layers were washed with brine (30 mL) and dried over Na2SO4. The crude product obtained by removal of the solvent in vacuo was purified by flash column chromatography on silica (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v) to give the product (0.20 g, 50%) as oil; 1H NMR (CDC13, 500 MHz):
c5 9.76 (s, 1 H), 6.88-6.82 (m, 2 H), 6.74 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.61 (t, J= 7.3 Hz, 2 H), 2.45 (m, 2 H), 1.69-1.60 (m, 4 H).
[0317] 1-(2'-Methoxy-5'-fluorophenyl)pent-4-en-1-ol (12a): To a solution of 2-methoxy-5-fluorobenzaldehyde (3.0 g, 19.5 mmol) in THF (20 mL) at 0 C was added a solution 1-butenylmagnesium bromide (0.5 M in THF, 45 mL, 22.5 mmol) dropwise for 15 mm.
Then the reaction mixture was poured into a separatory funnel containing solution of saturated ammonium chloride (80 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4.
The solvent then was removed in vacuo and crude product was purified by flash column chromatography (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v) on silica to afford the product as oil (3.27 g, 93%); 1H NMR (CDC13, 500 MHz): 6 7.07 (dd, J= 3.1, 9.2 Hz, 1 H), 6.91 (dt, J=
3.1, 9.0 Hz, 1 H), 6.79 (dd, J= 4.2, 8.5 Hz, 1 H), 5.85 (m, 1 H), 5.04 (d, J=
18.0 Hz, 1 H), 4.97 (d, J= 13.5 Hz, 1 H), 4.90 (t, J= 6.3 Hz, 1 H), 3.83 (s, 3 H), 2.42 (bs, 1 H), 2.23-2.13 (m, 2 H), 1.84 (q, J= 7.7 Hz, 2 H).
[0318] The following compounds were prepared in a similar manner as 12a.
[0319] 5-Phenyl-1-penten-5-ol (12b): The product (1.14 g, 82%) was obtained as a yellow oil by chromatography on silica; (Rf = 0.36, Et0Ac/Hexane, 20:80, v:v);
(500 MHz, CDC13) 6 7.36-7.27 (m, 5H), 5.83 (m, 1 H), 5.04 (dt, J= 15.7, 1.8 Hz, 1 H), 4.98 (d, J= 10.4 Hz, 1 H), 4.70 (t, J= 6.5 Hz, 1 H), 2.21-1.80 (m, 5H).
[0320] 7-Pentafluoropheny1-1-hepten-5-ol (12e): The product (0.95 g, 48%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (500 MHz, CDC13) 6 5.83 (m, 1 H), 5.05 (dd, J= 1.8, 15.8 Hz, 1 H), 4.98 (dd, J= 1.3, 10.3 Hz, 1 H), 3.64 (m, 1 H), 2.91-2.75 (m, 2 H), 2.24-2.11 (m, 2 H), 1.78-1.65 (m, 2 H), 1.63-1.55 (m, 3 H).
[0321] 5-(4'-Chloropheny1)-1-penten-5-ol (12d): The product (1.97 g, 43%) was obtained as an oil by chromatography on silica; (Rf = 0.43, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (300 MHz, CDC13) 6 7.34-7.27 (m, 4 H), 5.90-5.66 (m, 1 H), 5.04 (d, J=
17.4 Hz, 1 H), 4.99 (d, J= 9.9 Hz, 1 H), 4.69 (m, 1 H), 2.17-2.08 (m, 2 H), 1.91-1.75 (m, 2 H).
[0322] 5-(4'-Bromopheny1)-1-penten-5-ol (12e) The product (2.45 g, 94%) was obtained as an oil by chromatography on silica; (Rf = 0.40, Et0Ac/Hexane, 25:75, v:v);
1H NMR (300 MHz, CDC13) d 7.46 (d, J= 8.4 Hz, 2 H), 7.21 (d, J= 8.4 Hz, 2 H), 5.82 (m, 1 H), 5.01 (m,2 H), 4.66 (t, J= 6.6 Hz, 1 H), 2.16-2.05 (m, 2 H), 1.92-1.74 (m, 2 H).
[0323] 5-(4'-Methoxypheny1)-1-penten-5-ol (12t): The product (2.98 g, 93%) was obtained as an oil by chromatography on silica; (Rf = 0.15, DCM/Hexane, 80:20, v:v); 1H
NMR (300 MHz, CDC13) d 7.27 (d, J= 8.7 Hz, 2 H), 6.88 (d, J= 8.7 Hz, 2 H), 5.83 (m, 1 H), 4.98 (m, 2 H), 4.65 (t, J= 6.6 Hz, 1 H), 3.81 (s 3 H), 2.17-2.04 (m, 2 H), 2.03-1.67 (m, 2 H).
[0324] 5-(4'-t-Butylpheny1)-1-penten-5-ol (12g): The product (2.04 g, 76%) was obtained as an oil by chromatography on silica; (Rf = 0.35, DCM/Hexane, 80:20, v:v); 1H
NMR (300 MHz, CDC13) d 7.36 (d, J= 8.4 Hz, 2 H), 7.27 (d, J= 8.4 Hz, 2 H), 5.84 (m, 1 H), 5.04 (d, J
= 17.2 Hz, 1 H), 4.98 (d, J= 10.0 Hz, 1 H), 2.20-2.06 (m, 2 H), 1.96-1.75 (m, 2 H), 1.31 (s, 9 H).
[0325] 5-(2'-Naphthyl)-1-penten-5-ol (12h): The product (1.47 g, 71%) was obtained as an oil by chromatography on silica; (Rf = 0.32, DCM/Hexane, 80:20, v:v); 1H
NMR (CDC13, 500 MHz): 6 7.86-7.78 (m, 4 H), 7.50-7.46 (m, 3 H), 5.85 (m, 1 H), 5.04 (d, J=
17.2 Hz, 1 H), 4.99 (d, J= 10.0 Hz, 1 H), 4.88 (t, J= 6.9 Hz, 1 H), 2.22-2.09 (m, 2 H), 2.05-1.85 (m, 2 H).
[0326] 5-(2'-Furanyl)pent-l-en-5-ol (121): The product (3.34 g, 85%) was obtained as an oil by chromatography on silica; (Rf = 0.19, Et0Ac/Hexane, 15:85, v:v); 1H NMR
(CDC13, 500 MHz): 6 7.38 (s, 1 H), 6.33(t, J= 2.2 Hz. 1 H), 6.24 (d, J= 3.2 Hz, 1 H), 5.83 (m, 1 H), 5.04 (d, J= 12.3 Hz, 1 H), 4.99 (d, J= 9.6 Hz, 1 H), 4.71 (t, J= 6.8 Hz, 1 H), 2.17 (m, 2 H), 1.96 (q, J= 7.2 Hz, 2 H), 1.89 (bs, 1 H).
[0327] 6-Phenylhex-1-en-5-ol (12j): The product (1.22 g, 95%) was obtained as an oil by chromatography on silica; (Rf = 0.12, Et0Ac/Hexane, 10:90, v:v); 1H NMR: (500 MHz,CDC13) 6 7.33-7.20 (m, 5 H), 5.04 (m, 1 H), 5.00 (m, 2 H), 3.85 (m, 1 H), 2.84 (m, 1 H), 2.69-2.65 (m, 1 H), 2.29-2.16 (m, 2 H), 1.67-1.58 (m, 2 H).
[0328] 7-Phenyl-1-hepten-5-ol (12k): The product (2.45 g, 58%) was obtained as an oil by chromatography on silica; (Rf = 0.43, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(CDC13, 500 MHz) 67.29-7.19 (m, 5 H), 5.85 (m, 1 H), 5.04 (td, J= 2.2, 14.0 Hz, 1 H), 4.97 (dd, J=1.7, 10.4 Hz, 1 H), 3.67 (m, 1 H), 2.80 (m, 1 H), 2.68 (m, 1 H), 2.22-2.13 (m, 2 H), 1.83-1.73 (m, 2 H), 1.62-1.54 (m, 3 H).
[0329] 7-(3'-Pyridiny1)-1-hepten-5-ol (121): The product (1.8 g, 52%) was obtained as an oil by chromatography on silica; (Rf = 0.15, Et0Ac/Hexane, 60:40, v:v); 1H NMR
(500 MHz, CDC13) 6 8.46 (s, 1 H), 8.42 (d, J= 4.2 Hz, 1 H), 7.51 (d, J= 8.0 Hz, 1 H), 7.20 (dd, J= 4.9, 7.8 Hz, 1 H), 5.82 (m, 1 H), 5.03 (d, J= 16.0 Hz, 1 H), 4.96 (d, J= 10.3 Hz, 1 H), 3.65 (m, 1 H), 2.81 (m, 1 H), 2.68 (m, 1 H), 2.23-2.11 (m, 2 H), 1.94 (bs, 1 H), 1.81-1.72 (m, 2 H), 1.63-1.56 (m, 2 H).
[0330] 7-(1'-Naphthyl)-1-hepten-5-ol (12m): The product (1.52 g, 56%) was obtained as an oil by chromatography on silica; (Rf = 0.12, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (300 MHz, CDC13) 6 8.06 (d, J= 7.8 Hz, 1 H), 7.85 (d, J= 7.8 Hz, 1 H), 7.71 (d, J=
7.8 Hz, 1 H), 7.54-7.33 (m, 4 H), 5.84 (m, 1 H), 5.04 (dd, J= 1.8, 17.4 Hz, 1 H), 4.99 (dd, J= 2.1, 10.2 Hz, 1 H), 3.75 (m, 1 H), 3.47-3.25 (m, 1 H), 3.16-3.06 (m, 1 H), 2.24-2.13 (m, 2 H), 1.94-1.85 (m, 2 H), 1.65-1.55 (m, 2 H).
[0331] 7-(p-(t-Butyldimethylsilyloxy)pheny1)-1-hepten-5-ol (12n): The product (0.85 g, 52%) was obtained as an oil by chromatography on silica; (Rf = 0.41, Et0Ac/Hexane, 25:75, v:v); 1H NMR (500 MHz, CDC13) 6 7.04 (d, J= 8.4 Hz, 2 H), 6.76 (d, J= 8.4 Hz, 2 H), 5.85-5.08 (m, 1 H), 5.50 (dd, J= 1.8, 15.8 Hz, 1 H), 4.96 (d, J= 10.4 Hz, 1 H), 3.66-3.62 (m, 1 H), 2.75-2.68 (m, 1 H), 2.64-2.57 (m, 1 H), 2.21-2.12 (m, 2 H), 1.77-1.71 (m, 2 H), 1.60-1.52 (m, 2 H), 0.98 (s, 9 H), 0.18 (s, 6 H).
[0332] 7-(2'-Methoxy-1'-naphthyl)-1-hepten-5-ol (120): The product (0.78 g, 43%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (500 MHz, CDC13) 6 5.83 (m, 1 H), 5.05 (dd, J= 1.8, 15.8 Hz, 1 H), 4.98 (dd, J= 1.3, 10.3 Hz, 1 H), 3.64 (m, 1 H), 2.91-2.75 (m, 2 H), 2.24-2.11 (m, 2 H), 1.78-1.65 (m, 2 H), 1.63-1.55 (m, 3 H).
[0321] 5-(4'-Chloropheny1)-1-penten-5-ol (12d): The product (1.97 g, 43%) was obtained as an oil by chromatography on silica; (Rf = 0.43, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (300 MHz, CDC13) 6 7.34-7.27 (m, 4 H), 5.90-5.66 (m, 1 H), 5.04 (d, J=
17.4 Hz, 1 H), 4.99 (d, J= 9.9 Hz, 1 H), 4.69 (m, 1 H), 2.17-2.08 (m, 2 H), 1.91-1.75 (m, 2 H).
[0322] 5-(4'-Bromopheny1)-1-penten-5-ol (12e) The product (2.45 g, 94%) was obtained as an oil by chromatography on silica; (Rf = 0.40, Et0Ac/Hexane, 25:75, v:v);
1H NMR (300 MHz, CDC13) d 7.46 (d, J= 8.4 Hz, 2 H), 7.21 (d, J= 8.4 Hz, 2 H), 5.82 (m, 1 H), 5.01 (m,2 H), 4.66 (t, J= 6.6 Hz, 1 H), 2.16-2.05 (m, 2 H), 1.92-1.74 (m, 2 H).
[0323] 5-(4'-Methoxypheny1)-1-penten-5-ol (12t): The product (2.98 g, 93%) was obtained as an oil by chromatography on silica; (Rf = 0.15, DCM/Hexane, 80:20, v:v); 1H
NMR (300 MHz, CDC13) d 7.27 (d, J= 8.7 Hz, 2 H), 6.88 (d, J= 8.7 Hz, 2 H), 5.83 (m, 1 H), 4.98 (m, 2 H), 4.65 (t, J= 6.6 Hz, 1 H), 3.81 (s 3 H), 2.17-2.04 (m, 2 H), 2.03-1.67 (m, 2 H).
[0324] 5-(4'-t-Butylpheny1)-1-penten-5-ol (12g): The product (2.04 g, 76%) was obtained as an oil by chromatography on silica; (Rf = 0.35, DCM/Hexane, 80:20, v:v); 1H
NMR (300 MHz, CDC13) d 7.36 (d, J= 8.4 Hz, 2 H), 7.27 (d, J= 8.4 Hz, 2 H), 5.84 (m, 1 H), 5.04 (d, J
= 17.2 Hz, 1 H), 4.98 (d, J= 10.0 Hz, 1 H), 2.20-2.06 (m, 2 H), 1.96-1.75 (m, 2 H), 1.31 (s, 9 H).
[0325] 5-(2'-Naphthyl)-1-penten-5-ol (12h): The product (1.47 g, 71%) was obtained as an oil by chromatography on silica; (Rf = 0.32, DCM/Hexane, 80:20, v:v); 1H
NMR (CDC13, 500 MHz): 6 7.86-7.78 (m, 4 H), 7.50-7.46 (m, 3 H), 5.85 (m, 1 H), 5.04 (d, J=
17.2 Hz, 1 H), 4.99 (d, J= 10.0 Hz, 1 H), 4.88 (t, J= 6.9 Hz, 1 H), 2.22-2.09 (m, 2 H), 2.05-1.85 (m, 2 H).
[0326] 5-(2'-Furanyl)pent-l-en-5-ol (121): The product (3.34 g, 85%) was obtained as an oil by chromatography on silica; (Rf = 0.19, Et0Ac/Hexane, 15:85, v:v); 1H NMR
(CDC13, 500 MHz): 6 7.38 (s, 1 H), 6.33(t, J= 2.2 Hz. 1 H), 6.24 (d, J= 3.2 Hz, 1 H), 5.83 (m, 1 H), 5.04 (d, J= 12.3 Hz, 1 H), 4.99 (d, J= 9.6 Hz, 1 H), 4.71 (t, J= 6.8 Hz, 1 H), 2.17 (m, 2 H), 1.96 (q, J= 7.2 Hz, 2 H), 1.89 (bs, 1 H).
[0327] 6-Phenylhex-1-en-5-ol (12j): The product (1.22 g, 95%) was obtained as an oil by chromatography on silica; (Rf = 0.12, Et0Ac/Hexane, 10:90, v:v); 1H NMR: (500 MHz,CDC13) 6 7.33-7.20 (m, 5 H), 5.04 (m, 1 H), 5.00 (m, 2 H), 3.85 (m, 1 H), 2.84 (m, 1 H), 2.69-2.65 (m, 1 H), 2.29-2.16 (m, 2 H), 1.67-1.58 (m, 2 H).
[0328] 7-Phenyl-1-hepten-5-ol (12k): The product (2.45 g, 58%) was obtained as an oil by chromatography on silica; (Rf = 0.43, Et0Ac/Hexane, 25:75, v:v); 1H NMR
(CDC13, 500 MHz) 67.29-7.19 (m, 5 H), 5.85 (m, 1 H), 5.04 (td, J= 2.2, 14.0 Hz, 1 H), 4.97 (dd, J=1.7, 10.4 Hz, 1 H), 3.67 (m, 1 H), 2.80 (m, 1 H), 2.68 (m, 1 H), 2.22-2.13 (m, 2 H), 1.83-1.73 (m, 2 H), 1.62-1.54 (m, 3 H).
[0329] 7-(3'-Pyridiny1)-1-hepten-5-ol (121): The product (1.8 g, 52%) was obtained as an oil by chromatography on silica; (Rf = 0.15, Et0Ac/Hexane, 60:40, v:v); 1H NMR
(500 MHz, CDC13) 6 8.46 (s, 1 H), 8.42 (d, J= 4.2 Hz, 1 H), 7.51 (d, J= 8.0 Hz, 1 H), 7.20 (dd, J= 4.9, 7.8 Hz, 1 H), 5.82 (m, 1 H), 5.03 (d, J= 16.0 Hz, 1 H), 4.96 (d, J= 10.3 Hz, 1 H), 3.65 (m, 1 H), 2.81 (m, 1 H), 2.68 (m, 1 H), 2.23-2.11 (m, 2 H), 1.94 (bs, 1 H), 1.81-1.72 (m, 2 H), 1.63-1.56 (m, 2 H).
[0330] 7-(1'-Naphthyl)-1-hepten-5-ol (12m): The product (1.52 g, 56%) was obtained as an oil by chromatography on silica; (Rf = 0.12, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (300 MHz, CDC13) 6 8.06 (d, J= 7.8 Hz, 1 H), 7.85 (d, J= 7.8 Hz, 1 H), 7.71 (d, J=
7.8 Hz, 1 H), 7.54-7.33 (m, 4 H), 5.84 (m, 1 H), 5.04 (dd, J= 1.8, 17.4 Hz, 1 H), 4.99 (dd, J= 2.1, 10.2 Hz, 1 H), 3.75 (m, 1 H), 3.47-3.25 (m, 1 H), 3.16-3.06 (m, 1 H), 2.24-2.13 (m, 2 H), 1.94-1.85 (m, 2 H), 1.65-1.55 (m, 2 H).
[0331] 7-(p-(t-Butyldimethylsilyloxy)pheny1)-1-hepten-5-ol (12n): The product (0.85 g, 52%) was obtained as an oil by chromatography on silica; (Rf = 0.41, Et0Ac/Hexane, 25:75, v:v); 1H NMR (500 MHz, CDC13) 6 7.04 (d, J= 8.4 Hz, 2 H), 6.76 (d, J= 8.4 Hz, 2 H), 5.85-5.08 (m, 1 H), 5.50 (dd, J= 1.8, 15.8 Hz, 1 H), 4.96 (d, J= 10.4 Hz, 1 H), 3.66-3.62 (m, 1 H), 2.75-2.68 (m, 1 H), 2.64-2.57 (m, 1 H), 2.21-2.12 (m, 2 H), 1.77-1.71 (m, 2 H), 1.60-1.52 (m, 2 H), 0.98 (s, 9 H), 0.18 (s, 6 H).
[0332] 7-(2'-Methoxy-1'-naphthyl)-1-hepten-5-ol (120): The product (0.78 g, 43%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (500 MHz, CDC13) 6 7.90 (d, J= 8.4 Hz, 1 H), 7.77 (d, J= 8.4 Hz, 1 H), 7.72 (d, J=
8.4 Hz, 1 H), 7.48 (t, J= 7.8 Hz, 1 H), 7.36-7.24 (m, 2 H), 5.81 (m, 1 H), 5.00 (m, 2 H), 3.93 (s 3 H), 3.45 (m, 1 H), 3.09 (t, J= 8.2 Hz, 2 H) 2.14-2.07 (m, 2 H), 1.89-1.82 (m, 2 H), 1.78-1.73 (m, 2 H).
[0333] 7-(4'-Methoxy-1'-naphthyl)-1-hepten-5-61 (12p): The product (0.67 g, 41%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (300 MHz, CDC13) 6 88.33 (d, J= 7.5 Hz, 1 H), 8.02 (d, J= 7.2 Hz, 1 H), 7.53 (m, 2 H), 7.26 (d, J= 7.8 Hz, 1 H), 6.76 (d, J= 6.0 Hz, 1 H), 5.87 (m, 1 H), 5.04 (dd, J= 1.8, 15.3 Hz, 4.99 (dd, J= 1.2, 10.2 Hz, 1 H), 4.01 (s, 3 H), 3.77 (m, 1 H), 3.28-3.18 (m, 1 H), 3.11-3.01 (m, 1 H), 2.26-2.16 (m,2 H), 1.84-1.84 (m, 2 H), 1.67-1.57 (m, 2H).
[0334] 5-(1'-Naphthyl)-1-penten-5-61 (12q) The product (0.46 g, 23%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Adilexane, 10:90, v:v); 1H
NMR (300 MHz, CDC13) 6 8.08 (m, 1 H), 7.87 (m, 1 H), 7.78 (d, J= 8.1 Hz, 1 H), 7.65 (d, J= 6.9 Hz, 1 H), 7.50 (m, 3 H), 5.89 (m, 1 H), 5.49 (m, 1 H), 5.04 (dd, J= 1.8, 15.6 Hz, 1 H), 4.99 (dd, J=
1.8, 10.2 Hz, 1 H), 2.30-2.24 (m, 2 H), 2.06-1.97 (m, 2 H).
[0335] 7-(4'-Flouro-3'-methylpheny1)-1-hepten-5-61 (12r): The product (1.33 g, 38%) was obtained as an oil by chromatography on silica; (Rf = 0.41, Et0Ac/Hexane, 25:75, v:v);
1H NMR (500 MHz, CDC13) 6 7.00-6.88 (m, 3 H), 5.88-5.80 (m, 1 H), 4.05 (dt, J=
1.9, 15.7 Hz, 1 H), 4.99-4.95 (m, 1 H), 3.67-3.62 (in, 1 H), 2.74-2.70 (m, 1 H), 2.64-2.57 (m, 1 H), 2.25 (s, 3 H), 2.24-2.05 (m, 2 H), 1.77-1.70 (m, 2 H), 1.63-1.53 (m, 3 H).
[0336] 7-(5'-Fluoro-2'-methoxyphenyl)hept-1-en-5-ol (12s): The product (3.7 g, 94%) was obtained as an oil by chromatography on silica; (Rf = 0.20, Et0Ac/Hexane, 15:85, v:v);
1H NMR (CDC13, 500 MHz): 6 6.86-6.82 (m, 2 H), 6.76 (dd, J= 4.6, 8.6 Hz, 1 H), 5.82 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.95 (d, J= 10.2 Hz, 1 H), 3.81 (s, 3 H), 3.55 (in, 1 H),2.75-2.69 (m, 2 H), 2.20 (m, 1 H), 2.10 (m, 1 H), 1.96 (bs, 1 H), 1.73-1.68 (m, 2 H), 1.60-1.53 (m, 3H).
[0337] 1-(2'-Methoxy-5'-fluorophenyl)hex-5-en-2-61 (12t): The product (0.64 g, 74%) was obtained as an oil by chromatography on silica; (Rf = 0.18, Et0Ac/Hexane, 12:88, v:v);
1H NMR (CDC13, 500 MHz): 6 6.90-6.88 (m, 2 H), 6.79 (dd, J= 4.7, 9.8 Hz, 1 H), 5.83 (m, 1 H), 5.04 (d, J= 17.1 Hz, 1 H), 4.97 (d, J= 10.1 Hz, 1 H), 3.85 (m,1 H), 3.81 (s, 3 H), 2.85 (dd, J= 4.0, 13.7 Hz, 1 H), 2.69 (dd, J= 8.1, 13.7 Hz, 1 H), 2.26 (m, 1 H), 2.17 (m, 1 H), 1.82 (bs, 1 H), 1.60 (m, 2 H).
8.4 Hz, 1 H), 7.48 (t, J= 7.8 Hz, 1 H), 7.36-7.24 (m, 2 H), 5.81 (m, 1 H), 5.00 (m, 2 H), 3.93 (s 3 H), 3.45 (m, 1 H), 3.09 (t, J= 8.2 Hz, 2 H) 2.14-2.07 (m, 2 H), 1.89-1.82 (m, 2 H), 1.78-1.73 (m, 2 H).
[0333] 7-(4'-Methoxy-1'-naphthyl)-1-hepten-5-61 (12p): The product (0.67 g, 41%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v); 1H
NMR (300 MHz, CDC13) 6 88.33 (d, J= 7.5 Hz, 1 H), 8.02 (d, J= 7.2 Hz, 1 H), 7.53 (m, 2 H), 7.26 (d, J= 7.8 Hz, 1 H), 6.76 (d, J= 6.0 Hz, 1 H), 5.87 (m, 1 H), 5.04 (dd, J= 1.8, 15.3 Hz, 4.99 (dd, J= 1.2, 10.2 Hz, 1 H), 4.01 (s, 3 H), 3.77 (m, 1 H), 3.28-3.18 (m, 1 H), 3.11-3.01 (m, 1 H), 2.26-2.16 (m,2 H), 1.84-1.84 (m, 2 H), 1.67-1.57 (m, 2H).
[0334] 5-(1'-Naphthyl)-1-penten-5-61 (12q) The product (0.46 g, 23%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Adilexane, 10:90, v:v); 1H
NMR (300 MHz, CDC13) 6 8.08 (m, 1 H), 7.87 (m, 1 H), 7.78 (d, J= 8.1 Hz, 1 H), 7.65 (d, J= 6.9 Hz, 1 H), 7.50 (m, 3 H), 5.89 (m, 1 H), 5.49 (m, 1 H), 5.04 (dd, J= 1.8, 15.6 Hz, 1 H), 4.99 (dd, J=
1.8, 10.2 Hz, 1 H), 2.30-2.24 (m, 2 H), 2.06-1.97 (m, 2 H).
[0335] 7-(4'-Flouro-3'-methylpheny1)-1-hepten-5-61 (12r): The product (1.33 g, 38%) was obtained as an oil by chromatography on silica; (Rf = 0.41, Et0Ac/Hexane, 25:75, v:v);
1H NMR (500 MHz, CDC13) 6 7.00-6.88 (m, 3 H), 5.88-5.80 (m, 1 H), 4.05 (dt, J=
1.9, 15.7 Hz, 1 H), 4.99-4.95 (m, 1 H), 3.67-3.62 (in, 1 H), 2.74-2.70 (m, 1 H), 2.64-2.57 (m, 1 H), 2.25 (s, 3 H), 2.24-2.05 (m, 2 H), 1.77-1.70 (m, 2 H), 1.63-1.53 (m, 3 H).
[0336] 7-(5'-Fluoro-2'-methoxyphenyl)hept-1-en-5-ol (12s): The product (3.7 g, 94%) was obtained as an oil by chromatography on silica; (Rf = 0.20, Et0Ac/Hexane, 15:85, v:v);
1H NMR (CDC13, 500 MHz): 6 6.86-6.82 (m, 2 H), 6.76 (dd, J= 4.6, 8.6 Hz, 1 H), 5.82 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.95 (d, J= 10.2 Hz, 1 H), 3.81 (s, 3 H), 3.55 (in, 1 H),2.75-2.69 (m, 2 H), 2.20 (m, 1 H), 2.10 (m, 1 H), 1.96 (bs, 1 H), 1.73-1.68 (m, 2 H), 1.60-1.53 (m, 3H).
[0337] 1-(2'-Methoxy-5'-fluorophenyl)hex-5-en-2-61 (12t): The product (0.64 g, 74%) was obtained as an oil by chromatography on silica; (Rf = 0.18, Et0Ac/Hexane, 12:88, v:v);
1H NMR (CDC13, 500 MHz): 6 6.90-6.88 (m, 2 H), 6.79 (dd, J= 4.7, 9.8 Hz, 1 H), 5.83 (m, 1 H), 5.04 (d, J= 17.1 Hz, 1 H), 4.97 (d, J= 10.1 Hz, 1 H), 3.85 (m,1 H), 3.81 (s, 3 H), 2.85 (dd, J= 4.0, 13.7 Hz, 1 H), 2.69 (dd, J= 8.1, 13.7 Hz, 1 H), 2.26 (m, 1 H), 2.17 (m, 1 H), 1.82 (bs, 1 H), 1.60 (m, 2 H).
[0338] 8-(5'-Fluoro-2'-methoxyphenyboet-l-en-5-ol (12u): The product (1.06 g, 61%) was obtained as an oil by chromatography on silica; (Rf = 0.15, Et0Ac/Hexane, 12:88, v:v);
1H NMR (CDC13, 500 MHz): 6 6.86-6.82 (m, 2 H), 6.74 (dd, J= 4.6, 8.6 Hz, 1 H), 5.85 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.97 (d, J= 10.2 Hz, 1 H), 3.79 (s, 3 H), 3.66 (m, 1 H), 2.60 (m, 2 H), 2.22-2.10 (m, 2 H), 1.74-1.47 (m, 7 H).
[0339] 9-(5'-Fluoro-2'-methoxyphenyl)non-1-en-5-ol (12v): The product (0.19 g, 71%) was obtained as an oil by chromatography on silica; (Rf = 0.25, Et0Ac/Hexane, 20:80, v:v);
1H NMR (CDC13, 500 MHz): 6 6.85-6.81 (m, 2 H), 6.74 (dd, J= 4.6, 8.6 Hz, 1 H), 5.84 (m, 1 H), 5.04 (dd, J= 15.8, 1.9 Hz, 1 H), 4.98 (d, J= 10.2, 1.3 Hz, 1 H), 3.79 (s, 3 H), 3.63 (m, 1 H), 2.59 (t, J= 7.6 Hz, 2 H), 2.23-2.11 (m, 2 H), 1.62-1.36 (m, 9 H).
[0340] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenyfltetrahydrafuran (13a): To a solution of 1-(2'-methoxy-5`-fluorophenyl)pent-4-en-1-ol (3.24 g, 18.0 mmol) in dry CH2C12 (50 mL) at 0 C was added N-bromosuccinimide (NBS, 3.56 g, 20.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. The solvent was then removed in vacuo and the remaining residue was purified by flash column chromatography (Rf = 0.28, Et0Ac/Hexane, 10:90, v:v) to afford the product (2.28 g, 44%) as oil; 1H NMR
(CDC13, 500 MHz): 8 7.15 (dd, J= 3.1, 9.2 Hz, 1 H), 6.88 (dt, J= 3.1, 9.0 Hz, 1 H), 6.76 (dd, = 4.2, 8.5 Hz, 1 H), 5.30 (t, J= 7.0 Hz, 0.65 H). 5.18 (t, J= 7.0 Hz, 0.35 H), 4.48 (p, J= 6.6 Hz, 0.65 H), 4.31 (p, J= 6.6 Hz, 0.35 H), 3.79 (s, 3 H), 3.56 (m, 1 H), 3.44 (m, 1 H), 2.51-2.42 (m, 1 H), 2.18 (m, 1 H), 1.90 (m, 1 H), 1.78-1.70 (m, 1 H).
[0341] The following compounds were prepared in a similar manner as 13a.
[0342] 2-Bromomethy1-5-phenyltetrahydrofuran (13b): The product (1.58 g, 94%) was obtained as an oil by chromatography on silica; (Rf = 0.45, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (CDC13, 500 MHz):6 7.38-7.24 (m, 5 H), 5.09 (t, J= 6.9 Hz, 0.66 H), 4.95 (m, 0.33 H), 4.47 (m, 0.66 H), 4.34 (m, 0.33 H), 3.58-3.44 (m, 2 H), 2.46-1.87 (m, 4 H).
[0343] 2-Bromomethy1-2-(pentaflourophenyl)tetrahydrofuran (13c): The product (0.79 g, 65%) was obtained as an oil by chromatography on silica; (Rf = 0.17, Et0Ac/Hexane, 3:97, v:v); 1H NMR (CDC13, 500 MHz) 6 4.24 (m, 1 H), 4.04 (m, 1 H), 3.43 (dd, J=
5.2, 15.3 Hz, 1 H), 3.35 (dd, J= 6.5, 10.3 Hz, 1 H), 2.83 (m, 1 H), 2.73 (1 H), 2.19-2.11 (in, 2 H), 1.83-1.57 (m, 4 H).
1H NMR (CDC13, 500 MHz): 6 6.86-6.82 (m, 2 H), 6.74 (dd, J= 4.6, 8.6 Hz, 1 H), 5.85 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.97 (d, J= 10.2 Hz, 1 H), 3.79 (s, 3 H), 3.66 (m, 1 H), 2.60 (m, 2 H), 2.22-2.10 (m, 2 H), 1.74-1.47 (m, 7 H).
[0339] 9-(5'-Fluoro-2'-methoxyphenyl)non-1-en-5-ol (12v): The product (0.19 g, 71%) was obtained as an oil by chromatography on silica; (Rf = 0.25, Et0Ac/Hexane, 20:80, v:v);
1H NMR (CDC13, 500 MHz): 6 6.85-6.81 (m, 2 H), 6.74 (dd, J= 4.6, 8.6 Hz, 1 H), 5.84 (m, 1 H), 5.04 (dd, J= 15.8, 1.9 Hz, 1 H), 4.98 (d, J= 10.2, 1.3 Hz, 1 H), 3.79 (s, 3 H), 3.63 (m, 1 H), 2.59 (t, J= 7.6 Hz, 2 H), 2.23-2.11 (m, 2 H), 1.62-1.36 (m, 9 H).
[0340] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenyfltetrahydrafuran (13a): To a solution of 1-(2'-methoxy-5`-fluorophenyl)pent-4-en-1-ol (3.24 g, 18.0 mmol) in dry CH2C12 (50 mL) at 0 C was added N-bromosuccinimide (NBS, 3.56 g, 20.0 mmol) portionwise and the reaction was warmed to room temperature for 12 h. The solvent was then removed in vacuo and the remaining residue was purified by flash column chromatography (Rf = 0.28, Et0Ac/Hexane, 10:90, v:v) to afford the product (2.28 g, 44%) as oil; 1H NMR
(CDC13, 500 MHz): 8 7.15 (dd, J= 3.1, 9.2 Hz, 1 H), 6.88 (dt, J= 3.1, 9.0 Hz, 1 H), 6.76 (dd, = 4.2, 8.5 Hz, 1 H), 5.30 (t, J= 7.0 Hz, 0.65 H). 5.18 (t, J= 7.0 Hz, 0.35 H), 4.48 (p, J= 6.6 Hz, 0.65 H), 4.31 (p, J= 6.6 Hz, 0.35 H), 3.79 (s, 3 H), 3.56 (m, 1 H), 3.44 (m, 1 H), 2.51-2.42 (m, 1 H), 2.18 (m, 1 H), 1.90 (m, 1 H), 1.78-1.70 (m, 1 H).
[0341] The following compounds were prepared in a similar manner as 13a.
[0342] 2-Bromomethy1-5-phenyltetrahydrofuran (13b): The product (1.58 g, 94%) was obtained as an oil by chromatography on silica; (Rf = 0.45, Et0Ac/Hexane, 25:75, v:v); 1H
NMR (CDC13, 500 MHz):6 7.38-7.24 (m, 5 H), 5.09 (t, J= 6.9 Hz, 0.66 H), 4.95 (m, 0.33 H), 4.47 (m, 0.66 H), 4.34 (m, 0.33 H), 3.58-3.44 (m, 2 H), 2.46-1.87 (m, 4 H).
[0343] 2-Bromomethy1-2-(pentaflourophenyl)tetrahydrofuran (13c): The product (0.79 g, 65%) was obtained as an oil by chromatography on silica; (Rf = 0.17, Et0Ac/Hexane, 3:97, v:v); 1H NMR (CDC13, 500 MHz) 6 4.24 (m, 1 H), 4.04 (m, 1 H), 3.43 (dd, J=
5.2, 15.3 Hz, 1 H), 3.35 (dd, J= 6.5, 10.3 Hz, 1 H), 2.83 (m, 1 H), 2.73 (1 H), 2.19-2.11 (in, 2 H), 1.83-1.57 (m, 4 H).
[0344] 5-Bromomethy1-2-(4'-ehlorophenyl)tetrahydrofuran (13d): The product (0.29 g, 23%) was obtained as an oil by chromatography on silica and mixture of cis and trans isomers (cis:trans, 2:1); (Rf = 0.40, Et0Ac/Hexane, 10:90, v:v); 1H NMR
(CDC13, 300 MHz): 6 7.29 (m, 4 H), 5.06 (dd, J= 1.8, 7.8 Hz, 0.67 H), 4.91 (dd, J= 2.1, 8.4 Hz, 0.33 H), 4.47 (m, 0.67 H), 4.33 (m, 0.33 H), 3.50 (m, 2 H), 2.44-2.14 (m, 2H), 1.99-1.78 (m, 2 H).
[0345] 2-Bromomethy1-5-(4'-bromopheny1)- tetrahydrofuran (13e): The product (1.74 g, 55%) was obtained as an oil by chromatography on silica; (Rf = 0.49, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 300 MHz): 6 7.46 (d, J= 8.1 Hz, 2 H), 7.20 (d, J= 8.1 Hz, 2 H), 5.04 (dd, J= 1.8, 7.8 Hz, 0.67 H), 4.90 (dd, J= 1.8, 8.1 Hz, 0.33 H), 4.47 (m, 0.67 H), 4.34 (m, 0.33 H), 3.50 (m, 2 H), 2.44-2.13 (m, 2 H), 2.00-1.71 (m, 2 H).
[0346] 2-Bromomethy1-5-(4'-methoxyphenyl)tetrahydrofuran (13f): The product (3.33 g, 81%) was obtained as an oil by chromatography on silica; (Rf = 0.36, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 500 MHz): 6 7.30 (d, J= 8.7 Hz, 1 H), 7.24 (d, J= 8.7 Hz, 1 H), 6.87 (d, J= 8.7 Hz, 1 H), 6.86 (d, J= 8.7 Hz, 1 H), 5.02 (dd, J= 1.8, 7.8 Hz, 0.67 H), 4.88 (dd, J=
2.7, 8.4 Hz, 0.33 H), 4.45 (m, 0.67 H), 4.30 (m, 0.33 H), 3.78 (s, 3 H), 3.49 (m, 2 H), 2.37-2.14 (m, 2 H), 2.00-1.83 (m, 2 H).
[0347] 2-(Bromomethyl)-5-(4'-(t-Butylphenyl)tetrahydrofuran (13g): The product (2.38 g, 87%) was obtained as an oil by chromatography on silica; (Rf = 0.54, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 500 MHz): 6 7.30 (m, 4 H), 5.05 (dd, J= 1.5, 7.8 Hz, 0.67 H), 4.91 (dd, J= 1.8, 8.1 Hz, 0.33 H), 4.45 (m, 0.67 H), 4.32 (m, 0.33 H), 3.48 (m, 2 H), 2.43-2.21 (m, 2H), 1.98-1.87 (m, 2 H), 1.30 (s, 12 H).
[0348] 2-Bromomethy1-5-(2'-naphthyl)tetrahydrofuran (13h): The product (1.37 g, 65%) was obtained as an oil by chromatography on silica; (Rf = 0.37, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 500 MHz): 6 7.81 (m, 4 H), 7.44 (m, 3 H), 5.27 (m, 0.70 H), 5.12 (m, 0.30 H), 4.57 (m, 0.7 H), 4.40 (m, 0.30 H), 3.55 (m, 2 H), 2.53-2.22 (m, 2 H), 2.07-1.94 (m, 2 H).
[0349] 2-Bromomethy1-5-(1'-furanyl)tetrahydrofuran (13i): The product (1.65 g, 50%) was obtained as an oil by chromatography on silica; (Rf = 0.20, Et0Ac/Hexane, 20:80, v:v);
1H NMR (CDC13, 500 MHz) 6 7.38 (s, 1 H), 6.32 (s, 1 H), 6.27 (dd, J= 3.2, 8.3 Hz, 1 H), 5.10 (t, J=6.8 Hz, 0.5 H), 5.00 (t, J= 6.7 Hz, 0.5 H), 4.39 (m, 0.5 H), 4.29 (m, 0.5 H), 3.51-3.35 (m, 2 H), 2.32-1.89 (m, 4 H).
(CDC13, 300 MHz): 6 7.29 (m, 4 H), 5.06 (dd, J= 1.8, 7.8 Hz, 0.67 H), 4.91 (dd, J= 2.1, 8.4 Hz, 0.33 H), 4.47 (m, 0.67 H), 4.33 (m, 0.33 H), 3.50 (m, 2 H), 2.44-2.14 (m, 2H), 1.99-1.78 (m, 2 H).
[0345] 2-Bromomethy1-5-(4'-bromopheny1)- tetrahydrofuran (13e): The product (1.74 g, 55%) was obtained as an oil by chromatography on silica; (Rf = 0.49, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 300 MHz): 6 7.46 (d, J= 8.1 Hz, 2 H), 7.20 (d, J= 8.1 Hz, 2 H), 5.04 (dd, J= 1.8, 7.8 Hz, 0.67 H), 4.90 (dd, J= 1.8, 8.1 Hz, 0.33 H), 4.47 (m, 0.67 H), 4.34 (m, 0.33 H), 3.50 (m, 2 H), 2.44-2.13 (m, 2 H), 2.00-1.71 (m, 2 H).
[0346] 2-Bromomethy1-5-(4'-methoxyphenyl)tetrahydrofuran (13f): The product (3.33 g, 81%) was obtained as an oil by chromatography on silica; (Rf = 0.36, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 500 MHz): 6 7.30 (d, J= 8.7 Hz, 1 H), 7.24 (d, J= 8.7 Hz, 1 H), 6.87 (d, J= 8.7 Hz, 1 H), 6.86 (d, J= 8.7 Hz, 1 H), 5.02 (dd, J= 1.8, 7.8 Hz, 0.67 H), 4.88 (dd, J=
2.7, 8.4 Hz, 0.33 H), 4.45 (m, 0.67 H), 4.30 (m, 0.33 H), 3.78 (s, 3 H), 3.49 (m, 2 H), 2.37-2.14 (m, 2 H), 2.00-1.83 (m, 2 H).
[0347] 2-(Bromomethyl)-5-(4'-(t-Butylphenyl)tetrahydrofuran (13g): The product (2.38 g, 87%) was obtained as an oil by chromatography on silica; (Rf = 0.54, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 500 MHz): 6 7.30 (m, 4 H), 5.05 (dd, J= 1.5, 7.8 Hz, 0.67 H), 4.91 (dd, J= 1.8, 8.1 Hz, 0.33 H), 4.45 (m, 0.67 H), 4.32 (m, 0.33 H), 3.48 (m, 2 H), 2.43-2.21 (m, 2H), 1.98-1.87 (m, 2 H), 1.30 (s, 12 H).
[0348] 2-Bromomethy1-5-(2'-naphthyl)tetrahydrofuran (13h): The product (1.37 g, 65%) was obtained as an oil by chromatography on silica; (Rf = 0.37, DCM/Hexane, 50:50, v:v); 1H NMR (CDC13, 500 MHz): 6 7.81 (m, 4 H), 7.44 (m, 3 H), 5.27 (m, 0.70 H), 5.12 (m, 0.30 H), 4.57 (m, 0.7 H), 4.40 (m, 0.30 H), 3.55 (m, 2 H), 2.53-2.22 (m, 2 H), 2.07-1.94 (m, 2 H).
[0349] 2-Bromomethy1-5-(1'-furanyl)tetrahydrofuran (13i): The product (1.65 g, 50%) was obtained as an oil by chromatography on silica; (Rf = 0.20, Et0Ac/Hexane, 20:80, v:v);
1H NMR (CDC13, 500 MHz) 6 7.38 (s, 1 H), 6.32 (s, 1 H), 6.27 (dd, J= 3.2, 8.3 Hz, 1 H), 5.10 (t, J=6.8 Hz, 0.5 H), 5.00 (t, J= 6.7 Hz, 0.5 H), 4.39 (m, 0.5 H), 4.29 (m, 0.5 H), 3.51-3.35 (m, 2 H), 2.32-1.89 (m, 4 H).
[0350] 2-Benzy1-5-bromomethyltetrahydrofuran (13j): The product (0.45 g, 65%) was obtained as an oil by chromatography on silica; (Rf = 0.55, DCM/Hexane, 50:50, v:v);1H
NMR (CDC13, 500 MHz) 6 7.20-7.29 (m, 5 H), 4.15-4.33 (in, 1 H), 3.27-3.45 (in, 2 H), 2.96 (dd, J= 5.6, 13.5 Hz, 1 H), 2.70-2.79 (m, 1 H), 1.91-2.11 (m, 2 H), 1.63-1.78 (m, 3 H).
[0351] 2-Bromomethy1-5-phenethyltetrahydrofuran (13k): The product (2.58 g, 74%) was obtained as an oil by chromatography on silica as a mixture of trans:cis =
2:1; (Rf = 0.26, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) 6 7.28-7.19 (m, 5H), 4.26 (m, 0.66 H), 4.15 (m, 0.33 H), 4.06 (m, 0.66 H), 3.94 (m, 0.33 H), 3.47-3.44 (m, 1 H), 3.37-3.34 (m, 1 H), 2.77-2.63 (m, 2 H), 2.19-1.76(m, 5H), 1.62-1.58 (m, 1 H).
[0352] 2-Bromomethy1-5-(3'-pyridinylethyl)tetrahydrofuran (131): The product (2.06 g, 81%) was obtained as a yellow oil by chromatography on silica; (Rf = 0.28, Et0Ac/Hexane,60:40, v:v); 1H NMR (500 MHz, CDC13) 6 8.53 (s, 1 H), 8.49 (d, J=
4.6 Hz, 1 H), 7.75 (m, 1 H), 7.38 (m, 1 H), 4.25 (m, 0.6 H), 4.14 (m, 0.4 H), 4.02 (m, 0.6 H), 3.92 (m, 0.4 H), 3.45-3.33 (m, 2 H), 2.85-2.72 (m, 2 H), 2.17-2.04 (m, 2 H), 1.91-1.77 (m, 3 H), 1.59 (m, 1 H).
[0353] 2-Bromomethy1-5-(1'-naphthyl)tetrahydrofuran (13m): The product (0.59 g, 93%) was obtained as an oil by chromatography on silica; (Rf = 0.50, DCM/Hexane, 50:50, v:v); 1 H NMR (500 MHz, CDC13) d 7.95-7.85 (m, 3 H), 7.76 (d, J= 8.1 Hz, 1 H), 7.64-7.44 (m, 3 H), 5.85 (t, J= 6.7 Hz, 0.30 H), 5.71 (t, J= 6.9 Hz, 0.70 H), 4.62 (m, 0.30 H), 4.43 (m, 0.7 H), 3.62 (m, 2 H), 2.67-2.55 (in, 1 H), 2.33-2.23 (m, 1 H), 2.08-1.92 (m, 2 H).
[0354] 2-(Bromomethyl)-5-(p-(t-Butyldimethylsilyloxyphenethyl)-tetrahydrofuran (13n): The product (0.75 g, 70%) was obtained as an oil by chromatography on silica; (Rf Et0Ac/Hexane, 15:85, v:v); 1H NMR (500 MHz, CDC13) 6 7.03 (d, J= 8.4 Hz, 2 H), 6.76 (d, J= 8.4 Hz, 2 H), 4.28-4.13 (m, 1 H), 4.05-3.90 (m, 1 H), 3.46-3.42 (m, 1 H), 3.36-3.32 (m, 1 H), 2.67-2.56 (m, 2 H), 2.16-1.55 (m, 6 H), 0.98 (s, 9 H), 0.18 (s, 6 H).
[0355] 2-Bromomethy1-5-(2'-methoxy-l'-naphthethyl)tetrahydrofuran (13o): The product (1.512 g, 97%) was obtained as an oil by chromatography on silica; (Rf = 0.50, Et0Ac/Hexane, 25:75, v:v); 1H NMR: (500 MHz,CDC13) 6 8.32-6.74 (m, 6 H), 4.30 (m, 0.67 H), 4.19 (m, 0.33 H), 4.12 (m, 0.67 H), 4.03 (m, 0.33 H), 3.99 (s, 3 H), 3.50-3.47 (m, 1 H), 3.41-3.37 (m, 1 H), 3.19-3.13 (m, 1 H), 3.05-2.99 (m, 1 H), 2.18-1.76 (m, 5 H), 1.66-1.59 (m, 1H).
NMR (CDC13, 500 MHz) 6 7.20-7.29 (m, 5 H), 4.15-4.33 (in, 1 H), 3.27-3.45 (in, 2 H), 2.96 (dd, J= 5.6, 13.5 Hz, 1 H), 2.70-2.79 (m, 1 H), 1.91-2.11 (m, 2 H), 1.63-1.78 (m, 3 H).
[0351] 2-Bromomethy1-5-phenethyltetrahydrofuran (13k): The product (2.58 g, 74%) was obtained as an oil by chromatography on silica as a mixture of trans:cis =
2:1; (Rf = 0.26, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) 6 7.28-7.19 (m, 5H), 4.26 (m, 0.66 H), 4.15 (m, 0.33 H), 4.06 (m, 0.66 H), 3.94 (m, 0.33 H), 3.47-3.44 (m, 1 H), 3.37-3.34 (m, 1 H), 2.77-2.63 (m, 2 H), 2.19-1.76(m, 5H), 1.62-1.58 (m, 1 H).
[0352] 2-Bromomethy1-5-(3'-pyridinylethyl)tetrahydrofuran (131): The product (2.06 g, 81%) was obtained as a yellow oil by chromatography on silica; (Rf = 0.28, Et0Ac/Hexane,60:40, v:v); 1H NMR (500 MHz, CDC13) 6 8.53 (s, 1 H), 8.49 (d, J=
4.6 Hz, 1 H), 7.75 (m, 1 H), 7.38 (m, 1 H), 4.25 (m, 0.6 H), 4.14 (m, 0.4 H), 4.02 (m, 0.6 H), 3.92 (m, 0.4 H), 3.45-3.33 (m, 2 H), 2.85-2.72 (m, 2 H), 2.17-2.04 (m, 2 H), 1.91-1.77 (m, 3 H), 1.59 (m, 1 H).
[0353] 2-Bromomethy1-5-(1'-naphthyl)tetrahydrofuran (13m): The product (0.59 g, 93%) was obtained as an oil by chromatography on silica; (Rf = 0.50, DCM/Hexane, 50:50, v:v); 1 H NMR (500 MHz, CDC13) d 7.95-7.85 (m, 3 H), 7.76 (d, J= 8.1 Hz, 1 H), 7.64-7.44 (m, 3 H), 5.85 (t, J= 6.7 Hz, 0.30 H), 5.71 (t, J= 6.9 Hz, 0.70 H), 4.62 (m, 0.30 H), 4.43 (m, 0.7 H), 3.62 (m, 2 H), 2.67-2.55 (in, 1 H), 2.33-2.23 (m, 1 H), 2.08-1.92 (m, 2 H).
[0354] 2-(Bromomethyl)-5-(p-(t-Butyldimethylsilyloxyphenethyl)-tetrahydrofuran (13n): The product (0.75 g, 70%) was obtained as an oil by chromatography on silica; (Rf Et0Ac/Hexane, 15:85, v:v); 1H NMR (500 MHz, CDC13) 6 7.03 (d, J= 8.4 Hz, 2 H), 6.76 (d, J= 8.4 Hz, 2 H), 4.28-4.13 (m, 1 H), 4.05-3.90 (m, 1 H), 3.46-3.42 (m, 1 H), 3.36-3.32 (m, 1 H), 2.67-2.56 (m, 2 H), 2.16-1.55 (m, 6 H), 0.98 (s, 9 H), 0.18 (s, 6 H).
[0355] 2-Bromomethy1-5-(2'-methoxy-l'-naphthethyl)tetrahydrofuran (13o): The product (1.512 g, 97%) was obtained as an oil by chromatography on silica; (Rf = 0.50, Et0Ac/Hexane, 25:75, v:v); 1H NMR: (500 MHz,CDC13) 6 8.32-6.74 (m, 6 H), 4.30 (m, 0.67 H), 4.19 (m, 0.33 H), 4.12 (m, 0.67 H), 4.03 (m, 0.33 H), 3.99 (s, 3 H), 3.50-3.47 (m, 1 H), 3.41-3.37 (m, 1 H), 3.19-3.13 (m, 1 H), 3.05-2.99 (m, 1 H), 2.18-1.76 (m, 5 H), 1.66-1.59 (m, 1H).
[0356] 2-Bromomethy1-5-(4'-methoxy-P-naphthethyptetrahydrofuran (13p): The product (1.31 g, 88%) was obtained as an oil by chromatography on silica; (Rf = 0.30, DCM/Hexane, 50:50, v:v); 1H NMR: (300 MHz,CDC13) 6 8.27 (d, J= 8.4 Hz, 1 H), 8.16 (d, J
= 8.4 Hz, 1 H), 8.07 (d, J= 8.4 Hz, 1 H), 7.79 (d, J= 8.4 Hz, 1 H), 7.67-7.38 (m, 2 H), 4.41-4.26 (m, 1 H), 4.21-4.02 (m, 1 H), 3.99 (s, 3 H), 3.83 (in, 2 H), 2.22-1.71 (M, 8 H).
[0357] 2-(Bromomethyl)-5-(4'-flouro-3'-methylphenethyl)- tetrahydrofuran (13q):
The product (0.53 g, 30%) was obtained as an oil by chromatography on silica;
(Rf = 0.30, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) 6 7.00-6.87 (m, 3 H), 4.27-3.90 (m, 2 H), 3.46-3.42 (m, 1 H), 3.37-3.32 (m, 1 H), 2.69-2.57 (m, 2 H), 2.24 (s, 3 H), 2.23-1.56 (in, 6H).
[0358] 2-(Bromomethy1)-5-(2'-methoxy-5'-fluorophenethy1)tetrahydrafuran (13r):
The product (0.45 g, 72%) was obtained as an oil by chromatography on silica with a mixture of trans:cis = 2:1; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H NMR (CDC13, 500 MHz): 6 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H).
[0359] 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrafuran (trans, 13s; cis, 13t): The cis (13s, 0.74 g, 20 %) and trans product (trans, 13t, 1.38 g, 42%) were separated as oils by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H
?.0 NMR (CDC13, 500 MHz) 13s: 6 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H);1H NMR (CDC13, 500 MHz) 13t: (5 6.88-6.82 (in, 2 H), 6.73 (dd, J= 4.6, 8.6 Hz, 1 H), 4.25 (m, 1 H), 4.04 (quintet, J= 6.7 Hz, 1 H), 3.78 (s, 3 H), 3.45 (dd, J=
4.2, 9.5 Hz, 1 H), 15 3.34 (dd, J= 6.4, 9.5 Hz, 1 H), 2.70 (m, 1 H), 2.60 (in, 1 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.87-1.56 (m, 4 H).
[0360] 2-(Bromomethy1)-5-(2'-methoxy-5'-fluorobenzy1)tetrahydrafuran (trans, 13u;
cis, 13v): The cis (13v, 238 mg, 13%) and trans product (trans, 13u, 663 mg, 36%) were separated as oils by chromatography on silica; (Rf = 0.12, Et0Ac/Hexane, 5:95, v:v); 1H
0 NMR (CDC13, 500 MHz) 13u: 6.93 (dd, J= 3.1, 9.1 Hz, 1 H), 6.86 (dt, J= 3.1, 9.1 Hz, 1 H), 6.74 (dd, J= 4.7, 9.0 Hz, 1 H), 4.33 (p, J= 6.7 Hz, 1 H), 4.26 (m, 1 H), 3.78 (s, 3 H), 3.45 (dd, J= 4.4, 9.9 Hz, 1 H), 3.33 (dd, J= 7.0, 10.2 Hz, 1 H), 2.92 (dd, J= 6.3, 13.5 Hz, 1 H), 2.71 (dd, J= 6.9, 13.5 Hz, 1 H), 2.14 (m, 1 H), 1.97 (m, 1 H), 1.76 (m, 1 H), 1.66 (m, 1 H);
1 H NMR (CDC13, 500 MHz) 13v: 6.94 (dd, J= 3.1, 9.1 Hz, 1 H), 6.87 (dt, J=
3.1, 9.1 Hz, 1 H), 6.75 (dd, J= 4.7, 9.0 Hz, 1 H), 4.21 (p, J= 6.7 Hz, 1 H), 4.16 (p, J= 5.8 Hz, 1 H), 3.79 (s, 3 H), 3.43 (dd, J= 5.1, 10.2 Hz, 1 H), 3.31 (dd, J= 6.5, 10.2 Hz, 1 H), 2.91 (dd, J= 6.2, 13.5 Hz, 1 H), 2.78 (dd, J= 6.3, 13.5 Hz, 1 H), 2.03 (m, 1 H), 1.93 (m, 1 H), 1.82 (m, 1 H), 1.66 (m, 1 H).
[0361] Trans-2-(bromomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydro furan (13w): The product (530 mg, 40%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H NMR (CDC13, MHz): (56.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (in, 1 H), 4.03 (in, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (in, 1 H), 1.67-1.46 (m, 5 H).
[0362] Cis-2-(bromomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydrofuran (13x): The product (110 mg, 10%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H NMR (CDC13, MHz): (56.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.13 (m, 1 H), 3.93 (m, 1 H), 3.78 (s,3 H), 3.42 (m, 1 H), 3.32 (m, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.06-1.96 (in, 2 H), 1.80-1.51 (m, 6 H).
[0363] Trans-2-(bromomethy1)-5-(4'-(2"-methoxy-5"-fluoropheny1)-1'-butyl)tetrahydro furan (13y): The product (80 mg, 32%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 4:96, v:v); 1H NMR (CDC13, MHz): (56.84-6.80 (in, 2 H), 6.73 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.01 (in, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 5.1, 10.3 Hz, 1 H), 3.34 (dd, J= 7.1, 10.3 Hz, 1 H), 2.58 (t, J= 7.7 Hz, 2 H), 2.15 (m, 1 H), 2.06 (m, 1 H), 1.75 (m, 1 H), 1.65-1.37 (m, 7 H).
[0364] 2-(N-Phthilimidomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (14a):
To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrafuran (1.28 g, 4.44 mmol), NaI (100 mg), potassium phthilimide (2.05 g, 11.1 mmol), and dry DMSO (10 mL). The reaction was heated to 70 C and stirred under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarbonate aqueous solution (sat.
NaHCO3/H20 = 1:1, 70 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The solvent was removed in vacuo and to afford crude product which was purified by flash column chromatography (Rf =
0.12, Et0Ac/Hexane, 20:80, v:v) to yield pure product (about 2:1 of trans: cis isomers, 1.14 g, 72%) as oil; 1H NMR (CDC13, 500 MHz): a 7.88-7.84 (m, 2 H), 7.73-7.69 (m, 2 H), 7.36 (dd, J= 3.1, 9.4 Hz, 0.35 H), 7.07 (dd, J= 3.1, 9.4 Hz, 0.65 H), 6.85 (dt, J=
3.1, 8.5 Hz.
0.35 H), 6.83 (dt, J= 3.1, 8.5 Hz. 0.65 H), 6.72 (dd, J= 4.2, 9.1 Hz, 1 H), 5.31 (t, J= 6.8 Hz, 0.65 H), 5.09 (t, J= 7.2 Hz, 0.35 H), 4.63 (m, 0.65 H), 4.39 (m, 0.35 H), 4.02 (dd, J= 7.4, 13.7 Hz, 0.35 H), 3.92 (dd, J= 8.1 13.7 Hz, 0.65 H), 3.87 (dd, J= 7.4, 13.7 Hz, 0.35 H), 3.85 (s, 1.95 H), 3.78 (s, 1.05 H), 3.70 (dd, J= 8.1 13.7 Hz, 0.65 H), 2.50 (m, 0.65 H), 2.41 (m, 0.35 H), 2.11-2.04 (m, 1 H), 1.84-1.68 (m, 2 H).
[0365] The following compounds were prepared in a similar manner as 14a.
[0366] 2-Pheny1-5-(N-phthlimidomethy1)tetrahydrofuran (14b): The product (1.42 g, 74%) was obtained as an oil by chromatography on silica and a mixture of the trans:cis = 2:1 isomers; (Rf = 0.16, Et0Ac/Hexane, 20:80, v:v); 1H NMR (CDC13, 500 MHz): a 7.85 (m, 2 H), 7.71 (in, 2 H), 7.39-7.21 (m, 5 H), 5.10 (t, J= 6.9 Hz, 0.66 H), 4.90 (t, J= 7.2 Hz, 0.33 H), 4.64 (m, 0.66 H), 4.46 (m, 0.33 H), 4.01 (dd, J= 7.3, 13.5 Hz, 0.33 H), 3.95 (dd, J= 8.2, 14.3 Hz, 0.66 H), 3.82 (dd, J= 5.2, 13.5 Hz, 0.66 H), 2.46-2.12 (in, 2 H), 1.92-1.81 (m, 2 H).
[0367] 2-(Pentafluorophenethyl)-5-(N-phthlimidomethyl)tetrahydrofuran (14c):
The product (0.25 g, 58%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v); 1H NMR (CDC13, 500 MHz) a 7.85 (dd, J= Hz, 2 H), 7.72 (dd, J= Hz, 2 H), 4.38 (m, 1 H), 4.04 (quintet, J= Hz, 1 H), 3.80 (dd, J= Hz, 1 H), 3.59 (dd, J=
Hz, 1 H), 2.73 (m, 2 H), 2.17-2.05 (m, 2 H), 1.76-1.53 (m, 4 H).
[0368] 2-(4'-Chloropheny1)-5-(N-phthalimidomethyl)tetrahydrofuran (14d): The product (0.11 g, 99%) was obtained as an oil by chromatography on silica; (Rf = 0.38, Et0Ac/Hexane, 40:60, v:v); 1H NMR (CDC13, 300 MHz); a 7.86-7.84 (m, 2 H), 7.72-7.69 (m, 2 H), 7.30-7.22 (m, 4 H), 5.06 (t, J= 6.9 Hz, 0.67 H), 4.85 (t, J= 7.2 Hz, 0.33 H), 4.61 (m, 0.67 H), 4.44 (m, 0.33 H), 3.90 (m, 0.66 H), 3.80 (m, 1.34 H), 2.44-2.25 (m, 1 H), 2.22-2.08 (m, 1 H), 1.88-1.74 (m, 2 H).
[0369] 2-(4'-Bromopheny1)-5-(N-phthalimidomethyl) tetrahydrofuran (14e): The product (4.6 g, 74%) was obtained as an oil by chromatography on silica; (Rf =
0.69, Et0Ac/Hexane, 40:60, v:v); 1H NMR (CDC13, 300 MHz); a 7.85-7.68 (m, 4 H), 7.45-7.39 (m, 2 H), 7.26-7.14 (in, 2 H), 5.04 (t, J= 6.9 Hz, 0.67 H), 4.84 (t, J= 7.2 Hz, 0.33 H), 4.61 (m, 0.67 H), 4.44 (m, 0.33 H), 3.89 (m, 0.66 H), 3.80 (m, 1.34 H), 2.45-2.37 (m, 1 H), 2.21-2.11 (m, 1 H), 1.88-1.77 (in, 2 H).
[0370] 2-(4'-Methoxypheny1)-5-(N-phthalimidomethyl)tetrahydrofuran (141): The product (0.74 g, 99%) was obtained as an oil by chromatography on silica; (Rf = 0.40, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 300 MHz); 6 7.87-7.67 (m, 4 H), 7.31-7.20 (m, 2 H), 6.87-6.80 (m, 2 H), 5.03 (t, J= 6.9 Hz, 0.67 H), 4.83 (t, J= 7.1 Hz, 0.33 H), 4.60 (m, 0.67 H), 4.43 (m, 0.33 H), 3.88 (m, 0.66 H), 3.79 (m, 1.34 H), 3.76 (s, 3 H), 2.41-2.31 (m, 1 H), 2.26-2.11 (m, 1 H), 1.92-1.75 (m, 2 H).
[0371] 2-(4'4-Butylpheny1)-5-(phthalimidomethyl)tetrahydrofuran (14g): The product (0.52 g, 68%) was obtained as an oil by chromatography on silica; (Rf = 0.52, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 300 MHz); 6 7.86-7.81 (m, 2 H), 7.71-7.67 (m, 2 H), 7.36-7.21 (m, 4 H), 5.06 (t, J= 6.9 Hz, 0.67 H), 4.87 (t, J= 7.1 Hz, 0.33 H), 4.61 (m, 0.67 H), 4.44 (m, 0.33 H), 3.99 (m, 0.33 H), 3.93 (m, 0.67 H), 3.80 (m, 0.33 H), 3.67 (m, 0.67 H), 2.44-2.24 (m, 1 H), 2.42-2.06 (m, 1 H), 1.96-1.78 (m, 2 H) 1.28 (s, 9 H).
[0372] 2-(2'-Naphthyl)-5-(phthalimidomethyl) tetrahydrofuran (14h): The product (0.58 g, 77%) was obtained as an oil by chromatography on silica; (Rf = 0.49, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz); 6 7.87-7.68 (in, 7 H), 7.48-7.37 (m, 4 H), 5.27 (t, J= 6.9 Hz, 0.53 H), 5.08 (t, J= 6.9 Hz, 0.47 H), 4.71 (m, 0.53 H), 4.52 (m, 0.47 H), 3.97 (m, 0.94 H), 3.85 (m, 1.06 H), 2.55-2.33 (m, 1 H), 2.25-2.12 (m, 1 H), 2.02-1.83 (m, 2 H).
[0373] 2-Phenethy1-5-(N-phthlimidomethyl)tetrahydrofuran(144): The product (0.43 g, 95%) was obtained as an oil by chromatography on silica; (Rf = 0.49, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz): 6 7.85 (m, 2 H), 7.71 (m, 2 H), 7.25-7.17 (m, 5 H), 4.39 (m, 0.66 H), 4.27 (m, 0.33 H), 4.05 (m, 0.66 H), 3.88 (m, 0.33 H), 3.86-3.80 (m, 1 H), 3.71 (dd, J= 5.3, 13.6 Hz, 0.33 H), 3.61 (dd, J= 5.2, 13.5 Hz, 0.66 H), 2.72-2.57 (m, 2 H), 2.17-1.53 (m, 4 H).
[0374] 5-(N-Phthalimidomethyl)-2-(3'-pyridinylethyl)tetrahydrofuran (14j): The product (233 mg, 26.5%) was obtained as an oil by chromatography on silica as a mixture of diastereomers, trans:cis = 1.5:1 isomers; (Rf = 0.24, Et0Ac/Hexane, 60:40, v:v); 1H NMR
(CDC13, 500 MHz): 6 8.44 (s, 1 H), 8.41 (m, 1 H), 7.85 (m, 2 H), 7.72 (m, 2 H), 7.50 (m, 1 H), 7.17 (m, 1 H), 4.39 (m, 0.6 H), 4.28 (m, 0.4 H), 4.03 (m, 0.6 H), 3.86 (m, 0.4 H), 3.86-3.80 (111, 1 H), 3.72 (dd, J= 5.2, 13.5 Hz, 0.4 H), 3.62 (dd, J= 4.5, 13.5 Hz, 0.6 H), 2.73-2.58 (m, 2 H), 2.12-2.06 (m, 2 H), 1.80-1.54 (m, 4H).
[0375] 2-(1 '-Naphthethyl)-5-(N-phthlimidomethyl)tetrahydrofuran (14k) The product (230 mg, 65%) was obtained as an oil by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 30:70, v:v); 1 H NMR (CDC13, 500 MHz): (58.09-8.01 (m, 1 H), 7.88-7.81 (m, 3 H), 7.74-7.68 (m, 3 H), 7.53-7.31 (m, 4 H), 4.43 (m, 0.65 H), 4.33 (m, 0.35 H), 4.16 (m, 0.65 H), 3.97 (m, 0.35 H), 3.81 (m, 0.7 H), 3.76 (m, 1.3 H), 3.19 (in, 1 H), 3.04 (in, 1 H), 2.17-1.53 (m, 6 H).
[0376] 2-(1 '-Naphthyl)-5-(N-phthlimidomethyl)tetrahydrofuran (141) The product (570 mg, 79%) was obtained as an oil by chromatography on silica; (Rf = 0.53, Et0Ac/Hexane, 30:70, v:v); 1H NMR (300 MHz, CDC13) : (587.86 (m, 4 H), 7.72 (m, 4 H), 7.48 (m, 3 H), 5.86 (t, J= 6.5 Hz, 0.3 H), 5.64 (t, J= 7.1 Hz, 0.7 H), 4.78 (m, 0.3 H), 4.53 (in, 0.7 H), 4.04 (in, 1.4 H), 3.91 (m, 0.6 H), 2.73-2.56 (m, 1 H), 2.25-2.14 (m, 1 H), 2.07-1.78 (m, 2 H).
[0377] Trans-2-(N-phthilimidomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (14m): The product (385 mg, 70%) was obtained as a white solid by chromatography on silica; (Rf = 0.50, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz): (57.85-7.84 (m, 2 H), 7.72-7.70 (m, 2 H), 6.91 (dd, J= 3.1, 9.1 Hz, 1 H), 6.82 (dt, J= 3.1, 9.1 Hz. 1 H), 6.72 (dd, J= 4.7, 9.1 Hz, 1 H), 4.41 (m, 1 H), 4.34 (p, J= 6.7 Hz, 1 H), 3.83 (dd, J= 8.1, 13.5 Hz, 1 H), 3.77 (s, 3 H), 3.62 (dd, J= 5.3 13.5 Hz, 1 H), 2.85 (dd, J= 6.4, 13.7 Hz, 1 H), 2.70 (dd, J= 6.4, 13.7 Hz, 1 H), 2.03 (m, 2 H), 1.64 (in, 2 H).
[0378] Cis-2-(N-phthilimidomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (14n): The product (138 mg, 47%) was obtained as a white solid by chromatography on silica; (Rf = 0.52, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz): (57.87-7.85 (m, 2 H), 7.71-7.70 (in, 2 H), 6.94 (dd, J= 3.1, 9.1 Hz, 1 H), 6.80 (dt, J= 3.1, 9.1 Hz. 1 H), 6.71 (dd, J= 4.7, 9.1 Hz, 1 H), 4.25 (m, 1 H), 4.11 (p, J= 6.7 Hz, 1 H), 3.84 (dd, J= 8.1, 13.8 Hz, 1 H), 3.75 (s, 3 H), 3.68 (dd, J= 5.2 13.8 Hz, 1 H), 2.84 (d, J= 6.3 Hz, 2 H), 1.98-1.92 (m, 2 H), 1.73-1.67 (m, 2 H).
[0379] Trans-2-(5'-flouro-T-methoxyphenethyl)-5-(phthalimidomethyl)tetrahydrofuran (140): The product (0.70 g, 57%) was obtained as a white solid by chromatography on silica; (Rf = 0.20, Et0Ac/Hexane, 20:80, v:v); 1H NMR
(CDC13, 500 MHz): (57.85-7.84 (m, 2 H), 7.72-7.71 (m, 2 H), 6.86 (dd, J= 3.1, 9.1 Hz, 1 H), 6.80 (dt, J= 3.1, 9.1 Hz. 1 H), 6.71 (dd, J= 4.7, 9.1 Hz, 1 H), 4.38 (m, 1 H), 4.05 (quintet, J
= 8.4 Hz, 1 H), 8.07 (d, J= 8.4 Hz, 1 H), 7.79 (d, J= 8.4 Hz, 1 H), 7.67-7.38 (m, 2 H), 4.41-4.26 (m, 1 H), 4.21-4.02 (m, 1 H), 3.99 (s, 3 H), 3.83 (in, 2 H), 2.22-1.71 (M, 8 H).
[0357] 2-(Bromomethyl)-5-(4'-flouro-3'-methylphenethyl)- tetrahydrofuran (13q):
The product (0.53 g, 30%) was obtained as an oil by chromatography on silica;
(Rf = 0.30, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) 6 7.00-6.87 (m, 3 H), 4.27-3.90 (m, 2 H), 3.46-3.42 (m, 1 H), 3.37-3.32 (m, 1 H), 2.69-2.57 (m, 2 H), 2.24 (s, 3 H), 2.23-1.56 (in, 6H).
[0358] 2-(Bromomethy1)-5-(2'-methoxy-5'-fluorophenethy1)tetrahydrafuran (13r):
The product (0.45 g, 72%) was obtained as an oil by chromatography on silica with a mixture of trans:cis = 2:1; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H NMR (CDC13, 500 MHz): 6 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H).
[0359] 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrafuran (trans, 13s; cis, 13t): The cis (13s, 0.74 g, 20 %) and trans product (trans, 13t, 1.38 g, 42%) were separated as oils by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H
?.0 NMR (CDC13, 500 MHz) 13s: 6 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H);1H NMR (CDC13, 500 MHz) 13t: (5 6.88-6.82 (in, 2 H), 6.73 (dd, J= 4.6, 8.6 Hz, 1 H), 4.25 (m, 1 H), 4.04 (quintet, J= 6.7 Hz, 1 H), 3.78 (s, 3 H), 3.45 (dd, J=
4.2, 9.5 Hz, 1 H), 15 3.34 (dd, J= 6.4, 9.5 Hz, 1 H), 2.70 (m, 1 H), 2.60 (in, 1 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.87-1.56 (m, 4 H).
[0360] 2-(Bromomethy1)-5-(2'-methoxy-5'-fluorobenzy1)tetrahydrafuran (trans, 13u;
cis, 13v): The cis (13v, 238 mg, 13%) and trans product (trans, 13u, 663 mg, 36%) were separated as oils by chromatography on silica; (Rf = 0.12, Et0Ac/Hexane, 5:95, v:v); 1H
0 NMR (CDC13, 500 MHz) 13u: 6.93 (dd, J= 3.1, 9.1 Hz, 1 H), 6.86 (dt, J= 3.1, 9.1 Hz, 1 H), 6.74 (dd, J= 4.7, 9.0 Hz, 1 H), 4.33 (p, J= 6.7 Hz, 1 H), 4.26 (m, 1 H), 3.78 (s, 3 H), 3.45 (dd, J= 4.4, 9.9 Hz, 1 H), 3.33 (dd, J= 7.0, 10.2 Hz, 1 H), 2.92 (dd, J= 6.3, 13.5 Hz, 1 H), 2.71 (dd, J= 6.9, 13.5 Hz, 1 H), 2.14 (m, 1 H), 1.97 (m, 1 H), 1.76 (m, 1 H), 1.66 (m, 1 H);
1 H NMR (CDC13, 500 MHz) 13v: 6.94 (dd, J= 3.1, 9.1 Hz, 1 H), 6.87 (dt, J=
3.1, 9.1 Hz, 1 H), 6.75 (dd, J= 4.7, 9.0 Hz, 1 H), 4.21 (p, J= 6.7 Hz, 1 H), 4.16 (p, J= 5.8 Hz, 1 H), 3.79 (s, 3 H), 3.43 (dd, J= 5.1, 10.2 Hz, 1 H), 3.31 (dd, J= 6.5, 10.2 Hz, 1 H), 2.91 (dd, J= 6.2, 13.5 Hz, 1 H), 2.78 (dd, J= 6.3, 13.5 Hz, 1 H), 2.03 (m, 1 H), 1.93 (m, 1 H), 1.82 (m, 1 H), 1.66 (m, 1 H).
[0361] Trans-2-(bromomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydro furan (13w): The product (530 mg, 40%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H NMR (CDC13, MHz): (56.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (in, 1 H), 4.03 (in, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (in, 1 H), 1.67-1.46 (m, 5 H).
[0362] Cis-2-(bromomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydrofuran (13x): The product (110 mg, 10%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 5:95, v:v); 1H NMR (CDC13, MHz): (56.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.13 (m, 1 H), 3.93 (m, 1 H), 3.78 (s,3 H), 3.42 (m, 1 H), 3.32 (m, 1 H), 2.60 (t, J= 7.3 Hz, 2 H), 2.06-1.96 (in, 2 H), 1.80-1.51 (m, 6 H).
[0363] Trans-2-(bromomethy1)-5-(4'-(2"-methoxy-5"-fluoropheny1)-1'-butyl)tetrahydro furan (13y): The product (80 mg, 32%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 4:96, v:v); 1H NMR (CDC13, MHz): (56.84-6.80 (in, 2 H), 6.73 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.01 (in, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 5.1, 10.3 Hz, 1 H), 3.34 (dd, J= 7.1, 10.3 Hz, 1 H), 2.58 (t, J= 7.7 Hz, 2 H), 2.15 (m, 1 H), 2.06 (m, 1 H), 1.75 (m, 1 H), 1.65-1.37 (m, 7 H).
[0364] 2-(N-Phthilimidomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (14a):
To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrafuran (1.28 g, 4.44 mmol), NaI (100 mg), potassium phthilimide (2.05 g, 11.1 mmol), and dry DMSO (10 mL). The reaction was heated to 70 C and stirred under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarbonate aqueous solution (sat.
NaHCO3/H20 = 1:1, 70 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The solvent was removed in vacuo and to afford crude product which was purified by flash column chromatography (Rf =
0.12, Et0Ac/Hexane, 20:80, v:v) to yield pure product (about 2:1 of trans: cis isomers, 1.14 g, 72%) as oil; 1H NMR (CDC13, 500 MHz): a 7.88-7.84 (m, 2 H), 7.73-7.69 (m, 2 H), 7.36 (dd, J= 3.1, 9.4 Hz, 0.35 H), 7.07 (dd, J= 3.1, 9.4 Hz, 0.65 H), 6.85 (dt, J=
3.1, 8.5 Hz.
0.35 H), 6.83 (dt, J= 3.1, 8.5 Hz. 0.65 H), 6.72 (dd, J= 4.2, 9.1 Hz, 1 H), 5.31 (t, J= 6.8 Hz, 0.65 H), 5.09 (t, J= 7.2 Hz, 0.35 H), 4.63 (m, 0.65 H), 4.39 (m, 0.35 H), 4.02 (dd, J= 7.4, 13.7 Hz, 0.35 H), 3.92 (dd, J= 8.1 13.7 Hz, 0.65 H), 3.87 (dd, J= 7.4, 13.7 Hz, 0.35 H), 3.85 (s, 1.95 H), 3.78 (s, 1.05 H), 3.70 (dd, J= 8.1 13.7 Hz, 0.65 H), 2.50 (m, 0.65 H), 2.41 (m, 0.35 H), 2.11-2.04 (m, 1 H), 1.84-1.68 (m, 2 H).
[0365] The following compounds were prepared in a similar manner as 14a.
[0366] 2-Pheny1-5-(N-phthlimidomethy1)tetrahydrofuran (14b): The product (1.42 g, 74%) was obtained as an oil by chromatography on silica and a mixture of the trans:cis = 2:1 isomers; (Rf = 0.16, Et0Ac/Hexane, 20:80, v:v); 1H NMR (CDC13, 500 MHz): a 7.85 (m, 2 H), 7.71 (in, 2 H), 7.39-7.21 (m, 5 H), 5.10 (t, J= 6.9 Hz, 0.66 H), 4.90 (t, J= 7.2 Hz, 0.33 H), 4.64 (m, 0.66 H), 4.46 (m, 0.33 H), 4.01 (dd, J= 7.3, 13.5 Hz, 0.33 H), 3.95 (dd, J= 8.2, 14.3 Hz, 0.66 H), 3.82 (dd, J= 5.2, 13.5 Hz, 0.66 H), 2.46-2.12 (in, 2 H), 1.92-1.81 (m, 2 H).
[0367] 2-(Pentafluorophenethyl)-5-(N-phthlimidomethyl)tetrahydrofuran (14c):
The product (0.25 g, 58%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v); 1H NMR (CDC13, 500 MHz) a 7.85 (dd, J= Hz, 2 H), 7.72 (dd, J= Hz, 2 H), 4.38 (m, 1 H), 4.04 (quintet, J= Hz, 1 H), 3.80 (dd, J= Hz, 1 H), 3.59 (dd, J=
Hz, 1 H), 2.73 (m, 2 H), 2.17-2.05 (m, 2 H), 1.76-1.53 (m, 4 H).
[0368] 2-(4'-Chloropheny1)-5-(N-phthalimidomethyl)tetrahydrofuran (14d): The product (0.11 g, 99%) was obtained as an oil by chromatography on silica; (Rf = 0.38, Et0Ac/Hexane, 40:60, v:v); 1H NMR (CDC13, 300 MHz); a 7.86-7.84 (m, 2 H), 7.72-7.69 (m, 2 H), 7.30-7.22 (m, 4 H), 5.06 (t, J= 6.9 Hz, 0.67 H), 4.85 (t, J= 7.2 Hz, 0.33 H), 4.61 (m, 0.67 H), 4.44 (m, 0.33 H), 3.90 (m, 0.66 H), 3.80 (m, 1.34 H), 2.44-2.25 (m, 1 H), 2.22-2.08 (m, 1 H), 1.88-1.74 (m, 2 H).
[0369] 2-(4'-Bromopheny1)-5-(N-phthalimidomethyl) tetrahydrofuran (14e): The product (4.6 g, 74%) was obtained as an oil by chromatography on silica; (Rf =
0.69, Et0Ac/Hexane, 40:60, v:v); 1H NMR (CDC13, 300 MHz); a 7.85-7.68 (m, 4 H), 7.45-7.39 (m, 2 H), 7.26-7.14 (in, 2 H), 5.04 (t, J= 6.9 Hz, 0.67 H), 4.84 (t, J= 7.2 Hz, 0.33 H), 4.61 (m, 0.67 H), 4.44 (m, 0.33 H), 3.89 (m, 0.66 H), 3.80 (m, 1.34 H), 2.45-2.37 (m, 1 H), 2.21-2.11 (m, 1 H), 1.88-1.77 (in, 2 H).
[0370] 2-(4'-Methoxypheny1)-5-(N-phthalimidomethyl)tetrahydrofuran (141): The product (0.74 g, 99%) was obtained as an oil by chromatography on silica; (Rf = 0.40, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 300 MHz); 6 7.87-7.67 (m, 4 H), 7.31-7.20 (m, 2 H), 6.87-6.80 (m, 2 H), 5.03 (t, J= 6.9 Hz, 0.67 H), 4.83 (t, J= 7.1 Hz, 0.33 H), 4.60 (m, 0.67 H), 4.43 (m, 0.33 H), 3.88 (m, 0.66 H), 3.79 (m, 1.34 H), 3.76 (s, 3 H), 2.41-2.31 (m, 1 H), 2.26-2.11 (m, 1 H), 1.92-1.75 (m, 2 H).
[0371] 2-(4'4-Butylpheny1)-5-(phthalimidomethyl)tetrahydrofuran (14g): The product (0.52 g, 68%) was obtained as an oil by chromatography on silica; (Rf = 0.52, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 300 MHz); 6 7.86-7.81 (m, 2 H), 7.71-7.67 (m, 2 H), 7.36-7.21 (m, 4 H), 5.06 (t, J= 6.9 Hz, 0.67 H), 4.87 (t, J= 7.1 Hz, 0.33 H), 4.61 (m, 0.67 H), 4.44 (m, 0.33 H), 3.99 (m, 0.33 H), 3.93 (m, 0.67 H), 3.80 (m, 0.33 H), 3.67 (m, 0.67 H), 2.44-2.24 (m, 1 H), 2.42-2.06 (m, 1 H), 1.96-1.78 (m, 2 H) 1.28 (s, 9 H).
[0372] 2-(2'-Naphthyl)-5-(phthalimidomethyl) tetrahydrofuran (14h): The product (0.58 g, 77%) was obtained as an oil by chromatography on silica; (Rf = 0.49, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz); 6 7.87-7.68 (in, 7 H), 7.48-7.37 (m, 4 H), 5.27 (t, J= 6.9 Hz, 0.53 H), 5.08 (t, J= 6.9 Hz, 0.47 H), 4.71 (m, 0.53 H), 4.52 (m, 0.47 H), 3.97 (m, 0.94 H), 3.85 (m, 1.06 H), 2.55-2.33 (m, 1 H), 2.25-2.12 (m, 1 H), 2.02-1.83 (m, 2 H).
[0373] 2-Phenethy1-5-(N-phthlimidomethyl)tetrahydrofuran(144): The product (0.43 g, 95%) was obtained as an oil by chromatography on silica; (Rf = 0.49, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz): 6 7.85 (m, 2 H), 7.71 (m, 2 H), 7.25-7.17 (m, 5 H), 4.39 (m, 0.66 H), 4.27 (m, 0.33 H), 4.05 (m, 0.66 H), 3.88 (m, 0.33 H), 3.86-3.80 (m, 1 H), 3.71 (dd, J= 5.3, 13.6 Hz, 0.33 H), 3.61 (dd, J= 5.2, 13.5 Hz, 0.66 H), 2.72-2.57 (m, 2 H), 2.17-1.53 (m, 4 H).
[0374] 5-(N-Phthalimidomethyl)-2-(3'-pyridinylethyl)tetrahydrofuran (14j): The product (233 mg, 26.5%) was obtained as an oil by chromatography on silica as a mixture of diastereomers, trans:cis = 1.5:1 isomers; (Rf = 0.24, Et0Ac/Hexane, 60:40, v:v); 1H NMR
(CDC13, 500 MHz): 6 8.44 (s, 1 H), 8.41 (m, 1 H), 7.85 (m, 2 H), 7.72 (m, 2 H), 7.50 (m, 1 H), 7.17 (m, 1 H), 4.39 (m, 0.6 H), 4.28 (m, 0.4 H), 4.03 (m, 0.6 H), 3.86 (m, 0.4 H), 3.86-3.80 (111, 1 H), 3.72 (dd, J= 5.2, 13.5 Hz, 0.4 H), 3.62 (dd, J= 4.5, 13.5 Hz, 0.6 H), 2.73-2.58 (m, 2 H), 2.12-2.06 (m, 2 H), 1.80-1.54 (m, 4H).
[0375] 2-(1 '-Naphthethyl)-5-(N-phthlimidomethyl)tetrahydrofuran (14k) The product (230 mg, 65%) was obtained as an oil by chromatography on silica; (Rf = 0.54, Et0Ac/Hexane, 30:70, v:v); 1 H NMR (CDC13, 500 MHz): (58.09-8.01 (m, 1 H), 7.88-7.81 (m, 3 H), 7.74-7.68 (m, 3 H), 7.53-7.31 (m, 4 H), 4.43 (m, 0.65 H), 4.33 (m, 0.35 H), 4.16 (m, 0.65 H), 3.97 (m, 0.35 H), 3.81 (m, 0.7 H), 3.76 (m, 1.3 H), 3.19 (in, 1 H), 3.04 (in, 1 H), 2.17-1.53 (m, 6 H).
[0376] 2-(1 '-Naphthyl)-5-(N-phthlimidomethyl)tetrahydrofuran (141) The product (570 mg, 79%) was obtained as an oil by chromatography on silica; (Rf = 0.53, Et0Ac/Hexane, 30:70, v:v); 1H NMR (300 MHz, CDC13) : (587.86 (m, 4 H), 7.72 (m, 4 H), 7.48 (m, 3 H), 5.86 (t, J= 6.5 Hz, 0.3 H), 5.64 (t, J= 7.1 Hz, 0.7 H), 4.78 (m, 0.3 H), 4.53 (in, 0.7 H), 4.04 (in, 1.4 H), 3.91 (m, 0.6 H), 2.73-2.56 (m, 1 H), 2.25-2.14 (m, 1 H), 2.07-1.78 (m, 2 H).
[0377] Trans-2-(N-phthilimidomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (14m): The product (385 mg, 70%) was obtained as a white solid by chromatography on silica; (Rf = 0.50, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz): (57.85-7.84 (m, 2 H), 7.72-7.70 (m, 2 H), 6.91 (dd, J= 3.1, 9.1 Hz, 1 H), 6.82 (dt, J= 3.1, 9.1 Hz. 1 H), 6.72 (dd, J= 4.7, 9.1 Hz, 1 H), 4.41 (m, 1 H), 4.34 (p, J= 6.7 Hz, 1 H), 3.83 (dd, J= 8.1, 13.5 Hz, 1 H), 3.77 (s, 3 H), 3.62 (dd, J= 5.3 13.5 Hz, 1 H), 2.85 (dd, J= 6.4, 13.7 Hz, 1 H), 2.70 (dd, J= 6.4, 13.7 Hz, 1 H), 2.03 (m, 2 H), 1.64 (in, 2 H).
[0378] Cis-2-(N-phthilimidomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (14n): The product (138 mg, 47%) was obtained as a white solid by chromatography on silica; (Rf = 0.52, Et0Ac/Hexane, 30:70, v:v); 1H NMR (CDC13, 500 MHz): (57.87-7.85 (m, 2 H), 7.71-7.70 (in, 2 H), 6.94 (dd, J= 3.1, 9.1 Hz, 1 H), 6.80 (dt, J= 3.1, 9.1 Hz. 1 H), 6.71 (dd, J= 4.7, 9.1 Hz, 1 H), 4.25 (m, 1 H), 4.11 (p, J= 6.7 Hz, 1 H), 3.84 (dd, J= 8.1, 13.8 Hz, 1 H), 3.75 (s, 3 H), 3.68 (dd, J= 5.2 13.8 Hz, 1 H), 2.84 (d, J= 6.3 Hz, 2 H), 1.98-1.92 (m, 2 H), 1.73-1.67 (m, 2 H).
[0379] Trans-2-(5'-flouro-T-methoxyphenethyl)-5-(phthalimidomethyl)tetrahydrofuran (140): The product (0.70 g, 57%) was obtained as a white solid by chromatography on silica; (Rf = 0.20, Et0Ac/Hexane, 20:80, v:v); 1H NMR
(CDC13, 500 MHz): (57.85-7.84 (m, 2 H), 7.72-7.71 (m, 2 H), 6.86 (dd, J= 3.1, 9.1 Hz, 1 H), 6.80 (dt, J= 3.1, 9.1 Hz. 1 H), 6.71 (dd, J= 4.7, 9.1 Hz, 1 H), 4.38 (m, 1 H), 4.05 (quintet, J
= 6.6 Hz, 1 H), 3.83 (dd, J= 8.0, 13.8 Hz, 1 H), 3.76 (s, 3 H), 3.62 (dd, J =
5.1 13.8 Hz, 1 H), 2.67-2.52 (m, 2 H), 2.11-2.04 (m, 2 H), 1.79-1.54 (m, 4 H).
[0380] Cis-2-(5'-flouro-V-methoxyphenethyl)-5-(phthalimidomethyl)tetrahydrofuran (14p): The product (0.26 g, 63%) was obtained as a white solid by chromatography on silica;
(Rf = 0.20, Et0Ac/Hexane, 20:80, v:v); 1H NMR (CDC13, 500 MHz): .5 7.86-7.85 (m, 2 H), 7.72-7.70 (m, 2 H), 6.86 (dd, J= 3.1, 9.1 Hz, 1 H), 6.81 (dt, J= 3.1, 9.1 Hz.
1 H), 6.71 (dd, J
= 4.7, 9.1 Hz, 1 H), 4.27 (quintet J= 6.1 Hz, 1 H), 3.88 (quintet, J= 6.6 Hz, 1 H), 3.82 (dd, J
= 8.0, 13.8 Hz, 1 H), 3.77 (s, 3 H), 3.72 (dd, J= 5.1 13.8 Hz, 1 H), 2.65-2.58 (m, 2 H), 2.04-1.97 (m, 2 H), 1.83-1.58 (m, 4 H).
[0381] Trans-2-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)-5-(N-phthilimidomethyl) tetrahydrafuran (14q): The product (0.15 g, 62%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 15:85, v:v); 1H NMR
(CDC13, 500 MHz): 6 7.84 (m, 2 H), 7.70 (m, 2 H), 6.84-6.79 (m, 2 H), 6.72 (dd, J = 4.6, 8.6 Hz, 1 H), 4.37 (m, 1 H), 4.05 (m, 1 H), 3.82 (dd, J = 8.3, 13.5 Hz, 1 H), 3.76 (s, 3 H), 3.59 (dd, J= 5.0, 13.5 Hz, 1 H), 2.57 (t, J= 7.1 Hz, 2 H), 2.06 (m, 2 H), 1.68-1.45 (m, 6 H).
[0382] Cis-2-(3'-(2"-methoxy-5"-fluoropheny1)-11-propy1)-5-(N-phthilimidomethy1) tetrahydrafuran (14r): The product (95 mg, 73%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 15:85, v:v); 1H NMR
(CDC13, 500 MHz): 87.84 (m, 2 H), 7.70 (m, 2 H), 6.84-6.80 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.25 (m, 1 H), 3.86 (m, 1 H), 3.81 (dd, J= 8.3, 13.5 Hz, 1 H), 3.77 (s, 3 H), 3.68 (dd, J= 5.0, 13.5 Hz, 1 H), 2.58 (t, J= 7.1 Hz, 2 H), 2.00-1.95 (m, 2 H), 1.74-1.49 (m, 6 H).
[0383] Trans-2-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propy1)-5-(N-phthilimidomethyl) tetrahydrafuran (14s): The product (67 mg, 69%) was obtained as an oil by chromatography on silica; (Rf = 0.15, Et0Ac/Hexane, 20:80, v:v); 1H NMR
(CDC13, 500 MHz): 6 7.84 (m, 2 H), 7.70 (m, 2 H), 6.83-6.79 (m, 2 H), 6.72 (dd, J= 4.3, 8.3 Hz, 1 H), 4.36 (m, 1 H), 4.01 (m, 1 H), 3.81 (dd, J= 8.3, 13.5 Hz, 1 H), 3.77 (s, 3 H), 2.55 (,J= 7.8 Hz, 2 H), 2.07 (m, 2 H), 1.68-1.39 (m, 8 H).
[0384] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (16a) and eis-2-(eyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (16b):
To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (1.23 g, 4.3 mmol), NaI (100 mg), potassium cyanide (0.7 g, 10.6 mmol), and dry DMSO (15 mL). The mixture was heated to 70 C and stirred under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20= 1:1, 80 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The solvent was removed in vacuo and the crude product was purified by flash column chromatography (Rf = 0.2, Et0Ac/Hexane, 20:80, v:v) A very careful analysis and collection of early fractions resulted in the trans isomer (16a, 0.55 g, 55%): 1H NMR (CDC13, 500 MHz): 87.11 (dd, J= 3.1 9.2 Hz, 1 H), 6.89 (dt, J= 3.1, 9.0 Hz, 1 H), 6.76 (dd, J= 4.2, 8.5 Hz, 1 H), 5.33 (t, J= 7.1 Hz, 1 H), 4.49 (p, J= 6.1 Hz, 1 H), 3.79 (s, 3 H), 2.69 (dd, J= 6.1, 16.7 Hz, 1 H), 2.66 (dd, J= 6.1 16.7 Hz, 1 H), 2.57 (m, 1 H), 2.25 (m, 1 H), 1.92 (m, 1 H), 1.77 (m, 1 H); The rest of the fractions were collected and upon removal of the solvent a white colored solid formed. Further purification of this solid by triturating with hexane resulted in the cis isomer (16b, 250 mg, 25%); 6 7.24 (dd, J= 3.1 9.2 Hz, 1 H), 6.90 (dt, J= 3.1, 9.0 Hz, 1 H), 6.76 (dd, J= 4.2, 8.5 Hz, 1 H), 5.14 (t, J= 7.4 Hz, 1 H), 4.28 (p, J= 6.1 Hz, 1 H), 3.80 (s, 3 H), 2.73 (d, J= 5.8 Hz, 1 H), 2.46 (m, 1 H), 2.24 (m, 1 H), 1.83 (m, 1 H), 1.77 (m, 1 H);
[0385] The following compounds were prepared in a similar manner as 16a.
[0386] 2-Cyanomethy1-5-(2'-furanyl)tetrahydrofuran (16c): The product (0.2 g, 43%) was obtained as an oil by chromatography on silica as a mixture of trans:cis =
1:1 isomers;
(Rf= 0.20, Et0Ac/Hexane, 20:80, v:v); 1H NMR (CDC13, 500 MHz): 67.39 (s, 1 H), 6.33-6.25 (m, 2 H), 5.15 (t, J= 6.8 Hz, 0.5 H), 4.98 (t, J= 6.7 Hz, 0.5 H), 4.38 (m, 0.5 H), 4.30 (m, 0.5 H), 2.66 (m, 2 H), 2.38-1.90 (m, 4 H).
[0387] 2-Benzy1-5-cyanomethyltetrahydrofuran (16d): The product (0.33 g, 74%) was obtained as an oil by chromatography on silica as a mixture of the trans:cis =
2:1 isomers; (Rf = 0.50, Et0Ac/Hexane, 25:75, v:v); 1H NMR: (300 MHz,CDC13) 6 7.30-7.18 (m, 5 H), 4.28-4.24 (m, 0.67 H), 4.15-4.08 (m, 1 H), 3.91-3.89 (m, 0.33 H), 2.78-2.53 (m, 4 H), 2.68-2.25 (m, 4 H).
[0388] 2-(Cyanomethyl)-5-(4'-hydroxyphenethyl) tetrahydrofuran (16e): The product (0.34 g, 78%) was obtained as an oil by chromatography on silica; (Rf = 0.31, Et0Ac/Hexane, 50:50, v:v); 1H NMR (500 MHz, CDC13) 6 7.76-7.73 (m, 2 H), 7.05-7.03 (m, 2 H), 5.27 (m, 2 H), 4.27-4.09 (m, 1 H), 4.08-3.88 (m, 1 H), 2.69-2.53 (m, 4 H), 2.13-2.09 (m, 2 H), 1.86-1.57 (m, 4 H).
5.1 13.8 Hz, 1 H), 2.67-2.52 (m, 2 H), 2.11-2.04 (m, 2 H), 1.79-1.54 (m, 4 H).
[0380] Cis-2-(5'-flouro-V-methoxyphenethyl)-5-(phthalimidomethyl)tetrahydrofuran (14p): The product (0.26 g, 63%) was obtained as a white solid by chromatography on silica;
(Rf = 0.20, Et0Ac/Hexane, 20:80, v:v); 1H NMR (CDC13, 500 MHz): .5 7.86-7.85 (m, 2 H), 7.72-7.70 (m, 2 H), 6.86 (dd, J= 3.1, 9.1 Hz, 1 H), 6.81 (dt, J= 3.1, 9.1 Hz.
1 H), 6.71 (dd, J
= 4.7, 9.1 Hz, 1 H), 4.27 (quintet J= 6.1 Hz, 1 H), 3.88 (quintet, J= 6.6 Hz, 1 H), 3.82 (dd, J
= 8.0, 13.8 Hz, 1 H), 3.77 (s, 3 H), 3.72 (dd, J= 5.1 13.8 Hz, 1 H), 2.65-2.58 (m, 2 H), 2.04-1.97 (m, 2 H), 1.83-1.58 (m, 4 H).
[0381] Trans-2-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)-5-(N-phthilimidomethyl) tetrahydrafuran (14q): The product (0.15 g, 62%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 15:85, v:v); 1H NMR
(CDC13, 500 MHz): 6 7.84 (m, 2 H), 7.70 (m, 2 H), 6.84-6.79 (m, 2 H), 6.72 (dd, J = 4.6, 8.6 Hz, 1 H), 4.37 (m, 1 H), 4.05 (m, 1 H), 3.82 (dd, J = 8.3, 13.5 Hz, 1 H), 3.76 (s, 3 H), 3.59 (dd, J= 5.0, 13.5 Hz, 1 H), 2.57 (t, J= 7.1 Hz, 2 H), 2.06 (m, 2 H), 1.68-1.45 (m, 6 H).
[0382] Cis-2-(3'-(2"-methoxy-5"-fluoropheny1)-11-propy1)-5-(N-phthilimidomethy1) tetrahydrafuran (14r): The product (95 mg, 73%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 15:85, v:v); 1H NMR
(CDC13, 500 MHz): 87.84 (m, 2 H), 7.70 (m, 2 H), 6.84-6.80 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.25 (m, 1 H), 3.86 (m, 1 H), 3.81 (dd, J= 8.3, 13.5 Hz, 1 H), 3.77 (s, 3 H), 3.68 (dd, J= 5.0, 13.5 Hz, 1 H), 2.58 (t, J= 7.1 Hz, 2 H), 2.00-1.95 (m, 2 H), 1.74-1.49 (m, 6 H).
[0383] Trans-2-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propy1)-5-(N-phthilimidomethyl) tetrahydrafuran (14s): The product (67 mg, 69%) was obtained as an oil by chromatography on silica; (Rf = 0.15, Et0Ac/Hexane, 20:80, v:v); 1H NMR
(CDC13, 500 MHz): 6 7.84 (m, 2 H), 7.70 (m, 2 H), 6.83-6.79 (m, 2 H), 6.72 (dd, J= 4.3, 8.3 Hz, 1 H), 4.36 (m, 1 H), 4.01 (m, 1 H), 3.81 (dd, J= 8.3, 13.5 Hz, 1 H), 3.77 (s, 3 H), 2.55 (,J= 7.8 Hz, 2 H), 2.07 (m, 2 H), 1.68-1.39 (m, 8 H).
[0384] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (16a) and eis-2-(eyanomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (16b):
To a vial under Ar was added 2-(bromomethyl)-5-(2'-methoxy-5'-fluorophenyl)tetrahydrafuran (1.23 g, 4.3 mmol), NaI (100 mg), potassium cyanide (0.7 g, 10.6 mmol), and dry DMSO (15 mL). The mixture was heated to 70 C and stirred under Ar for 12 h. After it was cooled to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3: H20= 1:1, 80 mL). The organics were extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The solvent was removed in vacuo and the crude product was purified by flash column chromatography (Rf = 0.2, Et0Ac/Hexane, 20:80, v:v) A very careful analysis and collection of early fractions resulted in the trans isomer (16a, 0.55 g, 55%): 1H NMR (CDC13, 500 MHz): 87.11 (dd, J= 3.1 9.2 Hz, 1 H), 6.89 (dt, J= 3.1, 9.0 Hz, 1 H), 6.76 (dd, J= 4.2, 8.5 Hz, 1 H), 5.33 (t, J= 7.1 Hz, 1 H), 4.49 (p, J= 6.1 Hz, 1 H), 3.79 (s, 3 H), 2.69 (dd, J= 6.1, 16.7 Hz, 1 H), 2.66 (dd, J= 6.1 16.7 Hz, 1 H), 2.57 (m, 1 H), 2.25 (m, 1 H), 1.92 (m, 1 H), 1.77 (m, 1 H); The rest of the fractions were collected and upon removal of the solvent a white colored solid formed. Further purification of this solid by triturating with hexane resulted in the cis isomer (16b, 250 mg, 25%); 6 7.24 (dd, J= 3.1 9.2 Hz, 1 H), 6.90 (dt, J= 3.1, 9.0 Hz, 1 H), 6.76 (dd, J= 4.2, 8.5 Hz, 1 H), 5.14 (t, J= 7.4 Hz, 1 H), 4.28 (p, J= 6.1 Hz, 1 H), 3.80 (s, 3 H), 2.73 (d, J= 5.8 Hz, 1 H), 2.46 (m, 1 H), 2.24 (m, 1 H), 1.83 (m, 1 H), 1.77 (m, 1 H);
[0385] The following compounds were prepared in a similar manner as 16a.
[0386] 2-Cyanomethy1-5-(2'-furanyl)tetrahydrofuran (16c): The product (0.2 g, 43%) was obtained as an oil by chromatography on silica as a mixture of trans:cis =
1:1 isomers;
(Rf= 0.20, Et0Ac/Hexane, 20:80, v:v); 1H NMR (CDC13, 500 MHz): 67.39 (s, 1 H), 6.33-6.25 (m, 2 H), 5.15 (t, J= 6.8 Hz, 0.5 H), 4.98 (t, J= 6.7 Hz, 0.5 H), 4.38 (m, 0.5 H), 4.30 (m, 0.5 H), 2.66 (m, 2 H), 2.38-1.90 (m, 4 H).
[0387] 2-Benzy1-5-cyanomethyltetrahydrofuran (16d): The product (0.33 g, 74%) was obtained as an oil by chromatography on silica as a mixture of the trans:cis =
2:1 isomers; (Rf = 0.50, Et0Ac/Hexane, 25:75, v:v); 1H NMR: (300 MHz,CDC13) 6 7.30-7.18 (m, 5 H), 4.28-4.24 (m, 0.67 H), 4.15-4.08 (m, 1 H), 3.91-3.89 (m, 0.33 H), 2.78-2.53 (m, 4 H), 2.68-2.25 (m, 4 H).
[0388] 2-(Cyanomethyl)-5-(4'-hydroxyphenethyl) tetrahydrofuran (16e): The product (0.34 g, 78%) was obtained as an oil by chromatography on silica; (Rf = 0.31, Et0Ac/Hexane, 50:50, v:v); 1H NMR (500 MHz, CDC13) 6 7.76-7.73 (m, 2 H), 7.05-7.03 (m, 2 H), 5.27 (m, 2 H), 4.27-4.09 (m, 1 H), 4.08-3.88 (m, 1 H), 2.69-2.53 (m, 4 H), 2.13-2.09 (m, 2 H), 1.86-1.57 (m, 4 H).
[0389] 2-Cyanomethy1-5-(2'-methoxy-l'-naphthethyptetrahydrofuran (16f): The product (0.43 g, 56%) was obtained as an oil by chromatography on silica; (Rf = 0.31, Et0Ac/Hexane, 25:75, v:v); 1H NMR: (500 MHz,CDC13) 6 8.0-7.27 (m, 6 H), 4.31 (m, 0.5 H), 4.18 (m, 0.5 H), 4.01 (m, 0.5 H), 3.95 (s, 3 H), 3.72 (m, 0.5 H), 3.22-3.08 (m, 2 H), 2.64-2.55 (m, 1 H), 2.24-2.16 (m, 2 H), 1.91-1.65 (m, 3 H), 1.58 (bs, 1 H), 1.24 (t, J= 7.1 Hz, 1 H).
[0390] 2-Cyanomethy1-5-(4'-methoxy-1y-naphthethyptetrahydrofuran (16g): The product (0.31 g, 45%) was obtained as an oil by chromatography on silica; TLC
(Si02) Rf =
0.30, 25% Et0Ac/Hexanes; 1H NMR: (300 MHz,CDC13) (58.1-7.27 (in, 6 H), 4.40 -4.24 (m, 1 H), 4.21-4.03 (m, 1 H), 3.99 (s, 3 H), 3.15 (m, 2 H), 2.64-1.24 (m, 8 H).
[0391] 2-Cyanomethy1-5-(4'-flouro-3'-methylphenethyl)tetrahydrofuran (16h):
The product (0.22 g, 85%) was obtained as an oil by chromatography on silica; (Rf = 0.25, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) (57.00-6.88 (m, 3 H), 4.28-3.87 (m, 2 H), 2.70-2.56 (m, 4 H), 2.24 (s, 3 H), 2.23-1.58 (m, 6 H).
[0392] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (161) and cis-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (16j):
The product was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); trans isomer (161, 170 mg, 27%): 1H NMR (CDC13, 500 MHz): (56.89 (dt, J=
3.1, 9.0 Hz, 1 H), 6.86 (dd, J= 3.1 9.2 Hz, 1 H), 6.76 (dd, J= 4.2, 8.5 Hz, 1 H), 4.38 (p, J=
6.8 Hz, 1 H), 4.27 (p, J= 6.1 Hz, 1 H), 3.79 (s, 3 H), 2.90 (dd, J= 6.3, 13.5 Hz, 1 H), 2.72 (dd, J= 6.5 13.5 Hz, 1 H), 2.58 (m, 2 H), 2.19 (m, 1 H), 2.06 (m, 1 H), 1.77 (m, 1 H), 1.68 (m, 1 H); cis isomer (16j, 77 mg, 12%); (56.90 (dd, J= 3.1 9.2 Hz, 1 H), 6.83 (dt, J= 3.1, 9.0 Hz, 1 H), 6.71 (dd, J= 4.2, 8.5 Hz, 1 H), 4.14 (p, J= 6.8 Hz, 1 H), 4.10 (p, J= 6.1 Hz, 1 H), 3.75 (s, 3 H), 2.87 (dd, J= 6.5, 13.5 Hz, 1 H), 2.78 (dd, J= 6.2 13.5 Hz, 1 H), 2.52 (m, 2 H), 2.06 (m, 1 H), 1.92 (m, 1 H), 1.76-1.69 (m, 2 H).
[0393] Trans-2-Cyanomethy1-5-(5'-flouro-2-methoxyphenethyl)tetrahydrofuran (16k):
The product (0.45 g, 86%) was obtained as an oil by chromatography on silica;
(Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1H NMR (500 MHz, CDC13) (56.87-6.82 (m, 2 H), 6.74 (dd, J=
4.3, 8.5 Hz, 1 H), 4.26 (quintet, J= 6.2 Hz, 1 H), 4.09 (m, 1 H), 3.79 (s, 3 H), 2.72-2.53 (m, 4 H), 2.22-2.04 (m, 2 H), 1.84-1.60 (in, 4 H).
[0394] Cis-2-Cyanomethy1-5-(5'-flouro-2-methoxyphenethyl)tetrahydrofuran (161):
The product (0.20 g, 80%) was obtained as an oil by chromatography on silica;
(Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1H NMR (500 MHz, CDC13) (56.88-6.82 (m, 2 H), 6.74 (dd, J=
4.3, 8.5 Hz, 1 H), 4.26 (quintet, J= 6.1 Hz, 1 H), 3.90 (quintet, J= 6.7 Hz, 1 H), 3.79 (s, 3 H), 2.73 (m, 1 H), 2.59 (t, J= 5.2 Hz, 2 H), 2.53 (in, 1 H), 2.14-2.02 (m, 2 H), 1.89-1.57 (m, 4H).
[0395] Trans-2-Cyanomethy1-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydra furan: The product (71 mg, 85%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): (56.84-6.81 (m, 2 H), 6.73 (dd, J= 4.2, 8.5 Hz, 1 H), 4.22 (p, J= 6.8 Hz, 1 H), 4.09 (m, 1 H), 3.79 (s, 3 H), 2.62-2.52 (m, 411), 2.18 (m, 1 H), 2.12 (m, 1 H), 1.78 (m, 1 H), 1.69-1.46 (m, 3 H).
[0396] Cis-2-Cyanomethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyfltetrahydrafuran (16n, 22 mg, 18%): The product (22 mg, 18%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1 H
NMR (CDC13, 500 MHz): (56.86-6.81 (in, 2 H), 6.73 (dd, J= 4.2, 8.5 Hz, 1 H), 4.11 (m, 1 H), 3.90 (m, 1 H), 3.79 (s, 3 H), 2.62-2.55 (m, 4 H), 2.10 (m, 1 H), 2.01 (m, 1 H), 1.78 (m, 1 H), 1.69-1.46 (in, 3 H).
[0397] 2-Cyanomethy1-5-(4'-(2"-methoxy-5"-fluoropheny1)-1`-butyl)tetrahydrafuran (160): The product (40 mg, 33%) was obtained as an oil by chromatography on silica; (Rf =
0.12, Et0Ac/Hexane, 15:85, v:v); 1H NMR (CDC13, 500 MHz): (56.84-6.80 (m, 2 H), 6.74 (dd, J= 4.2, 8.5 Hz, 1 H), 4.22 (quintet, J= 6.4 Hz, 0.5 H), 4.11 (quintet, J=
6.2 Hz, 0.5 H), 4.07 (m, 0.5 H), 3.87 (quintet, J= 6.6 Hz, 0.5 H), 3.78 (s, 3 H), 2.61-2.55 (in, 4 H), 2.21-1.95 (m, 2 H), 2.01 (m, 1 H), 1.77 (m, 1 H), 1.66-1.34 (m, 6 H).
[0398] 2-Aminomethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (18a): To a vial under Ar was added 2-(N-phthalimidomethyl)-5-(T-methoxy-5'-fluorophenyl)tetrahydrafuran (225 mg, 0.63 mmol), hydrazine hydrate (150 mg, 4.9 mmol), and methanol (10 mL). The mixture was stirred at room temperature for 12 h.
The solvent was then removed in vacuo and the crude product was purified by column flash chromatography to yield the pure product (Rf = 0.10, Methanol/DCM, 10:90, v:v) (90 mg, 60%, trans : cis = 3:2) as a viscous oil; 1 H NMR (CDC13, 500 MHz): (57.19 (m 1 H), 6.87(m 1 H), 6.75(m 1 H), 5.20 (t, J= 7.1 Hz, 0.58 H),), 5.11 (t, J= 7.1 Hz, 0.4211), 4.24 (in, 0.58 H), 4.04 (in, 0.42 H), 2.93-2.78 (m, 2 H), 2.41 (m, 1 H), 2.03 (m, 1 H), 1.79 (s, 2 H), 1.75-1.63 (m, 2 H); HRMS (ESI) [M+Hr in/z cacld for Ci2HI7FN02 226.1243, found 226.1255;
[0390] 2-Cyanomethy1-5-(4'-methoxy-1y-naphthethyptetrahydrofuran (16g): The product (0.31 g, 45%) was obtained as an oil by chromatography on silica; TLC
(Si02) Rf =
0.30, 25% Et0Ac/Hexanes; 1H NMR: (300 MHz,CDC13) (58.1-7.27 (in, 6 H), 4.40 -4.24 (m, 1 H), 4.21-4.03 (m, 1 H), 3.99 (s, 3 H), 3.15 (m, 2 H), 2.64-1.24 (m, 8 H).
[0391] 2-Cyanomethy1-5-(4'-flouro-3'-methylphenethyl)tetrahydrofuran (16h):
The product (0.22 g, 85%) was obtained as an oil by chromatography on silica; (Rf = 0.25, Et0Ac/Hexane, 20:80, v:v); 1H NMR (500 MHz, CDC13) (57.00-6.88 (m, 3 H), 4.28-3.87 (m, 2 H), 2.70-2.56 (m, 4 H), 2.24 (s, 3 H), 2.23-1.58 (m, 6 H).
[0392] Trans-2-(Cyanomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (161) and cis-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrafuran (16j):
The product was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); trans isomer (161, 170 mg, 27%): 1H NMR (CDC13, 500 MHz): (56.89 (dt, J=
3.1, 9.0 Hz, 1 H), 6.86 (dd, J= 3.1 9.2 Hz, 1 H), 6.76 (dd, J= 4.2, 8.5 Hz, 1 H), 4.38 (p, J=
6.8 Hz, 1 H), 4.27 (p, J= 6.1 Hz, 1 H), 3.79 (s, 3 H), 2.90 (dd, J= 6.3, 13.5 Hz, 1 H), 2.72 (dd, J= 6.5 13.5 Hz, 1 H), 2.58 (m, 2 H), 2.19 (m, 1 H), 2.06 (m, 1 H), 1.77 (m, 1 H), 1.68 (m, 1 H); cis isomer (16j, 77 mg, 12%); (56.90 (dd, J= 3.1 9.2 Hz, 1 H), 6.83 (dt, J= 3.1, 9.0 Hz, 1 H), 6.71 (dd, J= 4.2, 8.5 Hz, 1 H), 4.14 (p, J= 6.8 Hz, 1 H), 4.10 (p, J= 6.1 Hz, 1 H), 3.75 (s, 3 H), 2.87 (dd, J= 6.5, 13.5 Hz, 1 H), 2.78 (dd, J= 6.2 13.5 Hz, 1 H), 2.52 (m, 2 H), 2.06 (m, 1 H), 1.92 (m, 1 H), 1.76-1.69 (m, 2 H).
[0393] Trans-2-Cyanomethy1-5-(5'-flouro-2-methoxyphenethyl)tetrahydrofuran (16k):
The product (0.45 g, 86%) was obtained as an oil by chromatography on silica;
(Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1H NMR (500 MHz, CDC13) (56.87-6.82 (m, 2 H), 6.74 (dd, J=
4.3, 8.5 Hz, 1 H), 4.26 (quintet, J= 6.2 Hz, 1 H), 4.09 (m, 1 H), 3.79 (s, 3 H), 2.72-2.53 (m, 4 H), 2.22-2.04 (m, 2 H), 1.84-1.60 (in, 4 H).
[0394] Cis-2-Cyanomethy1-5-(5'-flouro-2-methoxyphenethyl)tetrahydrofuran (161):
The product (0.20 g, 80%) was obtained as an oil by chromatography on silica;
(Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1H NMR (500 MHz, CDC13) (56.88-6.82 (m, 2 H), 6.74 (dd, J=
4.3, 8.5 Hz, 1 H), 4.26 (quintet, J= 6.1 Hz, 1 H), 3.90 (quintet, J= 6.7 Hz, 1 H), 3.79 (s, 3 H), 2.73 (m, 1 H), 2.59 (t, J= 5.2 Hz, 2 H), 2.53 (in, 1 H), 2.14-2.02 (m, 2 H), 1.89-1.57 (m, 4H).
[0395] Trans-2-Cyanomethy1-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydra furan: The product (71 mg, 85%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Et0Ac/Hexane, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): (56.84-6.81 (m, 2 H), 6.73 (dd, J= 4.2, 8.5 Hz, 1 H), 4.22 (p, J= 6.8 Hz, 1 H), 4.09 (m, 1 H), 3.79 (s, 3 H), 2.62-2.52 (m, 411), 2.18 (m, 1 H), 2.12 (m, 1 H), 1.78 (m, 1 H), 1.69-1.46 (m, 3 H).
[0396] Cis-2-Cyanomethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyfltetrahydrafuran (16n, 22 mg, 18%): The product (22 mg, 18%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Et0Ac/Hexane, 10:90, v:v); 1 H
NMR (CDC13, 500 MHz): (56.86-6.81 (in, 2 H), 6.73 (dd, J= 4.2, 8.5 Hz, 1 H), 4.11 (m, 1 H), 3.90 (m, 1 H), 3.79 (s, 3 H), 2.62-2.55 (m, 4 H), 2.10 (m, 1 H), 2.01 (m, 1 H), 1.78 (m, 1 H), 1.69-1.46 (in, 3 H).
[0397] 2-Cyanomethy1-5-(4'-(2"-methoxy-5"-fluoropheny1)-1`-butyl)tetrahydrafuran (160): The product (40 mg, 33%) was obtained as an oil by chromatography on silica; (Rf =
0.12, Et0Ac/Hexane, 15:85, v:v); 1H NMR (CDC13, 500 MHz): (56.84-6.80 (m, 2 H), 6.74 (dd, J= 4.2, 8.5 Hz, 1 H), 4.22 (quintet, J= 6.4 Hz, 0.5 H), 4.11 (quintet, J=
6.2 Hz, 0.5 H), 4.07 (m, 0.5 H), 3.87 (quintet, J= 6.6 Hz, 0.5 H), 3.78 (s, 3 H), 2.61-2.55 (in, 4 H), 2.21-1.95 (m, 2 H), 2.01 (m, 1 H), 1.77 (m, 1 H), 1.66-1.34 (m, 6 H).
[0398] 2-Aminomethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (18a): To a vial under Ar was added 2-(N-phthalimidomethyl)-5-(T-methoxy-5'-fluorophenyl)tetrahydrafuran (225 mg, 0.63 mmol), hydrazine hydrate (150 mg, 4.9 mmol), and methanol (10 mL). The mixture was stirred at room temperature for 12 h.
The solvent was then removed in vacuo and the crude product was purified by column flash chromatography to yield the pure product (Rf = 0.10, Methanol/DCM, 10:90, v:v) (90 mg, 60%, trans : cis = 3:2) as a viscous oil; 1 H NMR (CDC13, 500 MHz): (57.19 (m 1 H), 6.87(m 1 H), 6.75(m 1 H), 5.20 (t, J= 7.1 Hz, 0.58 H),), 5.11 (t, J= 7.1 Hz, 0.4211), 4.24 (in, 0.58 H), 4.04 (in, 0.42 H), 2.93-2.78 (m, 2 H), 2.41 (m, 1 H), 2.03 (m, 1 H), 1.79 (s, 2 H), 1.75-1.63 (m, 2 H); HRMS (ESI) [M+Hr in/z cacld for Ci2HI7FN02 226.1243, found 226.1255;
HPLC > 96% (tR = 4.30 min, 40(A):55(B):5(C):0.01(D); tR = 5.04 min, 20(A):75(B):5(C):0.01(D)).
[0399] The following compounds were prepared in a similar manner as 18a.
[0400] 2-Aminomethy1-5-phenyltetrahydrofuran (15b): The product (33 mg, 65%) was obtained as an oil by chromatography on silica; (Rf= 0.11, Methanol/DCM, 10:90, v:v); 1H
NMR:(CDC13, 500 MHz): 6 7.33 (m, 5 H), 4.97 (m, 0.66 H), 4.90 (t, J= 7.7 Hz, 0.34 H), 4.25 (m, 0.66 H), 4.06 (m, 0.34 H), 2.93-2.78 (m, 2 H), 2.35 (m, 1 H), 2.09 (m, 1 H), 1.96-1.70( m, 2 H), 1.62 (bs, 2 H); LRMS (ESI) [M+H] m/z cacld for CiiHBNO 178 found 178.
[0401] 2-(Aminomethyl)-5-(2'-naphthyptetrahydrofuran (15e): The product (27 mg, 66%) was obtained as an oil by chromatography on silica; (Rf= 0.14, Methanol/DCM, 15:85, v:v); 1H NMR (500 MHz, CDC13) 6 7.84-7.78 (m, 4H), 7.47-7.41 (m, 3 H), 5.14 (t, J= 7.2 Hz, 0.33 H), 5.04 (t, J= 7.4 Hz, 0.67 H), 4.38-4.33 (m, 0.33 H), 4.16-4.14 (m, 0.66 H), 3.01-2.83 (m, 2 H), 2.60 (bs, 2 H), 2.42-2.34 (in, 1 H), 2.16-2.07 (m, 1 H), 1.97-1.86 (m, 1 H), 1.79-1.72 (1 H); LRMS (ESI) [M+H] ni/z cacld for C15I-117N0 228 found 228.
[0402] 2-(Aminomethyl)-5-phenethyltetrahydrofuran (15d): The product (23 mg, 55%) was obtained as an oil by chromatography on silica; (Rf= 0.12, Methanol/DCM, 15:85, v:v);
1H NMR (500 MHz, CDC13) 6 7.27-7.19 (m, 5 H), 4.01-3.85 (m, 2 H), 2.83-2.62 (m, 4 H), 2.03-1.50 (m, 8 H); LRMS (ESI) [M+Hr m/z cacld for C13Hi9N0 206 found 206.
[0403] 2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran (15a): The product (43 mg, 52%) was obtained as an oil by chromatography on silica; (Rf= 0.13, Methanol/DCM, 15:85, v:v); 1 HNMR (500 MHz, CDC13) 6 8.08-8.06 (m, 1 H), 7.85 (d, J= 7.6 Hz, 1 H), 7.71 (d, J.= 7.6 Hz, 1 H), 7.52-7.45 (m, 2 H), 7.39 (t, J= 7.6 Hz, 1 H), 7.35 (d, J= 6.8 Hz, 1 H), 4.05-3.90 (m, 2 H), 3.25 (m, 1 H), 3.11 (m, 1 H), 2.86-2.70 (m, 2 H), 2.07-1.89 (m, 4 H), 1.63-1.55 (m, 2 H), 1.48 (bs, 2 H); LRMS (ESI) [M+H] m/z cacld for C17H2iN0 256 found 256.
[0404] 2-(Aminornethyl)-5-(1.'-naphthyl)tetrahydrofuran (15e): The product (39 g, 85%) was obtained as an oil by chromatography on silica; (Rf= 0.13, Methanol/DCM, 15:85, v:v); 1H NMR (500 MHz, CDC13) 6 7.96-7.93 (in, 1 H), 7.89-7.85 (1 H), 7.76-7.74 (m, 1 H), 7.71-7.69 (m, 1 H), 7.63 (d, J= 7.1 Hz, 1 H), 7.50-7.43 (m, 3 H), 5.74 (t, J=
7.0 Hz, 0.33 H), 5.61 (t, J= 7.3 Hz, 0.67 H), 4.38-4.28 (m, 0.33 H), 4.19-4.16 (m, 0.67 H), 3.02-2.88 (m, 1 H), 2.62-2.52 (m, 1 H), 2.15 (bs, 2 H), 2.14-1.71 (m, 3 H); LRMS (ESI) [M+Hr nilz cacld for C15K3N0 228 found 228.
[0405] 2-Aminomethy1-5-(p-chlorophenyltetrahydrofuran (15f): The product (16 mg, 71%) was obtained as an oil by chromatography on silica; (Rf = 0.14, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (57.34-7.27 (m, 4 H), 4.95 (t, J= 6.9 Hz, 0.66 H), 4.83 (t, J= 6.7 Hz, 0.34 H), 4.35 (in, 0.66 H), 4.15 (m, 0.34 H), 3.40 (bs, 2 H), 2.99-2.81 (in, 2 H), 2.32 (m, 1 H), 2.08 (m, 1 H), 1.84-1.68 (in, 2 H); LRMS (ESI) [M+H]+ m/z cacld for CI IHNC1NO 212 found 212.
[0406] 2-Aminomethy1-5-(p-bromophenyltetrahydrofuran (15g): The product (16 mg, 48%) was obtained as an oil by chromatography on silica; (Rf = 0.13, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (57.42-7.20 (m, 4 H), 4.95 (t, J= 6.9 Hz, 0.66 H), 4.86 (t, J= 6.7 Hz, 0.34 H), 4.26 (m, 0.66 H), 4.08 (m, 0.34 H), 2.83-2.79 (m, 2 H), 2.38-1.71 (m, 6 H); LRMS (EST) [M+H] m/z cacld for C11H14BrNO 256 found 256.
[0407] 2-Aminomethy1-5-pentafluorophenethyltetrahydrofuran (15h): The product (30 mg, 53%) was obtained as an oil by chromatography on silica; (Rf =0.14, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (54.05 (in, 0.60 H), 3.92 (m, 1 H), 3.86 (m, 0.40 H), 2.89-2.70 (m, 2 H), 2.74 (m, 2 H), 2.63 (bs, 2 H), 2.08-1.99 (m, 2 H), 1.82-1.54 (m, 4 H); LRMS (ESI) [M+1-1]+ m/z cacld for C13H14F5N0 296 found 296.
[0408] 2-(Aminomethyl)-5-(3'-pyridinylethyl)tetrahydrofuran (151): The product (12 mg, 35%) was obtained as an oil by chromatography on silica; (Rf = 0.09, Methanol/DCM, 15:85, v:v); 1 HNMR (500 MHz, CDC13) 6 8.46 (s, 1 H), 8.42 (d, J= 4.1 Hz, 1 H), 7.51 (m, 1 H), 7.19 (dd, J= 4.8, 7.7 Hz, 1 H), 4.02-3.83 (m, 2 H), 2.82-2.63 (m, 4 H), 2.07-1.53 (m, 8 H); LRMS (ESI) [M+H] m/z cacld for C12H18N20 207 found 207.
[0409] 2-Aminomethy1-5-(p-methoxypheny)ltetrahydrofuran (15j): The product (18 mg, 55%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (57.27 (m, 2 H), 6.87 (m, 2 H), 4.92 (m, 0.66 H), 4.83 (t, J= 6.7 Hz, 0.34 H), 4.26 (m, 0.66 H), 4.07 (m, 0.34 H), 3.79 (s, 1 H), 3.78 (s, 2 H), 2.92-2.78 (m, 2 H), 2.57 (bs, 2 H), 2.29 (m, 1 H), 2.10, m, 1 H), 1.88-1.69 (m, 2 H); LRMS
(ESI) [M+H]+ m/z cacld for C12H17NO2 208 found 208.
[0410] 2-Arninomethy1-5-(p-t-buty1pheny1)tetrahydrofuran (15k): The product (21 mg, 54%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz): 7.36-7.24 (m, 4 H), 4.96 (m, 0.66 H), 4.86 (m, 0.34 H), 4.46 (bs, 2 H), 4.34 (m, 0.66 H), 4.13 (m, 0.34 H), 3.00-2.80 (m, 2 H), 2.29 (m, 1 H), 2.10 (m, 1 H), 1.97-1.68 (m, 2 H), 1.30 (s, 9 H); LRMS (ESI) [M+Hr m/z cacld for Ci5H23N0 234 found 234.
[0411] Trans-2-aminomethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (18a):
The product (41 mg, 30%, trans : cis = 0.95:0.05) was obtained as an oil by chromatography on silica; (Rf= 0.08, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz):
87.18 (dd, J
= 3.1, 9.4 Hz, 1 H), 6.87(dt, J= 3.1, 8.5 Hz. 1 H), 6.75(dd, J= 4.2, 9.1 Hz, 1 H), 5.20 (t, J=
7.1 Hz, 1 H),), 4.24 (m, 1 H), 2.82 (m, 2 H), 2.44 (m, 1 H), 2.04 (m, 1 H), 1.71-1.69 (m, 2 H), 1.67 (s, 2 H); HRMS (ESI) [M+11]+ m/z cacld for C121117FN02 226.1243, found 226.1257; HPLC > 96% (tR = 4.30 min, 40(A):55(B):5(C):0.01(D); tR = 5.04 mm, 20(A):75(B):5(C):0.01(D)).
[0412] Trans-2-aminomethy1-5-(2'-methoxy-5'-fluorophenylmethyfltetrahydrofuran (18e): The product (54 mg, 60%) was obtained as an oil by chromatography on silica; (Rf=
0.10, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): 86.93 (dd, J= 3.1, 8.8 Hz, 1 H), 6.86 (dt, J= 3.1, 8.8 Hz, 1 H), 6.75 (dd, J= 3.1, 8.8 Hz, 1 H), 4.23 (m, 1 H), ), 4.08 (m 1 H), 3.79 (s, 3 H), 2.91 (dd, J= 13.5, 6.5 Hz, 2 H), 2.78 (m, 1 H), 2.72 (m, 1 H), 2.18 (bs, 2 H), 2.02-1.92 (m, 2 H), 1.64- 1.55 (m, 2 H); HRMS (EST) [M+111+ m/z cacld for C13H0FN02 240.1400, found 240.1423; HPLC > 98% (tR = 4.68 mm, 40(A):55(B):5(C):0.01(D); tR = 5.04 mm, 20(A):75(B):5(C):0.01(D)).
[0413] Cis-2-aminomethy1-5-(2'-methoxy-5'-fluorophenylmethyfltetrahydrofuran (181): The product (26 mg, 73%) was obtained as an oil by chromatography on silica; (Rf =
0.09, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): 6 6.93 (dd, J= 3.1, 8.8 Hz, 1 H), 6.86 (dt, J= 3.1, 8.8 Hz, 1 H), 6.77 (dd, J= 3.1, 8.8 Hz, 1 H), 4.15 (m, 1 H),), 3.97 (m 1 H), 3.79 (s, 3 H), 2.91 (dd, J= 13.5, 6.6 Hz, 2 H), 2.76 (dd, J= 13.5, 6.6 Hz, 2 H), 2.43 (bs, 2 H), 1.93 (m, 2 H), 1.63 (m, 2 H); HRMS (ESI) [M+11]+ m/z cacld for Ci3HDFN02 240.1400, found 240.1423; HPLC > 98% (tR = 4.69 min, 40(A):55(B):5(C):0.01(D); tR = 5.06 min, 20(A):75(B):5(C):0.01(D)).
[0414] Trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (181) The product (197 mg, 85%) was obtained as an oil by chromatography on silica; (Rf=
0.09, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): 6 6.87 (dt, J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.74 (dd, J= 4.3, 8.5 Hz, 1 H), 4.01 (m, 1 H), 3.93 (quintet, J= 6.8 Hz, 1 H), 3.78 (s, 3 H), 2.76-2.67 (m, 3 H), 2.60 (m, 1 H), 2.06-1.99 (m, 2 H), 1.84 (m, 1 H), 1.78 (bs, 2 H), 1.70 (m, 1 H), 1.59-1.54 (m, 2 H); HRMS
(EST) [M+H]
m/z cacld for Ci4H21FN02 254.1556, found 254.1573; HPLC > 98% (tR = 4.48 min, 40(A):55(B):5(C):0.01(D); tR = 5.76 min, 20(A):75(B):5(C):0.01(D)).
[0415] Cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran 18j):
The product (125 mg, 73%) was obtained as an oil by chromatography on silica;
(Rf= 0.10, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): a 6.87 (dt,J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.72 (dd, J= 4.3, 8.5 Hz, 1 H), 3.91-3.87 (m, 2 H), 3.79 (s, 3 H), 2.83-2.57 (m, 4 H), 2.00-1.52 (m, 6 H) 1.84 (bs, 2 H); HRMS (EST) [M+H]
m/z cacld for Ci4H2iFNO2 254.1556, found 254.1551; HPLC > 98% (tR = 4.50 min, 40(A):55(B):5(C):0.01(D); tR = 5.81 min, 20(A):75(B):5(C):0.01(D)).
[0416] Trans-2-aminomethy1-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran (18m): The product (42 mg, 87%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): 6 6.86-6.80 (m, 2 H), 6.74 (dd, J= 4.7, 8.8 Hz, 1 H), 4.01 (p, J= 6.2 Hz, 1 H), 3.93 (p, J= 7.2 Hz, 1 H), 3.78 (s, 3 H), 2.85-2.67 (m, 2 H), 2.60 (t, J= 7.2 Hz, 2 H), 2.34 (bs, 2 H), 2.03-1.98 (m, 2 H), 1.68-1.46 (m, 6 H); HRMS (ESI) [M+Hr m/z cacld for Ci5H23FN02 268.1713, found 268.1709; HPLC > 95% (tR = 4.70 min, 40(A):55(B):5(C):0.01(D);
tR = 5.10 min, 10(A):85(B):5(C):0.01(D)).
[0417] Cis-2-aminomethy1-5-(3'-(2"-methoxy-5"-fluorophenyl)-3'-propyl)tetrahydrofuran (18n): The product (42 mg, 87%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): 6 6.85 (dd, J= 3.0, 9.6, Hz, 1 H), 6.82 (dd, J= 3.0, 8.3 Hz, 1 H), 6.73 (dd, J= 4.7, 8.9 Hz, 1 H), 3.94 (m, 1 H), 3.85 (m, 1 H), 3.78 (s, 3 H), 3.00-2.60 (m, 4 H), 2.60 (t, J= 7.2 Hz, 2 H),1.98-1.92 (m, 2 H), 1.68-1.46 (m, 6 H); HRMS (ESI) [M+Hr nilz cacld for 268.1713, found 268.1702; HPLC > 98% (tR = 4.71 min, 40(A):55(B):5(C):0.01(D);
tR = 5.10 min, 10(A):85(B):5(C):0.01(D)).
[0418] Trans -2-Aminomethy1-5-(5"-fluoro-2"-methoxypheny1-4'-butyl)tetrahydrofuran (18q): The product (33 mg, 95%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): 6 6.85-6.80 (m, 2 H), 6.72 (dd, J - 4.7, 8.9 Hz, 1 H), 4.02 (m, 1 H), 3.92 (m, 1 H), 3.78 (s, 3 H), 2.90-2.70 (bm, 2 H), 2.58 (t, J= 7.6 Hz, 2 H), 2.32 (bs, 2 H), 2.02 (m, 1 H), 1.64-1.35 (m, 9 H); MS: 282 (MH+), 264, 139; HRMS (EST) [M+Hr m/z cacld for Ci6H25FN02 282.2869, found 282.1889; HPLC > 98% (tR = 4.83 mm, 40(A):55(B):5(C):0.01(D); tR = 5.17 min, 10(A):85(B):5(C):0.01(D)).
[0419] Trans-2-aminoethy1-5-(2'-methoxy-5'-fluorophenyfltetrahydrofuran (18c):
To a vial under Ar was added Raney Ni that was washed with ethanol (200 proof, 3 times) and trans-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrafuran (80 mg, 0.35 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated to boiling and purged with H2 three times. A balloon filled with H2 was attached to the flask and the reaction was stirred for 48 h at room temperature. The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (Rf= 0.10, Methanol/DCM, 10:90, v:v) to result in the pure product (43.7 mg, 52%); 1H NMR:(CDC13, 500 MHz): 87.15 (dd, J= 3.1, 9.4 Hz, 1 H), 6.86(dt, J= 3.1, 8.5 Hz. 1 H), 6.74 (dd, J= 4.2, 9.1 Hz, 1 H), 5.21 (t, J=
7.1 Hz, 1 H),), 4.25 (m 1 H), 3.78 (s, 3 H), 2.91 (m, 2 H), 2.46 (m, 1 H), 2.08 (m, 1 H), 1.73-1.66 (m, 6 H);
HRMS (ESI) [M+H] m/z cacld for Ci3H0PN02 240.1400, found 240.1401; HPLC > 95%
(tR = 4.71 min, 40(A):55(B):5(C):0.01(D); tR = 5.25 min, 10(A):85(B):5(C):0.01(N=
[0420] The following compounds were prepared in a similar manner as 18c.
[0421] 2-Aminoethy1-5-(2'-methoxyl-l'-naphthethyfltetrahydrofuran (17a): The product (43 mg, 56%) was obtained as an oil by chromatography on silica; (Rf =
0.10, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 8.00 (bs, 2 H), 7.92 (d, J= 8.6 Hz, 1 H), 7.75 (m, 1 H), 7.69 (m, 1 H), 7.50 (m, 1 H), 7.31 (m, 1 H), 7.23 (m, 1 H), 4.05 (m, 1.3 H), 3.94 (s, 1 H), 3.93 (s, 2 H), 3.85 (m, 0.7 H), 3.28 (m, 1 H), 3.14-3.07 (m, 3 H), 2.04-1.80 (m, 7 H), 1.52 (m, 1 H); LRMS (EST) [M+H] in/z cacld for C19H25NO2 300 found 300.
[0422] 2-Aminoethy1-5-(4'-methoxyl-l'-naphthethyl)tetrahydrofuran (17b): The product (33 mg, 35%) was obtained as an oil by chromatography on silica; (Rf =
0.10, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 8.35 (bs, 2 H), 7.30 (d, J= 8.6 Hz, 1 H), 7.94 (d, J= 8.6 Hz, 1 H), 7.69 (m, 1 H), 7.50 (m, 1 H), 7.20 (m, 1 H), 6.73 (m, 1 H), 4.05 (m, 1.3 H), 3.96 (s, 1 H), 3.95 (s, 2 H), 3.90 (m, 0.7 H), 3.29 (m, 1 H), 3.16-2.92 (m, 3 H), 2.06-1.77 (m, 7 H), 1.52 (m, 1 H); LRMS (EST) [M+Hr m/z cacld for Ci9H25NO2 300 found 300.
[0423] 2-Aminoethy1-5-(4'-flouro-3'-methy1phenethy1)tetrahydrofuran (17c): The product (117 mg, 45%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 7.00-6.87 (m, 3 H), 4.08-3.79 (m, 1 H), 3.28-3.25 (m, 1 H), 3.14-3.09 (m, 1 H), 2.63-2.52 (m, 2 H), 2.23 (m, 1 H), 2.06-1.48 (m, 8 H); LRMS (ESI) [M+H] m/z cacld for Ci5H22FN0 252 found 252.
[0424] 2-(2'-aminoethyl)-5-benzyltetrahydrofuran (17d): The product (133 mg, 34%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v);
1H NMR: (CDC13, 500 MHz): 6 7.29-7.20 (m, 5 H), 4.19 (quintet, J= 6.6 Hz, 0.66 H), 4.04 (m, 1 H), 3.91 (m, 0.34 H), 2.94 (dd, J= 5.8, 13.4 Hz, 1 H), 2.81 (bs, 2 H), 2.70 (dd, J= 7.1, 13.4 Hz, 1 H), 2.17-1.48 (m, 6 H); LRMS (ESI) [M+1-1]+ m/z cacld for Ci2H17N0 192 found 192.
[0425] 2-Aminoethy1-5-(4'-hydoxyphenethyl)tetrahydrofuran (17e): The product (112 mg, 32%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 7.01 (d, J= 8.3 Hz, 2 H), 6.78 (d, J=
8.2 Hz, 2 H), 3.98-3.94 (M, 1 H), 3.90-3.82 (m, 1 H), 2.99-2.94 (m, 1 H), 2.88-2.84 (m, 1 H), 2.64-2.58 (m, 2 H), 2.03-1.93 (m, 2 H), 1.84-1.67 (m, 4 H), 1.51-1.48 (m, 2 H); LRMS
(EST) [M+Hr m/z cacld for Ci4H21NO2 236 found 236.
[0426] 2-(2'-aminoethyl)-5-(2"-furyl)tetrahydrofuran (17f): The product (16 mg, 40%) was obtained as an oil by chromatography on silica; (Rf = 0.09, Methanol/DCM, 10:90, v:v);
1H NMR: (CDC13, 500 MHz): 6 7.34 (d, J= 1.2 Hz, 1 H), 6.31(t, J= 2.1 Hz, 1 H), 6.24(dd, J
= 3.2, 6.6 Hz, 1 H), 5.01(t, J= 7.0 Hz, 0.5 H), 4.89 (t, J= 7.0 Hz, 0.5 H), 4.17 (m, 0.5 H), 4.06 (m, 0.5 H), 2.85 (m, 2 H), 2.30-1.70 (m, 6 H), 2.09 (s, 2 H); LRMS (ESI) [M+H] m/z cacld for Ci0Hi5NO2 182 found 182.
[0427] Cis-2-aminoethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (18d) The product (43 mg, 42%) was obtained as an oil by chromatography on silica; (Rf =
0.11, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz): 7.21 (dd, J= 3.1, 9.4 Hz, 1 H), 6.87(dt, J= 3.1, 8.5 Hz. 1 H), 6.74 (dd, J= 4.2, 9.1 Hz, 1 H), 5.10 (t, J= 7.1 Hz, 1 H), ), 4.06 (p, J= 5.8 Hz, 1 H), 3.79 (s, 3 H), 2.92 (m, 2 H), 2.36 (m, 1 H), 2.04 (m, 1 H), 1.88 (m, 1 H), 1.79 (m, 1 H), 1.65 (m, 1 H), 1.56 (m, 1 H), 1.46 (bs, 2 H); HRMS (ESI) [M+Hr m/z cacld for C13H19FN02 240.1400, found 240.1403; HPLC > 96% (tR = 4.72 min, 40(A):55(B):5(C):0.01(D); tR = 5.27 min, 10(A):85(B):5(C):0.01(D)).
[0428] Trans-2-aminoethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran (18g) The product (41 mg, 45%) was obtained as an oil by chromatography on silica; (Rf =
0.09, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.92 (dd, J= 8.8. 3.1 Hz, 1 H), 6.85 (dt, J= 3.1, 8.8 Hz, 1 H), 6.75 (dd, J == 4.5, 8.7 Hz, 1 H), 4.23 (p, J=
6.6 Hz, 1 H), 4.06 (m 1 H), 3.78 (s, 3 H), 2.88 (dd, J= 6.4, 13.5 Hz, 1 H), 2.82 (broad, 2 H), ), 2.70 (dd, J-6.4, 13.5 Hz, 1 H), 2.03 (m, 1 H), 1.92 (m, 1 H), 1.91 (bs, 2 H), 1.69-1,48 (m, 4 H); HRMS
(ESI) [M+Hr- m/z cacld for C141121FN02 254.1556, found 254.1548; HPLC > 96%
(tR = 4.35 mm, 40(A):55(B):5(C):0.01(D); tR = 5.53 min, 20(A):75(B):5(C):0.01(D)).
[0429] Cis-2-aminoethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran (18h) The product (31 mg, 41%) was obtained as an oil by chromatography on silica; (Rf =
0.10, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.95 (dd, J= 9.2. 3.1 Hz, 1 H), 6.88 (dt, J= 3.1, 8.5 Hz, 1 H), 6.78 (dd, J == 4.7, 9.1 Hz, 1 H), 4.11 (p, J=
6.8 Hz, 1 H), 3.94 (p, J= 6.4 Hz, 1 H), 3.81 (s, 3 H), 2.91 (dd, J= 6.6, 13.5 Hz, 1 H), 2.87 (broad, 2 H), 2.78 (dd, J= 6.6, 13.5 Hz, 1 H), 1.96 (m, 2 H), 1.88 (bs, 2 H), 1.72 (m, 2 H), 1.64-1.55 (m, 2 H); HRMS (ESI) [M+11]+ m/z cacld for C14H2IFN02 254.1556, found 254.1546; HPLC
>
96% (tR = 4.35 min, 40(A):55(B):5(C):0.01(D); tR = 5.53 min, 20(A):75(B):5(C):0.01(D)).
[0430] Trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (18k) The product (192 mg, 40%) was obtained as an oil by chromatography on silica;
(Rf = 0.12, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.87 (dt, J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.72 (dd, J= 4.3, 8.5 Hz, 1 H), 4.03 (m, 1 H), 3.96 (m, 1 H), 3.78 (s, 3 H), 2.84 (bm, 2 H), 2.68 (m, 1 H), 2.58 (m, 1 H), 2.03 (m, 2 H), 1.83 (bs, 2 H), 1.72-1.60 (m, 4 H), 1.54 (m, 2 H); HRMS (ESI) [1\4+Hr m/z cacld for C15H23FN02 268.1713, found 268.1733; HPLC > 97% (tR = 4.67 mm, 40(A):55(B):5(C):0.01(D);
tR = 5.05 mm, 10(A):85(B):5(C):0.01(D)).
[0431] Cis-2-Aminoethy1-5-(2'-methoxy-5'-fluorophenethyptetrahydrofuran (181):
The product (29 mg, 34%) was obtained as an oil by chromatography on silica;
(Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz): 6 6.87-6.72 (m, 3 H), 4.05-3.81 (m, 2 H), 3.79 (s, 3 H), 2.71-2.56 (m, 2 H), 2.30 (bs, 2 H), 2.07-1.50 (m, 10 H); HRMS (ESI) [M+H] m/z cacld for C15H23FN02 268.1713, found 268.1701; HPLC > 96% (tR = 4.65 min, 40(A):55(B):5(C):0.01(D); tR = 5.05 min, 10(A):85(B):5(C):0.01(D)).
[0432] Cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (181) The product (118 mg, 54%) was obtained as an oil by chromatography on silica;
TLC (Si02) Rf '=. 0.10, 90% DCM/Me0H; 1H NMR: (CDC13, 500 MHz): 6 6.86 (dt, J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.73 (dd, J= 4.3, 8.5 Hz, 1 H), 3.89 (m, 1 H), 3.82 (m, 1 H), 3.78 (s, 3 H), 2.85 (t, J= 6.9 Hz, 2 H), 2.68 (m, 1 H), 2.60 (m, 1 H), 1.96 (m, 2 H), 1.86-1.67 (n, 4 H), 1.76 (bs, 2 H), 1.53 (m, 2 H); HRMS (ESI) [M+Hr trilz cacld for Ci5H23FN02 268.1713, found 268.1701; HPLC > 96% (tR = 4.65 min, 40(A):55(B):5(C):0.01(D);
tR = 5.05 min, 10(A):85(B):5(C):0.01(D)).
[0433] Trans-2-aminoethy1-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyfltetra hydrofuran (180): The product (24 mg, 47%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.86-6.80 (m, 2 H), 6.73 (dd, J= 4.4, 8.5 Hz, 1 H), 4.02 (m, 1 H), 3.96 (m, 1 H), 3.78 (s, 3 H), 2.88 (b, 2 H), 2.61 (bs, 2 H), 2.58 (t, J= 7.0 Hz, 2 H), 2.02 (m, 2 H), 1.72-1.44 (m, 8 H); HRMS (ESI) [M+Hr m/z cacld for C16H25FN02 282.1869, found 282.1875; HPLC > 95% (tR = 4.70 min, 40(A):55(B):5(C):0.01(D); tR = 5.09 min, 10(A):85(B):5(C):0.01(D)).
[0434] Cis-2-aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrofuran (18p): The product (11 mg, 46%) was obtained as an oil by chromatography on silica; (Rf = 0.09, Methanol/DCM, 10:90, v:v); 1H NMR:
(CDC13, 500 MHz): 6 6.84 (dd, J= 3.1, 9.2 Hz, 1 H), 6.82 (dd, J= 3.1, 8.4 Hz, 1 H), 6.73 (dd, J= 4.7, 9.1 Hz, 1 H), 3.92 (m, 1 H), 3.82 (m, 1 H), 3.79 (s, 3 H), 3.09 (m, 1 H), 2.99 (m, 1 H), 2.60 (t, J
= 7.0 Hz, 2 H), 1.96 (m, 2 H), (m, 2 H), 1.65-1.47 (m, 8 H); HRMS (EST) [M+Hr m/z cacld for Ci6H25FN02 282.1869, found 282.1875; HPLC > 95% (tR = 4.70 min, 40(A):55(B):5(C):0.01(D); tR = 5.09 min, 10(A):85(B):5(C):0.01 (D)).
[0435] 2-Aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-butyl)tetrahydrofuran (18r): The product (20 mg, 46%) was obtained as an oil by chromatography on silica; (Rf=
0.10, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.84-6.72 (m, 2 H), 6.72 (dd, J= 4.7, 9.1 Hz, 1 H), 4.03 (m, 0.5 H), 3.93 (m, 0.5 H), 3.89 (m, 0.5 H), 3.81 (in, 0.5 H), 3.78 (s, 3 H), 2.88 (bm, 2 H), 2.57 (t, J= 7.5 Hz, 2 H), 2.27 (bs, 2 H), 2.17-1.93 (in, 2 H), 1.73-1.33 (m, 10 H); HRMS (ESI) [M+Hr m/z cacld for Ci7H27FN02 296.2026, found 296.2015; HPLC > 96% (tR = 4.74 min, 40(A):55(B):5(C):0.01(D); tR = 5.17 min, 10(A):85(B):5(C):0.01(D)).
[0436] (2-{5-[2-(5-Fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-yll-ethyl)-earbamic ethyl ester (19): In a flame dried 20 mL scintillation vial was placed K2CO3 (239mg, 1.73 mmol, 6.0 eq) and anhydrous THF (5.0 mL). The vial was purged with Ar(o and then chilled in an ice bath. Ethyl chloroforrnate (156 mg, 1.44 mmol, 5.0 eq) was added via syringe followed by a slow addition of 18k/1 (77 mg, 0.29 mmol, 1.0 eq) dissolved in THF (1.5 mL). The reaction was stirred at 0 C for 0.5 hrs and then warmed to rt and stirred for an additional 3 hrs. The reaction was then stopped by addition of sat.
NaHC030q) and extracted with Et0Ac (3 x 20 mL). The organic layer was washed with brine and dried over Na2SO4, filtered through paper, and concentrated under reduced pressure to yield crude product that was used in the next step of the synthesis. (Rf = 0.40, Methanol/DCM, 2:98, v:v); 1H NMR (CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.12 (q, J= 7.1 Hz, 2 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 2 H), 2.08-1.51 (m, 10 H) 1.3 (t, J= 7.2 Hz, 3 H). LRMS (EST) [M+11]+ calcd for Ci8H27FN04 340 found 340.
[0437] (2-{542-(5-Fluoro-2-methoxy-pheny1)-ethylFtetrahydro-furan-2-yll-ethyl)-methyl-amine (20): In a flame dried round bottom flask, purged with Ar(g), was placed 19 (112 mg, 0.33 mmol, 1.0 eq) and anhydrous THF (1.6 mL). The flask was then cooled with an ice bath while stirring for 15 min. LAH (1.0 M, 1.32 mL, 1.32 mmol, 4.0 eq) was then slowly added via a syringe over a period of 5 mm. The reaction was allowed to warm to rt and stirred an additional 4 hrs. The reaction was then stopped by addition of ice cold Me0H
and then stirred at rt for an additional 15 min. The resulting solution was transferred to a beaker with the aid of 1N HCl(aq) and then made basic with 10 M Na011(4. The basic solution was then extracted with Et20 (3 x 20 mL) and the organic layer was washed with brine. The Et20 layer was dried over Mg2SO4 for 15 min and filtered through paper and concentrated to an oil under reduced pressure to afford the crude product. The oil was purified with PTLC and eluted with MeOH:CH2C12 (5:95). (Rf = 0.05, Methanol/DCM, 5:95, v:v); 1H NMR (CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 5 H), 2.08-1.51 (m, 10 H); HRMS (ESI) [M+Hr calcd for Ci6H25FN02 282.3784, found 282.3762; HPLC > 97% (tR = 30.23 mm, 100(A):0.5(D);
tR
26.05 mm, 90(A):10(C):0.5(D)).
[0399] The following compounds were prepared in a similar manner as 18a.
[0400] 2-Aminomethy1-5-phenyltetrahydrofuran (15b): The product (33 mg, 65%) was obtained as an oil by chromatography on silica; (Rf= 0.11, Methanol/DCM, 10:90, v:v); 1H
NMR:(CDC13, 500 MHz): 6 7.33 (m, 5 H), 4.97 (m, 0.66 H), 4.90 (t, J= 7.7 Hz, 0.34 H), 4.25 (m, 0.66 H), 4.06 (m, 0.34 H), 2.93-2.78 (m, 2 H), 2.35 (m, 1 H), 2.09 (m, 1 H), 1.96-1.70( m, 2 H), 1.62 (bs, 2 H); LRMS (ESI) [M+H] m/z cacld for CiiHBNO 178 found 178.
[0401] 2-(Aminomethyl)-5-(2'-naphthyptetrahydrofuran (15e): The product (27 mg, 66%) was obtained as an oil by chromatography on silica; (Rf= 0.14, Methanol/DCM, 15:85, v:v); 1H NMR (500 MHz, CDC13) 6 7.84-7.78 (m, 4H), 7.47-7.41 (m, 3 H), 5.14 (t, J= 7.2 Hz, 0.33 H), 5.04 (t, J= 7.4 Hz, 0.67 H), 4.38-4.33 (m, 0.33 H), 4.16-4.14 (m, 0.66 H), 3.01-2.83 (m, 2 H), 2.60 (bs, 2 H), 2.42-2.34 (in, 1 H), 2.16-2.07 (m, 1 H), 1.97-1.86 (m, 1 H), 1.79-1.72 (1 H); LRMS (ESI) [M+H] ni/z cacld for C15I-117N0 228 found 228.
[0402] 2-(Aminomethyl)-5-phenethyltetrahydrofuran (15d): The product (23 mg, 55%) was obtained as an oil by chromatography on silica; (Rf= 0.12, Methanol/DCM, 15:85, v:v);
1H NMR (500 MHz, CDC13) 6 7.27-7.19 (m, 5 H), 4.01-3.85 (m, 2 H), 2.83-2.62 (m, 4 H), 2.03-1.50 (m, 8 H); LRMS (ESI) [M+Hr m/z cacld for C13Hi9N0 206 found 206.
[0403] 2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran (15a): The product (43 mg, 52%) was obtained as an oil by chromatography on silica; (Rf= 0.13, Methanol/DCM, 15:85, v:v); 1 HNMR (500 MHz, CDC13) 6 8.08-8.06 (m, 1 H), 7.85 (d, J= 7.6 Hz, 1 H), 7.71 (d, J.= 7.6 Hz, 1 H), 7.52-7.45 (m, 2 H), 7.39 (t, J= 7.6 Hz, 1 H), 7.35 (d, J= 6.8 Hz, 1 H), 4.05-3.90 (m, 2 H), 3.25 (m, 1 H), 3.11 (m, 1 H), 2.86-2.70 (m, 2 H), 2.07-1.89 (m, 4 H), 1.63-1.55 (m, 2 H), 1.48 (bs, 2 H); LRMS (ESI) [M+H] m/z cacld for C17H2iN0 256 found 256.
[0404] 2-(Aminornethyl)-5-(1.'-naphthyl)tetrahydrofuran (15e): The product (39 g, 85%) was obtained as an oil by chromatography on silica; (Rf= 0.13, Methanol/DCM, 15:85, v:v); 1H NMR (500 MHz, CDC13) 6 7.96-7.93 (in, 1 H), 7.89-7.85 (1 H), 7.76-7.74 (m, 1 H), 7.71-7.69 (m, 1 H), 7.63 (d, J= 7.1 Hz, 1 H), 7.50-7.43 (m, 3 H), 5.74 (t, J=
7.0 Hz, 0.33 H), 5.61 (t, J= 7.3 Hz, 0.67 H), 4.38-4.28 (m, 0.33 H), 4.19-4.16 (m, 0.67 H), 3.02-2.88 (m, 1 H), 2.62-2.52 (m, 1 H), 2.15 (bs, 2 H), 2.14-1.71 (m, 3 H); LRMS (ESI) [M+Hr nilz cacld for C15K3N0 228 found 228.
[0405] 2-Aminomethy1-5-(p-chlorophenyltetrahydrofuran (15f): The product (16 mg, 71%) was obtained as an oil by chromatography on silica; (Rf = 0.14, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (57.34-7.27 (m, 4 H), 4.95 (t, J= 6.9 Hz, 0.66 H), 4.83 (t, J= 6.7 Hz, 0.34 H), 4.35 (in, 0.66 H), 4.15 (m, 0.34 H), 3.40 (bs, 2 H), 2.99-2.81 (in, 2 H), 2.32 (m, 1 H), 2.08 (m, 1 H), 1.84-1.68 (in, 2 H); LRMS (ESI) [M+H]+ m/z cacld for CI IHNC1NO 212 found 212.
[0406] 2-Aminomethy1-5-(p-bromophenyltetrahydrofuran (15g): The product (16 mg, 48%) was obtained as an oil by chromatography on silica; (Rf = 0.13, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (57.42-7.20 (m, 4 H), 4.95 (t, J= 6.9 Hz, 0.66 H), 4.86 (t, J= 6.7 Hz, 0.34 H), 4.26 (m, 0.66 H), 4.08 (m, 0.34 H), 2.83-2.79 (m, 2 H), 2.38-1.71 (m, 6 H); LRMS (EST) [M+H] m/z cacld for C11H14BrNO 256 found 256.
[0407] 2-Aminomethy1-5-pentafluorophenethyltetrahydrofuran (15h): The product (30 mg, 53%) was obtained as an oil by chromatography on silica; (Rf =0.14, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (54.05 (in, 0.60 H), 3.92 (m, 1 H), 3.86 (m, 0.40 H), 2.89-2.70 (m, 2 H), 2.74 (m, 2 H), 2.63 (bs, 2 H), 2.08-1.99 (m, 2 H), 1.82-1.54 (m, 4 H); LRMS (ESI) [M+1-1]+ m/z cacld for C13H14F5N0 296 found 296.
[0408] 2-(Aminomethyl)-5-(3'-pyridinylethyl)tetrahydrofuran (151): The product (12 mg, 35%) was obtained as an oil by chromatography on silica; (Rf = 0.09, Methanol/DCM, 15:85, v:v); 1 HNMR (500 MHz, CDC13) 6 8.46 (s, 1 H), 8.42 (d, J= 4.1 Hz, 1 H), 7.51 (m, 1 H), 7.19 (dd, J= 4.8, 7.7 Hz, 1 H), 4.02-3.83 (m, 2 H), 2.82-2.63 (m, 4 H), 2.07-1.53 (m, 8 H); LRMS (ESI) [M+H] m/z cacld for C12H18N20 207 found 207.
[0409] 2-Aminomethy1-5-(p-methoxypheny)ltetrahydrofuran (15j): The product (18 mg, 55%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 15:85, v:v); 1H NMR:(CDC13, 500 MHz): (57.27 (m, 2 H), 6.87 (m, 2 H), 4.92 (m, 0.66 H), 4.83 (t, J= 6.7 Hz, 0.34 H), 4.26 (m, 0.66 H), 4.07 (m, 0.34 H), 3.79 (s, 1 H), 3.78 (s, 2 H), 2.92-2.78 (m, 2 H), 2.57 (bs, 2 H), 2.29 (m, 1 H), 2.10, m, 1 H), 1.88-1.69 (m, 2 H); LRMS
(ESI) [M+H]+ m/z cacld for C12H17NO2 208 found 208.
[0410] 2-Arninomethy1-5-(p-t-buty1pheny1)tetrahydrofuran (15k): The product (21 mg, 54%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz): 7.36-7.24 (m, 4 H), 4.96 (m, 0.66 H), 4.86 (m, 0.34 H), 4.46 (bs, 2 H), 4.34 (m, 0.66 H), 4.13 (m, 0.34 H), 3.00-2.80 (m, 2 H), 2.29 (m, 1 H), 2.10 (m, 1 H), 1.97-1.68 (m, 2 H), 1.30 (s, 9 H); LRMS (ESI) [M+Hr m/z cacld for Ci5H23N0 234 found 234.
[0411] Trans-2-aminomethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (18a):
The product (41 mg, 30%, trans : cis = 0.95:0.05) was obtained as an oil by chromatography on silica; (Rf= 0.08, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz):
87.18 (dd, J
= 3.1, 9.4 Hz, 1 H), 6.87(dt, J= 3.1, 8.5 Hz. 1 H), 6.75(dd, J= 4.2, 9.1 Hz, 1 H), 5.20 (t, J=
7.1 Hz, 1 H),), 4.24 (m, 1 H), 2.82 (m, 2 H), 2.44 (m, 1 H), 2.04 (m, 1 H), 1.71-1.69 (m, 2 H), 1.67 (s, 2 H); HRMS (ESI) [M+11]+ m/z cacld for C121117FN02 226.1243, found 226.1257; HPLC > 96% (tR = 4.30 min, 40(A):55(B):5(C):0.01(D); tR = 5.04 mm, 20(A):75(B):5(C):0.01(D)).
[0412] Trans-2-aminomethy1-5-(2'-methoxy-5'-fluorophenylmethyfltetrahydrofuran (18e): The product (54 mg, 60%) was obtained as an oil by chromatography on silica; (Rf=
0.10, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): 86.93 (dd, J= 3.1, 8.8 Hz, 1 H), 6.86 (dt, J= 3.1, 8.8 Hz, 1 H), 6.75 (dd, J= 3.1, 8.8 Hz, 1 H), 4.23 (m, 1 H), ), 4.08 (m 1 H), 3.79 (s, 3 H), 2.91 (dd, J= 13.5, 6.5 Hz, 2 H), 2.78 (m, 1 H), 2.72 (m, 1 H), 2.18 (bs, 2 H), 2.02-1.92 (m, 2 H), 1.64- 1.55 (m, 2 H); HRMS (EST) [M+111+ m/z cacld for C13H0FN02 240.1400, found 240.1423; HPLC > 98% (tR = 4.68 mm, 40(A):55(B):5(C):0.01(D); tR = 5.04 mm, 20(A):75(B):5(C):0.01(D)).
[0413] Cis-2-aminomethy1-5-(2'-methoxy-5'-fluorophenylmethyfltetrahydrofuran (181): The product (26 mg, 73%) was obtained as an oil by chromatography on silica; (Rf =
0.09, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): 6 6.93 (dd, J= 3.1, 8.8 Hz, 1 H), 6.86 (dt, J= 3.1, 8.8 Hz, 1 H), 6.77 (dd, J= 3.1, 8.8 Hz, 1 H), 4.15 (m, 1 H),), 3.97 (m 1 H), 3.79 (s, 3 H), 2.91 (dd, J= 13.5, 6.6 Hz, 2 H), 2.76 (dd, J= 13.5, 6.6 Hz, 2 H), 2.43 (bs, 2 H), 1.93 (m, 2 H), 1.63 (m, 2 H); HRMS (ESI) [M+11]+ m/z cacld for Ci3HDFN02 240.1400, found 240.1423; HPLC > 98% (tR = 4.69 min, 40(A):55(B):5(C):0.01(D); tR = 5.06 min, 20(A):75(B):5(C):0.01(D)).
[0414] Trans-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (181) The product (197 mg, 85%) was obtained as an oil by chromatography on silica; (Rf=
0.09, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): 6 6.87 (dt, J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.74 (dd, J= 4.3, 8.5 Hz, 1 H), 4.01 (m, 1 H), 3.93 (quintet, J= 6.8 Hz, 1 H), 3.78 (s, 3 H), 2.76-2.67 (m, 3 H), 2.60 (m, 1 H), 2.06-1.99 (m, 2 H), 1.84 (m, 1 H), 1.78 (bs, 2 H), 1.70 (m, 1 H), 1.59-1.54 (m, 2 H); HRMS
(EST) [M+H]
m/z cacld for Ci4H21FN02 254.1556, found 254.1573; HPLC > 98% (tR = 4.48 min, 40(A):55(B):5(C):0.01(D); tR = 5.76 min, 20(A):75(B):5(C):0.01(D)).
[0415] Cis-2-(aminomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran 18j):
The product (125 mg, 73%) was obtained as an oil by chromatography on silica;
(Rf= 0.10, Methanol/DCM, 10:90, v:v); 1H NMR (CDC13, 500 MHz): a 6.87 (dt,J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.72 (dd, J= 4.3, 8.5 Hz, 1 H), 3.91-3.87 (m, 2 H), 3.79 (s, 3 H), 2.83-2.57 (m, 4 H), 2.00-1.52 (m, 6 H) 1.84 (bs, 2 H); HRMS (EST) [M+H]
m/z cacld for Ci4H2iFNO2 254.1556, found 254.1551; HPLC > 98% (tR = 4.50 min, 40(A):55(B):5(C):0.01(D); tR = 5.81 min, 20(A):75(B):5(C):0.01(D)).
[0416] Trans-2-aminomethy1-5-((2"-methoxy-5"-fluoropheny1)-3'-propyl)tetrahydrofuran (18m): The product (42 mg, 87%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): 6 6.86-6.80 (m, 2 H), 6.74 (dd, J= 4.7, 8.8 Hz, 1 H), 4.01 (p, J= 6.2 Hz, 1 H), 3.93 (p, J= 7.2 Hz, 1 H), 3.78 (s, 3 H), 2.85-2.67 (m, 2 H), 2.60 (t, J= 7.2 Hz, 2 H), 2.34 (bs, 2 H), 2.03-1.98 (m, 2 H), 1.68-1.46 (m, 6 H); HRMS (ESI) [M+Hr m/z cacld for Ci5H23FN02 268.1713, found 268.1709; HPLC > 95% (tR = 4.70 min, 40(A):55(B):5(C):0.01(D);
tR = 5.10 min, 10(A):85(B):5(C):0.01(D)).
[0417] Cis-2-aminomethy1-5-(3'-(2"-methoxy-5"-fluorophenyl)-3'-propyl)tetrahydrofuran (18n): The product (42 mg, 87%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): 6 6.85 (dd, J= 3.0, 9.6, Hz, 1 H), 6.82 (dd, J= 3.0, 8.3 Hz, 1 H), 6.73 (dd, J= 4.7, 8.9 Hz, 1 H), 3.94 (m, 1 H), 3.85 (m, 1 H), 3.78 (s, 3 H), 3.00-2.60 (m, 4 H), 2.60 (t, J= 7.2 Hz, 2 H),1.98-1.92 (m, 2 H), 1.68-1.46 (m, 6 H); HRMS (ESI) [M+Hr nilz cacld for 268.1713, found 268.1702; HPLC > 98% (tR = 4.71 min, 40(A):55(B):5(C):0.01(D);
tR = 5.10 min, 10(A):85(B):5(C):0.01(D)).
[0418] Trans -2-Aminomethy1-5-(5"-fluoro-2"-methoxypheny1-4'-butyl)tetrahydrofuran (18q): The product (33 mg, 95%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR
(CDC13, 500 MHz): 6 6.85-6.80 (m, 2 H), 6.72 (dd, J - 4.7, 8.9 Hz, 1 H), 4.02 (m, 1 H), 3.92 (m, 1 H), 3.78 (s, 3 H), 2.90-2.70 (bm, 2 H), 2.58 (t, J= 7.6 Hz, 2 H), 2.32 (bs, 2 H), 2.02 (m, 1 H), 1.64-1.35 (m, 9 H); MS: 282 (MH+), 264, 139; HRMS (EST) [M+Hr m/z cacld for Ci6H25FN02 282.2869, found 282.1889; HPLC > 98% (tR = 4.83 mm, 40(A):55(B):5(C):0.01(D); tR = 5.17 min, 10(A):85(B):5(C):0.01(D)).
[0419] Trans-2-aminoethy1-5-(2'-methoxy-5'-fluorophenyfltetrahydrofuran (18c):
To a vial under Ar was added Raney Ni that was washed with ethanol (200 proof, 3 times) and trans-2-(cyanomethyl)-5-(2'-methoxy-5'-fluorophenyptetrahydrafuran (80 mg, 0.35 mmol) that was treated with a small amount of Raney Ni in ethanol. The vial was then evacuated to boiling and purged with H2 three times. A balloon filled with H2 was attached to the flask and the reaction was stirred for 48 h at room temperature. The reaction mixture was then filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by flash column chromatography (Rf= 0.10, Methanol/DCM, 10:90, v:v) to result in the pure product (43.7 mg, 52%); 1H NMR:(CDC13, 500 MHz): 87.15 (dd, J= 3.1, 9.4 Hz, 1 H), 6.86(dt, J= 3.1, 8.5 Hz. 1 H), 6.74 (dd, J= 4.2, 9.1 Hz, 1 H), 5.21 (t, J=
7.1 Hz, 1 H),), 4.25 (m 1 H), 3.78 (s, 3 H), 2.91 (m, 2 H), 2.46 (m, 1 H), 2.08 (m, 1 H), 1.73-1.66 (m, 6 H);
HRMS (ESI) [M+H] m/z cacld for Ci3H0PN02 240.1400, found 240.1401; HPLC > 95%
(tR = 4.71 min, 40(A):55(B):5(C):0.01(D); tR = 5.25 min, 10(A):85(B):5(C):0.01(N=
[0420] The following compounds were prepared in a similar manner as 18c.
[0421] 2-Aminoethy1-5-(2'-methoxyl-l'-naphthethyfltetrahydrofuran (17a): The product (43 mg, 56%) was obtained as an oil by chromatography on silica; (Rf =
0.10, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 8.00 (bs, 2 H), 7.92 (d, J= 8.6 Hz, 1 H), 7.75 (m, 1 H), 7.69 (m, 1 H), 7.50 (m, 1 H), 7.31 (m, 1 H), 7.23 (m, 1 H), 4.05 (m, 1.3 H), 3.94 (s, 1 H), 3.93 (s, 2 H), 3.85 (m, 0.7 H), 3.28 (m, 1 H), 3.14-3.07 (m, 3 H), 2.04-1.80 (m, 7 H), 1.52 (m, 1 H); LRMS (EST) [M+H] in/z cacld for C19H25NO2 300 found 300.
[0422] 2-Aminoethy1-5-(4'-methoxyl-l'-naphthethyl)tetrahydrofuran (17b): The product (33 mg, 35%) was obtained as an oil by chromatography on silica; (Rf =
0.10, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 8.35 (bs, 2 H), 7.30 (d, J= 8.6 Hz, 1 H), 7.94 (d, J= 8.6 Hz, 1 H), 7.69 (m, 1 H), 7.50 (m, 1 H), 7.20 (m, 1 H), 6.73 (m, 1 H), 4.05 (m, 1.3 H), 3.96 (s, 1 H), 3.95 (s, 2 H), 3.90 (m, 0.7 H), 3.29 (m, 1 H), 3.16-2.92 (m, 3 H), 2.06-1.77 (m, 7 H), 1.52 (m, 1 H); LRMS (EST) [M+Hr m/z cacld for Ci9H25NO2 300 found 300.
[0423] 2-Aminoethy1-5-(4'-flouro-3'-methy1phenethy1)tetrahydrofuran (17c): The product (117 mg, 45%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 7.00-6.87 (m, 3 H), 4.08-3.79 (m, 1 H), 3.28-3.25 (m, 1 H), 3.14-3.09 (m, 1 H), 2.63-2.52 (m, 2 H), 2.23 (m, 1 H), 2.06-1.48 (m, 8 H); LRMS (ESI) [M+H] m/z cacld for Ci5H22FN0 252 found 252.
[0424] 2-(2'-aminoethyl)-5-benzyltetrahydrofuran (17d): The product (133 mg, 34%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v);
1H NMR: (CDC13, 500 MHz): 6 7.29-7.20 (m, 5 H), 4.19 (quintet, J= 6.6 Hz, 0.66 H), 4.04 (m, 1 H), 3.91 (m, 0.34 H), 2.94 (dd, J= 5.8, 13.4 Hz, 1 H), 2.81 (bs, 2 H), 2.70 (dd, J= 7.1, 13.4 Hz, 1 H), 2.17-1.48 (m, 6 H); LRMS (ESI) [M+1-1]+ m/z cacld for Ci2H17N0 192 found 192.
[0425] 2-Aminoethy1-5-(4'-hydoxyphenethyl)tetrahydrofuran (17e): The product (112 mg, 32%) was obtained as an oil by chromatography on silica; (Rf = 0.11, Methanol/DCM, 10:90, v:v); 1H NMR (500 MHz, CDC13) 6 7.01 (d, J= 8.3 Hz, 2 H), 6.78 (d, J=
8.2 Hz, 2 H), 3.98-3.94 (M, 1 H), 3.90-3.82 (m, 1 H), 2.99-2.94 (m, 1 H), 2.88-2.84 (m, 1 H), 2.64-2.58 (m, 2 H), 2.03-1.93 (m, 2 H), 1.84-1.67 (m, 4 H), 1.51-1.48 (m, 2 H); LRMS
(EST) [M+Hr m/z cacld for Ci4H21NO2 236 found 236.
[0426] 2-(2'-aminoethyl)-5-(2"-furyl)tetrahydrofuran (17f): The product (16 mg, 40%) was obtained as an oil by chromatography on silica; (Rf = 0.09, Methanol/DCM, 10:90, v:v);
1H NMR: (CDC13, 500 MHz): 6 7.34 (d, J= 1.2 Hz, 1 H), 6.31(t, J= 2.1 Hz, 1 H), 6.24(dd, J
= 3.2, 6.6 Hz, 1 H), 5.01(t, J= 7.0 Hz, 0.5 H), 4.89 (t, J= 7.0 Hz, 0.5 H), 4.17 (m, 0.5 H), 4.06 (m, 0.5 H), 2.85 (m, 2 H), 2.30-1.70 (m, 6 H), 2.09 (s, 2 H); LRMS (ESI) [M+H] m/z cacld for Ci0Hi5NO2 182 found 182.
[0427] Cis-2-aminoethy1-5-(2'-methoxy-5'-fluorophenyl)tetrahydrofuran (18d) The product (43 mg, 42%) was obtained as an oil by chromatography on silica; (Rf =
0.11, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz): 7.21 (dd, J= 3.1, 9.4 Hz, 1 H), 6.87(dt, J= 3.1, 8.5 Hz. 1 H), 6.74 (dd, J= 4.2, 9.1 Hz, 1 H), 5.10 (t, J= 7.1 Hz, 1 H), ), 4.06 (p, J= 5.8 Hz, 1 H), 3.79 (s, 3 H), 2.92 (m, 2 H), 2.36 (m, 1 H), 2.04 (m, 1 H), 1.88 (m, 1 H), 1.79 (m, 1 H), 1.65 (m, 1 H), 1.56 (m, 1 H), 1.46 (bs, 2 H); HRMS (ESI) [M+Hr m/z cacld for C13H19FN02 240.1400, found 240.1403; HPLC > 96% (tR = 4.72 min, 40(A):55(B):5(C):0.01(D); tR = 5.27 min, 10(A):85(B):5(C):0.01(D)).
[0428] Trans-2-aminoethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran (18g) The product (41 mg, 45%) was obtained as an oil by chromatography on silica; (Rf =
0.09, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.92 (dd, J= 8.8. 3.1 Hz, 1 H), 6.85 (dt, J= 3.1, 8.8 Hz, 1 H), 6.75 (dd, J == 4.5, 8.7 Hz, 1 H), 4.23 (p, J=
6.6 Hz, 1 H), 4.06 (m 1 H), 3.78 (s, 3 H), 2.88 (dd, J= 6.4, 13.5 Hz, 1 H), 2.82 (broad, 2 H), ), 2.70 (dd, J-6.4, 13.5 Hz, 1 H), 2.03 (m, 1 H), 1.92 (m, 1 H), 1.91 (bs, 2 H), 1.69-1,48 (m, 4 H); HRMS
(ESI) [M+Hr- m/z cacld for C141121FN02 254.1556, found 254.1548; HPLC > 96%
(tR = 4.35 mm, 40(A):55(B):5(C):0.01(D); tR = 5.53 min, 20(A):75(B):5(C):0.01(D)).
[0429] Cis-2-aminoethy1-5-(2'-methoxy-5'-fluorobenzyl)tetrahydrofuran (18h) The product (31 mg, 41%) was obtained as an oil by chromatography on silica; (Rf =
0.10, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.95 (dd, J= 9.2. 3.1 Hz, 1 H), 6.88 (dt, J= 3.1, 8.5 Hz, 1 H), 6.78 (dd, J == 4.7, 9.1 Hz, 1 H), 4.11 (p, J=
6.8 Hz, 1 H), 3.94 (p, J= 6.4 Hz, 1 H), 3.81 (s, 3 H), 2.91 (dd, J= 6.6, 13.5 Hz, 1 H), 2.87 (broad, 2 H), 2.78 (dd, J= 6.6, 13.5 Hz, 1 H), 1.96 (m, 2 H), 1.88 (bs, 2 H), 1.72 (m, 2 H), 1.64-1.55 (m, 2 H); HRMS (ESI) [M+11]+ m/z cacld for C14H2IFN02 254.1556, found 254.1546; HPLC
>
96% (tR = 4.35 min, 40(A):55(B):5(C):0.01(D); tR = 5.53 min, 20(A):75(B):5(C):0.01(D)).
[0430] Trans-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (18k) The product (192 mg, 40%) was obtained as an oil by chromatography on silica;
(Rf = 0.12, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.87 (dt, J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.72 (dd, J= 4.3, 8.5 Hz, 1 H), 4.03 (m, 1 H), 3.96 (m, 1 H), 3.78 (s, 3 H), 2.84 (bm, 2 H), 2.68 (m, 1 H), 2.58 (m, 1 H), 2.03 (m, 2 H), 1.83 (bs, 2 H), 1.72-1.60 (m, 4 H), 1.54 (m, 2 H); HRMS (ESI) [1\4+Hr m/z cacld for C15H23FN02 268.1713, found 268.1733; HPLC > 97% (tR = 4.67 mm, 40(A):55(B):5(C):0.01(D);
tR = 5.05 mm, 10(A):85(B):5(C):0.01(D)).
[0431] Cis-2-Aminoethy1-5-(2'-methoxy-5'-fluorophenethyptetrahydrofuran (181):
The product (29 mg, 34%) was obtained as an oil by chromatography on silica;
(Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR:(CDC13, 500 MHz): 6 6.87-6.72 (m, 3 H), 4.05-3.81 (m, 2 H), 3.79 (s, 3 H), 2.71-2.56 (m, 2 H), 2.30 (bs, 2 H), 2.07-1.50 (m, 10 H); HRMS (ESI) [M+H] m/z cacld for C15H23FN02 268.1713, found 268.1701; HPLC > 96% (tR = 4.65 min, 40(A):55(B):5(C):0.01(D); tR = 5.05 min, 10(A):85(B):5(C):0.01(D)).
[0432] Cis-2-(aminoethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran (181) The product (118 mg, 54%) was obtained as an oil by chromatography on silica;
TLC (Si02) Rf '=. 0.10, 90% DCM/Me0H; 1H NMR: (CDC13, 500 MHz): 6 6.86 (dt, J= 3.0, 8.9 Hz, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.73 (dd, J= 4.3, 8.5 Hz, 1 H), 3.89 (m, 1 H), 3.82 (m, 1 H), 3.78 (s, 3 H), 2.85 (t, J= 6.9 Hz, 2 H), 2.68 (m, 1 H), 2.60 (m, 1 H), 1.96 (m, 2 H), 1.86-1.67 (n, 4 H), 1.76 (bs, 2 H), 1.53 (m, 2 H); HRMS (ESI) [M+Hr trilz cacld for Ci5H23FN02 268.1713, found 268.1701; HPLC > 96% (tR = 4.65 min, 40(A):55(B):5(C):0.01(D);
tR = 5.05 min, 10(A):85(B):5(C):0.01(D)).
[0433] Trans-2-aminoethy1-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyfltetra hydrofuran (180): The product (24 mg, 47%) was obtained as an oil by chromatography on silica; (Rf = 0.10, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.86-6.80 (m, 2 H), 6.73 (dd, J= 4.4, 8.5 Hz, 1 H), 4.02 (m, 1 H), 3.96 (m, 1 H), 3.78 (s, 3 H), 2.88 (b, 2 H), 2.61 (bs, 2 H), 2.58 (t, J= 7.0 Hz, 2 H), 2.02 (m, 2 H), 1.72-1.44 (m, 8 H); HRMS (ESI) [M+Hr m/z cacld for C16H25FN02 282.1869, found 282.1875; HPLC > 95% (tR = 4.70 min, 40(A):55(B):5(C):0.01(D); tR = 5.09 min, 10(A):85(B):5(C):0.01(D)).
[0434] Cis-2-aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrofuran (18p): The product (11 mg, 46%) was obtained as an oil by chromatography on silica; (Rf = 0.09, Methanol/DCM, 10:90, v:v); 1H NMR:
(CDC13, 500 MHz): 6 6.84 (dd, J= 3.1, 9.2 Hz, 1 H), 6.82 (dd, J= 3.1, 8.4 Hz, 1 H), 6.73 (dd, J= 4.7, 9.1 Hz, 1 H), 3.92 (m, 1 H), 3.82 (m, 1 H), 3.79 (s, 3 H), 3.09 (m, 1 H), 2.99 (m, 1 H), 2.60 (t, J
= 7.0 Hz, 2 H), 1.96 (m, 2 H), (m, 2 H), 1.65-1.47 (m, 8 H); HRMS (EST) [M+Hr m/z cacld for Ci6H25FN02 282.1869, found 282.1875; HPLC > 95% (tR = 4.70 min, 40(A):55(B):5(C):0.01(D); tR = 5.09 min, 10(A):85(B):5(C):0.01 (D)).
[0435] 2-Aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-butyl)tetrahydrofuran (18r): The product (20 mg, 46%) was obtained as an oil by chromatography on silica; (Rf=
0.10, Methanol/DCM, 10:90, v:v); 1H NMR: (CDC13, 500 MHz): 6 6.84-6.72 (m, 2 H), 6.72 (dd, J= 4.7, 9.1 Hz, 1 H), 4.03 (m, 0.5 H), 3.93 (m, 0.5 H), 3.89 (m, 0.5 H), 3.81 (in, 0.5 H), 3.78 (s, 3 H), 2.88 (bm, 2 H), 2.57 (t, J= 7.5 Hz, 2 H), 2.27 (bs, 2 H), 2.17-1.93 (in, 2 H), 1.73-1.33 (m, 10 H); HRMS (ESI) [M+Hr m/z cacld for Ci7H27FN02 296.2026, found 296.2015; HPLC > 96% (tR = 4.74 min, 40(A):55(B):5(C):0.01(D); tR = 5.17 min, 10(A):85(B):5(C):0.01(D)).
[0436] (2-{5-[2-(5-Fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-yll-ethyl)-earbamic ethyl ester (19): In a flame dried 20 mL scintillation vial was placed K2CO3 (239mg, 1.73 mmol, 6.0 eq) and anhydrous THF (5.0 mL). The vial was purged with Ar(o and then chilled in an ice bath. Ethyl chloroforrnate (156 mg, 1.44 mmol, 5.0 eq) was added via syringe followed by a slow addition of 18k/1 (77 mg, 0.29 mmol, 1.0 eq) dissolved in THF (1.5 mL). The reaction was stirred at 0 C for 0.5 hrs and then warmed to rt and stirred for an additional 3 hrs. The reaction was then stopped by addition of sat.
NaHC030q) and extracted with Et0Ac (3 x 20 mL). The organic layer was washed with brine and dried over Na2SO4, filtered through paper, and concentrated under reduced pressure to yield crude product that was used in the next step of the synthesis. (Rf = 0.40, Methanol/DCM, 2:98, v:v); 1H NMR (CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.12 (q, J= 7.1 Hz, 2 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 2 H), 2.08-1.51 (m, 10 H) 1.3 (t, J= 7.2 Hz, 3 H). LRMS (EST) [M+11]+ calcd for Ci8H27FN04 340 found 340.
[0437] (2-{542-(5-Fluoro-2-methoxy-pheny1)-ethylFtetrahydro-furan-2-yll-ethyl)-methyl-amine (20): In a flame dried round bottom flask, purged with Ar(g), was placed 19 (112 mg, 0.33 mmol, 1.0 eq) and anhydrous THF (1.6 mL). The flask was then cooled with an ice bath while stirring for 15 min. LAH (1.0 M, 1.32 mL, 1.32 mmol, 4.0 eq) was then slowly added via a syringe over a period of 5 mm. The reaction was allowed to warm to rt and stirred an additional 4 hrs. The reaction was then stopped by addition of ice cold Me0H
and then stirred at rt for an additional 15 min. The resulting solution was transferred to a beaker with the aid of 1N HCl(aq) and then made basic with 10 M Na011(4. The basic solution was then extracted with Et20 (3 x 20 mL) and the organic layer was washed with brine. The Et20 layer was dried over Mg2SO4 for 15 min and filtered through paper and concentrated to an oil under reduced pressure to afford the crude product. The oil was purified with PTLC and eluted with MeOH:CH2C12 (5:95). (Rf = 0.05, Methanol/DCM, 5:95, v:v); 1H NMR (CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 5 H), 2.08-1.51 (m, 10 H); HRMS (ESI) [M+Hr calcd for Ci6H25FN02 282.3784, found 282.3762; HPLC > 97% (tR = 30.23 mm, 100(A):0.5(D);
tR
26.05 mm, 90(A):10(C):0.5(D)).
Table 9. Inhibition of radioligand binding in HEK-hDAT, HEK-hSERT, and HEK-hNET
cells by 2,5-disubstituted tetrahydrofuran analogsa n1 n1 Cmp Trans:Ci Binding (1(1, nM) Reuptake (TC50, nM) Structures d s hDAT hSERT hNET hDAT hSERT hNET
Cocaine 371.2 276.7 1115.7 590 642 1281 15a 4111 0 NI12 18.5 23,3 3420.0 2:1 >10,000 0.8 >10,000 >10,000 IP 2.6 655.0 15b916.0 1 430 2767.0 147.3 1714.0 4111 0 NH2 2:1 23.0 1 5.0 12.0 11.0 111.0 22.2 437.0 15c 4111 512.0 45.0 28.0 4.1 58.5 W. 0 2:1 >10 k N112 33.0 4.0 10 0.8 13.8 15d . 0 N112 2:1 1505 68 2736 513.0 129.0 360.0 278 10 480 68.0 38.0 14.8 17a 10 , OCII 85.6 mi' 2:1 >10,000 >10,000 NDb ND ND
lir 9.2 17b . NII, 92.3 2:1 >10,000 >10,000 ND ND ND
110 19.1 15e 41 0 NI12 1.5:1 8519.0 174.0 1494.0 463.0 24.0 210.0 0 229.0 32.0 88.0 119 1.2 19.5 17c r 40 0 ""' 1.5:16376.0 688.0 882.0 509.0 30.0 374.0 893.0 119.0 22.0 136.0 4.0 110.0 15f a 4, 0 6830.0 1105.0 1106.0 313.1 31.9 61.2 NH, 2:1 419.0 110.0 203.0 76.1 4.0 18.9 15g Br 41 NH, 2:1 6117.0 1114.0 >10,000 167.1 50.3 59.5 o 895.0 36.0 68.6 2.7 20.5 Cmp Trans: Ci Binding (Ki, nM) Reuptalce (TC50, nM) Structures d s hDAT hSERT hNET hDAT hSERT
hNET
15h F 0 F F 0 NH2 1.5:1 >10,000 2126.0 634.0 4589 225.0 1541.0 F 1180.0 179.0 692.0 88.0 99.0 F
17d -1.--------..\/o)--------------NH, 2:1 >10,000 3822.3 >10,000 564.8 2260 347 881.8 154 203 70.1 151 _.,---..,Ni----------N1 1, 4546.0 8517.3 2721.3 I 2:1 >10,000 2125.9 977.0 >10,000 718.2 >10,000 15j ll,c0 4I 0 NH, 2:1 >10,000 6877.0 2013.0 667.5 617.1+ 92.0 414.0 67.0 214.8 150.2 29.5 17e no 111 0 NH 5498.0 7483.0 5947.0 2532+ 4041 2126 1.5:1 381.0 977.0 550.0 298 845 345 15k NH, 2:1 >10,000 >10,000 4543.0+ 4300.7 636.5 2322.3 266.0 918.9 190.7 800.7 17f 1 \ 0 o NH' 1:1 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 a Drug inhibition of [1251]-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET
cell membranes. Values represent the mean 1 SEM for three to four experiments unless the mean of three experiments exceeded 10 ILIM;
b ND, not done.
cells by 2,5-disubstituted tetrahydrofuran analogsa n1 n1 Cmp Trans:Ci Binding (1(1, nM) Reuptake (TC50, nM) Structures d s hDAT hSERT hNET hDAT hSERT hNET
Cocaine 371.2 276.7 1115.7 590 642 1281 15a 4111 0 NI12 18.5 23,3 3420.0 2:1 >10,000 0.8 >10,000 >10,000 IP 2.6 655.0 15b916.0 1 430 2767.0 147.3 1714.0 4111 0 NH2 2:1 23.0 1 5.0 12.0 11.0 111.0 22.2 437.0 15c 4111 512.0 45.0 28.0 4.1 58.5 W. 0 2:1 >10 k N112 33.0 4.0 10 0.8 13.8 15d . 0 N112 2:1 1505 68 2736 513.0 129.0 360.0 278 10 480 68.0 38.0 14.8 17a 10 , OCII 85.6 mi' 2:1 >10,000 >10,000 NDb ND ND
lir 9.2 17b . NII, 92.3 2:1 >10,000 >10,000 ND ND ND
110 19.1 15e 41 0 NI12 1.5:1 8519.0 174.0 1494.0 463.0 24.0 210.0 0 229.0 32.0 88.0 119 1.2 19.5 17c r 40 0 ""' 1.5:16376.0 688.0 882.0 509.0 30.0 374.0 893.0 119.0 22.0 136.0 4.0 110.0 15f a 4, 0 6830.0 1105.0 1106.0 313.1 31.9 61.2 NH, 2:1 419.0 110.0 203.0 76.1 4.0 18.9 15g Br 41 NH, 2:1 6117.0 1114.0 >10,000 167.1 50.3 59.5 o 895.0 36.0 68.6 2.7 20.5 Cmp Trans: Ci Binding (Ki, nM) Reuptalce (TC50, nM) Structures d s hDAT hSERT hNET hDAT hSERT
hNET
15h F 0 F F 0 NH2 1.5:1 >10,000 2126.0 634.0 4589 225.0 1541.0 F 1180.0 179.0 692.0 88.0 99.0 F
17d -1.--------..\/o)--------------NH, 2:1 >10,000 3822.3 >10,000 564.8 2260 347 881.8 154 203 70.1 151 _.,---..,Ni----------N1 1, 4546.0 8517.3 2721.3 I 2:1 >10,000 2125.9 977.0 >10,000 718.2 >10,000 15j ll,c0 4I 0 NH, 2:1 >10,000 6877.0 2013.0 667.5 617.1+ 92.0 414.0 67.0 214.8 150.2 29.5 17e no 111 0 NH 5498.0 7483.0 5947.0 2532+ 4041 2126 1.5:1 381.0 977.0 550.0 298 845 345 15k NH, 2:1 >10,000 >10,000 4543.0+ 4300.7 636.5 2322.3 266.0 918.9 190.7 800.7 17f 1 \ 0 o NH' 1:1 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 a Drug inhibition of [1251]-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET
cell membranes. Values represent the mean 1 SEM for three to four experiments unless the mean of three experiments exceeded 10 ILIM;
b ND, not done.
Table 10. Inhibition of radioligand binding in HEK-hDAT, HEK-hSERT, and HEK-Iil\TET
cells by 2,5-disubstituted tetrahydrofuran analogs with a methoxy flouro substituted aromatic group' 441) Me0 fl1 0 n2 Cmpd Isomers Chain Length Binding (K1, nM) Reuptake (IC% nM) n1 n2 total hDAT hSERT hNET hDAT hSERT 11NET
18a trans 0 1 1 >10,000 6307.3+ 71991.5 >10,000 2071.0 >10,000 790.4 4395.5 903.1 18b trans:cis 0 1 1 42764.3 6885.8 57015.9 >10,000 9029.0 >10,000 1.5:1 56016.1 1645.5 13820.0 12154.2 18c trans 0 2 2 32934.5 1808.1 27495.3 >10,000 1117.4 >10,000 21884.8 616.2 5017.8 812.8 18d cis 0 2 2 >10,000 4772.3 48874.3 >10,000 2575.7 >10,000 297.0 10868.4 424.4 18e trans 1 1 2 27238.0 192.0 24116.0 28935.0 122.0 7983.0 10600.0 25.0 3005.0 1866.0 40.0 1966.0 181 cis 1 1 2 97181.0 151.0 9085.0 18675.0 111.0 3392.0 11971.0 20.0 1600.0 3384.0 37.0 1278.0 18g trans 1 2 3 51018.0 20.0 1782.0 38435.0 27.0 1774.0 847.0 1.0 313.0 14472 8.0 566.0 18h cis 1 2 3 34791.0 21.0 455.0 36335.0 23.0 1864.0 125.0 2.0 44.0 9680.0 6.0 536.0 181 trans 2 1 3 14499.0 3.2 5993.0 8555.0 2.5 628.0 3185.0 0.2 283.0 741.0 0.7 66.0 18j cis 2 1 3 30316.0 21.9 8520.0 34303.0 11.7 4746.0 3020.0 3.6 108.0 7696.0 3.0 1608.0 18k trans 2 2 4 6500.0 2.1 + 2440.0 27850.0 2.5 481.0 Me0 fl1 0 n2 Cmpd Isomers Chain Length Binding (Kb nM) Reuptake nM) n1 n2 total hDAT hSERT hNET hDAT hSERT hNET
828.0 0.2 215.0 5129.0 0.6 158.0 181 cis 2 2 4 16371.0 19.3 12100.0 36710.0 17.5 3101.0+
2006.0 0.9 810.0 1174.0 2.7 1243.0 18m trans 3 1 4 7328.0 0.8 8541.0 7618.3 2.1 2934.0 315.0 0.3 1289.0 722.6 0.6 611.0 18n cis 3 1 4 4576.01 2.8 20180.0 6288.0 2.6 2857.0 1112.0 0.1 2470.0 1470.0 0.7 539.0 18o trans:cis 3 2 5 7307.0 1.1 10600.0 16987 2.3 1930.0+
2.5:1 1331.0 0.1 1880.0 1352 0.6 463.0 18p trans:cis 3 2 5 21186.0 7.0 30430.0 41257.0 7.4 1:3 2687.0 0.8 1630.0 11506.0 0.3 1742.0 18q trans 4 1 5 3868.0 1 4.0 2222.0 16540.0 84.0 7124.0 423.0 1.1 350.0 4025.0 31.0 2043.0 18r trans:cis 4 2 6 3387.0 2.0 4064.0 37460.0 31.0 8530.0 1:1 266.0 0.7 1204.0 1854 9.0 1511.0 a Drug inhibition of [1251]-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET
cell membranes. Values represent the mean SEM for three to four experiments unless the mean of three experiments exceeded 101.1M.
cells by 2,5-disubstituted tetrahydrofuran analogs with a methoxy flouro substituted aromatic group' 441) Me0 fl1 0 n2 Cmpd Isomers Chain Length Binding (K1, nM) Reuptake (IC% nM) n1 n2 total hDAT hSERT hNET hDAT hSERT 11NET
18a trans 0 1 1 >10,000 6307.3+ 71991.5 >10,000 2071.0 >10,000 790.4 4395.5 903.1 18b trans:cis 0 1 1 42764.3 6885.8 57015.9 >10,000 9029.0 >10,000 1.5:1 56016.1 1645.5 13820.0 12154.2 18c trans 0 2 2 32934.5 1808.1 27495.3 >10,000 1117.4 >10,000 21884.8 616.2 5017.8 812.8 18d cis 0 2 2 >10,000 4772.3 48874.3 >10,000 2575.7 >10,000 297.0 10868.4 424.4 18e trans 1 1 2 27238.0 192.0 24116.0 28935.0 122.0 7983.0 10600.0 25.0 3005.0 1866.0 40.0 1966.0 181 cis 1 1 2 97181.0 151.0 9085.0 18675.0 111.0 3392.0 11971.0 20.0 1600.0 3384.0 37.0 1278.0 18g trans 1 2 3 51018.0 20.0 1782.0 38435.0 27.0 1774.0 847.0 1.0 313.0 14472 8.0 566.0 18h cis 1 2 3 34791.0 21.0 455.0 36335.0 23.0 1864.0 125.0 2.0 44.0 9680.0 6.0 536.0 181 trans 2 1 3 14499.0 3.2 5993.0 8555.0 2.5 628.0 3185.0 0.2 283.0 741.0 0.7 66.0 18j cis 2 1 3 30316.0 21.9 8520.0 34303.0 11.7 4746.0 3020.0 3.6 108.0 7696.0 3.0 1608.0 18k trans 2 2 4 6500.0 2.1 + 2440.0 27850.0 2.5 481.0 Me0 fl1 0 n2 Cmpd Isomers Chain Length Binding (Kb nM) Reuptake nM) n1 n2 total hDAT hSERT hNET hDAT hSERT hNET
828.0 0.2 215.0 5129.0 0.6 158.0 181 cis 2 2 4 16371.0 19.3 12100.0 36710.0 17.5 3101.0+
2006.0 0.9 810.0 1174.0 2.7 1243.0 18m trans 3 1 4 7328.0 0.8 8541.0 7618.3 2.1 2934.0 315.0 0.3 1289.0 722.6 0.6 611.0 18n cis 3 1 4 4576.01 2.8 20180.0 6288.0 2.6 2857.0 1112.0 0.1 2470.0 1470.0 0.7 539.0 18o trans:cis 3 2 5 7307.0 1.1 10600.0 16987 2.3 1930.0+
2.5:1 1331.0 0.1 1880.0 1352 0.6 463.0 18p trans:cis 3 2 5 21186.0 7.0 30430.0 41257.0 7.4 1:3 2687.0 0.8 1630.0 11506.0 0.3 1742.0 18q trans 4 1 5 3868.0 1 4.0 2222.0 16540.0 84.0 7124.0 423.0 1.1 350.0 4025.0 31.0 2043.0 18r trans:cis 4 2 6 3387.0 2.0 4064.0 37460.0 31.0 8530.0 1:1 266.0 0.7 1204.0 1854 9.0 1511.0 a Drug inhibition of [1251]-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET
cell membranes. Values represent the mean SEM for three to four experiments unless the mean of three experiments exceeded 101.1M.
Table 11. Calculated correlation ratios for binding and reuptake selectivity for hSERT
Binding Selectivity Reuptake Selectivity hDAT/hSERT hNET/hSERT hDAT/hSERT hNET/hSERT
Compound Ki/Ki K1/K1 IC50/1050 IC50/1050 18a 1.6 11.4 4.8 4.8 18b 6.2 8.3 1.1 1.1 18c 18.2 15.2 8.9 8.9 18d 2.1 10.2 3.9 3.9 18e 141.9 125.6 237.2 65.4 181 643.6 60.2 168.2 30.6 18g 2550.9 89.1 1423.5 65.7 18h 1656.7 21.7 1579.8 81.0 181 4530.9 1872.8 3422.0 251.2 18j 1384.3 389.0 2931.9 405.6 18k 3095.2 1161.9 11140.0 192.4 181 848.2 626.9 2097.7 177.2 18m 9160.0 10676.3 3627.8 1397.1 18n 1634.3 7207.1 2418.5 1098.8 18o 6642.7 9636.4 7385.7 839.1 18p 3026.6 4347.1 5575.3 693.6 18q 967.0 555.5 196.9 84.8 18r 1693.5 2032.0 1208.4 275.2 WO 2006/025920 PCT/US2005/021818.
Table 12. Calculated correlation ratios of uptake inhibition to binding affinity for the hSERT
hSERT
Compound IC50/ Kia 18a 0.33 18b 1.31 18c 0.62 18d 0.54 18e 0.64 18f 0.74 18g 1.35 18h 1.10 181 0.78 18j 0.53 18k 1.19 181 0.91 18m 2.63 18n 0.93 18o 2.09 18p 1.06 18q 21.00 18r 15.50 a The IC50 value for potency of uptake inhibition was divided by the Ki value for potency of binding to obtain the correlation ratio listed.
Binding Selectivity Reuptake Selectivity hDAT/hSERT hNET/hSERT hDAT/hSERT hNET/hSERT
Compound Ki/Ki K1/K1 IC50/1050 IC50/1050 18a 1.6 11.4 4.8 4.8 18b 6.2 8.3 1.1 1.1 18c 18.2 15.2 8.9 8.9 18d 2.1 10.2 3.9 3.9 18e 141.9 125.6 237.2 65.4 181 643.6 60.2 168.2 30.6 18g 2550.9 89.1 1423.5 65.7 18h 1656.7 21.7 1579.8 81.0 181 4530.9 1872.8 3422.0 251.2 18j 1384.3 389.0 2931.9 405.6 18k 3095.2 1161.9 11140.0 192.4 181 848.2 626.9 2097.7 177.2 18m 9160.0 10676.3 3627.8 1397.1 18n 1634.3 7207.1 2418.5 1098.8 18o 6642.7 9636.4 7385.7 839.1 18p 3026.6 4347.1 5575.3 693.6 18q 967.0 555.5 196.9 84.8 18r 1693.5 2032.0 1208.4 275.2 WO 2006/025920 PCT/US2005/021818.
Table 12. Calculated correlation ratios of uptake inhibition to binding affinity for the hSERT
hSERT
Compound IC50/ Kia 18a 0.33 18b 1.31 18c 0.62 18d 0.54 18e 0.64 18f 0.74 18g 1.35 18h 1.10 181 0.78 18j 0.53 18k 1.19 181 0.91 18m 2.63 18n 0.93 18o 2.09 18p 1.06 18q 21.00 18r 15.50 a The IC50 value for potency of uptake inhibition was divided by the Ki value for potency of binding to obtain the correlation ratio listed.
Table 13. Effect of Hepatic Microsomes on Metabolic Stability of SSRIs MLMa RLMb Compound t1/2 (min) k t112 (min) 18k/1 56.0 0.0124 106.3 0.00652 20 58.5 0.0118 129.0 0.00537 a MLM, mouse liver microsomes;
b RLM, rat liver microsomes.
Example 29: Dual inhibitors of Phosphodiesterase-4 and Serotonin Reuptake [0438] A new class of compounds showing antidepressant-like activity in the forced swim test in mice was synthesized by linking a novel selective serotonin reuptake inhibitor (S SRI) to a PDE4 inhibitor. The SSRIs 2-aminoethy1-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran and 2-aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrofuran were both individually linked to the PDE4 inhibitor 443,4-dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one via a five carbon chain. The dual PDE4 inhibitor/SSRI showed potent and selective serotonin reuptake inhibition (ICso values of 127-194 nM). The dual PDE4 inhibitor/SSRI also inhibited PDE4D3 with Ki values ranging from 1.2-2.0 nM. The dual PDE4 inhibitor/SSRI was significantly more effective than the individual SSRI alone or fluoxetine at standard doses and on a molar basis, the antidepressant-like effect of the dual PDE4 inhibitor/SSRI 21 showed a 129-fold increase in in vivo efficacy compared to fluoxetine.
Introduction [0439] A central hypothesis is that anti-depressant activity is due to a deficiency of excitatory neurotransmitters at post-synaptic sites of the brain. This has been an attractive theory because tricyclics inhibit the re-uptake of certain biogenic amines including norepinephrine (NE), serotonin (5-HT) and dopamine (DA). Agents such as fluoxetine and fluvoxamine are selective serotonin reuptake inhibitors (SSRIs). Although the biogenic amine/selective uptake inhibitor theory has achieved considerable prominence, much remains to be discovered concerning existing anti-depressant therapies as well as new modalities.
[0440] Conventional tricyclic anti-depressants may require 1 to 4 weeks of therapy to observe clinical improvement and may involve longer-term adaptive changes in receptor sensitivity. Animals treated repeatedly with SSRIs, such as fluoxetine, down-regulate the serotonin transporter (SERT). The extent of SSRI uptake inhibition after repeated treatment is greater than that observed after acute drug treatment. This results in progressive increase in extracellular 5-HT concentrations and stimulation of postsynaptic receptors.
Tricyclics are extensively metabolized and high concentrations are found in the liver, lung and brain.
Metabolism of antidepressants may play a significant role in overall efficacy.
With acute treatment, SSRIs will increase 5-HT receptor-mediated cAMP signaling. Upon repeated treatment with SSRIs, this effect will be blunted (i.e., some tolerance development), since phosphodiesterases (PDEs) are up-regulated and cAMP hydrolysis is increased.
[0441] Cyclic nucleotide PDEs comprise a diverse group of enzymes that are important regulators of signal transduction pathways (Beavo et al., MoL Pharmacol., 46, (1994); Conti, M. and Jin, S.L., Frog. Nucleic Acid Res., 63, 1-38 (1999);
Houslay, M.D., Frog. Nucleic Acid Res. MoL Biol., 69, 249-315 (2001); Loughney, K. and Ferguson, K., "Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods," in Phosphodiesterase Inhibitors; Schudt et al., Eds.; Academic Press: San Diego;
pp 1-19 (1996)). PDEs within a family that are coded by distinct genes, (e.g., PDE4A, PDE4B, PDE4C, and PDE4D), are referred to as "subtypes" and their selective inhibitors as "subtype-selective" inhibitors. Enzymes in the PDE4 family have been shown to be particularly important in neuropsychopharmacology (Houslay, M.D., Frog.
Nucleic Acid Res.
MoL Biol., 69, 249-315 (2001)). PDE4 hydrolyzes cAMP formed by stimulation of beta adrenergic receptor-linked adenylyl cyclase in rat cerebral cortical slices (Ye, Y. and O'Donnell, J. M., J. Neurochem., 66, 1894-1902 (1996)). Rolipram, a selective inhibitor of PDE4, has been reported to have antidepressant activity in both preclinical and clinical tests and to produce memory-enhancing effects in a number of animal models. It has been shown that increased cAMP increases the expression of a number of PDE4 variants in neurons.
Thus, in this case, the adaptation of PDE4 that occurs in response to repeated treatment with SSRIs is homeostatic and in opposition to the acute effect of the drugs.
[0442] Selective inhibitors of PDE4, such as rolipram, produce antidepressant-like effects in a number of preclinical tests sensitive to antidepressants. They antagonize the behavioral and physiological effects of reserpine (Wachtel, H., J. Pharm. Pharmacol., 35, (1983); Wachtel et al., Neuropharmacology, 25, 1119-1126 (1986)) reduce the time of immobility in the forced-swim test in rats and mice (Overstreet, D.H., Neurosci. Biobehav.
Rev., 17, 51-68 (1993); Saccomano et al., J. Med. Chem., 34, 291-298 (1991);
Zhang et al., Neuro-psychopharmacology, 27, 587-595 (2002)) and reduce response rate and increase reinforcement rate of rats under a differential-reinforcement-of-low-rate (DRL) schedule (O'Donnell, J.M., J. Pharmacol. Exp. Ther., 254, 147-157 (1990); O'Donnell, J.
M. and Frith, S., Pharmacol. Biochem. Behav., 63, 185-192 (1999)). Results of a number of clinical reports support the conclusion that PDE4 inhibitors have antidepressant activity (Eckmann et al., Cum Ther. Res. 43, 291-295 (1988); Fleischhacker et al., Neuropsycho biology, 26, 59-64 (1992); Horowski et al., Curr. Ther. Res., 38, 23-29 (1985); Scott et al., Eur. J. Clin.
Pharmacol., 40, 127-129 (1991); Zeller et al., Pharmacopsychiatry, 17, 188-190 (1984)).
[0443] If tricyclics and fluoxetine produce their effects in part via activation of cAMP
signaling, then loss of the PDE4 subtype involved in this pathway actually would enhance their ability to increase cAMP and alter subsequent pharmacology. Dual PDE4 inhibitor/SSRIs offer advantages beyond simple additive effects. Dual PDE4 inhibitors/SSRIs block the effect of the up-regulation of PDE4. The overall increase in 5-HT-mediated cAMP signaling will be preserved with repeated treatment. To verify this hypothesis, an SSRI was chemically linked to a PDE4 inhibitor and the dual inhibitor/SSRI was examined in vitro and in vivo for pharmacological activity.
Results PDE4 inhibitors [0444] Compound 19 is a known PDE4 inhibitor (Van der Mey et al., J Med Chem., 44, 2523-2535 (2001)) and derivatives were synthesized to examine whether additional pharmacological properties could be introduced into 19 while still preserving inhibitory activity. Thus, a template with potent PDE4 inhibitory activity was chemically combined with a molecule possessing potent SSRI function to make a compound with a dual inhibitory profile. Compounds 19, 21, and 22 were tested for.inhibition of cAMP hydrolysis by recombinant isoforms of human PDE4D3, human PDE4B3, and human PDE4A1, in vitro.
The Ki value for inhibition of human PDE4D3 for 19, 21 and 22 was 6.3,nM, 2.0 nM and 1.2 nM, respectively (see Table 14). The increase in potency for 21 and 22 compared with 19 suggested that N-substitution increased inhibition of human PDE4D (Van der Mey et al., J.
Med. Chem., 45, 2526-2533 (2002)). For human PDE4B3, the Ki values for inhibition of cAMP hydrolysis for 19, 21 and 22 were 250 nM, 199 nM and 500 nM, respectively. In the case of human PDE4A1, compounds 19, 21 and 22 all showed Ki values for inhibition of cAMP hydrolysis with values greater than 1 M. Thus, 19, 21 and 22 possessed PDE4B3/PDE4D3 and PDE4A1/PDE4D3 inhibitory selectivity ratios of 40-, 100-, 417- and <159-, <500- and <833-fold, respectively.
Selective Serotonin Reuptake Inhibitors [0445] Compounds 14 and 15 were derived from molecular dissection of aryltropanes (Feng et al., Bioorg. Med. Chem., 11, 775-780 (2003)) and are potent inhibitors of serotonin reuptake (see Table 15). Compounds 19, 20, 21, and 22 were also tested for binding and reuptake inhibition of the human DA transporter (hDAT), the human serotonin transporter (hSERT), and the human norepinephrine transporter (hNET), in vitro. Compounds 14 and 15 were potent inhibitors of radiolabeled RTI-55 binding to the hSERT values of 2.1 and 1.1 nM, respectively) (see Table 15). Compounds 14 and 15 were equal to or more potent and selective than fluoxetine in reuptake inhibition of the hSERT. Compounds related to the PDE4 inhibitor (i.e., 19 and 20) were ineffective at inhibiting RTI-55 binding to the hSERT
values >109p,M). For inhibition of neurotransmitter uptake, 14 and 15 were most efficacious valaues of 2.5 and 2.3 nM, respectively) (see Table 15). For 14 and 15, the selectivity of either binding potency or reuptake efficacy for hSERT was very large.
Thus, the binding selectivity ratios Ki(hDAT)/Ki(hSERT) and Ki(hNET)/Ki(hSERT) for 14 and 15 were 3095, 1162 and 6642, 9636, respectively. The reuptake inhibition selectivity ratios IC50(hDAT)/IC50(hSERT) and IC50(hNET)/IC50(hSERT) for 14 and 15 were 11,140, 192 and 7386, 839, respectively. The PDE4 inhibitors 19 and 20 had essentially no measurable effect on inhibition of radiolabeled RTI-55 binding or reuptake of any of the neurotransmitter transporters examined (see Table 15).
Dual PDE4 inhibitor/SSRIs [0446] The dual PDE4 inhibitor/S SRIs (i.e., compounds 21 and 22) were potent inhibitors of binding of radiolabeled RTI-55 to the hSERT having Ki values for of 156 and 194 nM, respectively. For compounds 21 and 22, inhibition of neurotransmitter uptake was highly selective for the hSERT (i.e., IC50 values of 127 and 104 nM, respectively) (see Table 15).
For 21 and 22, the selectivity of either binding potency or reuptake efficacy was greatest for hSERT. Thus, the binding selectivity ratios Ki(hDAT)/Ki(hSERT) and Ki(hNET)/Ki(hSERT) for 21 and 22 were 16, 11 and 28, 38, respectively. The reuptake inhibition selectivity ratios IC50(hDAT)/IC50(hSERT) and IC50(hNET)/IC50(hSERT) for 21 and 22 were 28, 8 and 28, and 38, respectively. In so far as the pharmacological values of Table 15 are concerned, SSRIs 14 and 15 cannot be directly compared with dual PDE4 inhibitor/SSRIs 21 and 22 because the former are pure trans diastereomers and the latter are a mixture of diastereomers.
b RLM, rat liver microsomes.
Example 29: Dual inhibitors of Phosphodiesterase-4 and Serotonin Reuptake [0438] A new class of compounds showing antidepressant-like activity in the forced swim test in mice was synthesized by linking a novel selective serotonin reuptake inhibitor (S SRI) to a PDE4 inhibitor. The SSRIs 2-aminoethy1-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrofuran and 2-aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrofuran were both individually linked to the PDE4 inhibitor 443,4-dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one via a five carbon chain. The dual PDE4 inhibitor/SSRI showed potent and selective serotonin reuptake inhibition (ICso values of 127-194 nM). The dual PDE4 inhibitor/SSRI also inhibited PDE4D3 with Ki values ranging from 1.2-2.0 nM. The dual PDE4 inhibitor/SSRI was significantly more effective than the individual SSRI alone or fluoxetine at standard doses and on a molar basis, the antidepressant-like effect of the dual PDE4 inhibitor/SSRI 21 showed a 129-fold increase in in vivo efficacy compared to fluoxetine.
Introduction [0439] A central hypothesis is that anti-depressant activity is due to a deficiency of excitatory neurotransmitters at post-synaptic sites of the brain. This has been an attractive theory because tricyclics inhibit the re-uptake of certain biogenic amines including norepinephrine (NE), serotonin (5-HT) and dopamine (DA). Agents such as fluoxetine and fluvoxamine are selective serotonin reuptake inhibitors (SSRIs). Although the biogenic amine/selective uptake inhibitor theory has achieved considerable prominence, much remains to be discovered concerning existing anti-depressant therapies as well as new modalities.
[0440] Conventional tricyclic anti-depressants may require 1 to 4 weeks of therapy to observe clinical improvement and may involve longer-term adaptive changes in receptor sensitivity. Animals treated repeatedly with SSRIs, such as fluoxetine, down-regulate the serotonin transporter (SERT). The extent of SSRI uptake inhibition after repeated treatment is greater than that observed after acute drug treatment. This results in progressive increase in extracellular 5-HT concentrations and stimulation of postsynaptic receptors.
Tricyclics are extensively metabolized and high concentrations are found in the liver, lung and brain.
Metabolism of antidepressants may play a significant role in overall efficacy.
With acute treatment, SSRIs will increase 5-HT receptor-mediated cAMP signaling. Upon repeated treatment with SSRIs, this effect will be blunted (i.e., some tolerance development), since phosphodiesterases (PDEs) are up-regulated and cAMP hydrolysis is increased.
[0441] Cyclic nucleotide PDEs comprise a diverse group of enzymes that are important regulators of signal transduction pathways (Beavo et al., MoL Pharmacol., 46, (1994); Conti, M. and Jin, S.L., Frog. Nucleic Acid Res., 63, 1-38 (1999);
Houslay, M.D., Frog. Nucleic Acid Res. MoL Biol., 69, 249-315 (2001); Loughney, K. and Ferguson, K., "Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods," in Phosphodiesterase Inhibitors; Schudt et al., Eds.; Academic Press: San Diego;
pp 1-19 (1996)). PDEs within a family that are coded by distinct genes, (e.g., PDE4A, PDE4B, PDE4C, and PDE4D), are referred to as "subtypes" and their selective inhibitors as "subtype-selective" inhibitors. Enzymes in the PDE4 family have been shown to be particularly important in neuropsychopharmacology (Houslay, M.D., Frog.
Nucleic Acid Res.
MoL Biol., 69, 249-315 (2001)). PDE4 hydrolyzes cAMP formed by stimulation of beta adrenergic receptor-linked adenylyl cyclase in rat cerebral cortical slices (Ye, Y. and O'Donnell, J. M., J. Neurochem., 66, 1894-1902 (1996)). Rolipram, a selective inhibitor of PDE4, has been reported to have antidepressant activity in both preclinical and clinical tests and to produce memory-enhancing effects in a number of animal models. It has been shown that increased cAMP increases the expression of a number of PDE4 variants in neurons.
Thus, in this case, the adaptation of PDE4 that occurs in response to repeated treatment with SSRIs is homeostatic and in opposition to the acute effect of the drugs.
[0442] Selective inhibitors of PDE4, such as rolipram, produce antidepressant-like effects in a number of preclinical tests sensitive to antidepressants. They antagonize the behavioral and physiological effects of reserpine (Wachtel, H., J. Pharm. Pharmacol., 35, (1983); Wachtel et al., Neuropharmacology, 25, 1119-1126 (1986)) reduce the time of immobility in the forced-swim test in rats and mice (Overstreet, D.H., Neurosci. Biobehav.
Rev., 17, 51-68 (1993); Saccomano et al., J. Med. Chem., 34, 291-298 (1991);
Zhang et al., Neuro-psychopharmacology, 27, 587-595 (2002)) and reduce response rate and increase reinforcement rate of rats under a differential-reinforcement-of-low-rate (DRL) schedule (O'Donnell, J.M., J. Pharmacol. Exp. Ther., 254, 147-157 (1990); O'Donnell, J.
M. and Frith, S., Pharmacol. Biochem. Behav., 63, 185-192 (1999)). Results of a number of clinical reports support the conclusion that PDE4 inhibitors have antidepressant activity (Eckmann et al., Cum Ther. Res. 43, 291-295 (1988); Fleischhacker et al., Neuropsycho biology, 26, 59-64 (1992); Horowski et al., Curr. Ther. Res., 38, 23-29 (1985); Scott et al., Eur. J. Clin.
Pharmacol., 40, 127-129 (1991); Zeller et al., Pharmacopsychiatry, 17, 188-190 (1984)).
[0443] If tricyclics and fluoxetine produce their effects in part via activation of cAMP
signaling, then loss of the PDE4 subtype involved in this pathway actually would enhance their ability to increase cAMP and alter subsequent pharmacology. Dual PDE4 inhibitor/SSRIs offer advantages beyond simple additive effects. Dual PDE4 inhibitors/SSRIs block the effect of the up-regulation of PDE4. The overall increase in 5-HT-mediated cAMP signaling will be preserved with repeated treatment. To verify this hypothesis, an SSRI was chemically linked to a PDE4 inhibitor and the dual inhibitor/SSRI was examined in vitro and in vivo for pharmacological activity.
Results PDE4 inhibitors [0444] Compound 19 is a known PDE4 inhibitor (Van der Mey et al., J Med Chem., 44, 2523-2535 (2001)) and derivatives were synthesized to examine whether additional pharmacological properties could be introduced into 19 while still preserving inhibitory activity. Thus, a template with potent PDE4 inhibitory activity was chemically combined with a molecule possessing potent SSRI function to make a compound with a dual inhibitory profile. Compounds 19, 21, and 22 were tested for.inhibition of cAMP hydrolysis by recombinant isoforms of human PDE4D3, human PDE4B3, and human PDE4A1, in vitro.
The Ki value for inhibition of human PDE4D3 for 19, 21 and 22 was 6.3,nM, 2.0 nM and 1.2 nM, respectively (see Table 14). The increase in potency for 21 and 22 compared with 19 suggested that N-substitution increased inhibition of human PDE4D (Van der Mey et al., J.
Med. Chem., 45, 2526-2533 (2002)). For human PDE4B3, the Ki values for inhibition of cAMP hydrolysis for 19, 21 and 22 were 250 nM, 199 nM and 500 nM, respectively. In the case of human PDE4A1, compounds 19, 21 and 22 all showed Ki values for inhibition of cAMP hydrolysis with values greater than 1 M. Thus, 19, 21 and 22 possessed PDE4B3/PDE4D3 and PDE4A1/PDE4D3 inhibitory selectivity ratios of 40-, 100-, 417- and <159-, <500- and <833-fold, respectively.
Selective Serotonin Reuptake Inhibitors [0445] Compounds 14 and 15 were derived from molecular dissection of aryltropanes (Feng et al., Bioorg. Med. Chem., 11, 775-780 (2003)) and are potent inhibitors of serotonin reuptake (see Table 15). Compounds 19, 20, 21, and 22 were also tested for binding and reuptake inhibition of the human DA transporter (hDAT), the human serotonin transporter (hSERT), and the human norepinephrine transporter (hNET), in vitro. Compounds 14 and 15 were potent inhibitors of radiolabeled RTI-55 binding to the hSERT values of 2.1 and 1.1 nM, respectively) (see Table 15). Compounds 14 and 15 were equal to or more potent and selective than fluoxetine in reuptake inhibition of the hSERT. Compounds related to the PDE4 inhibitor (i.e., 19 and 20) were ineffective at inhibiting RTI-55 binding to the hSERT
values >109p,M). For inhibition of neurotransmitter uptake, 14 and 15 were most efficacious valaues of 2.5 and 2.3 nM, respectively) (see Table 15). For 14 and 15, the selectivity of either binding potency or reuptake efficacy for hSERT was very large.
Thus, the binding selectivity ratios Ki(hDAT)/Ki(hSERT) and Ki(hNET)/Ki(hSERT) for 14 and 15 were 3095, 1162 and 6642, 9636, respectively. The reuptake inhibition selectivity ratios IC50(hDAT)/IC50(hSERT) and IC50(hNET)/IC50(hSERT) for 14 and 15 were 11,140, 192 and 7386, 839, respectively. The PDE4 inhibitors 19 and 20 had essentially no measurable effect on inhibition of radiolabeled RTI-55 binding or reuptake of any of the neurotransmitter transporters examined (see Table 15).
Dual PDE4 inhibitor/SSRIs [0446] The dual PDE4 inhibitor/S SRIs (i.e., compounds 21 and 22) were potent inhibitors of binding of radiolabeled RTI-55 to the hSERT having Ki values for of 156 and 194 nM, respectively. For compounds 21 and 22, inhibition of neurotransmitter uptake was highly selective for the hSERT (i.e., IC50 values of 127 and 104 nM, respectively) (see Table 15).
For 21 and 22, the selectivity of either binding potency or reuptake efficacy was greatest for hSERT. Thus, the binding selectivity ratios Ki(hDAT)/Ki(hSERT) and Ki(hNET)/Ki(hSERT) for 21 and 22 were 16, 11 and 28, 38, respectively. The reuptake inhibition selectivity ratios IC50(hDAT)/IC50(hSERT) and IC50(hNET)/IC50(hSERT) for 21 and 22 were 28, 8 and 28, and 38, respectively. In so far as the pharmacological values of Table 15 are concerned, SSRIs 14 and 15 cannot be directly compared with dual PDE4 inhibitor/SSRIs 21 and 22 because the former are pure trans diastereomers and the latter are a mixture of diastereomers.
Finally, the data shows that SSRIs 14 and 15 and the PDE4 inhibitor/SSRIs 21 and 22 were relatively selective for the hSERT and did not potently interact with hDAT or hNET (Table 15).
In Vivo Studies [0447] The PDE4 inhibitor (i.e., 19), the SSRI (i.e., 14) and the dual PDE4 inhibitor/SSRI
(i.e., 21) were examined for acute and subchronic antidepressant-like effects in vivo. (See Figure 15.) Acute treatment of ICR mice with either 19 or 21, at doses of 0.3 and 3 mg/kg, decreased duration of immobility in a dose-dependent manner in the forced-swim test (FST).
Compared to vehicle control, the higher dose of 19 or 21 (3 mg/kg) significantly reduced immobility in the FST (P <0.05). In contrast, acute administration of fluoxetine (40 mg/kg) or repeated treatment with rolipram (0.5 mg/kg, i.p., once a day for 8 days) was required to produce similar antidepressant-like effects in the FST (Zhang et al., Neuro-psychopharmacology, 27, 587-595 (2002)). On a molar basis, compound 21 (0.5 mol/kg) was 129-fold more efficacious than fluoxetine (65 p,mol/kg) in the FST. Acute treatment with rolipram (0.5 mg/kg, did not alter FST behavior in agreement with the literature (Zhang et al., Neuro-psychopharmacology, 27, 587-595 (2002)). The SSRI, compound 14, at the doses used (i.e., 10 and 30 mg/kg) tended to decrease immobility, but it was not statistically significant.
[0448] Because Balb/c mice have been reported to exhibit a relatively high immobility baseline and are sensitive to fluoxetine challenge in the FST (Lucid et al., Psychopharmacology, 155, 315-322 (2001)) the in vivo studies described above were repeated. Acute administration of fluoxetine (20 mg/kg), 14 (10 mg/kg), or 15 (10 mg/kg) did not markedly alter the duration of immobility in the FST in Balb/c mice.
(See Figure 16.) In contrast, subchronic administration of a lower dose of fluoxetine (10 mg/kg) significantly decreased immobility (P <0.05). (See Figure 17.) However, subchronic treatment with 14 (10 mg/kg) or 21 (1 mg/kg) did not change immobility compared to vehicle control. (See id.) It is possible that these in vivo results for 14 or 15 were a consequence of metabolic instability. To test this possibility, the in vitro metabolic stability of 14, 15, 19, 21, 22 and 24 was examined.
In Vitro Metabolic Studies [0449] The in vitro metabolism of compounds 14, 15, and 24 were examined in the presence of mouse and human liver microsomes supplemented with NADPH to examine the metabolic stability of the compounds. Compounds 19, 21 and 22 were examined in the presence of mouse and human liver microsomes supplemented with NADPH. An efficient HPLC method was established to afford separation of the starting material from any putative metabolites (e.g., aldehyde, hydroxylamine, nitrone). Aerobic incubations of 14 and 24 in the presence of mouse and rat liver microsomes supplemented with NADPH showed a time-dependent loss of substrate. For 14 and 24, the calculated half life was 56 or 106 and 58 or 129 mins, respectively, in the presence of mouse and rat liver microsomes (see Table 16). In the presence of mouse liver microsomes, compounds 19 and 21 showed considerable metabolic stability having calculated half lives of 211 and 154 mins, respectively.
Compound 21 was not detectably metabolized in the presence of human liver microsomes.
No detectable metabolic instability of compound 22 was observed in the presence of either mouse or human liver microsomes up to 60 mm (see Table 16).
Discussion [0450] A dual PDE4 inhibitor/SSRI was synthesized by linking an SSRI with a inhibitor via a five carbon linker. Previously, it was shown that the potency of PDE4 inhibition of 19 was not diminished by addition of lipophilic bulk to the phthalazin-l-one nitrogen atom. Thus, elaboration of 21 and 22 afforded a PDE4 inhibitor linked to an SSRI
that retained considerable pharmacological activity. Thus, compared to 19, compounds 21 and 22 had more potency at inhibiting PDE4. The dual PDE4 inhibitor/SSRIs 21 and 22 possessed considerable potency for inhibition of binding of RTI-55 and inhibition of 5-HT
reuptake in the presence of the hSERT. Compared to 14 and 15, however, some loss of functional activity was lost. A significant amount of loss of functional activity was due to the fact that 21 and 22 was tested as a 2:1 and 3:1 mixture of trans:cis diastereomers. Studies have shown that the trans diastereomer of 14 or 15 possess about 7-fold more hSERT
reuptake inhibition activity than the cis diastereomer (unpublished data).
While some loss in in vitro binding potency and reuptake inhibition of the hSERT was observed in chemically linking SSRIs 14 and 15 to compound 20, nevertheless, significant in vivo activity was retained.
[0451] PDE4D inhibition results in a pattern of behavior that is indicative of an anti-depressant-like effect (Lucki, I., Behav. Pharnzacol., 8, 523-532 (1997);
Porsolt, R. D., Rev Neurosci., 11, 53-58 (2000)). This suggests that PDE4D is critical in mediating the antidepressant-like effects of PDE4 inhibitors. The PDE4 inhibitor 19 and the dual PDE4 inhibitor/SSRI 21 at doses of 0.3 and 3 mg/kg, decreased duration of immobility in the FST
in a dose-dependent manner in ICR mice. Compared to the vehicle control, 3 mg/kg significantly reduced immobility in the FST (P < 0.05). Acute administration of 14 decreased immobility in the FST but this was not reach statistical significance. In contrast, 40 mg/kg of fluoxetine or repeated treatment with rolipram (0.5 mg/kg, i.p., once a day for 8 days) was required to produce similar antidepressant-like effects in the FST; acute treatment with 0.5 mg/kg rolipram did not alter FST behavior.
[0452] Acute administration of fluoxetine (20 mg/kg), or 14 (10 mg/kg) did not alter the duration of immobility in the FST in Balb/c mice but SSRIs are known to not significantly [0 affect changes in FST after acute administration. In contrast, subchronic administration of a lower dose of fluoxetine (10 mg/kg) significantly decreased immobility (P
<0.05). However, subchronic treatment with 14 or 15 (10 or 1 mg/kg, respectivley) did not change immobility compared to the vehicle control. The lack of an affect may be partially explained on the basis of metabolic instability because 14 and 15 are metabolized at an appreciable rate while dual PDE4 inhibitor/SSRIs 21 and 22 are quite metabolically stable.
[0453] Reduction in the catabolism of cAMP might be expected to increase the sensitivity to and effectiveness of antidepressants. Evidence points to the PDE4D subtype as an important component of the signaling pathway involved in mediation of antidepressant effects on behavior. A potent and selective inhibitor of PDE4D might show antidepressant activity with a more limited side-effect profile. By combining a selective PDE4 inhibitor with an S SRI, synergistic antidepressant effects might be observed. On a molar basis, the dual PDE4 inhibitor/SSRI 21 showed a 129-fold increase in in vivo efficacy compared to fluoxetine.
[0454] Dual PDE4 inhibitor/SSRIs offer an advantage over simple additive effects. Dual PDE4 inhibitor/SSRIs offer the advantage of blocking the effect of the up-regulation of the PDE4. While PDE4 expression will still increase, its hydrolytic functional activity will be blocked. Thus, the overall increase in serotonin receptor-mediated cAMP
signaling will be preserved with repeated treatment.
Experimental Section:
[0455] General. Chemicals used in this study were of the highest purity available.
Commercially available reagents were purchased from Aldrich Chemical Company (Milwaukee, WI) or VVVR (San Diego, CA) and were used as received. All moisture sensitive reactions were carried out in flame-dried glassware under an argon atmosphere.
Tetrahydrofuran (THF) and toluene were freshly distilled from calcium hydride under an argon atmosphere. Methanol (CH3OH) was passed through a column of neutral alumina and stored over 3A molecular sieves prior to use. Rolipram, fluoxetine, diethyleneaminetetracetic acid (DETAPAC) and all the compounds of the NADPH-generating system were obtained from Sigma Chemical Company (St. Louis, MO). Human liver, pooled female liver and pooled male rat liver microsomes were purchased from BD Gentest Corp. (Woburn, MA).
The human liver microsomes had the following functional activities (nmol/min/mg of protein): phenacetin 0-deethylase (0.18), coumarin 7-hydroxylase (2.0), (S)-mephenytoin N-demethylase (0.05), diclofenac 4'-hydroxylase (1.9), (S)-mephenytoin 4'-hydroxylase (0.03), bufuralol r-hydroxylase (0.12), chlorzoxazone 6-hydroxylase (1.5), testosterone 6P-hydroxylase (4.6), and methyl p-tolyl sulfide oxidase (4.3). The pooled male rat liver microsomes had the following functional activities (nmol/min/mg of protein):
testosterone 613-hydroxylase (5.8) and nicotine oxidase (2.2). The pooled female mouse liver microsomes had the following functional activities (nmol/min/mg of protein): 7-ethoxyresorufin 0-deethylase (0.39), p-nitrophenol hydroxylase (1.9), lauric acid-hydroxylase (0.86), and testosterone 6f3-hydroxylase (5.0). Cocaine was provided by the National Institute on Drug Abuse, NIH (Bethesda, MD). RTI-55 was a kind gift of Dr. Ivy Carroll (RTI, Research Triangle Park, NC). [31-1]-DA, [31-1]-5-HT, [31-1]-NE and [1251]-RTI-55 were purchased from Dupont-New England Nuclear (Boston, MA). The preparation of the hDAT used was described previously (Eshleman et al., J. Pharmaeol. Exper. Ther., 274, 276-283 (1995)).
The hSERT cDNA and HEK cells transfected with hNET cDNA was supplied by Dr.
Randy Blakely (Vanderbilt University, Nashville, TN). Analytical thin-layer chromatography (TLC) was done on K6F silica gel 60 A glass-backed plates from Whatman (Clifton, NJ).
Compounds were detected using UV absorption at 254 nm and/or stained with 12 (iodine).
Flash chromatography was done on (60 A) pore silica gel from E. Merck (Darmstadt, Germany).
[0456] Instrument Analysis. NMR spectra were recorded with a Braker spectrometer operating at 500 MHz (NuMega Resonance Labs, Inc., San Diego, CA) or at 300 MHz by an inhouse Varian spectrometer (Palo Alto, CA) using the solvent specified.
Chemical shifts were reported in parts per million (ppm, 8) using residual solvent signals as internal standards. Low resolution mass spectroscopy (LRMS) was done with an HP 1100 mass spectrometer (HT Laboratories, San Diego, CA) using electrospray ionization (ESI) or with an inhouse Hitachi M-8000 3DQMS (ion trap) mass spectrometer using ESI. High resolution mass spectroscopy (HRMS) was done with a Micromass LCT time of flight mass spectrometer at the University of Montana Mass Spectral Facility (Missoula, MT) using ESI.
[0457] The 2,5-disubstituted tetrahydrofurans and the dual PDE4 inhibitor/SSRIs were characterized by 1H NMR, LRMS, HRMS and their purities (> 95%) were quantified by HPLC in two distinct solvent systems. Analytical HPLC measurements were run on a Hitachi L-6200 system equipped with a Hitachi L-7400 UV detector. Separations were done with a 5 pm,.4.6 mm x 250 mm, Axxi-chrom silica column (Richard Scientific, Novato, CA) or with a 5 pm, 4.6 mm x 250 mm Supelco HS F5 pentafluorophenyl column (Supelco Inc., 0 Bellefonte, PA). For analysis of the SSRIs and dual PDE4 inhibitor/SSRIs, standard HPLC
conditions utilized an isocratic, ternary-solvent system consisting of solvents A (methanol), B
(isopropanol) and C (HC104) set at a flow rate of 1.5 mL/min (straight-phase), or A, D
(water) and E (HCO2H) set at a flow rate of 1.0 mL/min (reverse-phase) with UV-vis detection (k = 254 nm) with retention times (tR) evaluated in minutes. Typical HPLC
[5 analyses involved two distinct isocratic elution systems per compound of interest. Solvent conditions for the isocratic elution systems were varied depending on the compound and its specific chromatographic properties. 1H NMR and mass spectra were consistent with the assigned structures.
[0458] Transporter Binding Assays. HEK-hDAT, -hSERT, or -hNET cells were grown 20 until confluent as described previously (Eshleman et aL, J. Pharmaeol.
Exper. Ther., 289, 877-885 (1999)). Cells were scraped from plates and centrifuged for 20 min at 30,000 x g and the pellet was re-suspended in 0.32 M sucrose with a Polytron at a setting of 1 for 5 sec.
Assays contained 50 L of membrane preparation, 25 pi, of the test compound and 25 p,L of [1251ATI-55 (40-80 pM final concentration) in a final volume of 250 L Krebs HEPES buffer 25 (25 mM HEPES, 122 mM NaC1, 5 mM KC1, 1.2 mM MgSO4, 2.5 mM CaC12, 1 p,M
pargyline, 100 p,M tropolone, 2 mg glucose/mL and 0.2 mg ascorbic acid/mL at pH 7.4.).
Membranes were pre-incubated with test compounds for 10 mM before addition of [125IATI-55. Specific binding was determined as the difference in binding observed in the presence and absence of 5 NI mazindol (HEK-hDAT and hNET) or 5 jiM imipramine (HEK-hSERT).
30 The incubations were done in the dark and terminated by filtration onto a Whatman GF/C
filters using a 96-well Tomtech cell harvester (Tomtech, Orange, CT).
Scintillation fluid was added to each filter spot and radioactivity remaining on the filter was determined using a Wallace B-plate reader (Wallace Labs, Cranbury, NJ.).
In Vivo Studies [0447] The PDE4 inhibitor (i.e., 19), the SSRI (i.e., 14) and the dual PDE4 inhibitor/SSRI
(i.e., 21) were examined for acute and subchronic antidepressant-like effects in vivo. (See Figure 15.) Acute treatment of ICR mice with either 19 or 21, at doses of 0.3 and 3 mg/kg, decreased duration of immobility in a dose-dependent manner in the forced-swim test (FST).
Compared to vehicle control, the higher dose of 19 or 21 (3 mg/kg) significantly reduced immobility in the FST (P <0.05). In contrast, acute administration of fluoxetine (40 mg/kg) or repeated treatment with rolipram (0.5 mg/kg, i.p., once a day for 8 days) was required to produce similar antidepressant-like effects in the FST (Zhang et al., Neuro-psychopharmacology, 27, 587-595 (2002)). On a molar basis, compound 21 (0.5 mol/kg) was 129-fold more efficacious than fluoxetine (65 p,mol/kg) in the FST. Acute treatment with rolipram (0.5 mg/kg, did not alter FST behavior in agreement with the literature (Zhang et al., Neuro-psychopharmacology, 27, 587-595 (2002)). The SSRI, compound 14, at the doses used (i.e., 10 and 30 mg/kg) tended to decrease immobility, but it was not statistically significant.
[0448] Because Balb/c mice have been reported to exhibit a relatively high immobility baseline and are sensitive to fluoxetine challenge in the FST (Lucid et al., Psychopharmacology, 155, 315-322 (2001)) the in vivo studies described above were repeated. Acute administration of fluoxetine (20 mg/kg), 14 (10 mg/kg), or 15 (10 mg/kg) did not markedly alter the duration of immobility in the FST in Balb/c mice.
(See Figure 16.) In contrast, subchronic administration of a lower dose of fluoxetine (10 mg/kg) significantly decreased immobility (P <0.05). (See Figure 17.) However, subchronic treatment with 14 (10 mg/kg) or 21 (1 mg/kg) did not change immobility compared to vehicle control. (See id.) It is possible that these in vivo results for 14 or 15 were a consequence of metabolic instability. To test this possibility, the in vitro metabolic stability of 14, 15, 19, 21, 22 and 24 was examined.
In Vitro Metabolic Studies [0449] The in vitro metabolism of compounds 14, 15, and 24 were examined in the presence of mouse and human liver microsomes supplemented with NADPH to examine the metabolic stability of the compounds. Compounds 19, 21 and 22 were examined in the presence of mouse and human liver microsomes supplemented with NADPH. An efficient HPLC method was established to afford separation of the starting material from any putative metabolites (e.g., aldehyde, hydroxylamine, nitrone). Aerobic incubations of 14 and 24 in the presence of mouse and rat liver microsomes supplemented with NADPH showed a time-dependent loss of substrate. For 14 and 24, the calculated half life was 56 or 106 and 58 or 129 mins, respectively, in the presence of mouse and rat liver microsomes (see Table 16). In the presence of mouse liver microsomes, compounds 19 and 21 showed considerable metabolic stability having calculated half lives of 211 and 154 mins, respectively.
Compound 21 was not detectably metabolized in the presence of human liver microsomes.
No detectable metabolic instability of compound 22 was observed in the presence of either mouse or human liver microsomes up to 60 mm (see Table 16).
Discussion [0450] A dual PDE4 inhibitor/SSRI was synthesized by linking an SSRI with a inhibitor via a five carbon linker. Previously, it was shown that the potency of PDE4 inhibition of 19 was not diminished by addition of lipophilic bulk to the phthalazin-l-one nitrogen atom. Thus, elaboration of 21 and 22 afforded a PDE4 inhibitor linked to an SSRI
that retained considerable pharmacological activity. Thus, compared to 19, compounds 21 and 22 had more potency at inhibiting PDE4. The dual PDE4 inhibitor/SSRIs 21 and 22 possessed considerable potency for inhibition of binding of RTI-55 and inhibition of 5-HT
reuptake in the presence of the hSERT. Compared to 14 and 15, however, some loss of functional activity was lost. A significant amount of loss of functional activity was due to the fact that 21 and 22 was tested as a 2:1 and 3:1 mixture of trans:cis diastereomers. Studies have shown that the trans diastereomer of 14 or 15 possess about 7-fold more hSERT
reuptake inhibition activity than the cis diastereomer (unpublished data).
While some loss in in vitro binding potency and reuptake inhibition of the hSERT was observed in chemically linking SSRIs 14 and 15 to compound 20, nevertheless, significant in vivo activity was retained.
[0451] PDE4D inhibition results in a pattern of behavior that is indicative of an anti-depressant-like effect (Lucki, I., Behav. Pharnzacol., 8, 523-532 (1997);
Porsolt, R. D., Rev Neurosci., 11, 53-58 (2000)). This suggests that PDE4D is critical in mediating the antidepressant-like effects of PDE4 inhibitors. The PDE4 inhibitor 19 and the dual PDE4 inhibitor/SSRI 21 at doses of 0.3 and 3 mg/kg, decreased duration of immobility in the FST
in a dose-dependent manner in ICR mice. Compared to the vehicle control, 3 mg/kg significantly reduced immobility in the FST (P < 0.05). Acute administration of 14 decreased immobility in the FST but this was not reach statistical significance. In contrast, 40 mg/kg of fluoxetine or repeated treatment with rolipram (0.5 mg/kg, i.p., once a day for 8 days) was required to produce similar antidepressant-like effects in the FST; acute treatment with 0.5 mg/kg rolipram did not alter FST behavior.
[0452] Acute administration of fluoxetine (20 mg/kg), or 14 (10 mg/kg) did not alter the duration of immobility in the FST in Balb/c mice but SSRIs are known to not significantly [0 affect changes in FST after acute administration. In contrast, subchronic administration of a lower dose of fluoxetine (10 mg/kg) significantly decreased immobility (P
<0.05). However, subchronic treatment with 14 or 15 (10 or 1 mg/kg, respectivley) did not change immobility compared to the vehicle control. The lack of an affect may be partially explained on the basis of metabolic instability because 14 and 15 are metabolized at an appreciable rate while dual PDE4 inhibitor/SSRIs 21 and 22 are quite metabolically stable.
[0453] Reduction in the catabolism of cAMP might be expected to increase the sensitivity to and effectiveness of antidepressants. Evidence points to the PDE4D subtype as an important component of the signaling pathway involved in mediation of antidepressant effects on behavior. A potent and selective inhibitor of PDE4D might show antidepressant activity with a more limited side-effect profile. By combining a selective PDE4 inhibitor with an S SRI, synergistic antidepressant effects might be observed. On a molar basis, the dual PDE4 inhibitor/SSRI 21 showed a 129-fold increase in in vivo efficacy compared to fluoxetine.
[0454] Dual PDE4 inhibitor/SSRIs offer an advantage over simple additive effects. Dual PDE4 inhibitor/SSRIs offer the advantage of blocking the effect of the up-regulation of the PDE4. While PDE4 expression will still increase, its hydrolytic functional activity will be blocked. Thus, the overall increase in serotonin receptor-mediated cAMP
signaling will be preserved with repeated treatment.
Experimental Section:
[0455] General. Chemicals used in this study were of the highest purity available.
Commercially available reagents were purchased from Aldrich Chemical Company (Milwaukee, WI) or VVVR (San Diego, CA) and were used as received. All moisture sensitive reactions were carried out in flame-dried glassware under an argon atmosphere.
Tetrahydrofuran (THF) and toluene were freshly distilled from calcium hydride under an argon atmosphere. Methanol (CH3OH) was passed through a column of neutral alumina and stored over 3A molecular sieves prior to use. Rolipram, fluoxetine, diethyleneaminetetracetic acid (DETAPAC) and all the compounds of the NADPH-generating system were obtained from Sigma Chemical Company (St. Louis, MO). Human liver, pooled female liver and pooled male rat liver microsomes were purchased from BD Gentest Corp. (Woburn, MA).
The human liver microsomes had the following functional activities (nmol/min/mg of protein): phenacetin 0-deethylase (0.18), coumarin 7-hydroxylase (2.0), (S)-mephenytoin N-demethylase (0.05), diclofenac 4'-hydroxylase (1.9), (S)-mephenytoin 4'-hydroxylase (0.03), bufuralol r-hydroxylase (0.12), chlorzoxazone 6-hydroxylase (1.5), testosterone 6P-hydroxylase (4.6), and methyl p-tolyl sulfide oxidase (4.3). The pooled male rat liver microsomes had the following functional activities (nmol/min/mg of protein):
testosterone 613-hydroxylase (5.8) and nicotine oxidase (2.2). The pooled female mouse liver microsomes had the following functional activities (nmol/min/mg of protein): 7-ethoxyresorufin 0-deethylase (0.39), p-nitrophenol hydroxylase (1.9), lauric acid-hydroxylase (0.86), and testosterone 6f3-hydroxylase (5.0). Cocaine was provided by the National Institute on Drug Abuse, NIH (Bethesda, MD). RTI-55 was a kind gift of Dr. Ivy Carroll (RTI, Research Triangle Park, NC). [31-1]-DA, [31-1]-5-HT, [31-1]-NE and [1251]-RTI-55 were purchased from Dupont-New England Nuclear (Boston, MA). The preparation of the hDAT used was described previously (Eshleman et al., J. Pharmaeol. Exper. Ther., 274, 276-283 (1995)).
The hSERT cDNA and HEK cells transfected with hNET cDNA was supplied by Dr.
Randy Blakely (Vanderbilt University, Nashville, TN). Analytical thin-layer chromatography (TLC) was done on K6F silica gel 60 A glass-backed plates from Whatman (Clifton, NJ).
Compounds were detected using UV absorption at 254 nm and/or stained with 12 (iodine).
Flash chromatography was done on (60 A) pore silica gel from E. Merck (Darmstadt, Germany).
[0456] Instrument Analysis. NMR spectra were recorded with a Braker spectrometer operating at 500 MHz (NuMega Resonance Labs, Inc., San Diego, CA) or at 300 MHz by an inhouse Varian spectrometer (Palo Alto, CA) using the solvent specified.
Chemical shifts were reported in parts per million (ppm, 8) using residual solvent signals as internal standards. Low resolution mass spectroscopy (LRMS) was done with an HP 1100 mass spectrometer (HT Laboratories, San Diego, CA) using electrospray ionization (ESI) or with an inhouse Hitachi M-8000 3DQMS (ion trap) mass spectrometer using ESI. High resolution mass spectroscopy (HRMS) was done with a Micromass LCT time of flight mass spectrometer at the University of Montana Mass Spectral Facility (Missoula, MT) using ESI.
[0457] The 2,5-disubstituted tetrahydrofurans and the dual PDE4 inhibitor/SSRIs were characterized by 1H NMR, LRMS, HRMS and their purities (> 95%) were quantified by HPLC in two distinct solvent systems. Analytical HPLC measurements were run on a Hitachi L-6200 system equipped with a Hitachi L-7400 UV detector. Separations were done with a 5 pm,.4.6 mm x 250 mm, Axxi-chrom silica column (Richard Scientific, Novato, CA) or with a 5 pm, 4.6 mm x 250 mm Supelco HS F5 pentafluorophenyl column (Supelco Inc., 0 Bellefonte, PA). For analysis of the SSRIs and dual PDE4 inhibitor/SSRIs, standard HPLC
conditions utilized an isocratic, ternary-solvent system consisting of solvents A (methanol), B
(isopropanol) and C (HC104) set at a flow rate of 1.5 mL/min (straight-phase), or A, D
(water) and E (HCO2H) set at a flow rate of 1.0 mL/min (reverse-phase) with UV-vis detection (k = 254 nm) with retention times (tR) evaluated in minutes. Typical HPLC
[5 analyses involved two distinct isocratic elution systems per compound of interest. Solvent conditions for the isocratic elution systems were varied depending on the compound and its specific chromatographic properties. 1H NMR and mass spectra were consistent with the assigned structures.
[0458] Transporter Binding Assays. HEK-hDAT, -hSERT, or -hNET cells were grown 20 until confluent as described previously (Eshleman et aL, J. Pharmaeol.
Exper. Ther., 289, 877-885 (1999)). Cells were scraped from plates and centrifuged for 20 min at 30,000 x g and the pellet was re-suspended in 0.32 M sucrose with a Polytron at a setting of 1 for 5 sec.
Assays contained 50 L of membrane preparation, 25 pi, of the test compound and 25 p,L of [1251ATI-55 (40-80 pM final concentration) in a final volume of 250 L Krebs HEPES buffer 25 (25 mM HEPES, 122 mM NaC1, 5 mM KC1, 1.2 mM MgSO4, 2.5 mM CaC12, 1 p,M
pargyline, 100 p,M tropolone, 2 mg glucose/mL and 0.2 mg ascorbic acid/mL at pH 7.4.).
Membranes were pre-incubated with test compounds for 10 mM before addition of [125IATI-55. Specific binding was determined as the difference in binding observed in the presence and absence of 5 NI mazindol (HEK-hDAT and hNET) or 5 jiM imipramine (HEK-hSERT).
30 The incubations were done in the dark and terminated by filtration onto a Whatman GF/C
filters using a 96-well Tomtech cell harvester (Tomtech, Orange, CT).
Scintillation fluid was added to each filter spot and radioactivity remaining on the filter was determined using a Wallace B-plate reader (Wallace Labs, Cranbury, NJ.).
[0459] Inhibition of Substrate Uptake. HEK-hDAT, -hSERT or -hNET cells were grown as described above. Cells were scraped from the plates and suspended cells were added to a 96-well plate containing test compounds and Krebs-HEPES buffer in a final assay volume of 0.5 mL. After a 10 mM preincubation in a 25 C water bath, [3H]-labeled neurotransmitter (50 mL, 20 nM final concentration) was added and the assay was initiated.
After 10 mM the incubation was terminated by filtration onto GF/C filters presoaked with 0.05%
polyethylenimine using a Tomtech call harvester and scintillation counting as described above. Specific uptake was defined as the difference in uptake in the presence and absence of 5 mM mazindol (hDAT and hNET) or 5 mM imipramine (hSERT).
[0460] PDE4 Assay. PDE4 enzyme assays were carried out as described previously.
Studies with recombinant PDE4 enzymes were carried out in the laboratory of Professor Marco Conti (Stanford University, Palo Alto, CA).
[0461] Data Analysis. GraphPad Prism (GraphPad Software, San Diego, CA) was used to determine the saturation and binding kinetic data. IC50 values were converted to Ki values using the Cheng-Prusoff equation.
[0462] Mouse and Rat Liver Microsome Stability Assay. Microsomal incubations (final volume 0.25 mL) with the SSRIs, dual PDE4 inhibitor/SSRIs or PDE4 inhibitor was done with an HPLC assay as described above. Diluted stocks of either mouse, human or rat liver microsomes (0.5 mg of protein), 100 M potassium phosphate buffer (pH 7.4), 0.5 mM
NADP+, 0.5 mM glucose-6-phosphate, 5 IU/mL glucose-6-phosphate dehydrogenase, 0.6 mM DETAPAC, and 3 mM MgC12 were combined and placed on ice. For a metabolic stability assay, either vehicle or 40 M test compound was added and the incubation was initiated at 37 C with constant shaking. After 0, 10, 25, 40 and 60 min, the incubations were stopped by the addition of 1 mL CH2C12/2-propanol (3:1, v:v). After thorough mixing, the organic layer was separated from the aqueous portion by centrifugation at 12,000 x g. The organic material was evaporated with a stream of argon. The residue was dissolved in methanol (200 L) and the sample was analyzed by HPLC.
[0463] In Vivo Evaluation of Selected Compounds. Separate non-habituated male mice were used in the conduct of this work. Fully approved animal protocols were used and the studies were done in keeping with the NIH standards for use of experimental animals.
[0464] Experiment 1. Forty male ICR mice, weighed 26.2 0.3 g, were housed in a temperature-controlled room (22-23 C) and maintained on a 12-hour on 12-hour off light cycle (lights on at 6:00 AM). Water and food were freely available in the home cages. The mice were randomly divided into four groups: (A) vehicle; (B) compound 14; (C) compound 19; and (D) compound 21 and administered compounds dissolved in 0.9% saline containing 5% dimethyl sulfoxide (DMSO). Saline containing the same percentage of DMSO
was used as vehicle. The lower doses were tested followed by the larger doses 1 week later, when the mice were again randomly divided into four groups as described above. The forced-swim test (FST) was carried out as described previously. Mice were given a swimming pretest session, once a day for two successive days. Twenty-four hours after the last session, mice were injected vehicle or the lower dose of each test compound by the i.p.
route 30 min prior to the FST. One week later, administration of the larger dose of each of the test compounds was repeated. During the pretest and test sessions, each mouse was placed for 6 min in a plastic cylinder (45 cm high x 20 cm diameter), which was filled to a depth of 28 cm with water (23 1 C). The duration of immobility, which was defined as floating in an upright position without additional activity other than that necessary for the animal to keep its head above water, was recorded.
[0465] Experiment 2 Forty Balb/c male mice weighing 22.4 0.1 g were used in this experiment, which was carried out in two sessions. In each session, the mice were divided in four groups: (A) Vehicle (saline containing 5% DMSO), (B) fluoxetine 20 mg/kg, (C) TV-II-101 10 mg/kg, and (D) TV-093 10 mg/kg for the first session; (A) Vehicle, (B) Fluoxetine 10 mg/kg, (C) TV-II-093 10 mg/kg, and (D) TV-II-099 mg/kg for the second session, which was carried out 4 weeks later. Mice in the first session were treated with vehicle or the drugs acutely, whereas mice in the second sessions were treated subchronically, i.e., vehicle or drugs were given i.p. 23, 5, and 1 hr before the FST. The experiment was performed similar to Experiment 1 except for the pretest training, which was not carried out in the second session.
[0466] Statistics All in vivo data were analyzed by one-way analyses of variance (ANOVA) followed by Dunnett's tests for post hoc comparisons of individual means.
Synthesis [0467] Ethy1-3-(5'-fluoro-2'-methoxypheny1)-2-propenoate (2): To a solution of fluoro-2-methoxybenzaldehyde (4.3 g, 28.0 mmol) in dry CH2C12 (30 mL) at 0 C
was added carbethoxymethylenetriphenylphosphorane (10.7 g, 30.1 mmol) portion-wise and the reaction was warmed to room temperature and stirred for 12 h. The solvent was then removed in vacuo and the residue was purified by flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.2) to yield the product (6.0 g, 95%) as a 4:1 mixture of trans:cis diastereomers; 1H
NMR (CDC13, 500 MHz): 6 7.93 (d, J= 16.2 Hz, 0.8 H), 7.33 (dd, J= 3.1, 9.2 Hz, 0.2 H), 7.21 (dd, J= 3.1, 9.2, Hz, 0.8 H), 7.08 (d, J= 12.5 Hz, 0.2 H), 7.03 (dt, J=
3.0, 8.8 Hz, 0.8 H), 6.99 (dt, J= 3.0, 8.8 Hz, 0.2 H), 6.84 (dd, J= 3.1, 8.6 Hz, 0.8 H), 6.79 (dd, J= 3.3, 9.1 Hz, 0.2 H), 6.47 (d, J= 16.2 Hz, 0.8 H), 5.99 (d, J= 12.5 hz, 0.2 H), 4.25 (q, J= 7.1 Hz, 1.6 H), 4.15 (q, J= 7.0 Hz, 0.4 H), 3.86 (s, 2.4 H), 3.81 (s, 0.6 H), 1.34 (t, J=
7.1 Hz, 2.4 H), 1.22 (t, J= 7.0 Hz, 0.6 H).
[0468] Ethyl-4-(5'-fluoro-2'-methoxyphenyl)propanoate (3): To a solution of 2 (6.0 g, 27.0 mmol) in ethanol (200 proof, 40 mL) under Ar was added Pd/C (10%, 250 mg) and the flask containing the mixture was evacuated and purged with H2 three times. A
balloon containing H2 was attached to the flask and the reaction was allowed to stir for 15 h at room temperature. The reaction mixture was filtered through a pad of silica and eluted with Et0Ac/hexane, 50:50, v:v. The crude product obtained by removal of the solvent in vacuo was purified by a flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf =
0.27) to give the product (5.8 g, 95%); 1H NMR (CDC13, 500 MHz): 6 6.89-6.84 (m, 2 H), 6.74 (dd, J
= 4.7, 9.8 Hz, 1 H), 4.12 (q, J= 7.1 Hz, 2 H), 3.79 (s, 3 H), 2.91 (t, J= 7.7 Hz, 2 H), 2.59 (t, J
= 7.7 Hz, 2 H), 1.24 (t, J= 7.2 Hz, 3 H).
[0469] 3-(5'-Fluoro-2'-methoxyphenyl)propanal (4): To a solution of 3 (5.8 g, 25.7 mmol) in dry toluene (40 mL) under an atmosphere of Ar was added a DIBAL
solution (1 M
in toluene, 30 mL, 30 mmol) at -78 C. The reaction was stirred at -78 C for 2 h. Methanol (2 mL) was then added to the mixture and the reaction was allowed to warm to 0 C.
The reaction mixture was then poured into a separatory funnel containing HC1 solution (1 N, 100 mL). The organic fraction was extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product obtained by removal of the solvent in vacuo was purified by flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.1) to give the product (3.1 g, 66%); 1H NMR
(CDC13, 500 MHz): 6 9.80 (s, 1 H), 6.88-6.86 (m, 2 H), 6.75 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.91 (t, J= 7.4 Hz, 2 H), 2.72 (t, J= 7.4 Hz, 2 H).
[0470] 1-(5'-Fluoro-2'-methoxypheny1)-4-ethylenedioxy-1-butene (5): To a suspension of 2-(1,3-dioxolan-2-yl)ethyltriphenylphosphonium bromide (5.0 g, 11.3 mmol) in THF (30 mL) under an atmosphere of Ar was added NaH (60% in mineral oil, 0.48 g, 11.3 mmol) and the mixture obtained was heated to reflux for 1 h. The orange suspension obtained was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (1.54 g, 10.0 mmol) was added and the reaction was warmed to room temperature and continued with stirring for 12 h.
The reaction mixture was poured to a separatory funnel containing ammonium chloride aqueous solution 5, (sat. NH4C1/H20 50:50, v:v, 50 mL). The organics were extracted with Et0Ac (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over sodium sulfate. The solvent was then removed in vacuo and the crude product obtained was purified by flash column chromatography (Et0Ac/hexane, 7:93, v:v, Rf = 0.15) to give the product (2.63 g, 66%) as a 4:1 mixture of cis and trans diastereomers: 1H NMR (major isomer):
(CDC13, 500 MHz): 8 7.08 (dd, J= 3.1, 8.7 Hz, 1 H), 6.93 (dt, J= 3.1, 8.7 Hz, 1 H), 6.78 (dd, J= 4.3, 8.7 Hz, 1 H), 6.63 (d, J= 11.9 Hz, 1 H), 5.83 (td, J= 7.3 Hz, 11.9 Hz, 1 H),4.99 (t, J= 4.6 Hz, 1 H), 4.02-3.99 (m, 2 H), 3.9-3.87 (m, 2 H), 3.8 (s, 3 H), 2.64-2.62 (m, 2 H).
[0471] 4-(5'-Fluoro-2'-methoxypheny1)-1-ethylenedioxybutane (6): To a solution of 5 (1.75 g, 7.3 mmol) in ethanol (200 proof, 80 mL) under an atmosphere of Ar was added Pd/C
(10%, 300 mg) and the flask containing the mixture was evacuated and purged with H2 three times. A balloon of H2 gas was attached to the flask and the reaction was allowed to proceed for 72 h at room temperature. The reaction mixture was then filtered through a pad of Celite eluted with Et0H. The crude product was obtained by removal of the solvent in vacuo. . 1H
NMR (CDC13, 500 MHz): 8 6.87-6.72 (m, 3 H), 4.87 (t, J= 3.8 Hz, 1 H), 3.97-3.95 (m, 2 H), 3.86-3.83 (m, 2 H), 3.79 (s, 3 H), 2.64-2.62 (m, 2 H), 2.44 (td, J= 1.7, 7.2 Hz, 2 H), 1.92 (quintet, J= 7.5 Hz, 2 H).
[0472] 4-(5'-Fluoro-2'-methoxyphenyl)butyraldehyde (7): To a solution of 6 (1.7g, 7.0 mmol) in THF (60 mL) was added HC1 (1 N, 3 mL) and the reaction was stirred at room temperature for 48 h. The reaction mixture was then poured into a separatory funnel containing water (60 mL). The organic fraction was extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate.
The crude product obtained by removal of the solvent in vacuo was purified by flash column chromatography (Et0Adhexane, 10:90, v:v, Rf = 0.1) to give the product (1.03 g, 53% from 3a); 1H NMR (CDC13, 500 MHz): 8 9.76 (s, 1 H), 6.88-6.83 (m, 2 H), 6.75 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.63 (t, J= 7.4 Hz, 2 H), 2.44 (t, J= 7.4 Hz, 2 H), 1.92 (quintet, J=
7.4 Hz, 2 H).
After 10 mM the incubation was terminated by filtration onto GF/C filters presoaked with 0.05%
polyethylenimine using a Tomtech call harvester and scintillation counting as described above. Specific uptake was defined as the difference in uptake in the presence and absence of 5 mM mazindol (hDAT and hNET) or 5 mM imipramine (hSERT).
[0460] PDE4 Assay. PDE4 enzyme assays were carried out as described previously.
Studies with recombinant PDE4 enzymes were carried out in the laboratory of Professor Marco Conti (Stanford University, Palo Alto, CA).
[0461] Data Analysis. GraphPad Prism (GraphPad Software, San Diego, CA) was used to determine the saturation and binding kinetic data. IC50 values were converted to Ki values using the Cheng-Prusoff equation.
[0462] Mouse and Rat Liver Microsome Stability Assay. Microsomal incubations (final volume 0.25 mL) with the SSRIs, dual PDE4 inhibitor/SSRIs or PDE4 inhibitor was done with an HPLC assay as described above. Diluted stocks of either mouse, human or rat liver microsomes (0.5 mg of protein), 100 M potassium phosphate buffer (pH 7.4), 0.5 mM
NADP+, 0.5 mM glucose-6-phosphate, 5 IU/mL glucose-6-phosphate dehydrogenase, 0.6 mM DETAPAC, and 3 mM MgC12 were combined and placed on ice. For a metabolic stability assay, either vehicle or 40 M test compound was added and the incubation was initiated at 37 C with constant shaking. After 0, 10, 25, 40 and 60 min, the incubations were stopped by the addition of 1 mL CH2C12/2-propanol (3:1, v:v). After thorough mixing, the organic layer was separated from the aqueous portion by centrifugation at 12,000 x g. The organic material was evaporated with a stream of argon. The residue was dissolved in methanol (200 L) and the sample was analyzed by HPLC.
[0463] In Vivo Evaluation of Selected Compounds. Separate non-habituated male mice were used in the conduct of this work. Fully approved animal protocols were used and the studies were done in keeping with the NIH standards for use of experimental animals.
[0464] Experiment 1. Forty male ICR mice, weighed 26.2 0.3 g, were housed in a temperature-controlled room (22-23 C) and maintained on a 12-hour on 12-hour off light cycle (lights on at 6:00 AM). Water and food were freely available in the home cages. The mice were randomly divided into four groups: (A) vehicle; (B) compound 14; (C) compound 19; and (D) compound 21 and administered compounds dissolved in 0.9% saline containing 5% dimethyl sulfoxide (DMSO). Saline containing the same percentage of DMSO
was used as vehicle. The lower doses were tested followed by the larger doses 1 week later, when the mice were again randomly divided into four groups as described above. The forced-swim test (FST) was carried out as described previously. Mice were given a swimming pretest session, once a day for two successive days. Twenty-four hours after the last session, mice were injected vehicle or the lower dose of each test compound by the i.p.
route 30 min prior to the FST. One week later, administration of the larger dose of each of the test compounds was repeated. During the pretest and test sessions, each mouse was placed for 6 min in a plastic cylinder (45 cm high x 20 cm diameter), which was filled to a depth of 28 cm with water (23 1 C). The duration of immobility, which was defined as floating in an upright position without additional activity other than that necessary for the animal to keep its head above water, was recorded.
[0465] Experiment 2 Forty Balb/c male mice weighing 22.4 0.1 g were used in this experiment, which was carried out in two sessions. In each session, the mice were divided in four groups: (A) Vehicle (saline containing 5% DMSO), (B) fluoxetine 20 mg/kg, (C) TV-II-101 10 mg/kg, and (D) TV-093 10 mg/kg for the first session; (A) Vehicle, (B) Fluoxetine 10 mg/kg, (C) TV-II-093 10 mg/kg, and (D) TV-II-099 mg/kg for the second session, which was carried out 4 weeks later. Mice in the first session were treated with vehicle or the drugs acutely, whereas mice in the second sessions were treated subchronically, i.e., vehicle or drugs were given i.p. 23, 5, and 1 hr before the FST. The experiment was performed similar to Experiment 1 except for the pretest training, which was not carried out in the second session.
[0466] Statistics All in vivo data were analyzed by one-way analyses of variance (ANOVA) followed by Dunnett's tests for post hoc comparisons of individual means.
Synthesis [0467] Ethy1-3-(5'-fluoro-2'-methoxypheny1)-2-propenoate (2): To a solution of fluoro-2-methoxybenzaldehyde (4.3 g, 28.0 mmol) in dry CH2C12 (30 mL) at 0 C
was added carbethoxymethylenetriphenylphosphorane (10.7 g, 30.1 mmol) portion-wise and the reaction was warmed to room temperature and stirred for 12 h. The solvent was then removed in vacuo and the residue was purified by flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.2) to yield the product (6.0 g, 95%) as a 4:1 mixture of trans:cis diastereomers; 1H
NMR (CDC13, 500 MHz): 6 7.93 (d, J= 16.2 Hz, 0.8 H), 7.33 (dd, J= 3.1, 9.2 Hz, 0.2 H), 7.21 (dd, J= 3.1, 9.2, Hz, 0.8 H), 7.08 (d, J= 12.5 Hz, 0.2 H), 7.03 (dt, J=
3.0, 8.8 Hz, 0.8 H), 6.99 (dt, J= 3.0, 8.8 Hz, 0.2 H), 6.84 (dd, J= 3.1, 8.6 Hz, 0.8 H), 6.79 (dd, J= 3.3, 9.1 Hz, 0.2 H), 6.47 (d, J= 16.2 Hz, 0.8 H), 5.99 (d, J= 12.5 hz, 0.2 H), 4.25 (q, J= 7.1 Hz, 1.6 H), 4.15 (q, J= 7.0 Hz, 0.4 H), 3.86 (s, 2.4 H), 3.81 (s, 0.6 H), 1.34 (t, J=
7.1 Hz, 2.4 H), 1.22 (t, J= 7.0 Hz, 0.6 H).
[0468] Ethyl-4-(5'-fluoro-2'-methoxyphenyl)propanoate (3): To a solution of 2 (6.0 g, 27.0 mmol) in ethanol (200 proof, 40 mL) under Ar was added Pd/C (10%, 250 mg) and the flask containing the mixture was evacuated and purged with H2 three times. A
balloon containing H2 was attached to the flask and the reaction was allowed to stir for 15 h at room temperature. The reaction mixture was filtered through a pad of silica and eluted with Et0Ac/hexane, 50:50, v:v. The crude product obtained by removal of the solvent in vacuo was purified by a flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf =
0.27) to give the product (5.8 g, 95%); 1H NMR (CDC13, 500 MHz): 6 6.89-6.84 (m, 2 H), 6.74 (dd, J
= 4.7, 9.8 Hz, 1 H), 4.12 (q, J= 7.1 Hz, 2 H), 3.79 (s, 3 H), 2.91 (t, J= 7.7 Hz, 2 H), 2.59 (t, J
= 7.7 Hz, 2 H), 1.24 (t, J= 7.2 Hz, 3 H).
[0469] 3-(5'-Fluoro-2'-methoxyphenyl)propanal (4): To a solution of 3 (5.8 g, 25.7 mmol) in dry toluene (40 mL) under an atmosphere of Ar was added a DIBAL
solution (1 M
in toluene, 30 mL, 30 mmol) at -78 C. The reaction was stirred at -78 C for 2 h. Methanol (2 mL) was then added to the mixture and the reaction was allowed to warm to 0 C.
The reaction mixture was then poured into a separatory funnel containing HC1 solution (1 N, 100 mL). The organic fraction was extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. The crude product obtained by removal of the solvent in vacuo was purified by flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.1) to give the product (3.1 g, 66%); 1H NMR
(CDC13, 500 MHz): 6 9.80 (s, 1 H), 6.88-6.86 (m, 2 H), 6.75 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.91 (t, J= 7.4 Hz, 2 H), 2.72 (t, J= 7.4 Hz, 2 H).
[0470] 1-(5'-Fluoro-2'-methoxypheny1)-4-ethylenedioxy-1-butene (5): To a suspension of 2-(1,3-dioxolan-2-yl)ethyltriphenylphosphonium bromide (5.0 g, 11.3 mmol) in THF (30 mL) under an atmosphere of Ar was added NaH (60% in mineral oil, 0.48 g, 11.3 mmol) and the mixture obtained was heated to reflux for 1 h. The orange suspension obtained was cooled to 0 C and 5-fluoro-2-methoxybenzaldehyde (1.54 g, 10.0 mmol) was added and the reaction was warmed to room temperature and continued with stirring for 12 h.
The reaction mixture was poured to a separatory funnel containing ammonium chloride aqueous solution 5, (sat. NH4C1/H20 50:50, v:v, 50 mL). The organics were extracted with Et0Ac (3 x 80 mL) and the combined organic layers were washed with brine (60 mL) and dried over sodium sulfate. The solvent was then removed in vacuo and the crude product obtained was purified by flash column chromatography (Et0Ac/hexane, 7:93, v:v, Rf = 0.15) to give the product (2.63 g, 66%) as a 4:1 mixture of cis and trans diastereomers: 1H NMR (major isomer):
(CDC13, 500 MHz): 8 7.08 (dd, J= 3.1, 8.7 Hz, 1 H), 6.93 (dt, J= 3.1, 8.7 Hz, 1 H), 6.78 (dd, J= 4.3, 8.7 Hz, 1 H), 6.63 (d, J= 11.9 Hz, 1 H), 5.83 (td, J= 7.3 Hz, 11.9 Hz, 1 H),4.99 (t, J= 4.6 Hz, 1 H), 4.02-3.99 (m, 2 H), 3.9-3.87 (m, 2 H), 3.8 (s, 3 H), 2.64-2.62 (m, 2 H).
[0471] 4-(5'-Fluoro-2'-methoxypheny1)-1-ethylenedioxybutane (6): To a solution of 5 (1.75 g, 7.3 mmol) in ethanol (200 proof, 80 mL) under an atmosphere of Ar was added Pd/C
(10%, 300 mg) and the flask containing the mixture was evacuated and purged with H2 three times. A balloon of H2 gas was attached to the flask and the reaction was allowed to proceed for 72 h at room temperature. The reaction mixture was then filtered through a pad of Celite eluted with Et0H. The crude product was obtained by removal of the solvent in vacuo. . 1H
NMR (CDC13, 500 MHz): 8 6.87-6.72 (m, 3 H), 4.87 (t, J= 3.8 Hz, 1 H), 3.97-3.95 (m, 2 H), 3.86-3.83 (m, 2 H), 3.79 (s, 3 H), 2.64-2.62 (m, 2 H), 2.44 (td, J= 1.7, 7.2 Hz, 2 H), 1.92 (quintet, J= 7.5 Hz, 2 H).
[0472] 4-(5'-Fluoro-2'-methoxyphenyl)butyraldehyde (7): To a solution of 6 (1.7g, 7.0 mmol) in THF (60 mL) was added HC1 (1 N, 3 mL) and the reaction was stirred at room temperature for 48 h. The reaction mixture was then poured into a separatory funnel containing water (60 mL). The organic fraction was extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (80 mL) and dried over sodium sulfate.
The crude product obtained by removal of the solvent in vacuo was purified by flash column chromatography (Et0Adhexane, 10:90, v:v, Rf = 0.1) to give the product (1.03 g, 53% from 3a); 1H NMR (CDC13, 500 MHz): 8 9.76 (s, 1 H), 6.88-6.83 (m, 2 H), 6.75 (dd, J= 4.6, 8.6 Hz, 1 H), 3.79 (s, 3 H), 2.63 (t, J= 7.4 Hz, 2 H), 2.44 (t, J= 7.4 Hz, 2 H), 1.92 (quintet, J=
7.4 Hz, 2 H).
[0473] 7-(5'-Fluoro-2'-methoxyphenyl)hept-1-en-5-ol (8): To a solution of 4 (3.0 g, 19.5 mmol) in THF (20 mL) at 0 C was added a solution 1-butenylmagnesium bromide (0.5 M in THF, 45 mL, 22.5 mmol) dropwise for 15 min. The reaction mixture was poured into a solution of saturated ammonium chloride (80 mL) in a separatory funnel. The organic fraction was extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The product was purified by flash column chromatography (Et0Ac/hexane, 15:85, v:v, Rf= 0.2) to give the product as a colorless oil (3.7 g, 94%); 1H NMR (CDC13, 500 MHz): 8 6.86-6.82 (m, 2 H), 6.76 (dd, J=
4.6, 8.6 Hz, 1 H), 5.82 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.95 (d, J= 10.2 Hz, 1 H), 3.81 (s, 3 H), 3.55 (m, 1 H), 2.75-2.69 (m, 2 H), 2.2 (m, 1 H), 2.1 (m, 1 H), 1.96 (bs, 1 H), 1.73-1.68 (m, 2 H), 1.6-1.53 (m, 3 H).
[0474] The following compound was prepared in a similar manner.
[0475] 8-(5'-Fluoro-V-methoxyphenyl)oct-1-en-5-ol (9): The product was purified by flash column chromatography (Et0Ac/hexane, 12.5:87.5, v:v, Rf = 0.15) as a colorless oil (1.06 g, 61%); 1H NMR (CDC13, 500 MHz): 8 6.86-6.82 (m, 2 H), 6.74 (dd, J=
4.6, 8.6 Hz, 1 H), 5.85 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.97 (d, J= 10.2 Hz, 1 H), 3.79 (s, 3 H), 3.66 (m, 1 H), 2.6 (in, 2 H), 2.22-2.1 (m, 2 H), 1.74-1.47 (m, 7 H).
[0476] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrafuran (10):
To a solution of 8 (3.24 g, 18.0 mmol) in dry CH2C12 (50 mL) at 0 C was added N-bromosuccinimide (3.56 g, 20.0 mmol) portion-wise and the reaction was warmed to room temperature and stirred for 12 h. Solvent was then removed in vacuo and the product was purified by flash column chromatography (Et0Ac/hexane, 5:95, v:v, Rf = 0.1) and resulted in a colorless oil as a 2:1 mixture of trans:cis diastereomers; 1H NMR (CDC13, 500 MHz): 8 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (in, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.6 (t, J=
7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H).
[0477] The following compound was prepared in a similar manner.
[0478] 2-(Bromomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydrofuran (11): the product was purified by flash column chromatography (Et0Ac/hexane, 5:95, v:v, .Rf = 0.1) to provide a product (530 mg, 40%) as a colorless oil; 1H
NMR (CDC13, 500 MHz): 8 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J=
6.4, 9.7 Hz, 1 H), 2.6 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H).
[0479] 2-Cyanomethy1-5-(5'-flouro-2-methoxyphenethyl)tetrahydrofuran (12): To a vial under an atmosphere of Ar(g) was added 10 (1.23 g, 4.3 mmol), NaI (100 mg), potassium cyanide (0.7 g, 10.6 mmol), and dry DMSO (15 mL). The mixture obtained was heated to 70 C under an atmosphere of Ar for 12 h. After cooling to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3/H20, 50:50, v:v, 80 mL). The organic fraction was extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent was then removed in vacuo and the crude product obtained (0.45 g, 86%) was purified by flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.11); as a 2:1 mixture of trans/cis diastereomers. 1H NMR (500 MHz, CDC13) 6.88-6.82 (m, 2 H), 6.74 (dd, J= 4.3, 8.5 Hz, 1 H), 4.26 (m, 1 H), 4.09 (m, 0.65 H), 3.90 (m, 0.35 H)3.79 (s, 3 H), 2.72-2.53 (m, 4 H), 2.22-2.04 (m, 2 H), 1.84-1.6 (m, 4 H).
[0480] The following compound was prepared in a similar manner.
[0481] 2-Cyanomethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrafuran (13): the product (0.2 g, 80%) was purified by chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.11) as a 2:1 mixture of trans/cis diastereomers; 1H NMR (CDC12, 500 MHz): 8 6.86-6.81 (m, 2 H), 6.73 (dd, J= 4.2, 8.5 Hz, 1 H), 4.22 (p, J= 6.8 Hz, 0.65 H), 4.11 (m, 0.35 H) 4.09 (m, 0.65 H), 3.9 (m, 0.35 H), 3.79 (s, 3 H), 2.62-2.52 (m, 4 H), 2.18 (m, 1 H), 2.12 (m, 1 H), 1.78 (m, 1 H), 1.69-1.46 (m, 3 H).
[0482] 2-Aminoethy1-5-(2`-methoxy-5'-fluorophenethyl)tetrahydrofuran (14): To a round bottom flask under an atmosphere of Ar was added Raney Ni that was washed with methanol. Compound 12 (80 mg, 0.3 mmol), dissolved in 2 M NH3 in methanol was added to the flask. The flask was evacuated and purged with H2 once. A balloon containing H2 gas was then attached to the flask and the reaction was allowed to stirr for 4 h at room temperature. The reaction mixture was filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by preparative TLC and eluted with (Me0H/CH2C12, 10:90, v:v, Rf = 0.1) to give the product (55 mg, 70%) as a 2:1 mixture of trans/cis diastereomers; 1H NMR: (CDC13, 500 MHz): 8 6.87 (m, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.72 (m, 1 H), 4.03 (m, 0.65 H), 3.96 (m, 0.65 H), 3.89 (m, 0.35 H), 3.82 (m, 0.35 H), 3.78 (s, 3 H), 2.68 (m, 1 H), 2.58 (m, 1 H), 2.03 (m, 2 H), 1.83 (bs, 2 H), 1.86-1.6 (m, 4 H), 1.54 (m, 2 H); HRMS (ESI) [M+11.]+ calcd for C15H23FN02 268.1713, found 268.1701;
HPLC > 96% pure (tR = 4.66 mm, 40(A):55(B):5(C):0.01(D); tR = 5.05 min, 10(A):85(B):5(C):0.01(D)).
[0483] The following compound was prepared in a similar manner.
[0484] 2-Aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrofuran (15): the product (24 mg, 47%), was isolated as 3:1 mixture of trans/cis diastereomers (Me0H/CH2C12, 10:90, v:v, Rf = 0.1): 1H NMR: (CDC13, 500 MHz): 8 6.86-6.8 (m, 2 H), 6.73 (m, 1 H), 4.02 (m, 0.65 H), 3.96 (m, 0.65 H), 3.92 (m, 0.35 H), 3.82 (m, 0.35 H), 3.78 (s, 3 H), 3.09 (m, 1 H), 2.99 (m, 1 H), 2.6 (bs, 2 H), 1.96 (m, 2 H), 1.83-1.77 (m, 2 H), 1.65-1.47 (m, 8 H); HRMS (ESI) [M+H] calcd for C16H25FN02 282.1875, found 282.1869; HPLC
>
95% pure (tR = 4.70 min, 40(A):55(B):5(C):0.01(D), tR = 5.09 10(A):85(B):5(C):0.01(D)).
[0485] 3,4-Dimethoxyphenylmagnesium bromide (17): Into a flame dried round bottom flask with a magnetic stir bar was placed anhydrous THF (150 mL) and Mg(s) turlings (1.43 g, 58.8 mmol, 1.0 eq). The flask was then fitted with a pressure equalizing addition funnel containing 4-bromo-1,2-dimethoxybenzene solution that was added slowly over a period of 45 min while stirring at rt. Once the addition was complete I2(,) (500 mg) was added and the reaction was brought to reflux and stirred for 12 hrs. The Grignard reagent was cooled and used immediately in the following reaction.
[0486] 6-(3,4-Dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid (18): A
solution of 17 (59 mmol, 0.29 M) in THF was added dropwise to an ice-cooled solution of cis-1,2,3,6-tetrahydrophthalic anhydride in THF (120 mL) over a 1 hr period. After the addition was complete, the resulting mixture was stirred for another 30 min at 0 C. The reaction mixture was allowed to warm to rtand stirred overnight. The reaction was then stopped with sat.
NH4C1 and the pH adjusted to 2 with concentrated HC1(aq) and then extracted with diethyl ether. The organic layer was washed with water and subsequently extracted with 1 M NaOH.
The combined aqueous extract was acidified with concentrated HC1 and extracted with Et0Ac (3x 100 mL). The organic layers were combined and dried over MgSO4, filtered, and concentrated under reduced pressure to afford oil. The oil was dissolved CH2C12 and filtered through silica gel to remove the dicarboxylic acid formed during workup. The product was recrystallized from diethyl ether to afford pure product (1.62 g, 10%) as a white solid; mp =
109 C; LRMS ESI Ern-HI cacld for C16141805 289, found m/z 289; 1H NMR (CDC13, MHz): 8 7.60-7.53 (m, 2 H), 6.92 (d, J= 8.4 Hz, 1 H), 5.84-5.82 (m, 1 H), 5.71-5.68 (m, 1 H), 4.03-4.00 (m, 1 H), 3.98 (s, 3 H), 3.95 (s, 1 H), 3.10-3.07 (in, 1 H), 2.90-2.84 (m, 1 H), 2.54-2.44 (m, 3 H).
[0487] 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (19):
A
mixture of 18 (610 mg, 2,1 mmol, 1.0 eq) and hydrazine hydrate (168 mg, 5.25 mmol, 2.5 eq) in Et0H (10 mL) was refluxed for 4 hrs. The reaction was then cooled to rt and concentrated under reduced pressure to afford a white precipitate. The precipitate was dissolved in Et0Ac and washed with Na2SO4(aq), 1 N HC1(aq), and water. The organic layer was then dried over MgSO4, filtered, and concentrated to give a white precipitate. The precipitate was recrystalized in Et0H to afford the product as white crystals (376 mg, 63%);
HRMS ESI
[M+Hr calcd for C16H18N203 287.3385, found m/z 287.3379; 1H NMR (CDC13, 500 MHz):
8 8.53 (bs, 1 H), 7.46 (d, J= 2.0 Hz, 1 H), 7.23 (dd, J= 2.0, 8.4 Hz, 1 H), 6.87 (d, J= 8.4 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.72-5.7 (m, 1 H), 3.94 (s, 3 H), 3.93 (s, 3 H), 3.40 (dt, J= 5.5, 8.7 Hz, 1 H), 3.01-2.97 (m, 1 H), 2.85 (t, J= 6.0 Hz, 1 H), 2.26-2.19 (m, 3 H);
HRMS (ESI) [M+11]+ calcd for C16H19N203 287.3385, found 287.3376; HPLC > 98% pure (tR ----4.93, 70(A):30(E); tR = 5.33, 50(A):50(E)).
[0488] 2-(5-Bromo-penty1)-4-(3,4-dimethoxy-phenyl_-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (20): Sodium hydride (60% dispersion in oil, 44 mg, 1.1 mmol, 1.1 eq) was added to a solution 19 (287 mg, 1.0 mmol, 1.0 eq). The mixture was stirred at rt for 30 mm whereupon it took on a slight yellow color. 1,5-Dibromopentane (600 mg, 2.6 mmol, 2.6 eq) was added via syringe and the reaction was stirred for 30 mm at rt while the yellow color dissipated to an almost clear solution. The reaction was stopped with the addition of water and then transferred to a separatory funnel and extracted with Et20 (3 x 30 mL). The organic fractions were combined and dried over MgSO4, filtered, and concentrated to afford an oil.
The product was purified on silica and eluted with CH2C12 to afford a clear oil; 1H NMR
(CDC13, 500 MHz): 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J=
8.5 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.7-5.67 (m, 1 H), 4.01-3.97 (m, 1 H), 3.95 (s, 3 H), 3.92 (s, 3 H), 3.79-3.74 (m, 1 H), 2.22-2.18 (m, 2 H), 2.1-2.04 (m, 1 H), 1.94-1.86 (m , 4 H), 1.74-1.69 (m, 4 H), 1.63-1.56 (m, 1 H), 1.52-1.46 (m, 2 H); LRMS ESI [M+H] calcd for C21H28BrN203 436, found m/z 435 (Br79), 437 (Br81).
[0489] 4-(3,4-Dimethoxy-pheny1)-2-[5-(2-{542-(5-flouro-2-methoxy-pheny1)-ethyll-thtrahydro-furan-2-y11-ethylamino)-pentyll-4,5,8,8a-tetrahydro-2H-phthalazin-1-one (21): Into a flame dried round bottom flask under an atmosphere of Ar(g), cesium hydroxide monohydrate (23 mg, 0.14 mmol, 1.0 eq) and DMF (0.5 mL) was stirred for 30 min at rt.
Compound 14 (37 mg, 0.14 mmol, 1.0 eq) in DMF (0.3 mL) was then added via syringe and the resulting mixture stirred at rt. After stirring an additional 30 min, compound 20 (72 mg, 0.16 mmol, 1.2 eq) dissolved in DMF (0.3 mL) was added and stirred for an additional 18 hrs at rt. The reaction was washed with Et0Ac (30 mL) and then filtered and the filtrate was washed with water in a separatory funnel. The organic layer was dried with Na2SO4, filtered, and concentrated to oil. The product was purified by preparative TLC
(developed with Me0H/CH2C12, 5:95, v:v, Rf = 0.2) to afford an oil (27 mg, 0.04 mmol, 31%);
(CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J-8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.81-5.79 (m, 1 H), 5.71 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.8 (s, 3 H), 3.79-3.74 (m, 1 H), 3.36-3.31 (m, 1 H), 3.03-3.00 (m, 1 H), 2.81-2.78 (m, 2 H), 2.73-2.37 (m, 5 H), 2.30-2.19 (m, 3 H), 2.09-1.97 (m, 3 H), 1.87-1.26 (m, 14 H); HRMS (ESI) [M+11]+ cacld for C36H49FN305 622.8007, found 622.8025; HPLC > 99% pure (tR = 3.80 min, 55(A):45(B):0.02(D), tR = 4.53 min, (A):60(B):0.02(D)).
[0490] The following compound was prepared in a similar manner.
[0491] 4-(3,4-Dimethoxy-phenyl)-2-15-(2-{5-[3-(5-fluoro-2-methoxy-phenyl)-propyl]-tetrahydro-furan-2-yll-ethylamino)-pentyl-4a,5,8,8a-tetrahydro-2H-phthalaziu-1-one (22): the product was isolated by preparative TLC and (developed with Me0H/CH2C12, 5:95, v:v, Rf = 0.2); 1HNMR (CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J=
2.0, 8.5 Hz, 1 H), 6.87 (d, J= 8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.80-5.77 (m, 1 H), 5.69-5.66 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.77 (s, 3 H), 3.79-3.74 (m, 1 H), 3.33-3.3 (m, 1 H), 3.0-2.96 (m, 1 H), 2.81-2.57 (m, 7 H), 2.22-2.17 (m, 3 H), 2.04-1.34 (m, 19 H); HRMS (ESI) [M+Hr calcd for C371151FN305 636.8275, found 636.826; HPLC > 98% pure (tR= 3.86 min, 55(A):45(B):0.02(D); tR = 4.54 min, 40(A):60(B):0.02(D)).
[0492] (2-{5-[2-(5-Fluoro-2-methoxy-pheny1)-ethyl]-tetrahydro-furan-2-yll-ethyl)-carbainie ethyl ester (23): Into a flame dried 20 mL vial was placed K2CO3 (239 mg, 1.73 mmol, 6.0 eq) and anhydrous THF (5.0 mL). The vial was purged with Ar(g) and then cooled in an ice bath. Ethyl chloroformate (156 mg, 1.44 mmol, 5.0 eq) was then added via syringe followed by slow addition of 14 (77 mg, 0.29 mmol, 1.0 eq) dissolved in THF
(1.5 mL). The reaction was stirred at 0 C for 0.5 hrs and then warmed to rt and allowed to stir an additional 3 hrs. The reaction was then stopped with sat. NaHC030q) and extracted with Et0Ac (3 x 20 mL). The organic layer was washed with brine and dried over Na2SO4, filtered, and concentrated under reduced pressure to yield crude product that was used in the next step of the synthesis. TLC: Me0H/CH2C12 (2:98, v:v), Rf 0.4; 1H NMR (CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.12 (q, J= 7.1 Hz, 2 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 2 H), 2.08-1.51 (m, 10 H) 1.3 (t, J= 7.2 Hz, 3 H). LRMS (ESI) [M+11]+ calcd for C18H27FN04 340 found 340.
[0493] (2-{542-(5-Fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-y1}-ethyl)-methyl-amine (24): Into a flame dried round bottom flask, purged with Ar(g), was placed 23 (112 mg, 0.33 mmol, 1.0 eq) and anhydrous THF (1.6 mL). The flask was cooled with an ice bath and stirred for 15 min. LAH (1.0 M, 1.32 mL, 1.32 mmol, 4.0 eq) was then slowly added via syringe over a period of 5 min. The reaction was allowed to warm to rt and stirred an additional 4 hrs. The reaction was then stopped with ice cold Me0H and then stirred for an additional 15 min at rt. The resulting solution was acidified with 1N
HC1(aq) and then transferred to a beaker and then made basic with 10 M Na0Hom. The basic solution was then extracted with diethyl ether (3 x 20 mL) and then the organic layer was washed with brine.
The diethyl ether extract was dried over Mg2SO4 for 15 min and then filtered and concentrated to oil under reduced pressure to afford the crude product. The oil was purified with preparative TLC (developed with Me0H/CH2C12, 5:95, v:v, Rf 0.05); 1H NMR
(CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 5 H), 2.08-1.51 (m, 10 H); HRMS (ESI) [M+Hr calcd for C16H25FN02 282.3784, found 282.3762; HPLC > 97% pure (tR = 30.23 min, 100(A):0.5(D); tR = 26.05 min, 90(A):10(C):0.5(D)).
4.6, 8.6 Hz, 1 H), 5.82 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.95 (d, J= 10.2 Hz, 1 H), 3.81 (s, 3 H), 3.55 (m, 1 H), 2.75-2.69 (m, 2 H), 2.2 (m, 1 H), 2.1 (m, 1 H), 1.96 (bs, 1 H), 1.73-1.68 (m, 2 H), 1.6-1.53 (m, 3 H).
[0474] The following compound was prepared in a similar manner.
[0475] 8-(5'-Fluoro-V-methoxyphenyl)oct-1-en-5-ol (9): The product was purified by flash column chromatography (Et0Ac/hexane, 12.5:87.5, v:v, Rf = 0.15) as a colorless oil (1.06 g, 61%); 1H NMR (CDC13, 500 MHz): 8 6.86-6.82 (m, 2 H), 6.74 (dd, J=
4.6, 8.6 Hz, 1 H), 5.85 (m, 1 H), 5.04 (d, J= 17.3 Hz, 1 H), 4.97 (d, J= 10.2 Hz, 1 H), 3.79 (s, 3 H), 3.66 (m, 1 H), 2.6 (in, 2 H), 2.22-2.1 (m, 2 H), 1.74-1.47 (m, 7 H).
[0476] 2-(Bromomethyl)-5-(2'-methoxy-5'-fluorophenethyl)tetrahydrafuran (10):
To a solution of 8 (3.24 g, 18.0 mmol) in dry CH2C12 (50 mL) at 0 C was added N-bromosuccinimide (3.56 g, 20.0 mmol) portion-wise and the reaction was warmed to room temperature and stirred for 12 h. Solvent was then removed in vacuo and the product was purified by flash column chromatography (Et0Ac/hexane, 5:95, v:v, Rf = 0.1) and resulted in a colorless oil as a 2:1 mixture of trans:cis diastereomers; 1H NMR (CDC13, 500 MHz): 8 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (in, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J= 6.4, 9.7 Hz, 1 H), 2.6 (t, J=
7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H).
[0477] The following compound was prepared in a similar manner.
[0478] 2-(Bromomethyl)-5-(3'-(2"-methoxy-5"-fluorophenyl)-1'-propyl)tetrahydrofuran (11): the product was purified by flash column chromatography (Et0Ac/hexane, 5:95, v:v, .Rf = 0.1) to provide a product (530 mg, 40%) as a colorless oil; 1H
NMR (CDC13, 500 MHz): 8 6.86-6.81 (m, 2 H), 6.72 (dd, J= 4.6, 8.6 Hz, 1 H), 4.22 (m, 1 H), 4.03 (m, 1 H), 3.78 (s, 3 H), 3.44 (dd, J= 4.3, 9.7 Hz, 1 H), 3.34 (dd, J=
6.4, 9.7 Hz, 1 H), 2.6 (t, J= 7.3 Hz, 2 H), 2.13 (m, 1 H), 2.05 (m, 1 H), 1.75 (m, 1 H), 1.67-1.46 (m, 5 H).
[0479] 2-Cyanomethy1-5-(5'-flouro-2-methoxyphenethyl)tetrahydrofuran (12): To a vial under an atmosphere of Ar(g) was added 10 (1.23 g, 4.3 mmol), NaI (100 mg), potassium cyanide (0.7 g, 10.6 mmol), and dry DMSO (15 mL). The mixture obtained was heated to 70 C under an atmosphere of Ar for 12 h. After cooling to room temperature, the reaction mixture was poured into a separatory funnel containing sodium bicarcarbonate aqueous solution (sat. NaHCO3/H20, 50:50, v:v, 80 mL). The organic fraction was extracted with Et0Ac (3 x 60 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The solvent was then removed in vacuo and the crude product obtained (0.45 g, 86%) was purified by flash column chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.11); as a 2:1 mixture of trans/cis diastereomers. 1H NMR (500 MHz, CDC13) 6.88-6.82 (m, 2 H), 6.74 (dd, J= 4.3, 8.5 Hz, 1 H), 4.26 (m, 1 H), 4.09 (m, 0.65 H), 3.90 (m, 0.35 H)3.79 (s, 3 H), 2.72-2.53 (m, 4 H), 2.22-2.04 (m, 2 H), 1.84-1.6 (m, 4 H).
[0480] The following compound was prepared in a similar manner.
[0481] 2-Cyanomethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrafuran (13): the product (0.2 g, 80%) was purified by chromatography (Et0Ac/hexane, 10:90, v:v, Rf = 0.11) as a 2:1 mixture of trans/cis diastereomers; 1H NMR (CDC12, 500 MHz): 8 6.86-6.81 (m, 2 H), 6.73 (dd, J= 4.2, 8.5 Hz, 1 H), 4.22 (p, J= 6.8 Hz, 0.65 H), 4.11 (m, 0.35 H) 4.09 (m, 0.65 H), 3.9 (m, 0.35 H), 3.79 (s, 3 H), 2.62-2.52 (m, 4 H), 2.18 (m, 1 H), 2.12 (m, 1 H), 1.78 (m, 1 H), 1.69-1.46 (m, 3 H).
[0482] 2-Aminoethy1-5-(2`-methoxy-5'-fluorophenethyl)tetrahydrofuran (14): To a round bottom flask under an atmosphere of Ar was added Raney Ni that was washed with methanol. Compound 12 (80 mg, 0.3 mmol), dissolved in 2 M NH3 in methanol was added to the flask. The flask was evacuated and purged with H2 once. A balloon containing H2 gas was then attached to the flask and the reaction was allowed to stirr for 4 h at room temperature. The reaction mixture was filtered through a plug of Celite and the crude product obtained after the removal of the solvent was purified by preparative TLC and eluted with (Me0H/CH2C12, 10:90, v:v, Rf = 0.1) to give the product (55 mg, 70%) as a 2:1 mixture of trans/cis diastereomers; 1H NMR: (CDC13, 500 MHz): 8 6.87 (m, 1 H), 6.82 (dd, J= 3.0, 8.5 Hz, 1 H), 6.72 (m, 1 H), 4.03 (m, 0.65 H), 3.96 (m, 0.65 H), 3.89 (m, 0.35 H), 3.82 (m, 0.35 H), 3.78 (s, 3 H), 2.68 (m, 1 H), 2.58 (m, 1 H), 2.03 (m, 2 H), 1.83 (bs, 2 H), 1.86-1.6 (m, 4 H), 1.54 (m, 2 H); HRMS (ESI) [M+11.]+ calcd for C15H23FN02 268.1713, found 268.1701;
HPLC > 96% pure (tR = 4.66 mm, 40(A):55(B):5(C):0.01(D); tR = 5.05 min, 10(A):85(B):5(C):0.01(D)).
[0483] The following compound was prepared in a similar manner.
[0484] 2-Aminoethy1-5-(3'-(2"-methoxy-5"-fluoropheny1)-1'-propyl)tetrahydrofuran (15): the product (24 mg, 47%), was isolated as 3:1 mixture of trans/cis diastereomers (Me0H/CH2C12, 10:90, v:v, Rf = 0.1): 1H NMR: (CDC13, 500 MHz): 8 6.86-6.8 (m, 2 H), 6.73 (m, 1 H), 4.02 (m, 0.65 H), 3.96 (m, 0.65 H), 3.92 (m, 0.35 H), 3.82 (m, 0.35 H), 3.78 (s, 3 H), 3.09 (m, 1 H), 2.99 (m, 1 H), 2.6 (bs, 2 H), 1.96 (m, 2 H), 1.83-1.77 (m, 2 H), 1.65-1.47 (m, 8 H); HRMS (ESI) [M+H] calcd for C16H25FN02 282.1875, found 282.1869; HPLC
>
95% pure (tR = 4.70 min, 40(A):55(B):5(C):0.01(D), tR = 5.09 10(A):85(B):5(C):0.01(D)).
[0485] 3,4-Dimethoxyphenylmagnesium bromide (17): Into a flame dried round bottom flask with a magnetic stir bar was placed anhydrous THF (150 mL) and Mg(s) turlings (1.43 g, 58.8 mmol, 1.0 eq). The flask was then fitted with a pressure equalizing addition funnel containing 4-bromo-1,2-dimethoxybenzene solution that was added slowly over a period of 45 min while stirring at rt. Once the addition was complete I2(,) (500 mg) was added and the reaction was brought to reflux and stirred for 12 hrs. The Grignard reagent was cooled and used immediately in the following reaction.
[0486] 6-(3,4-Dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid (18): A
solution of 17 (59 mmol, 0.29 M) in THF was added dropwise to an ice-cooled solution of cis-1,2,3,6-tetrahydrophthalic anhydride in THF (120 mL) over a 1 hr period. After the addition was complete, the resulting mixture was stirred for another 30 min at 0 C. The reaction mixture was allowed to warm to rtand stirred overnight. The reaction was then stopped with sat.
NH4C1 and the pH adjusted to 2 with concentrated HC1(aq) and then extracted with diethyl ether. The organic layer was washed with water and subsequently extracted with 1 M NaOH.
The combined aqueous extract was acidified with concentrated HC1 and extracted with Et0Ac (3x 100 mL). The organic layers were combined and dried over MgSO4, filtered, and concentrated under reduced pressure to afford oil. The oil was dissolved CH2C12 and filtered through silica gel to remove the dicarboxylic acid formed during workup. The product was recrystallized from diethyl ether to afford pure product (1.62 g, 10%) as a white solid; mp =
109 C; LRMS ESI Ern-HI cacld for C16141805 289, found m/z 289; 1H NMR (CDC13, MHz): 8 7.60-7.53 (m, 2 H), 6.92 (d, J= 8.4 Hz, 1 H), 5.84-5.82 (m, 1 H), 5.71-5.68 (m, 1 H), 4.03-4.00 (m, 1 H), 3.98 (s, 3 H), 3.95 (s, 1 H), 3.10-3.07 (in, 1 H), 2.90-2.84 (m, 1 H), 2.54-2.44 (m, 3 H).
[0487] 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (19):
A
mixture of 18 (610 mg, 2,1 mmol, 1.0 eq) and hydrazine hydrate (168 mg, 5.25 mmol, 2.5 eq) in Et0H (10 mL) was refluxed for 4 hrs. The reaction was then cooled to rt and concentrated under reduced pressure to afford a white precipitate. The precipitate was dissolved in Et0Ac and washed with Na2SO4(aq), 1 N HC1(aq), and water. The organic layer was then dried over MgSO4, filtered, and concentrated to give a white precipitate. The precipitate was recrystalized in Et0H to afford the product as white crystals (376 mg, 63%);
HRMS ESI
[M+Hr calcd for C16H18N203 287.3385, found m/z 287.3379; 1H NMR (CDC13, 500 MHz):
8 8.53 (bs, 1 H), 7.46 (d, J= 2.0 Hz, 1 H), 7.23 (dd, J= 2.0, 8.4 Hz, 1 H), 6.87 (d, J= 8.4 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.72-5.7 (m, 1 H), 3.94 (s, 3 H), 3.93 (s, 3 H), 3.40 (dt, J= 5.5, 8.7 Hz, 1 H), 3.01-2.97 (m, 1 H), 2.85 (t, J= 6.0 Hz, 1 H), 2.26-2.19 (m, 3 H);
HRMS (ESI) [M+11]+ calcd for C16H19N203 287.3385, found 287.3376; HPLC > 98% pure (tR ----4.93, 70(A):30(E); tR = 5.33, 50(A):50(E)).
[0488] 2-(5-Bromo-penty1)-4-(3,4-dimethoxy-phenyl_-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (20): Sodium hydride (60% dispersion in oil, 44 mg, 1.1 mmol, 1.1 eq) was added to a solution 19 (287 mg, 1.0 mmol, 1.0 eq). The mixture was stirred at rt for 30 mm whereupon it took on a slight yellow color. 1,5-Dibromopentane (600 mg, 2.6 mmol, 2.6 eq) was added via syringe and the reaction was stirred for 30 mm at rt while the yellow color dissipated to an almost clear solution. The reaction was stopped with the addition of water and then transferred to a separatory funnel and extracted with Et20 (3 x 30 mL). The organic fractions were combined and dried over MgSO4, filtered, and concentrated to afford an oil.
The product was purified on silica and eluted with CH2C12 to afford a clear oil; 1H NMR
(CDC13, 500 MHz): 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J=
8.5 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.7-5.67 (m, 1 H), 4.01-3.97 (m, 1 H), 3.95 (s, 3 H), 3.92 (s, 3 H), 3.79-3.74 (m, 1 H), 2.22-2.18 (m, 2 H), 2.1-2.04 (m, 1 H), 1.94-1.86 (m , 4 H), 1.74-1.69 (m, 4 H), 1.63-1.56 (m, 1 H), 1.52-1.46 (m, 2 H); LRMS ESI [M+H] calcd for C21H28BrN203 436, found m/z 435 (Br79), 437 (Br81).
[0489] 4-(3,4-Dimethoxy-pheny1)-2-[5-(2-{542-(5-flouro-2-methoxy-pheny1)-ethyll-thtrahydro-furan-2-y11-ethylamino)-pentyll-4,5,8,8a-tetrahydro-2H-phthalazin-1-one (21): Into a flame dried round bottom flask under an atmosphere of Ar(g), cesium hydroxide monohydrate (23 mg, 0.14 mmol, 1.0 eq) and DMF (0.5 mL) was stirred for 30 min at rt.
Compound 14 (37 mg, 0.14 mmol, 1.0 eq) in DMF (0.3 mL) was then added via syringe and the resulting mixture stirred at rt. After stirring an additional 30 min, compound 20 (72 mg, 0.16 mmol, 1.2 eq) dissolved in DMF (0.3 mL) was added and stirred for an additional 18 hrs at rt. The reaction was washed with Et0Ac (30 mL) and then filtered and the filtrate was washed with water in a separatory funnel. The organic layer was dried with Na2SO4, filtered, and concentrated to oil. The product was purified by preparative TLC
(developed with Me0H/CH2C12, 5:95, v:v, Rf = 0.2) to afford an oil (27 mg, 0.04 mmol, 31%);
(CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J-8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.81-5.79 (m, 1 H), 5.71 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.8 (s, 3 H), 3.79-3.74 (m, 1 H), 3.36-3.31 (m, 1 H), 3.03-3.00 (m, 1 H), 2.81-2.78 (m, 2 H), 2.73-2.37 (m, 5 H), 2.30-2.19 (m, 3 H), 2.09-1.97 (m, 3 H), 1.87-1.26 (m, 14 H); HRMS (ESI) [M+11]+ cacld for C36H49FN305 622.8007, found 622.8025; HPLC > 99% pure (tR = 3.80 min, 55(A):45(B):0.02(D), tR = 4.53 min, (A):60(B):0.02(D)).
[0490] The following compound was prepared in a similar manner.
[0491] 4-(3,4-Dimethoxy-phenyl)-2-15-(2-{5-[3-(5-fluoro-2-methoxy-phenyl)-propyl]-tetrahydro-furan-2-yll-ethylamino)-pentyl-4a,5,8,8a-tetrahydro-2H-phthalaziu-1-one (22): the product was isolated by preparative TLC and (developed with Me0H/CH2C12, 5:95, v:v, Rf = 0.2); 1HNMR (CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J=
2.0, 8.5 Hz, 1 H), 6.87 (d, J= 8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.80-5.77 (m, 1 H), 5.69-5.66 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.77 (s, 3 H), 3.79-3.74 (m, 1 H), 3.33-3.3 (m, 1 H), 3.0-2.96 (m, 1 H), 2.81-2.57 (m, 7 H), 2.22-2.17 (m, 3 H), 2.04-1.34 (m, 19 H); HRMS (ESI) [M+Hr calcd for C371151FN305 636.8275, found 636.826; HPLC > 98% pure (tR= 3.86 min, 55(A):45(B):0.02(D); tR = 4.54 min, 40(A):60(B):0.02(D)).
[0492] (2-{5-[2-(5-Fluoro-2-methoxy-pheny1)-ethyl]-tetrahydro-furan-2-yll-ethyl)-carbainie ethyl ester (23): Into a flame dried 20 mL vial was placed K2CO3 (239 mg, 1.73 mmol, 6.0 eq) and anhydrous THF (5.0 mL). The vial was purged with Ar(g) and then cooled in an ice bath. Ethyl chloroformate (156 mg, 1.44 mmol, 5.0 eq) was then added via syringe followed by slow addition of 14 (77 mg, 0.29 mmol, 1.0 eq) dissolved in THF
(1.5 mL). The reaction was stirred at 0 C for 0.5 hrs and then warmed to rt and allowed to stir an additional 3 hrs. The reaction was then stopped with sat. NaHC030q) and extracted with Et0Ac (3 x 20 mL). The organic layer was washed with brine and dried over Na2SO4, filtered, and concentrated under reduced pressure to yield crude product that was used in the next step of the synthesis. TLC: Me0H/CH2C12 (2:98, v:v), Rf 0.4; 1H NMR (CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.12 (q, J= 7.1 Hz, 2 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 2 H), 2.08-1.51 (m, 10 H) 1.3 (t, J= 7.2 Hz, 3 H). LRMS (ESI) [M+11]+ calcd for C18H27FN04 340 found 340.
[0493] (2-{542-(5-Fluoro-2-methoxy-pheny1)-ethyll-tetrahydro-furan-2-y1}-ethyl)-methyl-amine (24): Into a flame dried round bottom flask, purged with Ar(g), was placed 23 (112 mg, 0.33 mmol, 1.0 eq) and anhydrous THF (1.6 mL). The flask was cooled with an ice bath and stirred for 15 min. LAH (1.0 M, 1.32 mL, 1.32 mmol, 4.0 eq) was then slowly added via syringe over a period of 5 min. The reaction was allowed to warm to rt and stirred an additional 4 hrs. The reaction was then stopped with ice cold Me0H and then stirred for an additional 15 min at rt. The resulting solution was acidified with 1N
HC1(aq) and then transferred to a beaker and then made basic with 10 M Na0Hom. The basic solution was then extracted with diethyl ether (3 x 20 mL) and then the organic layer was washed with brine.
The diethyl ether extract was dried over Mg2SO4 for 15 min and then filtered and concentrated to oil under reduced pressure to afford the crude product. The oil was purified with preparative TLC (developed with Me0H/CH2C12, 5:95, v:v, Rf 0.05); 1H NMR
(CDC13, 500 MHz) 6.87-6.82 (m, 2 H), 6.74-6.71 (m, 1 H), 4.05-3.77 (m, 2 H), 3.78 (s, 3 H), 2.71-2.56 (m, 5 H), 2.08-1.51 (m, 10 H); HRMS (ESI) [M+Hr calcd for C16H25FN02 282.3784, found 282.3762; HPLC > 97% pure (tR = 30.23 min, 100(A):0.5(D); tR = 26.05 min, 90(A):10(C):0.5(D)).
Table 14. Inhibition of Recombinant PDE4 Isoforms with PDE4 inhibitors and Dual PDE4 Inhibitor/SSRIs Enzyme Compound Human Human Human (nM) K (nM) K1 (nM) 19 6.3 250 <1000 21 2.0 199 <1000 22 1.2 500 <1000 Rolipram 58.9 Table 15. Inhibition of radioligand binding and [311] neurotransmitter uptake in HEK-hDAT, HEK-hSERT and HEK-hNET ceilsa Binding (Ki, nM) Reuptake (IC50, nM) Compound Description hDAT hSERT hNET hDAT hSERT hNET
Cocaine 229 7.3 6670 1.1 1560 19,500 1020 Fluoxetine 850b 0.5 300 7600 2.9 180 6500 2.1 2440 27850 2.5 481 828 0.2 215 5129 0.6 158 7307 1.1 10600 16987 2.3 1930.0 SSR1 1331 0.1 1880 1352 0.6 463.0 19 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000 inhibitor N-modified PDE4 >100,000 >100,000 >100,000 >100,000 >100,000 inhibitor Dual 2478 156 1748 3556 127 957 21 inhibitor 451 30 257 377 15 146 22 Dual 1083 87 1269 1083 87 1269 Binding (Ki, nM) Reuptake (IC50, nM) Compound Description hDAT hSERT hNET hDAT hSERT hNET
inhibitor 66988 21.2 19332 > 18.4 20370 24 SSR1 14450 4.3 3577 100,000 6.1 3751 a Values are the mean S.E.M. of three to four experiments unless the mean of three experiments exceeded 100 uM. Drug inhibition of [1251]-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET cell membranes. Inhibition of [31-1]-DA, [311]-5-HT, [31-1]-NE in the presence of HEK-hDAT, HEK-hSERT, or HEK-hNET cells, respectively;
b Data taken from the literature.
Table 16. Effect of Hepatic Microsomes on the Metabolic Stability of SSRIs and Dual PDE4 inhibitor/SSRIs RLMa MLMb HLIVIc Compd t1/2 (min) ti/2 (min) tin. (min) 14 106.3 56.0 NAd 19 NA 211.3 NDe 21 NA 153.9 ND
24 129.0 58.5 NA
RLM, rat liver microsomes; b MLM, mouse liver microsomes; C HLM, human liver microsomes; d NA, Not available.; e ND, No detectable degradation observed in the presence of animal liver microsomes supplemented with NADPH for 60 mins.
Example 30: Other Dual SSRUPDE4 Inhibitors [0494] Initially, a PDE4 inhibitor was combined with highly potent and selective SSRIs to form dual SSRUPDE4 inhibitors (see, e.g., Figure 25). Summarized below is an extension of this study showing that well-recognized SSRIs can also be combined with PDE4 inhibitors to afford novel compounds with novel pharmacological activity. For example, nor fluoxetine (both enantiomers) was combined with a PDE4 inhibitor to give new dual inhibitors (see Figure 24). This approach can be extended, for example, to a SERT/NET reuptake inhibitor (duloxetine) by synthesizing the nor duloxetine compound and combining it with the PDE4 inhibitor (see Figure 27). During these studies it was necessary to determine the absolute configuration and enantiomeric purity of the norfluoxetine compounds by synthesizing the diastereomeric ureas (see Figure 26). Diagnostic NMR signals in the urea products provided a means of quantifying each enantiomer. The synthesis and characterization of the nor-compounds (see Figure 23) and dual inhibitor compounds are summarized below.
The synthesis of the PDE4 inhibitor and the coupling chemistry are also described, as well as pharmacological results of the new dual SSRUPDE4 inhibitors (using norfluoxetine) and constituent SSRIs (as the nor compounds) in in vitro studies.
Synthesis of PDE4/SSRI dual inhibitors [0495] 3,4-Dimethoxyphenylmagnesium bromide: Into a flame dried round bottom flask with a magnetic stir bar was placed anhydrous THF (150 mL) and Mg(s) turnings (1.43 g, 58.8 mmol, 1.0 eq). The flask was then fitted with a pressure equalizing addition funnel containing 4-bromo-1,2-dimethoxybenzene solution that was added slowly over a period of 45 min while stirring at rt. Once the addition was complete I2(,) (500 mg) was added and the reaction was brought to reflux and stirred for 12 hrs. The Grignard reagent was cooled and used immediately in the following reaction.
[0496] 6-(3,4-Dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid: A solution of grignard reagent (59 mmol, 0.29 M) in THF was added dropwise to an ice-cooled solution of cis-1,2,3,6-tetrahydrophthalic anhydride in THF (120 mL) over a 1 hr period.
After the addition was complete, the resulting mixture was stirred for another 30 min at 0 C. The reaction mixture was allowed to warm to rtand stirred overnight. The reaction was then stopped with sat. NH4C1 and the pH adjusted to 2 with concentrated HC1(aq) and then extracted with diethyl ether. The organic layer was washed with water and subsequently extracted with 1 M NaOH. The combined aqueous extract was acidified with concentrated HC1 and extracted with Et0Ac (3x 100 mL). The organic layers were combined and dried over MgSO4, filtered, and concentrated under reduced pressure to afford oil.
The oil was dissolved CH2C12 and filtered through silica gel to remove the dicarboxylic acid formed during workup. The product was recrystallized from diethyl ether to afford pure product (1.62 g, 10%); mp = 109 C; LRMS ESI [m-Hr cacld for C16E11805 289, found in/z 289; 1H
NMR (CDC13, 500 MHz): 8 7.60-7.53 (m, 2 H), 6.92 (d, I= 8.4 Hz, 1 H), 5.84-5.82 (m, 1 H), 5.71-5.68 (m, 1 H), 4.03-4.00 (m, 1 H), 3.98 (s, 3 H), 3.95 (s, 1 H), 3.10-3.07 (m, 1 H), 2.90-2.84 (m, 1 H), 2.54-2.44 (m, 3 H).
[0497] 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (19):
A
mixture of 18 (610 mg, 2,1 mmol, 1.0 eq) and hydrazine hydrate (168 mg, 5.25 mmol, 2.5 eq) in Et0H (10 mL) was refluxed for 4 hrs. The reaction was then cooled to it and concentrated under reduced pressure to afford a white precipitate. The precipitate was dissolved in Et0Ac and washed with Na2SO4(aq), 1 N HC1(ao, and water. The organic layer was then dried over MgSO4, filtered, and concentrated to give a white precipitate. The precipitate was recrystalized in Et0H to afford the product as white crystals (376 mg, 63%);
HRMS ESI
[M+H] calcd for C16H18N203 287.3385, found m/z 287.3379; 1H NMR (CDC13, 500 MHz):
8 8.53 (bs, 1 H), 7.46 (d, J= 2.0 Hz, 1 H), 7.23 (dd, J= 2.0, 8.4 Hz, 1 H), 6.87 (d, J= 8.4 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.72-5.7 (m, 1 H), 3.94 (s, 3 H), 3.93 (s, 3 H), 3.40 (dt, J= 5.5, 8.7 Hz, 1 H), 3.01-2.97 (m, 1 H), 2.85 (t, J= 6.0 Hz, 1 H), 2.26-2.19 (m, 3 H);
HRMS (ESI) [M+Hr calcd for C16H19N203 287.3385, found 287.3376; HPLC > 98% pure (tR =
4.93, 70(A):30(E); tR = 5.33, 50(A):50(E)).
[0498] 2-(5-Bromo-penty1)-4-(3,4-dimethoxy-phenyl -4a,5,8,8a-tetrahydro-21I-phthalazin-1-one (20): Sodium hydride (60% dispersion in oil, 44 mg, 1.1 mmol, 1.1 eq) was added to a solution 19 (287 mg, 1.0 mmol, 1.0 eq). The mixture was stirred at rt for 30 min whereupon it took on a slight yellow color. 1,5-Dibromopentane (600 mg, 2.6 mmol, 2.6 eq) was added via syringe and the reaction was stirred for 30 min at rt while the yellow color dissipated to an almost clear solution. The reaction was stopped with the addition of water and then transferred to a separatory funnel and extracted with Et20 (3 x 30 mL). The organic fractions were combined and dried over MgSO4, filtered, and concentrated to give an oil.
The product was purified on silica and eluted with CH2C12 to afford a clear oil; 1H NMR
(CDC13, 500 MHz): 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J=
8.5 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.7-5.67 (m, 1 H), 4.01-3.97 (m, 1 H), 3.95 (s, 3 H), 3.92 (s, 3 H), 3.79-3.74 (m, 1 H), 2.22-2.18 (m, 2 H), 2.1-2.04 (m, 1 H), 1.94-1.86 (m, 4 H), 1.74-1.69 (m, 4 H), 1.63-1.56 (m, 1 H), 1.52-1.46 (m, 2 H); LRMS ESI [M+H] calcd for C21H28BrN203 436, found m/z 435 (Br79), 437 (Br81).
[0499] (R) or (1S)-1-Chloro-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane: In a flame dried round bottom flask purged with Ar(g) was put the PPh3 (368 mg, 1.41 mmol, 1.2 eq) and 1.5 mL of THF. To this solution was added the DIAD (284 mg, 1.41 mmol, 1.2 eq) and the reaction was stirred at rt for 20 min. Then the a,a,cc-triflouro-p-cresol (190 mg, 1.17 mmol, 1.0 eq) dissolved in 0.5 mL of THF was added via syringe and the reaction was stirred at rt for 4 hrs until a light precipitate had formed and the solution had turned greenish in color.
The chiral alcohol (200 mg, 1.17 mmol, 1.0 eq) dissolved in 0.5 mL of THF was then added via syringe and the precipitate and color dissipated within 3 min after addition. The reaction was then stirred at rt overnight and then concentrated to oil. The crude oil was chromatographed on silica with 5% Et0Ac/Hexanes as an eluent to afford the pure product as a clear oil (242 mg, 66%); 1H NMR (CDC13, 300 MHz): 8 7.47 (d, J= 8.7 Hz, 2 H), 7.36 (m, H), 6.94 (d, J= 8.7 Hz, 2 H), 5.46 (dd, J= 3.9, 4.7 Hz, 1 H), 3.83 (m, 1 H), 3.62 (m, 1 H), 2.51 (m, 1 H), 2.25 (m, 1 H).
5 [0500] (R) or (S)-1-phthalimide-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane: In a 20 mL scintillation vial was put (R) or (S)-1-Chloro-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane (468 mg, 1.48 mmol, 1.0 eq), Nal (10 mg), potassium phthalimide (550 mg, 2.97 mmol, 2.0 eq) and DMSO (3 mL). The vial was then put in a 70 C oil bath and stirred for 13 hrs. When the reaction was complete the vial was cooled to rt and then quenched with H20.
The resulting solution was then put in a seperatory funnel and extracted with Et0Ac (3x25 mL). The organic layers were combined and washed with brine, dried over Na2SO4, filtered through paper, and then concentrated to a light yellow solid. The crude material was purified with silica chromatograpy with 25% Et0Ac/Hexanes as an eluent to afford pure product as a light yellow solid (461 mg, 73%); 1H NMR (CDC13, 300 MHz): 8 7.81 (m, 2 H), 7.70 (in, 2 H), 7.37 (d, J= 8.7 Hz, 2 H), 7.31 (m, 5 H), 6.81 (d, J= 8.7 Hz, 2 H), 5.28 (dd, J= 3.9, 5.5 Hz, 1 H), 3.95 (m, 2 H), 2.43 (m, 1 H), 2.22 (m, 1 H).
[0501] (R) or (S)-norfluoxetine: In a 20 mL scintillation vial was put (R) or (S)-1-phthalimide-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane (142 mg, 0.33 mmol, 1.0 eq) adn DCM (1 mL) and the solution was stirred until all of the phthalimide dissolved. Then Me0H (1 mL) followed by the hydrazine monohydrate was added to the vial and the reaction was stirred at rt for 8 hr's while a creamy white precipitate formed. When the reaction was complete it was concentrated in vacuo to a white solid and then transferred to a seperatory funnel with the aid of DCM and H20. The solution was extracted with DCM (1x25 mL) and then the aqueous layer was made basic (pH=12) with 10 M NaOH and then extracted again with DCM (2x25 mL). The organic layers were combined and washed with brine, dried over Na2SO4, filtered through paper, and concentrated to yellow oil (97 mg, 99%).
The resulting crude material was pure enough to use in the following reaction; 1H NMR
(CDC13, 300 MHz): 8 7.43 (d, J-= 8.7 Hz, 2 H), 7.29 (in, 5 H), 6.90 (d, J= 8.7 Hz, 2 H), 5.32 (dd, J= 3.6, 4.5 Hz, 1 H), 2.89 (t, J= 7.2 Hz, 2 H), 2.16 (m, 1 H), 1.97 (m, 1 H), 1.31 (bs, 2 H).
[0502] In a vial was put (R) or (S)-norfluoxetine (30 mg, 0.10 mmol, 1.0 eq), NaH (5 mg, 0.12 mmol, 1.2 eq) and DMF (0.3 mL) and then the reaction was stirred at rt for 20 mm.
Then the alkyl halide (44 mg, 0.10 mmol, 1.0 eq) dissolved in DMF (0.3 mL) was added via syringe and the reaction was stirred at rt overnight. When the reaction was complete it was transferred to a separatory funnel with the aid of Et20 and H20. Saturated NaHCO3 was added to the solution which was then extracted with Et20 (3x20 mL). The organic layers were combined and washed with H20 (2x30 mL) and brine. The organic layer was then dried over MgSO4, filtered through paper and concentrated to clear oil. The product was purified with RP PTLC using 100 mg per plate and eluting twice with CH3N/Me0H (1:1 vol:vol) and four more times with Me0H Rf = 0.1.
[0503] R enantiomer 1H NMR (CDC13, 300 MHz): 8 7.47-7.29 (in, 9 H), 6.90-6.86 (m, 3 H), 5.80-5.66 (m, 2 H), 5.31-5.27 (m, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.79-3.7 (m, 1 H), 3.36-3.28 (m, 1 H), 3.02-2.97 (m, 1 H), 2.77 (m, 2 H), 2.6 (m, 2 H), 2.23-2.00 (m, 5 H), 1.72-1.3 (m, 7 H), 0.87 (m, 2 H); LRMS ESI [M+1-11+ calcd for C37H42F3N304 650, found m/z 650, and 364; HPLC Supelco Discovery HS F5 HPLC column 39693-02 serial # 567517-U, (0.35% formic acid)/ CH3N/ Me0H (1:1:18 vol:vol) tR = 84.75; H20 (0.35% formic acid)/
CH3N/ Me0H (1:1:8 vol:vol) tR = 110.17.
[0504] S enantiomer 1H NMR (CDC13, 300 MHz): 8 7.47-7.24 (m, 9 H), 6.90-6.86 (m, 3 H), 5.81-5.66 (m, 2 H), 5.31-5.27 (m, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.79-3.7 (m, 1 H), 3.36-3.28 (m, 1 H), 3.02-2.97 (m, 1 H), 2.77 (m, 2 H), 2.6 (m, 2 H), 2.23-2.00 (m, 5 H), 1.72-1.3 (m, 7 H), 0.87 (m, 2 H); LRMS ESI [1\4+Hr calcd for C37H42F3N304 650, found m/z 650, and 364; HPLC Supelco Discovery HS F5 HPLC column 39693-02 serial # 567517-U, (0.35% formic acid)/ CH3N/ Me0H (1:1:18 vol:vol) tR = 83.68; H20 (0.35% formic acid)/
CH3N/ Me0H (1:1:8 vol:vol) tR = 109.47.
[0505] 4-(3,4-Dimethoxy-phenyl)-2-[5-(2-{5-[2-(5-flouro-2-methoxy-pheny1)-ethyl]-thtrahydro-furan-2-y1}-ethylamino)-penty1]-4,5,8,8a-tetrahydro-211-phthalazin-1-one (21): (See Figure 36.) Into a flame dried round bottom flask under an atmosphere of Ar(g), NaH (22 mg, 0.54 mmol, 1.2 eq) and DMF (2.0 mL) and then the primary amine (120 mg, 0.45 mmol, 1.0 eq) in DMF (0.3 mL) was added via syringe. The resulting mixture stirred at rt for 30 min and then the alkyl bromide (294 mg, 0.67 mmol, 1.5 eq) dissolved in DMF (0.3 mL) was added and stirred for an additional 18 hrs at rt. The reaction was washed with Et0Ac (30 mL) and then filtered and the filtrate was washed with water in a separatory funnel. The organic layer was dried with Na2SO4, filtered, and concentrated to oil. The product was purified by preparative TLC (developed with Me0H/CH2C12, 5:95, v:v, Rf = 0.2) to afford an oil (27 mg, 0.04 mmol, 31%); 1H NMR (CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J= 8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.81-5.79 (m, 1 H), 5.71 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.8 (s, 3 H), 3.79-3.74 (m, 1 H), 3.36-3.31 (m, 1 H), 3.03-3.00 (m, 1 H), 2.81-2.78 (m, 2 H), 2.73-2.37 (m, 5 H), 2.30-2.19 (m, 3 H), 2.09-1.97 (m, 3 H), 1.87-1.26 (m, 14 H); HRMS
(ESI) [M+11]+ cacld for C36H49FN305 622.8007, found 622.8025; HPLC > 99% pure (tit =
3.80 min, 55(A):45(B):0.02(D), tR = 4.53 min, 40 (A):60(B):0.02(D)).
[0506] 4-(3,4-Dimethoxy-pheny1)-245-(2-{5-[3-(5-fluoro-2-methoxy-pheny1)-propyl]-tetrahydro-furan-2-yll-ethylamino)-penty1-4a,5,8,8a-tetrahydro-2H-phthalazin-l-one (22): (See Figure 37.) The product was isolated by preparative TLC and (developed with Me0H/CH2C12, 5:95, ITN, Rf = 0.2); 1H NMR (CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J= 8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.80-5.77 (m, 1 H), 5.69-5.66 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.77 (s, 3 H), 3.79-3.74 (m, 1 H), 3.33-3.3 (m, 1 H), 3.0-2.96 (m, 1 H), 2.81-2.57 (m, 7 H), 2.22-2.17 (m, 3 H), 2.04-1.34 (m, 19 H); HRMS (ESI) [M+14]-1- calcd for 636.8275, found 636.826; HPLC > 98% pure (tR = 3.86 min, 55(A):45(B):0.02(D);
tR = 4.54 min, 40(A):60(B):0.02(D)).
[0507] N -(R)-[1-(1-naphthybethyl]-N-(8)-344-(triflouromethyl)phenoxy]-3-phenylpropylurea: (See Figure 38.) (R)-Norfluoxetine (44 mg, 0.15 mmol, 1.1 eq) and (R)-(-)-1-(1-naphyl)ethyl isocyanate (27 mg, 0.14 mmol, 1.0 eq) was put in a vial containing toluene (0.75 mL). The reaction stirred at room temperature for 13 hrs and then concentrated in vacuo to afford a light yellow oil. The product was purified with PTLC on silica and eluted with Et0Ac/ Hex (1:3, v:v, R=0.3). 1H NMR (CDC13, 500 MHz) 8 8.22-7.21 (m, 14 H), 6.71 (d, J= 8.7 Hz, 2 H), 5.53 (t, J= 6.6 Hz, 1 H), 5.01-4.93 (m, 1 H), 4.60 (bt, 1 H), 3.22 (m, 2 H), 2.04-1.96 (m, 2 H) 1.54 (d, J= 6.9 Hz, 3 H).
[0508] N'-(8)41-(1-maphthyl)ethyll-N-(8)-344-(triflouromethyl)phenoxyl-3-phenylpropylurea: (See Figure 39.) (S)-Norfluoxetine (44 mg, 0.15 mmol, 1.1 eq) and (R)-(-)-1-(1-naphypethyl isocyanate (27 mg, 0.14 nunol, 1.0 eq) was put in a vial containing toluene (0.75 mL). The reaction stirred at room temperature for 13 hrs and then concentrated in vacuo to afford a light yellow oil. The product was purified with PTLC on silica and eluted with Et0Ac/ Hex (1:3, v:v, Rf--0.3). 1H NMR (CDC13, 500 MHz) 8 8.22-7.21 (m, 14 H), 6.71 (d, J= 8.7 Hz, 2 H), 5.53 (t, J= 6.6 Hz, 1 H), 5.01-4.93 (m, 1 H), 4.60 (bt, 1 H), 3.22 (m, 2 H), 2.04-1.96 (m, 2 H) 1.61 (d, J= 6.9 Hz, 3 H).
Cocaine 229 7.3 6670 1.1 1560 19,500 1020 Fluoxetine 850b 0.5 300 7600 2.9 180 6500 2.1 2440 27850 2.5 481 828 0.2 215 5129 0.6 158 7307 1.1 10600 16987 2.3 1930.0 SSR1 1331 0.1 1880 1352 0.6 463.0 19 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000 inhibitor N-modified PDE4 >100,000 >100,000 >100,000 >100,000 >100,000 inhibitor Dual 2478 156 1748 3556 127 957 21 inhibitor 451 30 257 377 15 146 22 Dual 1083 87 1269 1083 87 1269 Binding (Ki, nM) Reuptake (IC50, nM) Compound Description hDAT hSERT hNET hDAT hSERT hNET
inhibitor 66988 21.2 19332 > 18.4 20370 24 SSR1 14450 4.3 3577 100,000 6.1 3751 a Values are the mean S.E.M. of three to four experiments unless the mean of three experiments exceeded 100 uM. Drug inhibition of [1251]-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET cell membranes. Inhibition of [31-1]-DA, [311]-5-HT, [31-1]-NE in the presence of HEK-hDAT, HEK-hSERT, or HEK-hNET cells, respectively;
b Data taken from the literature.
Table 16. Effect of Hepatic Microsomes on the Metabolic Stability of SSRIs and Dual PDE4 inhibitor/SSRIs RLMa MLMb HLIVIc Compd t1/2 (min) ti/2 (min) tin. (min) 14 106.3 56.0 NAd 19 NA 211.3 NDe 21 NA 153.9 ND
24 129.0 58.5 NA
RLM, rat liver microsomes; b MLM, mouse liver microsomes; C HLM, human liver microsomes; d NA, Not available.; e ND, No detectable degradation observed in the presence of animal liver microsomes supplemented with NADPH for 60 mins.
Example 30: Other Dual SSRUPDE4 Inhibitors [0494] Initially, a PDE4 inhibitor was combined with highly potent and selective SSRIs to form dual SSRUPDE4 inhibitors (see, e.g., Figure 25). Summarized below is an extension of this study showing that well-recognized SSRIs can also be combined with PDE4 inhibitors to afford novel compounds with novel pharmacological activity. For example, nor fluoxetine (both enantiomers) was combined with a PDE4 inhibitor to give new dual inhibitors (see Figure 24). This approach can be extended, for example, to a SERT/NET reuptake inhibitor (duloxetine) by synthesizing the nor duloxetine compound and combining it with the PDE4 inhibitor (see Figure 27). During these studies it was necessary to determine the absolute configuration and enantiomeric purity of the norfluoxetine compounds by synthesizing the diastereomeric ureas (see Figure 26). Diagnostic NMR signals in the urea products provided a means of quantifying each enantiomer. The synthesis and characterization of the nor-compounds (see Figure 23) and dual inhibitor compounds are summarized below.
The synthesis of the PDE4 inhibitor and the coupling chemistry are also described, as well as pharmacological results of the new dual SSRUPDE4 inhibitors (using norfluoxetine) and constituent SSRIs (as the nor compounds) in in vitro studies.
Synthesis of PDE4/SSRI dual inhibitors [0495] 3,4-Dimethoxyphenylmagnesium bromide: Into a flame dried round bottom flask with a magnetic stir bar was placed anhydrous THF (150 mL) and Mg(s) turnings (1.43 g, 58.8 mmol, 1.0 eq). The flask was then fitted with a pressure equalizing addition funnel containing 4-bromo-1,2-dimethoxybenzene solution that was added slowly over a period of 45 min while stirring at rt. Once the addition was complete I2(,) (500 mg) was added and the reaction was brought to reflux and stirred for 12 hrs. The Grignard reagent was cooled and used immediately in the following reaction.
[0496] 6-(3,4-Dimethoxy-benzoy1)-cyclohex-3-enecarboxylic acid: A solution of grignard reagent (59 mmol, 0.29 M) in THF was added dropwise to an ice-cooled solution of cis-1,2,3,6-tetrahydrophthalic anhydride in THF (120 mL) over a 1 hr period.
After the addition was complete, the resulting mixture was stirred for another 30 min at 0 C. The reaction mixture was allowed to warm to rtand stirred overnight. The reaction was then stopped with sat. NH4C1 and the pH adjusted to 2 with concentrated HC1(aq) and then extracted with diethyl ether. The organic layer was washed with water and subsequently extracted with 1 M NaOH. The combined aqueous extract was acidified with concentrated HC1 and extracted with Et0Ac (3x 100 mL). The organic layers were combined and dried over MgSO4, filtered, and concentrated under reduced pressure to afford oil.
The oil was dissolved CH2C12 and filtered through silica gel to remove the dicarboxylic acid formed during workup. The product was recrystallized from diethyl ether to afford pure product (1.62 g, 10%); mp = 109 C; LRMS ESI [m-Hr cacld for C16E11805 289, found in/z 289; 1H
NMR (CDC13, 500 MHz): 8 7.60-7.53 (m, 2 H), 6.92 (d, I= 8.4 Hz, 1 H), 5.84-5.82 (m, 1 H), 5.71-5.68 (m, 1 H), 4.03-4.00 (m, 1 H), 3.98 (s, 3 H), 3.95 (s, 1 H), 3.10-3.07 (m, 1 H), 2.90-2.84 (m, 1 H), 2.54-2.44 (m, 3 H).
[0497] 4-(3,4-Dimethoxy-pheny1)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one (19):
A
mixture of 18 (610 mg, 2,1 mmol, 1.0 eq) and hydrazine hydrate (168 mg, 5.25 mmol, 2.5 eq) in Et0H (10 mL) was refluxed for 4 hrs. The reaction was then cooled to it and concentrated under reduced pressure to afford a white precipitate. The precipitate was dissolved in Et0Ac and washed with Na2SO4(aq), 1 N HC1(ao, and water. The organic layer was then dried over MgSO4, filtered, and concentrated to give a white precipitate. The precipitate was recrystalized in Et0H to afford the product as white crystals (376 mg, 63%);
HRMS ESI
[M+H] calcd for C16H18N203 287.3385, found m/z 287.3379; 1H NMR (CDC13, 500 MHz):
8 8.53 (bs, 1 H), 7.46 (d, J= 2.0 Hz, 1 H), 7.23 (dd, J= 2.0, 8.4 Hz, 1 H), 6.87 (d, J= 8.4 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.72-5.7 (m, 1 H), 3.94 (s, 3 H), 3.93 (s, 3 H), 3.40 (dt, J= 5.5, 8.7 Hz, 1 H), 3.01-2.97 (m, 1 H), 2.85 (t, J= 6.0 Hz, 1 H), 2.26-2.19 (m, 3 H);
HRMS (ESI) [M+Hr calcd for C16H19N203 287.3385, found 287.3376; HPLC > 98% pure (tR =
4.93, 70(A):30(E); tR = 5.33, 50(A):50(E)).
[0498] 2-(5-Bromo-penty1)-4-(3,4-dimethoxy-phenyl -4a,5,8,8a-tetrahydro-21I-phthalazin-1-one (20): Sodium hydride (60% dispersion in oil, 44 mg, 1.1 mmol, 1.1 eq) was added to a solution 19 (287 mg, 1.0 mmol, 1.0 eq). The mixture was stirred at rt for 30 min whereupon it took on a slight yellow color. 1,5-Dibromopentane (600 mg, 2.6 mmol, 2.6 eq) was added via syringe and the reaction was stirred for 30 min at rt while the yellow color dissipated to an almost clear solution. The reaction was stopped with the addition of water and then transferred to a separatory funnel and extracted with Et20 (3 x 30 mL). The organic fractions were combined and dried over MgSO4, filtered, and concentrated to give an oil.
The product was purified on silica and eluted with CH2C12 to afford a clear oil; 1H NMR
(CDC13, 500 MHz): 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J=
8.5 Hz, 1 H), 5.8-5.77 (m, 1 H), 5.7-5.67 (m, 1 H), 4.01-3.97 (m, 1 H), 3.95 (s, 3 H), 3.92 (s, 3 H), 3.79-3.74 (m, 1 H), 2.22-2.18 (m, 2 H), 2.1-2.04 (m, 1 H), 1.94-1.86 (m, 4 H), 1.74-1.69 (m, 4 H), 1.63-1.56 (m, 1 H), 1.52-1.46 (m, 2 H); LRMS ESI [M+H] calcd for C21H28BrN203 436, found m/z 435 (Br79), 437 (Br81).
[0499] (R) or (1S)-1-Chloro-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane: In a flame dried round bottom flask purged with Ar(g) was put the PPh3 (368 mg, 1.41 mmol, 1.2 eq) and 1.5 mL of THF. To this solution was added the DIAD (284 mg, 1.41 mmol, 1.2 eq) and the reaction was stirred at rt for 20 min. Then the a,a,cc-triflouro-p-cresol (190 mg, 1.17 mmol, 1.0 eq) dissolved in 0.5 mL of THF was added via syringe and the reaction was stirred at rt for 4 hrs until a light precipitate had formed and the solution had turned greenish in color.
The chiral alcohol (200 mg, 1.17 mmol, 1.0 eq) dissolved in 0.5 mL of THF was then added via syringe and the precipitate and color dissipated within 3 min after addition. The reaction was then stirred at rt overnight and then concentrated to oil. The crude oil was chromatographed on silica with 5% Et0Ac/Hexanes as an eluent to afford the pure product as a clear oil (242 mg, 66%); 1H NMR (CDC13, 300 MHz): 8 7.47 (d, J= 8.7 Hz, 2 H), 7.36 (m, H), 6.94 (d, J= 8.7 Hz, 2 H), 5.46 (dd, J= 3.9, 4.7 Hz, 1 H), 3.83 (m, 1 H), 3.62 (m, 1 H), 2.51 (m, 1 H), 2.25 (m, 1 H).
5 [0500] (R) or (S)-1-phthalimide-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane: In a 20 mL scintillation vial was put (R) or (S)-1-Chloro-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane (468 mg, 1.48 mmol, 1.0 eq), Nal (10 mg), potassium phthalimide (550 mg, 2.97 mmol, 2.0 eq) and DMSO (3 mL). The vial was then put in a 70 C oil bath and stirred for 13 hrs. When the reaction was complete the vial was cooled to rt and then quenched with H20.
The resulting solution was then put in a seperatory funnel and extracted with Et0Ac (3x25 mL). The organic layers were combined and washed with brine, dried over Na2SO4, filtered through paper, and then concentrated to a light yellow solid. The crude material was purified with silica chromatograpy with 25% Et0Ac/Hexanes as an eluent to afford pure product as a light yellow solid (461 mg, 73%); 1H NMR (CDC13, 300 MHz): 8 7.81 (m, 2 H), 7.70 (in, 2 H), 7.37 (d, J= 8.7 Hz, 2 H), 7.31 (m, 5 H), 6.81 (d, J= 8.7 Hz, 2 H), 5.28 (dd, J= 3.9, 5.5 Hz, 1 H), 3.95 (m, 2 H), 2.43 (m, 1 H), 2.22 (m, 1 H).
[0501] (R) or (S)-norfluoxetine: In a 20 mL scintillation vial was put (R) or (S)-1-phthalimide-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane (142 mg, 0.33 mmol, 1.0 eq) adn DCM (1 mL) and the solution was stirred until all of the phthalimide dissolved. Then Me0H (1 mL) followed by the hydrazine monohydrate was added to the vial and the reaction was stirred at rt for 8 hr's while a creamy white precipitate formed. When the reaction was complete it was concentrated in vacuo to a white solid and then transferred to a seperatory funnel with the aid of DCM and H20. The solution was extracted with DCM (1x25 mL) and then the aqueous layer was made basic (pH=12) with 10 M NaOH and then extracted again with DCM (2x25 mL). The organic layers were combined and washed with brine, dried over Na2SO4, filtered through paper, and concentrated to yellow oil (97 mg, 99%).
The resulting crude material was pure enough to use in the following reaction; 1H NMR
(CDC13, 300 MHz): 8 7.43 (d, J-= 8.7 Hz, 2 H), 7.29 (in, 5 H), 6.90 (d, J= 8.7 Hz, 2 H), 5.32 (dd, J= 3.6, 4.5 Hz, 1 H), 2.89 (t, J= 7.2 Hz, 2 H), 2.16 (m, 1 H), 1.97 (m, 1 H), 1.31 (bs, 2 H).
[0502] In a vial was put (R) or (S)-norfluoxetine (30 mg, 0.10 mmol, 1.0 eq), NaH (5 mg, 0.12 mmol, 1.2 eq) and DMF (0.3 mL) and then the reaction was stirred at rt for 20 mm.
Then the alkyl halide (44 mg, 0.10 mmol, 1.0 eq) dissolved in DMF (0.3 mL) was added via syringe and the reaction was stirred at rt overnight. When the reaction was complete it was transferred to a separatory funnel with the aid of Et20 and H20. Saturated NaHCO3 was added to the solution which was then extracted with Et20 (3x20 mL). The organic layers were combined and washed with H20 (2x30 mL) and brine. The organic layer was then dried over MgSO4, filtered through paper and concentrated to clear oil. The product was purified with RP PTLC using 100 mg per plate and eluting twice with CH3N/Me0H (1:1 vol:vol) and four more times with Me0H Rf = 0.1.
[0503] R enantiomer 1H NMR (CDC13, 300 MHz): 8 7.47-7.29 (in, 9 H), 6.90-6.86 (m, 3 H), 5.80-5.66 (m, 2 H), 5.31-5.27 (m, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.79-3.7 (m, 1 H), 3.36-3.28 (m, 1 H), 3.02-2.97 (m, 1 H), 2.77 (m, 2 H), 2.6 (m, 2 H), 2.23-2.00 (m, 5 H), 1.72-1.3 (m, 7 H), 0.87 (m, 2 H); LRMS ESI [M+1-11+ calcd for C37H42F3N304 650, found m/z 650, and 364; HPLC Supelco Discovery HS F5 HPLC column 39693-02 serial # 567517-U, (0.35% formic acid)/ CH3N/ Me0H (1:1:18 vol:vol) tR = 84.75; H20 (0.35% formic acid)/
CH3N/ Me0H (1:1:8 vol:vol) tR = 110.17.
[0504] S enantiomer 1H NMR (CDC13, 300 MHz): 8 7.47-7.24 (m, 9 H), 6.90-6.86 (m, 3 H), 5.81-5.66 (m, 2 H), 5.31-5.27 (m, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.79-3.7 (m, 1 H), 3.36-3.28 (m, 1 H), 3.02-2.97 (m, 1 H), 2.77 (m, 2 H), 2.6 (m, 2 H), 2.23-2.00 (m, 5 H), 1.72-1.3 (m, 7 H), 0.87 (m, 2 H); LRMS ESI [1\4+Hr calcd for C37H42F3N304 650, found m/z 650, and 364; HPLC Supelco Discovery HS F5 HPLC column 39693-02 serial # 567517-U, (0.35% formic acid)/ CH3N/ Me0H (1:1:18 vol:vol) tR = 83.68; H20 (0.35% formic acid)/
CH3N/ Me0H (1:1:8 vol:vol) tR = 109.47.
[0505] 4-(3,4-Dimethoxy-phenyl)-2-[5-(2-{5-[2-(5-flouro-2-methoxy-pheny1)-ethyl]-thtrahydro-furan-2-y1}-ethylamino)-penty1]-4,5,8,8a-tetrahydro-211-phthalazin-1-one (21): (See Figure 36.) Into a flame dried round bottom flask under an atmosphere of Ar(g), NaH (22 mg, 0.54 mmol, 1.2 eq) and DMF (2.0 mL) and then the primary amine (120 mg, 0.45 mmol, 1.0 eq) in DMF (0.3 mL) was added via syringe. The resulting mixture stirred at rt for 30 min and then the alkyl bromide (294 mg, 0.67 mmol, 1.5 eq) dissolved in DMF (0.3 mL) was added and stirred for an additional 18 hrs at rt. The reaction was washed with Et0Ac (30 mL) and then filtered and the filtrate was washed with water in a separatory funnel. The organic layer was dried with Na2SO4, filtered, and concentrated to oil. The product was purified by preparative TLC (developed with Me0H/CH2C12, 5:95, v:v, Rf = 0.2) to afford an oil (27 mg, 0.04 mmol, 31%); 1H NMR (CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J= 8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.81-5.79 (m, 1 H), 5.71 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.8 (s, 3 H), 3.79-3.74 (m, 1 H), 3.36-3.31 (m, 1 H), 3.03-3.00 (m, 1 H), 2.81-2.78 (m, 2 H), 2.73-2.37 (m, 5 H), 2.30-2.19 (m, 3 H), 2.09-1.97 (m, 3 H), 1.87-1.26 (m, 14 H); HRMS
(ESI) [M+11]+ cacld for C36H49FN305 622.8007, found 622.8025; HPLC > 99% pure (tit =
3.80 min, 55(A):45(B):0.02(D), tR = 4.53 min, 40 (A):60(B):0.02(D)).
[0506] 4-(3,4-Dimethoxy-pheny1)-245-(2-{5-[3-(5-fluoro-2-methoxy-pheny1)-propyl]-tetrahydro-furan-2-yll-ethylamino)-penty1-4a,5,8,8a-tetrahydro-2H-phthalazin-l-one (22): (See Figure 37.) The product was isolated by preparative TLC and (developed with Me0H/CH2C12, 5:95, ITN, Rf = 0.2); 1H NMR (CDC13, 500 MHz) 8 7.47 (d, J= 2.0 Hz, 1 H), 7.25 (dd, J= 2.0, 8.5 Hz, 1 H), 6.87 (d, J= 8.5 Hz, 1 H), 6.86-6.81 (m, 2 H), 6.76-6.72 (m, 1 H), 5.80-5.77 (m, 1 H), 5.69-5.66 (m, 1 H), 4.01-3.97 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.77 (s, 3 H), 3.79-3.74 (m, 1 H), 3.33-3.3 (m, 1 H), 3.0-2.96 (m, 1 H), 2.81-2.57 (m, 7 H), 2.22-2.17 (m, 3 H), 2.04-1.34 (m, 19 H); HRMS (ESI) [M+14]-1- calcd for 636.8275, found 636.826; HPLC > 98% pure (tR = 3.86 min, 55(A):45(B):0.02(D);
tR = 4.54 min, 40(A):60(B):0.02(D)).
[0507] N -(R)-[1-(1-naphthybethyl]-N-(8)-344-(triflouromethyl)phenoxy]-3-phenylpropylurea: (See Figure 38.) (R)-Norfluoxetine (44 mg, 0.15 mmol, 1.1 eq) and (R)-(-)-1-(1-naphyl)ethyl isocyanate (27 mg, 0.14 mmol, 1.0 eq) was put in a vial containing toluene (0.75 mL). The reaction stirred at room temperature for 13 hrs and then concentrated in vacuo to afford a light yellow oil. The product was purified with PTLC on silica and eluted with Et0Ac/ Hex (1:3, v:v, R=0.3). 1H NMR (CDC13, 500 MHz) 8 8.22-7.21 (m, 14 H), 6.71 (d, J= 8.7 Hz, 2 H), 5.53 (t, J= 6.6 Hz, 1 H), 5.01-4.93 (m, 1 H), 4.60 (bt, 1 H), 3.22 (m, 2 H), 2.04-1.96 (m, 2 H) 1.54 (d, J= 6.9 Hz, 3 H).
[0508] N'-(8)41-(1-maphthyl)ethyll-N-(8)-344-(triflouromethyl)phenoxyl-3-phenylpropylurea: (See Figure 39.) (S)-Norfluoxetine (44 mg, 0.15 mmol, 1.1 eq) and (R)-(-)-1-(1-naphypethyl isocyanate (27 mg, 0.14 nunol, 1.0 eq) was put in a vial containing toluene (0.75 mL). The reaction stirred at room temperature for 13 hrs and then concentrated in vacuo to afford a light yellow oil. The product was purified with PTLC on silica and eluted with Et0Ac/ Hex (1:3, v:v, Rf--0.3). 1H NMR (CDC13, 500 MHz) 8 8.22-7.21 (m, 14 H), 6.71 (d, J= 8.7 Hz, 2 H), 5.53 (t, J= 6.6 Hz, 1 H), 5.01-4.93 (m, 1 H), 4.60 (bt, 1 H), 3.22 (m, 2 H), 2.04-1.96 (m, 2 H) 1.61 (d, J= 6.9 Hz, 3 H).
Pharmacological Results Table 17. Inhibition of radioligand binding and neurotransmitter uptake in HEK-hDAT, HEK-hSERT and HEK-hNET ceilsa Binding (Ki, nM) Reuptake nM) Compound Description hDAT hSERT hNET hDAT hSERT hNET
Cocaine 6670 1.1 1560 19,500 7.3 1020 Fluoxetine 850b 0.5 300 7600 2.9 180 4544 7.7 6528 >7658 6.8 2806 22(S) SSRI
1131 1.5 1194 305 2.6 22 3661 22.8 7338 7133 12.6 1995 22(R) SSRI
456 2.4 1390 891 9.1 518 Dual 3132 1215 4147 23(5) > 10 JAM >5737 >1011M
inhibitor 194 146 693 Dual 3305E 82 5827 6669 40 24(R) > 8277 inhibitor 408 22 1754 1626 15 a Values are the mean S.E.M. of three to four experiments unless the mean of three experiments exceeded 100 uM. Drug inhibition of [12511-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET cell membranes. Inhibition of [311]-DA, {3RJ-5-HT, [31-1]-NE in the presence of HEK-bDAT, HEK-hSERT, or }IEK-hNET cells, respectively;
b Data taken from the literature.
[0509] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the scope of the appended claims.
Cocaine 6670 1.1 1560 19,500 7.3 1020 Fluoxetine 850b 0.5 300 7600 2.9 180 4544 7.7 6528 >7658 6.8 2806 22(S) SSRI
1131 1.5 1194 305 2.6 22 3661 22.8 7338 7133 12.6 1995 22(R) SSRI
456 2.4 1390 891 9.1 518 Dual 3132 1215 4147 23(5) > 10 JAM >5737 >1011M
inhibitor 194 146 693 Dual 3305E 82 5827 6669 40 24(R) > 8277 inhibitor 408 22 1754 1626 15 a Values are the mean S.E.M. of three to four experiments unless the mean of three experiments exceeded 100 uM. Drug inhibition of [12511-RTI-55 binding in HEK-hDAT, HEK-hSERT, or HEK-hNET cell membranes. Inhibition of [311]-DA, {3RJ-5-HT, [31-1]-NE in the presence of HEK-bDAT, HEK-hSERT, or }IEK-hNET cells, respectively;
b Data taken from the literature.
[0509] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the scope of the appended claims.
Claims (19)
1. A compound of Formula XIV:
wherein D is a phenyl optionally substituted at the para position;
A is a phenyl;
E is 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one or pyrrolidin-2-one;
G is a phenyl optionally substituted at the para position, the meta position, or at both the para and the meta positions;
R3 is hydrogen;
subscripts b and c are each independently 1-6; and subscript d is 0, or a pharmaceutically acceptable salt thereof.
wherein D is a phenyl optionally substituted at the para position;
A is a phenyl;
E is 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one or pyrrolidin-2-one;
G is a phenyl optionally substituted at the para position, the meta position, or at both the para and the meta positions;
R3 is hydrogen;
subscripts b and c are each independently 1-6; and subscript d is 0, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, selected from the group consisting of:
4-(3,4-Dimethoxy-phenyl)-2-{5[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyl}-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-{5-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyl}-pyrrolidin-2-one.
4-(3,4-Dimethoxy-phenyl)-2-{5[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyl}-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, and 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-{5-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propylamino]-pentyl}-pyrrolidin-2-one.
3. A compound of claim 1 or 2, wherein said compound is a dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity.
4. The compound of claim 1, wherein D is 4-trifluoromethyl-phenyl.
5. The compound of claim 1, wherein b is 2.
6. The compound of claim 1, wherein c is 5.
7. The compound of claim 1, wherein E is 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, connected to (CH2)c at position 2 and to G at position 4.
8. The compound of claim 1, wherein E is pyrrolidin-2-one, connected to (CH2)c at position 1 and to G at position 4.
9. The compound of claim 1, wherein G is 3,4-dimethoxy-phenyl or 3-cyclopentyloxy-4-methoxy-phenyl.
10. A pharmaceutical composition comprising:
a compound of any one of claims 1 to 9; and a pharmaceutically acceptable carrier.
a compound of any one of claims 1 to 9; and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising:
a compound of any one of claims 1 to 9; and a pharmaceutically acceptable carrier, for use in treating or preventing a central nervous system (CNS) disease or disorder in a subject, suffering from a CNS disease or disorder amenable to treatment or prevention by inhibition of at least one of serotonin reuptake and phosphodiesterase 4 (PDE4) activity.
a compound of any one of claims 1 to 9; and a pharmaceutically acceptable carrier, for use in treating or preventing a central nervous system (CNS) disease or disorder in a subject, suffering from a CNS disease or disorder amenable to treatment or prevention by inhibition of at least one of serotonin reuptake and phosphodiesterase 4 (PDE4) activity.
12. The pharmaceutical composition of claim 11, wherein the compound is a dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity.
13. The pharmaceutical composition of claim 11, wherein the CNS disease or disorder is selected from the group consisting of depression, a drug addiction, anxiety, attention-deficit disorder, schizophrenia, and bipolar disorder.
14. The pharmaceutical composition of claim 11, wherein the CNS disease or disorder is a neurodegenerative disease or disorder.
15. The pharmaceutical composition of claim 14, wherein the neurodegenerative disease is Parkinson's Disease or Alzheimer's Disease.
16. The pharmaceutical composition of claim 11, wherein the compound induces non-addicting CNS stimulation in the subject.
17. The pharmaceutical composition of claim 11, wherein the subject has been diagnosed with the CNS disease or disorder.
18. The pharmaceutical composition of claim 11, wherein the subject is not suffering from a second disease or disorder.
19. The pharmaceutical composition of claim 11, wherein the subject is monitored for one or more symptoms of the CNS disease or disorder.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58121004P | 2004-06-19 | 2004-06-19 | |
US60/581,210 | 2004-06-19 | ||
PCT/US2005/021818 WO2006025920A2 (en) | 2004-06-19 | 2005-06-20 | Modulators of central nervous system neurotransmitters |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2579756A1 CA2579756A1 (en) | 2006-03-09 |
CA2579756C true CA2579756C (en) | 2013-04-30 |
Family
ID=36000474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2579756A Expired - Fee Related CA2579756C (en) | 2004-06-19 | 2005-06-20 | Modulators of central nervous system neurotransmitters |
Country Status (4)
Country | Link |
---|---|
US (2) | US8168635B2 (en) |
EP (1) | EP1771435A4 (en) |
CA (1) | CA2579756C (en) |
WO (1) | WO2006025920A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8552051B2 (en) * | 2009-03-20 | 2013-10-08 | H. L. Hall & Sons Limited | Use of pharmaceutical compositions containing mesembrenone |
PL2408460T3 (en) | 2009-03-20 | 2019-03-29 | Hg&H Pharmaceuticals (Pty) Limited | Sceletium extract and uses thereof |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
CN111574385B (en) * | 2020-05-27 | 2022-10-04 | 石家庄万业化工科技有限公司 | Synthesis method of 2- (2, 4, 6-trichlorophenoxy) ethyl propylamine |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL23782C (en) | 1926-04-03 | |||
US2857397A (en) * | 1956-02-27 | 1958-10-21 | Arthur C Cope | 2, 5-bis(phthalimidomethyl)-tetrahydrofuran |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
DE3413996A1 (en) * | 1984-04-13 | 1985-10-24 | Bayer Ag, 5090 Leverkusen | TETRAHYDROFURAN-2-YLMETHYLAMINE |
NO170884C (en) * | 1986-08-18 | 1992-12-23 | Hoffmann La Roche | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE PYRIMIDINE DERIVATIVES |
DE3715482A1 (en) * | 1987-05-08 | 1988-11-24 | Bayer Ag | PEST CONTROLS BASED ON SUBSTITUTED AMINOMETHYLHETEROCYCLES |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB9215274D0 (en) * | 1992-07-17 | 1992-09-02 | Scras | Derivatives of(phenylethyl-beta-ol)amine |
US5583147A (en) * | 1994-03-23 | 1996-12-10 | The Dupont Merck Pharmaceutical Company | Amides for the treatment of atherosclerosis |
GB9608199D0 (en) * | 1995-08-04 | 1996-06-26 | Hoffmann La Roche | Pyrimide nucleoside derivatives |
US6121307A (en) * | 1998-04-08 | 2000-09-19 | American Home Products Corp. | N-aryloxyethyl-indoly-alkylamines for the treatment of depression |
ATE356825T1 (en) * | 1998-07-09 | 2007-04-15 | Sankyo Co | ANTIBACTERIAL COMPOUNDS |
WO2001077089A1 (en) * | 2000-04-06 | 2001-10-18 | Astrazeneca Ab | New neurokinin antagonists for use as medicaments |
US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
-
2005
- 2005-06-20 WO PCT/US2005/021818 patent/WO2006025920A2/en active Application Filing
- 2005-06-20 EP EP05812931A patent/EP1771435A4/en not_active Withdrawn
- 2005-06-20 CA CA2579756A patent/CA2579756C/en not_active Expired - Fee Related
- 2005-06-20 US US11/629,797 patent/US8168635B2/en active Active
-
2012
- 2012-05-01 US US13/461,677 patent/US20130123253A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8168635B2 (en) | 2012-05-01 |
US20130123253A1 (en) | 2013-05-16 |
EP1771435A4 (en) | 2008-02-13 |
WO2006025920A2 (en) | 2006-03-09 |
EP1771435A2 (en) | 2007-04-11 |
US20080261967A1 (en) | 2008-10-23 |
WO2006025920A3 (en) | 2006-08-17 |
CA2579756A1 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5139307B2 (en) | Prolinamide derivatives as sodium channel modulators | |
JP5823476B2 (en) | Derivatives of pyrrolidine and piperidine as NK1 antagonists | |
CA2109585C (en) | Isoxazole and isothiazole compounds that enhance cognitive function | |
JP5139305B2 (en) | Prolinamide derivatives as sodium channel modulators | |
JP6285610B2 (en) | Azetidinyloxyphenylpyrrolidine compound | |
EP3209296B1 (en) | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors | |
TW200808813A (en) | Imidazo compounds | |
JP2010508343A (en) | Pharmacologically active N, N'-substituted 3,7-diazabicyclo [3.3.1] nonanes, pharmaceutical compositions based on them, and methods of their use | |
CA2582639A1 (en) | Thrombin receptor antagonists | |
Prevatt-Smith et al. | Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A | |
KR20080059297A (en) | Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels | |
JP7125495B2 (en) | Tetrahydroisoquinoline compounds, methods for their preparation, pharmaceutical compositions containing such compounds and uses thereof | |
JP2023512821A (en) | 3-pyrrolidine indole derivatives as serotonergic hallucinogens for the treatment of central nervous system disorders | |
HUT77520A (en) | Neuroprotective chroman-4,7-diol and 1-(4-hydroxiphenyl)-alkanol derivatives and pharmaceutical compositions containing them as activ agent | |
CA2579756C (en) | Modulators of central nervous system neurotransmitters | |
JP6496246B2 (en) | Indoline compounds as related to aldosterone synthase inhibitors | |
KR20120028872A (en) | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | |
CN109689656B (en) | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | |
WO2015121212A1 (en) | New compounds having a selective pde4d inhibiting activity | |
Cashman et al. | Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression | |
Torun et al. | Synthesis and structure–activity relationship studies of 3-biaryl-8-oxabicyclo [3.2. 1] octane-2-carboxylic acid methyl esters | |
EA031089B1 (en) | Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol | |
JP6493711B2 (en) | Use of tetrahydropyridine in the treatment of sodium channel related diseases and disorders | |
WO2016003296A1 (en) | (quinoline or isoquinoline)sulfonamides of cyclic amines as antipsychotic drugs | |
JP2003183269A (en) | Hydroisobenzofuran 1(3h)-one derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220620 |